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Abstract 
A shift from the “doomed” organ concept of an exposed pulp to the concept of hope and 
retrieval has been recently adopted with the introduction of vital pulp therapy. Microbial 
contamination of the capped pulp is the main cause of therapy failure and is a fundamental 
challenge of contemporary endodontics. Biosurfactants are tensioactive microbe-derived 
molecules with a potential antimicrobial/antiadhesive activity. This project aimed to 
investigate the role of biosurfactants, specifically probiotic-derived ones and a commercial-
sourced rhamnolipid (Sigma Aldrich), as novel endodontic antimicrobial therapies that can aid 
in reducing the incidence of infection and endodontic failure.    
Of five probiotic strains studied, Lactobacillus plantarum demonstrated significant 
antimicrobial activity against three Streptococcus anginosus group members; S. anginosus, S. 
constellatus and S. intermedius and against Enterococcus faecalis. A cell-bound biosurfactant 
(Lp-BS) was successfully extracted from the potential probiotic L. plantarum. Biochemical 
characterisation identified Lp-BS as a glycoprotein molecule that was capable of reducing 
surface tension and emulsifying hydrocarbons. For the endodontic pathogens studied, Lp-BS 
demonstrated no antibacterial activity up to concentrations of 50 mg/ml, but displayed 
significant antiadhesive potential at 20 mg/mL. Proteomic analysis revealed a rich 
heterogeneous proteinaceous nature of Lp-BS mixture and importantly identified three 
adhesin-like proteins raising the possibility for applications in pathogenic bacterial adhesion 
interference. Ten mg/ml Lp-BS induced high levels of apoptosis in pulpal fibroblasts at 24 h, 
resulting in significant reduction in cell number. No significant differences were reported in 
cell counts or histology of pulp tissue treated with 0.625-10 mg/mL Lp-BS in comparison to 
the controls, over a 24 h time period. Subsequent incubation with 10 mg/mL for 48 h revealed 
obvious pulp tissue toxicity. Partial purification of Lp-BS by means of size-exclusion 
chromatography resulted in five elution pools with the first fraction determined to retain the 
biosurfactant activity; this fraction can be further investigated for antimicrobial/antiadhesive 
effects. Rhamnolipid demonstrated substantial antimicrobial effect with minimum inhibitory 
concentrations determined to be 0.097 mg/mL against S. anginosus, 0.048 mg/mL against S. 
constellatus and S. intermedius and 50 mg/mL against E. faecalis. Rhamnolipid also reduced 
attachment of S. anginosus and S. intermedius to an abiotic surface. Of importance, 
rhamnolipid was shown to tolerate serum concentrations ≤ 5 % v/v. However, above this 
concentration inactivation of rhamnolipid effect was demonstrated. Application of 
rhamnolipid to rodent ex-vivo tooth model infected with S. anginosus and S. constellatus 
demonstrated significant antimicrobial activity and a mild immune response of pulp tissue in 
response to treatment was documented.  
This work provides the foundation for further investigation on Lp-BS adhesin-like proteins as 
a novel endodontic antiadhesive therapy. Furthermore, the cost-effective rhamnolipid with 
its antimicrobial and immune-modulatory effect covers two fundamental requirements of 
pulp tissue repair and therefore, opens future prospects for novel biosurfactants application 
in pulp therapy.  
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1 Chapter 1 Introduction  
1.1 General introduction  
Endodontics is defined as the field of dentistry that is concerned with the morphology, 
physiology, and pathology of human dental pulp and periradicular tissues (Sundqvist 1976). 
Pulpitis mainly results as a sequel of untreated dental caries of the enamel or dentine tissue, 
causing exposure of the internal dental tissue to the oral cavity which in turn can allow for 
the invasion of bacteria into the dental pulp. As the lesion progresses it can stimulate an 
inflammatory response in the pulp (Ali and Mulay 2015). Pulpitis can be classified clinically as 
either reversible or irreversible. The distinction between the two conditions is important since 
the former can be successfully reversed and allow healing either with or without pulp 
exposure while the latter leads to pulp necrosis (Piattelli and Traini 2007). Infected teeth that 
have been diagnosed clinically as having irreversible pulpitis are mostly treated by root canal 
therapy which basically involves removal of the devitalised pulp tissue and filling the root 
canal with inert materials. Current endodontic treatment strategies are meant to eradicate 
bacteria from the root canal system by mechanical (Byström and Sundqvist 1981) and 
chemical means (Kim 2014). It has been found that, besides their cost and time consumption, 
the outcome of these strategies vary considerably with a success rate ranging from 30 to 98 
% with the presence of persisting or secondary intraradicular infection accounting for the 
most common reason for failure  (Siqueira 2001; Friedman and Mor 2004;  Nair 2006). 
Furthermore, chemical treatments are reported to be associated with deleterious influences 
on the physical properties of dentine (Grigoratos et al. 2001; Andreasen et al. 2002) Therefore 
a shift towards biological alternatives in treating root canal without such deleterious effects 
on the dentine would be beneficial. Moreover, loss of vital pulp tissue excludes the possibility 
of reparative and regenerative dentinogenesis which is especially important in young 
permanent teeth where root formation has not been completed resulting in defected 
crown/root ratio and thin dentin wall predisposing the tooth to fracture. Therefore, 
maintaining pulp vitality appears to be important. In contemporary endodontics, vital pulp 
therapy (VPT) has been considered as an ultra-conservative treatment modality which is a 
new but challenging procedure to preserve a vital pulp (Asgary et al. 2014). This procedure, 
based on the level of pulp preservation, basically involves stepwise excavation, indirect pulp 
capping (IDPC), direct pulp capping (DPC), miniature pulpotomy (MP), partial pulpotomy and 
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coronal/complete pulpotomy (CP). Many factors affect the success rate of such vital therapy 
including a.) the remaining pulp being either non-inflamed or capable of healing; b.) proper 
control of haemorrhage; c.) application of a biocompatible/regenerative capping material; 
and d.) presence of a bacterial-tight seal (Witherspoon 2008; Aguilar and Linsuwanont 2011; 
Asgary and Ahmadyar 2013). The success of VPT has been proven on traumatically exposed 
pulps (Cvek 1978; Swift et al. 2003; Trope 2008). However, VPT on cariously exposed pulps 
has not been shown to be as successful (Cvek 1978; Barthel et al. 2000). The success rate has 
been reported to reduce over time (Amini and Parirokh 2008; Dammaschke et al. 2010; 
Hargreaves and Berman 2015). Microbial contamination seems to be the key factor in the 
outcome of VPT. Unfavourable outcomes can be caused by infection due to either remaining 
bacteria or due to the introduction of new bacteria (Barthel et al. 2000; Al-Hiyasat et al. 2006; 
Dammaschke et al. 2010; Neelakantan et al. 2012). The currently available VPTs are relatively  
expensive (Çalışkan and Güneri 2017) and not widely used in clinical practice even in 
developed countries (Chin et al. 2016). This highlights the need for more effective 
antimicrobial agents for pulp therapy particularly with the knowledge that the prescription of 
antibiotics is ineffective both before and after endodontic infection and systemic antibiotic 
administration has no effect in relieving painful pulpitis or resolving periradicular symptom 
(Aminoshariae and Kulild 2015). 
A considerable variety of diverse microbial species have been recognised as playing a role in 
pulpitis, with the major species responsible for the virulence shifting as the infection 
progresses (Featherstone 2000). This study focused on two significant type of oral pathogens; 
Streptococcus anginosus group (SAG) and Enterococcus faecalis (E. faecalis). Streptococcus 
anginosus group includes S. anginosus, S. intermedius and S. constellatus and is commonly 
considered as part of the body’s commensal microflora. Nonetheless these typically 
facultative  bacteria have been isolated as predominant components of a number of orofacial 
infections including dentoalveolar and periodontal abscesses, are often isolated in pure 
culture and are frequently associated with failed root canal treatment (Jacobs et al. 2003; 
Okayama et al. 2005; Ledezma-Rasillo et al. 2010). Whilst present in low numbers in dental 
plaque, it has been proposed that members of SAG can present early in the pathogenic 
process and may actually initiate infection, thereafter preparing the environment for 
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subsequent colonisation by anaerobic species (Aderhold et al. 1981; Gossling 1988; Shinzato 
and Saito 1994; Nagashima et al. 1999; Love and Jenkinson 2002).  
Based on this background, the development of new therapeutic treatments that can control 
infection and prevent re-infection, thus extending the life of the capped pulp has been an 
increasing need.  
Biosurfactants, amphiphilic tension-active agents of biological origin, have found themselves 
a niche in commercial markets due to their unique properties such as antiadhesive, 
antimicrobial, antitumor and immune-modulatory (Santos et al. 2016). In addition they have 
advantages over their synthetic counterparts in being eco-friendly, biodegradable and stable 
at pH and salinity extremities. Their applications have been growing recently to be used in 
various fields of industry, bioremediation and oil processing, biomedical and pharmaceuticals 
(Akbari et al. 2018). A wide range of bacterial species have been reported to produce 
biosurfactants including pathogenic and probiotic bacteria. Antimicrobial/antiadhesive 
effects of biosurfactants have been established in some studies against nosocomial pathogens 
on inanimate surfaces such as silicone rubber used in prostheses (Falagas 2009; Santos et al. 
2016), however there are no apparent studies investigating the potential for biosurfactants 
in preventing the establishment of pathogenic biofilms on mammalian tissues associated with 
endodontic infections. The work presented in this thesis will aim to achieve this, progressing 
from a number of in-vitro assays into utilizing an infective co-culture ex-vivo tooth model 
previously developed with our research group.  
The project aims to assess biosurfactants as an effective antimicrobial dental agent. 
Ultimately, an ideal endodontic product material should aim to: 
1- Sterilise the pulp during pulp therapy and reduce the incidence of failure due to re-
infection; 
2- Reduce the need for further and more complex treatment or tooth extraction; 
3- Reduce the need to use systemic antibiotics, which are often ineﬀective against the 
polymicrobial infections found in the tooth and impact negatively on the global 
problem of antimicrobial resistance; 
4- Employ green chemistry in endodontics.  
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1.2 Tooth anatomy 
1.2.1 Enamel 
Mature tooth enamel (Figure 1.1) is acellular, has no blood circulation and, in contrast to 
dentine, does not regenerate itself. It is the most mineralised tissue of the body containing 
96 % minerals which makes it able to absorb blunt heavy masticatory forces (Robinson et al. 
1998; Fincham et al. 1999). The enamel surface contains an adsorbed pellicle which is an 
acellular layer of salivary and other macromolecules and it has a protective role  (Siqueira et 
al. 2007). However, bacteria can interact with these pellicle molecules via a lock and key 
mechanism and may establish a biofilm in the form of plaque (Siqueira et al. 2012). Acid 
produced by plaque dwelling bacteria can affect the enamel. The high water content of the 
organic enamel matrix makes it permeable to hydrogen ions (Cawson and Odell 2008). As a 
consequence, enamel erodes leading to the development of dental caries. The latter 
considered as one of the most prevalent chronic diseases of humans all over the world 
(Selwitz et al. 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Tooth anatomy, cross section. (Blausen 2014) 
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1.2.2 Dentine 
Dentine is a mineralised connective tissue of the teeth which is covered by the enamel on the 
crown and cementum on the root and surrounds the entire pulp (Figure 1.1) (Nanci 2007). 
Odontoblasts produce  dentine and remain in place and active as a constant source for 
dentine synthesis (dentinogenesis) for the tooth lifespan (Couve 1986; Sloan et al. 1998; Sloan 
and Waddington 2009). These cells initially secrete a matrix (predentine) consisting of 
collagenous (primarily collagen type I) and non-collagenous proteins. Mineral hydroxyapatite 
constitutes 45 % of the dentine weight, while 33 % is organic material (largely type I collagen), 
and 22 % is fluid which is similar to plasma and contains albumin, ﬁbrinogen and 
immunoglobulin G (IgG) (Knutsson et al. 1994; Marshall et al. 1997). Rapid dentine production 
occurs during tooth development (primary dentinogenesis). After tooth eruption, secondary 
dentinogenesis occurs and is characterised by a lower rate of deposition and a diﬀerent gene 
expression proﬁle, including the up-regulation of matrix proteins osteocalcin and dentine 
matrix acidic phosphoprotein-1 (DMP-1) and down-regulation of collagen type I and dentine 
sialophosphoprotein (DSPP), amongst others (Simon et al. 2009).  
Dentine is characterised by being permeable due to the presence of closely packed channels, 
known as dentinal tubules, traversing its entire thickness and containing the cytoplasmic 
projections of odontoblast cells which enable the dentine to respond to external stimuli. 
Other than dynamic reaction to different stimuli, this tubular nature of dentine is considered 
of particular significance to infection as it permits bacteria and their products to diffuse 
through the dentine to the pulp, where they can provoke an immune reaction (Love and 
Jenkinson 2002). The protein-rich nature (particularly collagen) of both dentine and pulp 
allows for the attachment of bacteria possessing collagen-binding proteins, such as some 
Streptococcus species (Ackermans et al. 1981; Avilés-Reyes et al. 2017). However, pathogens 
and their products can escape these defences and further invade into dentinal tubules causing 
destruction of the odontoblasts which stimulates a further immune response in the pulp. 
    
1.2.3  Pulp 
The pulp is an unmineralised connective tissue that resides in the centre of the tooth in a 
space known as the pulpal chamber surrounded by the dentine. Odontoblasts, which are the 
pulp’s specialised cells, and undifferentiated mesenchymal pluripotent progenitor cells, 
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which may differentiate into dentine-forming cells upon stimulation, are capable of forming 
dentine throughout life (Yu and Abbott 2007; Sloan and Waddington 2009). Beside their role 
in dentine formation, odontoblasts may help as sensory transmitters (Matthews et al. 1996). 
These cells are proposed to communicate with each other through the presence of tight, 
adhering and gap junctions. Gap junctions are present between and among odontoblasts and 
nerve fibres (Ushiyama 1989) and can offer a passageway of low electrical resistance between 
and among the odontoblasts and nerve fibres. The dental pulp is a unique tissue, because it 
does not form hard tissue spontaneously, but possesses the ability to mineralise gradually 
due to the aging process or to secrete reparative dentine after pulp exposure (Decup et al. 
2000). For initial recognition and subsequent processing of antigens, the pulp is armed with 
cellular components of the immune system (Jontell et al. 1988; Jontell and Bergenholtz 1991; 
Jontell et al. 1998). The majority of these immune cells are peripheral T-cells (helper/inducer 
and cytotoxic/suppressor). Dendritic cells, the antigens presenting cells, are located in the 
odontoblastic layer (Okiji et al. 1997). In the more central region of the pulp are the 
macrophages which serve also as antigen-presenting cells (Jontell et al. 1988). Immune B-cells 
can present in healthy pulp in a small number and dramatically increase during infection 
(Farges et al. 2015). The pulp is also a sensory tissue registering different impulses such as 
thermal changes, mechanical distortion or trauma as a common sensation which pain 
(Holland 1994). Extracellular matrix (ECM) consisting mainly of collagens type I and III and 
proteoglycans such as decorin, biglycan, and versican, is secreted by fibroblasts within the 
pulp tissue (Shuttleworth et al. 1980; Goldberg and Smith 2004). This ECM provides support 
for the fibroblasts as well as acting as mediator of many of the cellular interaction. 
Additionally, the matrix can serve as a source of nutrients for the invading bacteria, which can 
adhere to the collagen component of the matrix. These collectively make the composition of 
the matrix a significant theme to be considered in studying pulpal disease.   
1.2.4 Dentine-pulp complex  
Functionally, physically and developmentally, the dentine and the pulp are related and can 
be considered together as dentine-pulp complex. They both originate from the mesenchymal 
cells and physically interact. The functional integrity of the dentine-pulp complex is elucidated 
during infection of the dentine as the odontoblasts act as the pulp’s ﬁrst line of defence, with 
processes that line the dentinal tubules able to sense the presence of bacteria and trigger an 
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immune response from the pulp before the bacteria have reached the pulpal chamber. The 
pulp dynamically responds as a functional unit by initiating inflammation and at the same 
time by forming reparative dentine by pulpal odontoblast-like cells as a defensive mechanism 
(Arnold et al. 2001).  
 
1.2.4.1 Tertiary dentinogenesis 
External influence such as injury or infection of the tooth including dental caries exposes the 
dentine-pulp complex to the oral cavity making it vulnerable to further infection and tissue 
damage. The pulp reacts by producing new dentine termed tertiary dentine (tertiary 
dentinogenesis). Such dentine can be produced with regular tubular matrix similar to primary 
and secondary dentine or dysplastic atubular dentine (Goldberg 2014). Biologically, tertiary 
dentine can be either reactionary or reparative (Smith et al. 2003) depending on the severity 
of the external stimuli. Mild stimuli cause up-regulation of the primary odontoblasts resulting 
in the production of reactionary dentine. When there is severe damage to the primary 
odontoblast cells by strong stimuli, newly differentiated odontoblast-like cells secret tertiary 
dentine, referred to as reparative dentine (Kuttler 1959; Lesot et al. 1993; Decup et al. 2000).    
TGF-beta/s are expressed by odontoblasts leading to sequestration of some isoforms within 
the dentine matrix (Vaahtokari et al. 1991). TGF-beta/s have been implicated in reactionary 
dentinogenesis (Lesot et al. 1994; Smith et al. 1995). Local stimulation of the odontoblasts-
secretion of extracellular matrix has been shown to be induced by TGF-beta1 and beta3 
isoforms resulting in a local reactionary dentinogenesis up-regulation reflected by the 
increase in predentine thickness (Sloan and Smith 1999). TGF-beta2 has been shown to exert 
little effect on the odontoblasts and has not been detected in the human teeth dentine matrix 
(Cassidy et al. 1997). Its role has been suggested to involve in the tooth size and shape (Chai 
et al. 1994). It has been suggested that reactionary dentinogenesis is mediated by similar 
processes to primary dentinogenesis. Simon et al. (2010) stimulated odontoblast-like MDPC-
23 cells with heat inactivated Streptococcus mutans and with growth factors known to 
stimulate reactionary dentinogenesis (TGF-beta1, TNF-alpha, and adrenomedullin). In these 
studies, activation of the p38 mitogen-activated protein kinase (MAPK) pathway was 
observed, which is also active during primary (but not secondary) dentinogenesis (Simon et 
al. 2010).   
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Reparative dentinogenesis, from a biological point of view, is a more complex process than 
reactionary dentinogenesis. It involves the recruitment of the progenitor cells from the dental 
pulp tissue. These cells then differentiate into odontoblast-like cells before they are able to 
secrete the reparative dentine matrix. These processes are mediated by a host of signalling 
molecules, including members of the TGF-beta family and bone morphogenic proteins (BMPs) 
(Kim 2017). The newly produced dentine should, ideally, be similar to tubular dentine where 
the new layer of odontoblasts can be adsorbed (Yoshiba et al. 1996). However, the hard tissue 
formation is variable between regular tubular dentine to a dysplastic atubular dentine. The 
objective of the tertiary dentinogenesis, whether reactionary or reparative, is the ultimate 
formation of a physical barrier against the insulting stimulus. If this fails, the pulp cells respond 
to this in the form of inflammatory reaction. 
1.3 Pulpal inflammation  
Inflammation of the pulp tissue is called pulpitis and can result as a response to exposure to 
different irritants such as microorganisms from carious lesions or their toxic by-products that 
diffuse through dentinal tubules (Love and Jenkinson 2002). As the tooth has a unique 
structure of the soft pulp being enclosed by hard tissues of the dentine, cementum and 
enamel, the pulpal inflammatory response is also unique when compared to other tissues. In 
the early pulp response to caries, the pulp is infiltrated locally, at sites beneath the offending 
carious injury, with inflammatory cells and mediators of the non-specific innate immunity, 
which are recruited through blood vessels of the pulp chamber. Polymorphonuclear (PMN) 
leukocytes and monocytes infiltrate the site of exposure after being stimulated by pathogen-
associated molecules (such as components of the bacterial cell wall, flagellin, peptidoglycans 
and lipoproteins) forming an area of liquefaction necrosis (Cooper et al. 2010). As stated 
earlier (Section 1.2.4.1), dentine matrix proteins such as TGF-beta isoforms are also involved 
in triggering the inflammatory immune response within the pulp tissue  (Lara et al. 2003; Abd-
Elmeguid et al. 2012). The intensity of inflammation and subsequent development of necrosis 
depends on the virulence of the offending pathogen and on how efficient the host response 
is. If the pulp is unable to eliminate the damaging irritants, the infection persists and more 
extensive damage is perused.  
The inflammatory orchestra, namely cell to cell communication, is coordinated by the 
secretion of protein molecules known as cytokines. The most important and extensively 
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investigated of cytokines are the interleukins (IL), tumour necrosis factors (TNF) and 
interferons (IFN). Over production of pro-inflammatory cytokines such as TNF-alpha, IFN-γ, IL-
1beta, IL-6, IL-8, and IL-18 is found to be a characteristic of the pulp inflammatory response 
to carious lesion. It has been shown also that the anti-inflammatory IL-10 cytokine, which is 
important in the development of regulatory T cells (Tregs) that controls host immune 
response to pathogens is up-regulated (Farges et al. 2011; Elsalhy et al. 2013). Furthermore, 
it has been recently advocated that odontoblasts play a role in early dental pulp immune 
reaction to carious pathogens. For instance, engagement of Toll-like receptor (TLR)-2, a 
pattern recognition molecule of odontoblast-like cells with lipoteichoic acid (LTA), a cell wall 
component of Gram-positive bacteria stimulated odontoblast-like cells to produce pro- (IL-6, 
IL-8) and anti-inflammatory (IL-10) cytokines (Farges et al. 2011). Pulpal inflammation has also 
been reported to involve the production of the anti-inflammatory nitric oxide (NO), its role 
has been proposed to involve promotion of odontoblast-like cell differentiation and 
formation of reparative dentine (Mei et al. 2007; Yasuhara et al. 2007). It has been suggested 
that the pathogen recognition receptors (PRRs) family of dental pulp innate immunity plays a 
key role in the first-line defense. Understanding of PRRs is critical in regards to pulp 
immunomodulation and development of new therapeutic agents in the field of endodontics 
(Jang et al. 2015).  
 Bacterial lipopolysaccharide (LPS) is a major component of the Gram negative bacterial cell 
wall. LPS plays a crucial role in the dentine-pulp immune response and has been shown to 
persist in the dentine even after disinfection of the tooth (Vianna et al. 2007). It can induce 
the secretion of pro-inﬂammatory cytokines from the pulpal cells, including TNF-alpha, IL-6 
and IL-8 (Nagaoka et al. 1996; Fouad and Acosta 2001). Lipopolysaccharide-binding protein 
(LBP), an acute-phase protein known to temper pro-inflammatory cytokine produced by 
bacteria-activated macrophages, has recently received special attention (Schumann 2011; 
Lee et al. 2012). Carrouel and colleagues (2013) studied the synthesis and accumulation of 
LBP in bacteria-challenged inflamed pulp. They concluded that LBP neutralises bacterial 
components before they reach or attach to pulp cells, accordingly restraining activation of the 
pulpal inflammatory/immune responses (Carrouel et al. 2013). Moreover, a study conducted 
by Ko et al. (2015) documented that human telomerase-derived peptide (GV1001) stimulated 
by LPS from P. gingivalis was found to be able to enter the pulp cell causing down regulation 
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of LPS-induced inflammatory process. This study emphasised the potential of GV1001 as an 
anti-inflammatory therapeutic target in vital pulp procedure as well as in the field of 
regenerative and tissue engineering.  
Triggering of the inflammatory cascades within the pulp may progress to cause pain and 
dentine resorption through neurogenic inflammation and hard tissue remodelling (Love and 
Jenkinson 2002; Baik et al. 2008; Choi et al. 2009) and, if left untreated, bacterial invasion 
may result in irreversible chronic pulp inflammation, most often after a long phase of chronic 
inflammation. Subsequently, pulp necrosis, infection of the root canal system, and periapical 
disease may occur (Heyeraas and Berggreen 1999; Love and Jenkinson 2002). Consequently, 
it is of potential importance to understand thoroughly the pulpal inflammatory process 
especially in the field of immunotherapeutic agent development and appropriate dental 
procedures.  
In contrast, a low-grade level of inflammation may be of a value for the dental repair 
processes (Farges et al. 2015). For instance, Paula-Silva and her team (2009) have reported 
that TNF-alpha may endorse the differentiation of pulp cells towards an odontoblastic 
phenotype. These TNF-alpha challenged pulp cells also demonstrated ability to induce 
mineralisation and increased expression of phosphoprotein and sialoprotein of the dentine 
(Paula-Silva et al. 2009).  
 
1.4 Oral microbiology  
The oral cavity is inhabited by a diverse range of microorganisms. It is estimated that the oral 
cavity may harbour up to 1000 different microbial species, whilst approximately 50 species 
are isolated per individual site. Many species are  unique to this niche as they have developed 
a distinct specificity for oral colonisation (Aas et al. 2005; Dewhirst et al. 2010; Griffen et al. 
2012; Abusleme et al. 2013). These microbial communities are regulated through 
sophisticated signalling systems and by host and environmental factors and are considered as 
a major driver of homeostasis or dysbiosis and ultimately health or disease. Mostly a 
homeostatic balance is found between the host and microbial communities, and the occupant 
microbiota is thought to contest with and exclude exogenous pathogens as a component of 
ecosystem stability, as well as contribute to normal tissue and immune system development 
(Kamada, Chen, et al. 2013; Kamada, Seo, et al. 2013). However, imbalance in this 
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homeostasis by environmental triggers gives opportunities for some of the oral microbes to 
transition from commensal relationship into pathogenic direct precursor of diseases such as 
dental caries and periodontitis, two of the most prevalent microbially induced disorders 
worldwide (Lamont et al. 2018).  
1.4.1 Microbiology of dental caries and pulpal infection 
Caries is considered as a principal global health issue and is the most widespread 
noncommunicable disease (World Health Organization 2013). It involves demineralisation of 
enamel and/or dentine by bacterial acid. The bacteria metabolise fermentable carbohydrate 
especially free sugar to produce acid, lowering the pH of the plaque to a critical value (< 5.5) 
causing dissolution of the hydroxyapatite of the tooth (Cawson and Odell 2008). The aetiology 
of dental caries has been described by three major hypothesis: specific plaque hypothesis, 
the nonspecific plaque hypothesis, and the ecological plaque hypothesis. From its name, the 
specific plaque hypothesis has proposed that only a few specific species, such as S. 
mutans and S. sobrinus, are actively involved  in the disease (Loesche 1992). In contrast, the 
nonspecific plaque hypothesis upholds that caries is the consequence of the overall activity 
of the total plaque microflora, which is comprised of many bacterial species (Theilade 1986). 
Lastly, the ecological plaque hypothesis suggests that caries is an outcome of a shifting change 
in the balance of the resident microflora driven by changes in local environmental 
circumstances (Marsh 1994). Advances in molecular techniques allow for the identification of 
more bacterial species that were previously detectable by culturable means alone, thus 
expanding the range of bacterial species that may be involved in dental caries.  Differences in 
bacterial profiles between primary and secondary teeth, as well as those of a number of 
health-associated and disease-associated species, were discovered using techniques based 
on extensive checkerboard DNA hybridisation analyses. Although the Gram-positive S. 
mutans has been long recognised as a major etiological agent of dental caries, it has been 
found that bacterial profiles alter with disease states and differ between primary and 
secondary dentitions. Bacterial genera other than S. mutans, e.g., species of the 
genera Veillonella, Lactobacillus, Bifidobacterium, and Propionibacterium, Actinomyces spp., 
and Atopobium spp., have also been identified using  molecular techniques to likely play a 
role in disease progression (Aas et al. 2008). Moreover, in a study that compared the bacterial 
species in childhood teeth with and without caries, some genera, such as S. sanguinis, were 
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associated with health, while others, such as S. mutans, other Streptococcus spp., Veillonella 
spp., Actinomyces spp., Bifidobacterium spp., and Lactobacillus fermentum, were associated 
with caries (Becker et al. 2002). A diverse bacterial community was also reported for species 
associated with the middle and advancing front of dental caries including S. 
mutans, Lactobacillus spp., Rothia dentocariosa, and Propionibacterium spp. (Munson et al. 
2004). Van der Hoeven et al. (1978) observed a reduction in caries and lower plaque lactate 
in rats infected with Veillonella alcalescens and S. mutans compared with S. mutans alone. 
This was proposed  to be due to the ability of the former species to utilise lactic acid into a 
weaker acid thus reduce its damaging effect (van der Hoeven et al. 1978).   
Even with the reported prevalence of S. mutans and Lactobacillus species in dental caries, 
Boyar et al. (1989) found examples of carious lesions with no evidence of these species 
present in extracted teeth that were banded to allow plaque growth ex-vivo, suggesting that 
these species are not always needed to start caries formation (Boyar et al. 1989). Strong 
associations were revealed for the anaerobes Micromonas micros (now named Parvimonas 
micra) and Porphyromonas endodontalis (detected by real-time polymerase chain reaction; 
PCR) and the development of inflammatory degeneration of pulp tissue (Martin et al. 2002). 
P. micra isolated from deep dentinal caries associated with pulp exposure was found 
associated with symptoms of throbbing pain in irreversible pulpitis (Rôças et al. 2015) and 
some strains have been shown to produce collagenase, which could account for its 
destructive nature in the collagen-rich pulp tissue (Ota-Tsuzuki and Alves Mayer 2010). 
Although enamel is the hardest tissue of the body, its porosity from demineralisation makes 
it more permeable to acid and pathogens. The bacteria can then diffuse into the relatively 
less mineralised dentino-enamel junction. The carious lesion can then spread laterally and 
pulpally through the dentinal tubules of the demineralised dentine causing cavity. Cavitation 
exposes the pulp-dentine complex to a range of oral microbes present in saliva and plaque. 
The dentine reacts to such bacterial insult by the formation of peritubular sclerotic dentine 
to block the dentinal tubules or through the formation of tertiary dentine based on the rate 
of progression and the type of stimuli to the pulp tissue as previously explained earlier 
(Section 1.2.4.1). If this fails, the carious lesion progresses changing the environment 
conditions. This is due to the reduction of carbohydrate, increase in pH and oxygen reduction. 
The changes in the environment appears to cause a shift in the microbiota from those 
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involved in the initiation of infection to those associated with progression. For example, 
microaerophilic opportunistic bacteria such as S. anginosus  survive successfully in such a 
niche (Massey et al. 1993; Marsh 2010).   
1.4.2 Pulp infection 
There are many ways for  microorganisms to reach and infect the pulp tissue (Estrela 2009): 
1- Dentinal tubules: especially after a deep carious lesion or during dental procedures. It has 
been shown that the bacteria can cross to the pulp when the distance between the base of 
the carious lesion where the bacteria reside and the pulp is 0.2 µm (Singh 2016); 2- Cavitation: 
trauma such as coronal fracture breaks the physical protective shield and exposes the pulp to 
the septic oral cavity; 3- Periodontal membrane: bacteria can reach pulp chamber from the 
gingival sulcus through the periodontal membrane via the lateral channel or the apical 
foramen. This can occur as a result of the migration of epithelial insertion to the establishment 
of periodontal pockets. 4- Defective restoration: bacteria can get access to the pulp in case 
the temporary seal is broken or if the tooth structure fractures before final restoration, or if 
the final restoration is inadequate. Once the root canal chamber is infected coronally, 
infection can progress apically until bacteria or their products get close to the periapical tissue 
initiating inflammatory apical periodontitis (Torabinejad et al. 1990). Bacteria can approach 
the pulp also from the blood in case of transient bacteraemia (anachoresis) or from adjacently 
infected tooth (Narayanan and Vaishnavi 2010). The microbiology of pulpitis is variable and 
complex, in one study using a traditional culture method (Gajan et al. 2009), Gram positive 
bacteria were reported in 67.8 % of the cases of primary root canal infection. The two most 
prevalent genera among the collected samples were Peptostreptococcus and Streptococcus 
spp. Black-pigmented bacteria including Prevotella and Porphyromonas species were also 
seen in primary pulpal infections (Gajan et al. 2009). In general, species most frequently found 
in primary root canal infections usually belong to the genera Streptococcus, Bacteroides, 
Fusobacterium, Prevotella, Porphyromonas, Treponema, Peptostreptococcus, Eubacterium 
and Actinomyces (Sundqvist 1992; Siqueira et al. 2002). E. faecalis has been also frequently 
isolated from necrotic pulps indicating its possible pathogenic involvement in late stage 
pulpitis (Salah et al. 2008). Ayre and colleagues (Ayre et al. 2018) modelled a mixed species 
ex-vivo pulp infection using S. anginosus and E. faecalis. This study showed that although S. 
anginosus reached log phase more rapidly in the presence of E. faecalis, the mixed species 
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co-cultured with the tooth model did not show more extensive cell death, attachment or 
inflammatory response from the dental pulp than the single species culture. However, a 
higher inflammatory response was shown to be elicited by E. faecalis alone. This was 
proposed by the authors to be due to its higher tendency to attach to the pulp vasculature. 
This finding may support a role for E. faecalis in the pathogenesis of pulpitis. Using molecular 
checkerboard DNA-DNA hybridisation assay, of bacteria isolated from 53 infected teeth 
included in the study of Siqueira’s team, Streptococci (mostly S. anginosus) were identified in 
22.6 % of the samples followed by Actinomyces spp. in 9.4 %, and E. faecalis in 7.5 %. In 
asymptomatic lesions, the most prevalent species were S. intermedius (11.5 % of the cases), E. 
faecalis (11.5 %), and S. anginosus (7.7 %). S. constellatus was the most prevalent species in 
pus samples (25.9 % of the cases). Other species isolated frequently from abscessed teeth 
were A. gerencseriae (14.8 %), S. gordonii (11.1 %), S. intermedius (11.1 %), A. israelii (7.4 %), 
S. anginosus (7.4 %), and S. sanguis (7.4 %). Interestingly, S. constellatus was the only species 
positively associated with acute peri-radicular abscess (Siqueira et al. 2002). 
A polymicrobial microbiota  has been reported  in cases of necrotic pulpal tissues (Siqueira et 
al. 2005) with species of Gram-negative anaerobes often isolated (Isabela N. Rôças et al. 
2004). If the necrotic pulp remains in situ with no intervention, then the infection can proceed 
deeply into the periapical tissue causing apical periodontitis which may lead to the more 
serious condition of abscess or granuloma formation. The microbiology of apical periodontitis 
is usually complex and strict anaerobes are often predominant. It has been shown that the 
most prevalent taxa in the apical root canal system are Olsenella uli, Prevotella baroniae, 
Porphyromonas endodontalis, Fusobacterium nucleatum, Tannerella forsythia (Siqueira and 
Rôças 2009; Rôças et al. 2010). Species of streptococci were also identified in cases of apical 
periodontitis such as the viridans group streptococci and S. anginosus group (Rôças et al. 
2010; Shweta and Prakash 2013). A systematic review correlating E. faecalis incidence in 
primary and persistence intraradicular infection has revealed that E. faecalis is more highly 
correlated with persistent intraradicular infections compared with untreated chronic 
periapical periodontitis (Zhang et al. 2015).  
The commensal SAG has been recognised as an early coloniser involved in the initiation of 
pulpitis and in periapical abscesses. E. faecalis has also been found to correlate with 
persistence endodontic infections and to play a role in the pathogenesis of pulpitis. Therefore 
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it would be worthwhile to have a clear understanding of their prevalence and pathogenicity 
which would help treatment and/or prevention of such infections.   
1.4.3 Streptococcus anginosus Group (SAG)  
The Streptococcus anginosus group (previously known as the S. milleri group) is a subclass of 
viridans streptococci that comprises three separate streptococcal species: S. anginosus, S. 
intermedius, and S. constellatus. These bacteria are Gram positive, facultative anaerobes that 
exhibit variable haemolysis patterns (alpha, beta, or gamma) on sheep blood agar and 
enhanced growth when grown in the presence of CO2. They are part of the normal microbiota 
of human oral and gastrointestinal tract but have a propensity for establishing abscesses and 
systemic infection.  However, their precise mechanisms of virulence are not yet fully clarified, 
taking into account the differences in intrinsic pathogenic factors among the individual 
species of the group.  It has been illustrated that SAG, particularly S. intermedius and S. 
constellatus have the ability to produce many enzymes such as hyaluronidase and  
chondroitin sulphate depolymerase (Homer et al. 1993; Jacobs et al. 1995). Bacterial-
hyaluronidase catalyses host tissues hydrolysis of hyaluronic acid which in turn increases the 
permeability of the tissue enhancing the bacterial invasion. Amongst the viridans 
streptococci, S. intermedius has been shown to synthesize the broadest range of glycoprotein- 
and glycosoaminoglycan-degrading enzymes (Homer et al. 1993). In the context of pulpal 
infection, the production of these enzymes may contribute to the virulence and pathogenicity 
of SAG as the pulp tissue is rich in substrates for these enzymes. It has been found that 16 out 
of 45 clinical samples taken from patients with periodontal abscess were positive for SAG 
mainly S. anginosus (Fisher and Russell 1993). This has been supported by another study’s 
finding which reported that, among dental plaque pathogens that were used as an inoculum 
for the formation of periapical abscess, SAG was the most frequently detected organism and 
the most prevalent in abscess lesions despite their low number in plaque (Okayama et al. 
2005). These studies further highlight the importance of SAG in pulp infection especially if 
accompanied by other pyogenic bacteria such as Prevotella intermedia and Porphyromonas 
endodontalis where the likelihood to develop abscess and granuloma become significant 
(Trowbridge and Stevens 1992; Shinzato and Saito 1994; Young et al. 1996; Nagashima et al. 
1999). Binding to fibronectin via the expression of cell surface adhesions by SAG members 
may contribute to their pathogenicity and some are able to bind to platelet-fibrin (Willcox 
16 
 
and Knox 1990; Kitada et al. 1997). A study has examined the adherence of SAGs to the matrix 
proteoglycans decorin and biglycan of soft gingival and alveolar bone. Of the SAGs members, 
S. constellatus showed the highest adherence followed by S. intermedius and the interaction 
is mediated by the conjugated glycosaminoglycan chain (Landrygan-Bakri et al. 2012). It has 
been shown that S. constellatus can resist phagocytosis in a murine model for pulmonary 
infections which has been proposed to be due to a polysaccharide capsule (Toyoda et al. 
1995). Toxin production has been reported for SAG including the potential virulence factor  
intermedilysin, a cytolytic toxin of S. intermedius (Nagamune et al. 2000). Biofilm formation 
is considered to be relevant to  virulence, and SAG biofilm formation potential has been 
studied and it has been documented that S. constellatus and S. intermedius have the capacity 
to form biofilm on abiotic materials which may contribute to their pathogenicity (Yamanaka 
et al. 2013). 
1.4.4 Enterococcus faecalis 
Enterococci are Gram positive facultative anaerobes with the ability to grow in the presence 
or absence of oxygen. Although enterococci are regarded as normal constituent of the human 
gastrointestinal microbiota, the bacteria have been associated with many infections of the 
urinary tract, surgical wounds, endocarditis and bacteraemia and chronic periapical 
periodontitis. They can survive in very harsh environmental conditions and can avoid 
antimicrobial challenges. Enterococcus species can grow at temperatures ranging from 10 °C 
to 45 °C, at extreme alkaline pH up to 9.6 and extreme salinity of 6.5 % NaCl. These may 
contribute to its ability to survive in the harsh environment of the root canal, especially filled 
ones, where there are nutritional deficiencies and limited means to escape the root canal 
medicaments. John et al.  (2015) has described E. faecalis as the “endodontists’ nightmare”  
as it has been identified in 24 % to 90 % of  cases of failed root canals (Rôças et al. 2004; 
Sedgley et al. 2006; Stuart et al. 2006; Zoletti et al. 2006).  
Many E. faecalis virulence factors have been identified and amongst the most extensively 
studied of them are aggregation substance, surface adhesin, sex pheromones, lipoteichoic 
acid, extracellular superoxide, gelatinase, hyaluronidase and cytolysin (hemolysin). 
Aggregation substance (AS), is involved in plasmid transfer and cell adherence and has been 
identified more frequently in pathogenic E. faecalis clinical isolates  than isolates from healthy 
volunteers which emphasised the role of AS in enterococcal infection (Coque et al. 1995; 
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Elsner et al. 2000). Surface adhesins (SA) are also suggested to be involved in the 
pathogenicity of E. faecalis. E. faecalis surface protein (Esp) has been found to associate with 
the primary attachment and biofilm formation of E. faecalis on abiotic surfaces (Toledo-Arana 
et al. 2001). The gene ace has been suggested to involve in the binding of E. faecalis to 
extracellular matrix proteins (Nallapareddy et al. 2000). E. faecalis sex pheromone system has 
been studied and it has been proposed that resistance to antibiotics and other virulence traits, 
like cytolysin production can be passed in strains of E. faecalis by mean of sex pheromone 
system (Clewell and Weaver 1989).  E. faecalis has been shown also to adhere to the root 
canal and dentinal walls forming a highly resistant biofilm (George et al. 2005). The bacteria 
adhere to the mineral part of the dentine probably through the effect of lipoteichoic acid 
(LTA) and to collagen via aggregation substances and surface adhesins which are likely to be 
expressed under stress (Rich et al. 1999) and are significant in initiating the enterococcal 
adherence to dentinal tubule walls (Hubble et al. 2003). Under conditions of nutrient 
limitations, E. faecalis can obtain nutrients from the dentine through the effect of bacterial 
hyaluronidase and other enzymes causing damage to the dentine tissue. 
1.4.5 Pattern of microbial colonisation  
To date, there have been two well characterised states of how bacteria can exist in nature 
and in the infected tissue; planktonic and biofilm form. In the root canal system, bacteria may 
be floating in the fluid phase of the main root canal unattached to any surfaces or can 
preferentially exist as attached aggregates to surfaces, forming matrix-enclosed biofilms 
(Siqueira et al. 2002). Any endodontic treatment strategy, to be successful, must take into 
account the pattern of bacterial existence in the root canal system. Planktonic bacterial cells 
are easier to be eradicated while sessile cells are more difficult and highly resistance to 
antimicrobial therapy.  
1.4.5.1 Steps of biofilm formation  
Biofilm establishment involves consecutive steps starting with initial reversible attachment to 
a biotic or abiotic surface (Sauer 2003). With the subsequent production of extracellular 
polymeric substance (EPS) which composes of DNA, proteins, lipids, and lipopolysaccharides 
of bacterial and host origin, bacterial cells irreversibly and firmly adhere to the surface 
(Okshevsky and Meyer 2015). The adsorbed cells then multiply, growing into microcolonies 
encapsulated in a layer of hydrogel. Finally, mature biofilm is settled with channels or pores 
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traversing the depth of it and free bacterial cells are released into the fluid phase maintaining 
the propagation of renewed communities and infection (Hall-Stoodley et al. 2004).  
 
1.4.5.2 Adaptation mechanisms  
One of the physiological and morphological surviving adaptation of pathogens is to develop 
into a protected community against environmental changes rather than a single individual. 
From this prospective, infected root canals may house microbial communities constituted of 
multiple populations (Mohammadi et al. 2014) which are mostly composed of different 
species  (Socransky and Haffajee 2002; Socransky and Haffajee 2005). In such communities, 
microorganisms have to respond to different nutritional, chemical and oxygen gradients 
probably via new optimised phenotypic properties expressing a large set of genes which are 
proposed to be different from those expressed by the planktonic state of the particular 
species (Li et al. 2000). Emerging evidence has suggested that this gene expression might take 
place in a well-regulated manner (Davey and O’toole 2000; Sauer et al. 2002; Stoodley et al. 
2002) and the so called two-component regulatory system is proposed to be involved which 
includes a histidine kinase and a response regulator (Hoch 2000; Miller and Bassler 2001; 
Scheie and Petersen 2004). To maintain cooperative ecological and functional balance of the 
biofilm realm, each population is suggested to be responsible for  a functional niche (Siqueira 
and Rôças 2009). Bacterial cells are proposed to communicate with each other through the 
release, sensing and reaction to small diffusible signal particles; a mechanism known as 
quorum sensing, which is a  basic chemical form of communication between different cells in 
the biofilm kingdom controlling a wide range of activities like nutrient requirement and 
pathogenicity (Harmsen et al. 2010; Li and Tian 2012).  
The recent interest in such communication pathways has built a strong background for further 
investigation on how to develop anti-biofilm therapy via interfering, in some way, with these 
messaging strategies. For instance, an orthologue of luxS, required for the synthesis of 
autoinducer-2 signal (AI-2) which in turn is involved in interspecies communication, was 
identified and sequenced from S. anginosus. Inactivation of this luxS was found to result in 
isogenic mutant S. anginosus strain of diminished capacity to form biofilm  (Petersen et al. 
2006).   
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1.4.5.3 Mechanisms of antimicrobial resistance of biofilm 
Biofilms may adopt antibiotic resistance mechanism/mechanisms to antagonise the effect of 
antibiotics. One of these proposed mechanisms is through encouraging the growth of certain 
species beneficial to the biofilm realm that are already resistant to the particular antibiotic 
perchance via quorum sensing communication and gene transfer (Svensäter and Bergenholtz 
2004). The association between LuxS gene, which has been shown to be involved in biofilm 
formation, and antibiotic susceptibility was studied (Abdul-Majeed 2008, PhD thesis). It was 
concluded from the study that S. anginosus luxS mutant displayed diminished ability to 
endure several subinhibitory concentrations of ampicillin and erythromycin compared to wild 
type strain.   
The so called ‘persister cells’, slow or non-growing dormant cells, is another offered biofilm 
antibiotic-resistant mechanism as the slow growth rates render the persister cells less 
sensitive to antibiotic treatment therefore they can survive and act as reservoirs providing 
cells that regrow causing relapsing chronic infection (Mah 2012) 
The availability of nutrients also affects the biofilm’s susceptibility to antibiotics. This has been 
supported by the finding that nutrient-limited biofilm of P. aeruginosa became highly 
antibiotic tolerant (Nguyen et al. 2011). Some chemical changes that occur in the biofilm such 
as oxygen depletion and acidic wastes accumulation have been reported to antagonise the 
effect of antibiotics (Athanassiadis et al. 2007).   
1.5 Current treatment options of dental pulpitis 
Worldwide, the age‐standardised prevalence of untreated dentine carious lesions in the 
primary dentition in the global population has remained static over two decades (1990-2010) 
at about 9 % while the prevalence of untreated caries in the permanent dentition was 35 %.  
This means caries continued to be the most prevalent health condition across the globe in 
2010, affecting around 2.4 billion people (Kassebaum et al. 2015). Uncontrolled caries leads 
to pulpitis which is considered as one of the most frequent causes for patients seeking 
emergency dental care (Keenan et al. 2005). Clinically, patients with pulpitis are presented to 
the clinic with increased sensitivity in the tooth, discomfort or pain. Treatment depends on 
the severity of the condition, which has two clinical classiﬁcations: reversible or irreversible 
pulpitis. Many factors play a role in the diagnosis of pulpitis including history and mode of the 
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pain, sensitivity of the affected tooth to different stimuli such hot and cold, tapping 
(percussion test) and electrical current pulp test (Mejàre et al. 2012). However, asymptomatic 
pulpitis can also occur especially in the elderly (Farac et al. 2012). In irreversible pulpitis, the 
damage is more severe and management must include removal of all the necrotic pulp in 
order to prevent further spread of infection into the periapical tissue. For reversibly infected 
pulp, vital pulp therapy can be considered. 
1.5.1 Vital pulp therapy (VPT) 
Vital pulp therapy is a procedure that aims to preserve and maintain pulp tissue that has been 
affected but not completely destroyed by deep caries, trauma or fault restorative procedures. 
The tissue must be vital and not necrotic because VPT is based on the regenerative potential 
of the dentine-pulp complex to promote pulp tissue healing and facilitate the formation of 
the reparative dentine (Aguilar and Linsuwanont 2011). It does involve the removal of the 
offending irritants and placement of a protective material either directly or indirectly over the 
exposed pulp (Hargreaves and Berman 2015). Importantly, a tight-sealed restoration must be 
overlaid on to decrease bacterial leakage from the restoration-dentine interface. The ultimate 
goal of this technique is to promote root development and apical closure in addition to the 
protective resistance to mastication forces compared with a root-canal-filled tooth  (Ward 
2002; Bergenholtz and Spångberg 2004; Dammaschke et al. 2010; Aguilar and Linsuwanont 
2011; Cohenca et al. 2013). Survival rates of teeth treated endodontically have been reported 
to be lower than those of as vital teeth particularly in molars therefore, every effort should 
be done to preserve a vital tooth (Caplan et al. 2005). The decision about whether to 
undertake VPT to an affected pulp is difficult. This depends on the clinical status of the pulp 
tissue which is in turn difficult to predict. The traditional school of thought is that VPT should 
only be performed in teeth with signs and symptoms of reversible pulpitis (Al-Hiyasat et al. 
2006). However, it is not easy nor precise to predict the severity of the inflammation of the 
pulp by clinical assessment based on sign and symptoms presented by the patients or through 
electric, thermal or radiographic assessment. Clinical diagnosis have been evidenced to 
contradict histology figures on occasions  (Mejàre et al. 2012). Moreover, successful 
treatment outcome has been reported in vital teeth with signs and symptoms of irreversible 
pulpitis and periapical lesions (Mejare and Cvek 1993; Matsuo et al. 1996; Teixeira et al. 2001; 
Asgary et al. 2015).  It has been recommended that VPT should be performed only in young 
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patients because of the high healing capacity of pulp tissue (Cvek 1978; Ward 2002). However 
preservation of the pulpally involved permanent tooth should also be considered in older 
people (Aguilar and Linsuwanont 2011). Therefore, it would be worth considering VPT before 
embarking on the more invasive and destructive root canal therapy.  
The differing methodologies followed in the different studies might give rise to difficulties in 
comparing treatment outcomes. However, most studies have noticed a favourable treatment 
outcome, which seems to be inconsistent with the clinical viewpoint that the VPT outcome is 
uncertain (Dammaschke et al. 2010). Many factors should be considered to achieve the best 
therapeutic result of VPT including an accurate diagnosis of the pulp status, skilful cleaning of 
the carious lesion, appropriate sealing to prevent microbial leakage in addition to the use of 
aseptic technique during the procedure (Stanley 1989; Nair et al. 2009; Ali et al. 2012). 
1.5.1.1 Indirect pulp capping 
Indirect pulp capping (IPC) is the procedure that can be performed as an attempt to preserve 
a carious dentine to avoid pulp exposure (American Academy of Pediatric Dentistry 2016). A 
high survival rate (> 90 %) has been reported for permanent teeth treated with IPC with 
clinical and radiographic signs of healing (Tziafas 2004; Maltz et al. 2007). The bioactive lining 
material should be able to stimulate the odontoblast cells to form reactionary and reparative 
dentine thus promote remineralisation of the exiting dentine and therefore encouraging the 
dentine-pulp complex (Hilton 2009).   
IPC can be performed by either of two approaches: the incomplete caries removal with no re-
entry -where the residual caries is sealed into the cavity with no further intervention- and the 
stepwise or two-step excavation approach-where the caries is removed over two stages with 
a gap of few months in between to allow for the formation of the reparative dentine before 
complete caries removal. Although the evidence is not satisfactory, it has been shown that 
there is no difference in the outcome of either the complete or incomplete caries removal 
(Ricketts et al. 2009). However, other systematic review concluded a better outcome with 
incomplete caries removal in comparison to the stepwise caries removal (Thompson et al. 
2008; Schwendicke et al. 2013). This provides evidence that the restoration can tight-seal the 
lesion from the oral environment effectively and subsequently depriving bacteria of nutrients.  
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1.5.1.2 Direct pulp capping  
Direct pulp capping (DPC) is defined as the treatment of vital pulp exposed due to mechanical 
or traumatic insult by sealing the pulpal wound with a biomaterial placed directly on exposed 
pulp. This material is supposed to facilitate formation of reparative dentine and maintain and 
protect a vital pulp (American Association of Endodontists guideline, 2003). The progenitor 
/stem cells in the underlying uninfected vital pulp is stimulated by the initiated inflammatory 
response from the damaged odontoblasts to produce reparative dentine (Tziafas 2004). 
Growth factors such as TGF family of cytokines released from the dentine matrix can induce 
stem cells differentiation. A lower success rate is seen to be associated with carious-
associated exposed dentine indicating a possible important role of the microorganisms in the 
outcome of DPC (Barthel et al. 2000; Al-Hiyasat et al. 2006; Dammaschke et al. 2010). It is 
therefore recommended that a microbial-tight restoration should be placed immediately on 
the exposed cavity besides following other aseptic techniques. 
A clinical study of DPC performed on 44 teeth with carious-exposed pulp demonstrated a 
success rate of 81.8 %. The study declared no association between patients’ age, sex, 
presence of spontaneous pain and size of exposure on the outcome. However, the extent of 
bleeding was recorded as an influential factor on the pulp tissue healing (Matsuo et al. 1996). 
Although still not clinically approved, Miniature pulpotomy procedure (MPP) has been 
proposed by Asgary and Ahmadyar (Asgary and Ahmadyar 2012) to improve the treatment 
outcome of DPT. They claimed that removal of infected dentine chips/damaged pulp tissue 
,specially injured odontoblast cells, would improve proximity/interaction of pulp covering 
agents to undifferentiated mesenchymal/stem cells and offer better control of bleeding and 
creating an improved seal using pulp covering agents.  
1.5.1.3 Pulpotomy 
Pulpotomy can be partial or full, in either case the inflamed tissue beneath pulp exposure is 
removed and a bioactive material is placed over the remaining pulp to allow for healing and 
reparative dentine formation (American Association of Endodontists guideline, 2003). In 
partial or Cvek pulpotomy, the inflamed tissue is removed to the level of healthy coronal pulp 
tissue. In full or complete pulpotomy, a surgical removal of the entire coronal portion of the 
vital pulp is performed to preserve the vitality of the remaining radicular portion. This 
procedure is followed when there is inflammation of the coronal part of the pulp. The 
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homeostasis should be achieved and a biomaterial should be placed on the remaining pulp 
tissue. A success rate of 93-96 % has been reported for partial pulpotomy (Nosrat and Nosrat 
2002; Kiatwateeratana et al. 2009). A recent study compared IPC and pulpotomy of 80 
primary molars, follow-up evaluation revealed 100% clinical success in teeth treated with 
mineral trioxide aggregate (MTA) pulpotomy and IPC. One radiographic failure of internal 
resorption detected at 3 months with MTA pulpotomy which was not statistically significant. 
This study findings may redirect the vital pulp therapy modalities towards IPC which offers 
several advantages over pulpotomy like less potential side effects, non-invasive, reduced 
chair time, child cooperation and cost-effectiveness. However, the cases were followed for 3 
months which is not enough to make a conclusive statement (Vidya et al. 2015). A high 
pulpotomy success rate between 96-100 % was recently reported on ferric sulphate and 
biodentine-treated primary molars respectively followed for 9 months (Sirohi et al. 2017). It 
has been shown that success rate is not influenced by the age and maturation of the root 
apex nor the restoration material used in pulpotomy (Alqaderi et al. 2016). In case of necrotic 
pulp, root canal therapy must be initiated. The whole affected pulp should be removed, the 
root canal system disinfected, the canals filled with inert fillers and then sealed properly to 
prevent microleakage.  
1.5.2 Agents used in vital pulp therapy 
The success of the pulp capping procedure greatly depends upon the circumstances under 
which it is performed and the prognosis depends upon the age, type, site and size of pulp 
exposure. In addition to this the pulp capping material should have the following ideal 
properties like: (Qureshi et al. 2014)  
 Stimulate reparative dentine formation 
 Maintain pulpal vitality 
 Release fluoride to prevent secondary caries 
 Bactericidal or bacteriostatic 
 Adhere to dentine 
 Adhere to restorative material 
 Resist forces during restoration placement and during the life of restoration 
 Sterile 
24 
 
 Radiopaque 
 Provide bacterial seal 
 
1.5.2.1 Calcium hydroxide  
Calcium hydroxide is considered as a major player in the development of VPT and has been 
considered as the gold standard for direct pulp capping materials for decades (Dammaschke 
et al. 2010). It can irritate pulp tissue cells thus stimulating pulp defense and repair (Cox et al. 
1996). It also shows the potential to extract growth factors from the dentine matrix which 
helps in dentine regeneration (Graham et al. 2006). The alkaline nature of this compound (> 
pH 12) has antimicrobial activity which add a benefit in treating carious lesions (Cox et al. 
1996; Barthel et al. 2003). Despite the long history, variable long term outcomes have been 
reported with the use of calcium hydroxide (Barthel et al. 2000; Robertson et al. 2001; Auschill 
et al. 2003). In a review of 14 clinical studies, including over 2,300 cases of calcium hydroxide 
pulp capping, a success rate of > 90 % was reported when pulp therapy performed by 
experienced clinicians (Dammaschke et al. 2010). However, a lower success rate was also 
reported. For instance, in one study, DPC with calcium hydroxide revealed a success rate of 
61 % (219 teeth out of 359 teeth) with a trend of decreasing success by age (Auschill et al. 
2003). Success rate of calcium hydroxide in primary molars was 79.9 % for teeth restored with 
a stainless steel crown and 60 % for those restored with amalgam followed for 1 year (Sonmez 
and Duruturk 2010). The low success rates reported might be due to the disadvantages held 
by the material. The high solubility of the self-cure formulation makes the pulp capping 
material subjective to dissolution over time (Prosser et al. 1982). However, a dentine bridging 
has been found to be initiated by the time calcium hydroxide dissolute (de Lourdes Rodrigues 
Accorinte et al. 2006). Moreover, calcium hydroxide lacks adhesive qualities and therefore 
provides a poor seal (Ferracane 2001). The presence of so-called “tunnel defects” in 
reparative dentine formed underneath calcium hydroxide pulp caps is an added criticism to 
the use of this material (Cox et al. 1995; Kitasako et al. 2008), though this happens only 
occasionally (de Lourdes Rodrigues Accorinte et al. 2006)(Silva et al. 2006). The formed 
tunnels and pores can provide a pathway for microbial leakage.  
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1.5.2.2 Mineral Trioxide Aggregate (MTA) 
Mineral Trioxide Aggregate has gained considerable attention as a direct pulp capping agent 
in recent years. It is basically composed of calcium oxide in the form of tricalcium silicate, 
dicalcium silicate and tricalcium aluminate. Bismuth oxide is added for radiopacity (Camilleri 
2008). Upon MTA reaction with water, calcium hydroxide is produced (Camilleri and Pitt Ford 
2006; Camilleri 2008) which gives rise to the MTA’s biocompatibility (Camilleri et al. 2005). 
Therefore MTA shares most of its properties with calcium hydroxides except that that MTA 
provides some seal to tooth structure (Ferk Luketić et al. 2008). As with calcium hydroxide, 
MTA has some disadvantages like high solubility, demonstrating 24 % loss after 78 days of 
storage in water (Fridland and Rosado 2003). Although it is aesthetically acceptable, the 
presence of iron in the MTA formulation may darken the tooth (Aeinehchi et al. 2003). A 
potential drawback for the use of MTA is its prolonged setting time (between 2 - 45 min) 
(Torabinejad et al. 1995; Islam et al. 2006) which requires the capping to be done in a two-
step procedure or using a quick-setting liner to protect the MTA. MTA is also difficult to handle 
and offers low cost-effectiveness when compared to calcium hydroxide.  
As a direct pulp capping material in carious-exposed pulp of primary teeth, MTA was found 
to be as successful as calcium hydroxide in cases followed for 24 months (Tuna and Ölmez 
2008). A similar finding was obtained in partial pulpotomy of permanent molars with deep 
caries where MTA showed clinical success rate comparable to calcium hydroxide with an 
average of 34.8 ± 4.4 months (Qudeimat et al. 2007). In mechanically exposed pulp, an equal 
effectiveness of MTA and calcium hydroxide was reported for 2-months followed permanent 
premolars (Accorinte et al. 2008). While another two studies conducted on mechanically 
exposed pulp revealed a superiority of MTA over calcium hydroxide (Chacko and Kurikose 
2006; Nair et al. 2009). A recent systematic review and meta-analysis aimed to compare the 
effect of MTA and calcium hydroxide for direct pulp capping suggested that MTA was superior 
to calcium hydroxide in direct pulp capping resulting in a lower failure rate (Zhu et al. 2015).  
1.5.2.3 Adhesive resins 
Self-etching adhesive systems have been provided as pulp capping materials. Reported 
outcomes were poor including the induction of unresolved inflammatory reaction and low 
grade pulp repair (Prager 1994; Accorinte et al. 2008; Cui et al. 2009). This might be due to 
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their vasorelaxant effect (Maddux et al. 2002) promoting bleeding which in turn may 
compromise the adhesive polymerisation and result in an increase in their cytotoxicity. It has 
therefore been suggested that the adhesive resins are unacceptable as pulp capping agents 
(Ghoddusi et al. 2014).  
1.6 Future advances in the materials and biological sciences 
The use of biomaterials has been extended recently to offer a therapeutic application in 
endodontics. Growth factors such as bone morphogenic proteins and TGF-beta have been 
reported to be involved in the mechanism of reparative dentine formation (Tziafas et al. 
2000). Recombinant human BMP-2, -4, and -7 are currently commercially available for 
experimental use and clinical trials. Other biomaterials such as bioceramic, biodentine, 
Emdogain (STRAUMANN, USA), propolis, tricalcium phosphate cement, and some other 
bioactive materials and even stem cells have also been suggested for VPT (Nakamura et al. 
2002; Min et al. 2009; Guven et al. 2011; Hirschman et al. 2012; Nowicka et al. 2013). They 
have shown to induce pulp tissue to produce tertiary dentine either through direct or indirect 
contact. The effect on dentine thickness has been shown to be dose-dependent (Ranly and 
Garcia-Godoy 2000). Despite the apparent promising results that can be obtained, further 
evaluation of the use of these materials as new strategies for VPT is required.   
Against all these data, it seems that VPT still needs further development of agents that 
combine properties of efficient dressing with growth factors in an easily handled carrier with 
advanced antimicrobial and anti-inflammatory properties delivered to the clinic with 
reasonable price (Ranly and Garcia-Godoy 2000; Fuks 2008). Bacterial biosurfactants, 
preferably of probiotic origins, can be one option.  
1.7 Probiotics 
As living microorganisms, probiotics are capable of producing many by-products such as 
organic acids, bacteriocin and biosurfactants, with broad different activities such as 
antimicrobial, antiadhesive and immune-modulatory effects and these have started to be 
used in industry and medicine.    
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1.7.1 What are probiotics? 
As a word, probiotic is derived from Latin word “pro”-for and Greek word “biotic”- life. The 
international definition of probiotics, which has been approved by the United Nations Food 
and Agriculture Organization (FAO) and the World Health Organization (WHO), is that 
“probiotics are live microorganisms which when administered in sufficient quantity confer a 
health benefit on the host”. The key points of this definition are that the microbes must be 
alive when introduced to the host by any means, and they must have evaluated health 
advantages in the host (Hamilton-Miller et al. 2003). Before their existence by modern 
science, the use of live microorganisms in food has a long history.  
The first observation of using bacteria for health benefits was documented by Eli Metchnikoff, 
the Nobel Prize winner for his pioneering discovery in the field of probiotics (McCann 2004). 
He had observed that Bulgarian peasants consuming diet high in fermented milk had a 
reduced incidence of enteric illnesses and lived longer. Their fermented food and intestines 
were found to contain bacterial strains including Lactobacillus bulgaricus. This successful 
treatment resulted in the development of different health resorts in Europe in the early 
1900s. Lilley and Stillwell in 1965 were the first who proposed the term “probiotic” as 
opposed to “antibiotic”, while Lactobacillus acidophilus was the first probiotic species 
introduced by Hull et al. in 1984 followed by Bifidobacterium bifidum by Holcombh et al. in 
1991 (cited in Gupta 2011).  
Probiotics can be subcategorised as probiotic drugs which are proposed to treat or prevent 
disease, probiotic foods including foods, food ingredients and dietary supplements, direct-fed 
microorganisms (probiotics for animal use) and genetically modified ones which are the 
designer probiotics (Sanders 2009). The majority of probiotics derive from the Lactobacillus 
or Bifidobacterium genera, followed by Saccharomyces Boulardii (a yeast) and less commonly 
used are strains of Escherichia coli or Bacillus coagulans. Virus is the category of microbe 
which is typically not regarded to be a probiotics and using them as live vaccines is considered 
to be outside the realm of probiotics (Sanders 2009). In 1994, as commonly prescribed 
antibiotics were becoming of less value because of bacterial resistance, the WHO considered 
probiotics to be the next most important immune defence mechanism (Gupta 2011).  This 
new thought has fed research for studying the possible application of probiotics in medicine 
and dentistry.  
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1.7.2 Criteria for selecting probiotics 
In 2002, a joint report by the FAO and WHO outlined a number of certain selection criteria 
and intrinsic physio-chemical properties for bacteria to be considered as probiotics (WHO 
2002).  The minimum requirements needed for probiotic status include: 
1. The assessment of strain identity (genus, species, strain level); from the current 
available evidence, it has been suggested that probiotics effects are strain specific. It 
is important to link a strain to a specific health effect as well as to enable surveillance 
and epidemiological studies. 
2. Screen potential probiotic strains in vitro: it is recommended that in vitro tests should 
be done before any subsequent animal or human in-vivo assessment. These in vitro 
tests performed on probiotics include: resistance to gastric acidity, bile acid and 
digestive enzymes, antimicrobial activity against potentially pathogenic bacteria, 
adherence ability to mucus and/or human epithelial cells, bile salt hydrolase activity, 
surface anti-adherence activity against pathogens and resistance to spermicides 
(applicable to probiotics for vaginal use). 
3. Safety assessment: requirements for proof that a probiotic strain is safe and without 
contamination in its delivery form. As a group, probiotics are generally regarded as 
safe (GRAS) organisms. However, four kinds of side effects are theoretically probiotics 
may be responsible for (Marteau 2001) which are systemic infections, harmful 
metabolic effects, undue immune stimulation in prone individuals and gene transfer.  
The required safety assessment includes the determination of antibiotic resistance 
profiles, estimation of certain metabolic activities such as D-lactate formation and bile 
salt deconjugation which is unwanted action in the small intestine, determination of 
side effects in human trial, post market epidemiological surveillance of adverse effects 
in consumers, haemolytic activity and toxin production. It is recommended that 
animal trials must be undertaken before starting human ones. Very few studies 
reported the possibility of systemic probiotic infections  (Oggioni et al. 1998,  Mackay 
et al. 1999, Rautio et al. 1999). However, in these rare examples all patients had 
serious underlying medical conditions.  
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4. In-vivo studies for substantiation of health effects in the target host. The efficacy 
outcome of studies on probiotics should be proven beneficial in human trial such as 
statistical and biological significant improvement in disorder, signs and symptoms, 
quality of life; reduction in incidence and prevalence of disease or rapid onset of relief. 
Physiological and technological strength are required for potential probiotic strains, 
and many of the clinically promising probiotics are unfortunately rendered unused 
because they are physiologically and technologically fragile (Mattila-Sandholm et al. 
2002) 
1.7.3 Mechanism of probiotics action 
The mechanisms underlying the beneficial effects of probiotics are largely unknown but are 
likely to be multifactorial (Figure 1.2). Different probiotic strains may use different 
mechanisms for their action and some might have multiple activities and can influence 
different stages that are considered their action targets (Sherman et al. 2010). The proposed 
mechanisms of probiotic action could be parallel to those assumed for the gut as below 
(Bermudez-Brito et al. 2012):  
1.7.3.1 Enhancement of the epithelial barrier 
Intestinal barrier is considered a major defence mechanism used for maintaining epithelial 
integrity. When this barrier function no longer exists, foreign antigens from bacterial or 
dietary origins can gain access to the submucosal layers and induce inflammatory reactions 
which may cause intestinal disorders, for example inflammatory bowel disease (Hooper et al. 
2001; Hooper et al. 2003; Sartor 2006). It has been found that the consumption of non-
pathogenic bacteria such as probiotics might contribute to intestinal barrier function but the 
precise mechanism by which probiotics boost intestinal barrier function is not precisely 
known. 
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Anderson et al. (2010) found that one possible probiotics mechanism was the enhanced 
expression of genes involved in tight junction signalling. In another study conducted to 
investigate the influence of certain probiotic species in T84 cell epithelial barrier model 
(Hummel et al. 2012), these probiotic strains were found to modulate many genes coding 
adherence junction proteins beside enhancing the phosphorylation of adherence junction 
proteins therefore positively controlling these barrier functionality.  
It was proposed that using probiotics may contribute to the strengthening of the epithelial 
Figure 1.2 Major proposed mechanisms of action of probiotics. Cited from (Bermudez-
Brito et al. 2012). 
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barrier by inhibition of cytokine-induced epithelial destruction which is a feature of 
inflammatory bowel disease. In two pieces of research conducted by Yan and his colleagues 
(Yan and Polk 2002; Yan et al. 2007) on Lactobacillus rhamnosus GG (LGG), two novel peptides 
known as p40 and p75 secreted by LGG were isolated and purified and shown to supress 
cytokine-induced cell apoptosis in two different intestinal epithelial cell models. Each of these 
purified protein preparations activated the anti-apoptotic Akt/protein kinase B, inhibited 
cytokine-induced epithelial cell apoptosis, and promoted cell growth in human and mouse 
colon epithelial cells and cultured mouse colon explants. TNF-induced colon epithelial 
damage was significantly reduced by p75 and p40. Immunodepletion of p75 and p40 from 
LGG-CM reversed LGG-CM activation of Akt and its inhibitory effects on cytokine-induced 
apoptosis and loss of intestinal epithelial cells. In addition, another study carried out by Tao 
and his co-researchers revealed that LGG secreted low molecular weight peptides which 
induce the expression of cytoprotective heat shock protein in gut epithelial and this may 
contribute to the beneficial effect of LGG as probiotic (Tao et al. 2006).  
Enhancing mucus secretion could be a proposed mechanism by which probiotics exert their 
healthy intestinal effect. Many studies have investigated this property but only in vitro. 
Further studies are required to test the in-vivo adherence of probiotics which is a key 
determinant of altering mucin expression in human intestine (Mattar et al. 2002; Mack et al. 
2003). Lactobacillus acidophilus was shown to increase MUC2 expression in HT29 cells 
independent of attachment (Kim et al. 2008). Since only few studies have been conducted in 
vivo, the results are inconsistent and further in vivo investigation are really needed to 
culminate into a conclusive statement. For instance, in three different studies, it was reported 
that VSL3, which contains some Lactobacillus species, improved the expression of  MUC2 , 
MUC3 and MUC5AC in HT29 cells (Otte and Podolsky 2004), while the same product did not 
demonstrate any effects on mucin expression when given to mice for 14 days (Gaudier et al. 
2005). Conversely but interestingly, VSL3 causes a 60-fold increase in MUC2 expression and a 
growth of mucin secretion when rats were given the same dose for 7 days (Caballero-Franco 
et al. 2007).  
 
1.7.3.2 Increased adhesion to surfaces and anti-adhesive effects  
Adhesion (at least transient) to oral/intestinal mucosa is one of the required elements for 
colonisation and is a key for the interaction between the probiotics and the host tissues. Good 
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adhesion places bacteria and host surfaces (fluids or epithelial tissues) in close contact thus 
assisting more probiotic effects such as immune modulation and pathogens antagonism 
(Juntunen et al. 2001; Perdigon et al. 2002; Hirano et al. 2003). It has been reported that 
several Lactobacillus proteins promoted adhesion to mucous (Van Tassell and Miller 2011). 
For example, surface adhesin displayed by L. acidophilus is assumed to mediate this 
attachment in vitro (Buck et al. 2005). Proteins are mainly involved in adhesion, however 
saccharide moieties and lipoteichoic acids have also been associated (Vélez et al. 2007).  
The probiotic adhesiveness to epithelial cells and the subsequent blocking adherence of 
pathogens is considered as one mechanism of the probiotic to exert their effects on the host. 
This antiadhesive effect could be the result of competitive binding to the same receptors or 
due to enhanced mucin production. It has been found that co-culturing of inHT20-MTX cells 
with L. plantarum 299v or L. rhamnosus GG actually enhanced induction of MUC3 which in 
turn inhibited the adhesion of enteropathogenic E. coli strain E2348/69 (Mack et al. 2003). 
Other mechanisms of antiadhesiveness could be degradation of carbohydrate receptors by 
secreted proteins, formation of established biofilm, production of receptors analogue or 
biosurfactant production (Oelschlaeger 2010).  
Orally, the colonisation ability of 17 different probiotic strains has been tested (Haukioja et 
al. 2006). Lactobacilli demonstrated better adherence to saliva-coated surface, thus they may 
compete for the same binding sites with Fusobacterium nucleatum which explains its reduced 
colonisation property. Accordingly, probiotics may have an effect on biofilm formation and 
on modification of the oral microflora. Moreover, probiotic strains can affect the structure of 
salivary pellicle on hydroxyapatite and by that means inhibit Streptococcus mutans adherence 
in vitro (Haukioja et al. 2006). A significant weakness in these in-vitro studies is their restricted 
ability to reintroduce consistent and reliable environmental conditions. In-vivo studies, using 
simulated biofilm formation to assess adhesion, can provide more reliable results that might 
explain the phenomena taking place.  
 
1.7.3.3 Competitive exclusion of pathogenic microorganisms 
The means by which one microorganism eliminates or lowers the growth of another one are 
variable and could be due to establishment of hostile microenvironment, abolition of 
existence bacterial receptor sites, formation and secretion of antimicrobial products and 
other selective metabolites and competitive exhaustion of essential nutrients (Rolfe 1991). 
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Specific probiotic adhesion to intestinal mucosa may inhibit pathogenic strains from 
colonising the gut (Servin 2004). The competitive effect of probiotics has been studied using 
human mucosal cells as well as in animal models. It was observed that the potent 
adhesiveness of L. rhamnosus to a colon epithelial cell line put forward the possibility that an 
avid interaction between the probiotic bacterium and the host tissue might be modifying 
intra-cellular processes and subsequently inhibiting the internalisation of pathogenic 
enterohemorrhagic E. coli (Hirano et al. 2003). Bacteria can change the surrounding 
environment to be hostile for their opponents such as  the formation and secretion of lactic 
and acetic acid (Schiffrin and Blum 2002). Another more important example is competition 
for iron which is essential for all bacteria apart from lactobacilli which do not require it for 
their natural growth and survival (Weinberg 1997). L. acidophilus and L. delbrueckii are able 
to bind ferric hydroxide at their cell surface, rendering it unavailable to pathogenic 
microorganisms (Elli et al. 2000). Yet, the E. coli strain, Nissle (EcN) is dependent on iron and 
able to efficiently compete with the pathogenic strains for this limited supply because it 
encodes at least seven iron uptake systems (Grozdanov et al. 2004; Große et al. 2006).  
 
1.7.3.4 Production of antimicrobial substances 
Production of substances with antimicrobial activity is one of the proposed mechanisms of 
probiotic actions. These antimicrobials include organic acids, hydrogen peroxide, 
deconjugated bile acids and inhibitory substance like bacteriocins and biosurfactants. Organic 
acids, mainly lactic and acetic acids, have potent antibacterial activity against Gram-positive 
bacteria (Alakomi et al. 2000; De Keersmaecker et al. 2006; Makras et al. 2006). The cidal 
power of these organic acids involves the reduction of intracellular pH and dissipation of the 
membrane potential (Kashket 1987; Ljungh and Wadström 2009). Lactic acid bacteria isolated 
from human oral cavity were observed to have antimicrobial activity against Streptococcus 
mutans and Porphyromonas gingivalis at highly acidic pH (Sookkhee et al. 2001). Hydrogen 
peroxide is considered as a non-specific antimicrobial especially against urogenital infection 
and bacterial vaginitis (Reid 2008; Pithva et al. 2011). Its antibacterial activity is attributed to 
its strong oxidizing effect on the bacterial cell and to the destruction of basic molecular 
structures of cell proteins (Lindgren and Dobrogosz 1990).  
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Bacteriocins are antimicrobial proteinaceous compounds produced by some probiotics and 
can have narrow or broad spectrum activity (Rogelj and Matijašić 1994; Cotter et al. 2005). 
These antimicrobial compounds have received considerable interest owing to their significant 
prospective usage in the food industry as natural preservatives (biopreservatives). The family 
of bacteriocins embraces different peptides and proteins of different sizes, microbial targets 
and mechanism of action and immunity (Garneau et al. 2002). Several mechanisms have been 
proposed for different bacteriocins effects. However, it was found that the majority of 
bacteriocins destroy susceptible bacteria by membrane permeabilization or by interference 
with essential enzymes; for instance, Nisin has been shown to form a complex with the cell 
wall precursor lipid II, in that way hindering cell wall biosynthesis. Afterward the complex 
aggregates and integrates with additional peptides to form a pore in the bacterial membrane 
(Pithva et al. 2011). Orally, bacteriocins have been proposed as one of different collective 
ways of preventing dental caries (Balakrishnan et al. 2000) via competition for the same target 
receptors and subsequent pathogen-attachment inhibition. An inventive therapeutic 
approach should be considered on the basis of the antimicrobial molecules produced by 
probiotics, which could be utilised as a potential foundation of new, antibiotic-like molecules.  
Biosurfactants derived from probiotics have also been shown to exert potential antimicrobial 
activity against a number of pathogenic bacteria and this will be reviewed later on this 
chapter.  
 
1.7.3.5 Antitoxin effects 
Bacterial toxins can be considered as key virulence factors. The antidiarrheal activity of 
probiotics can be attributed to their ability to protect the host against toxins. Two strains of 
Bifidobacterium were demonstrated to inhibit Shiga toxin expression of E. coli (STEC) O157:H7 
in vitro as well as in mice model. High concentration of acetic acid production was thought 
responsible for inhibition of Shiga toxin expression (Asahara et al. 2004). 
1.7.3.6 Modulation of the immune system 
Probiotics, live or dead, or their-derived components can influence host immune system in 
one or another way. Either by direct adhesion of probiotics to host cells or via released-
soluble compounds, a signalling cascade could be triggered leading to immune modulation. 
Grangette et al. (2005) revealed probiotic activity of L. plantarum when a mutant strain with 
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enhanced anti-inflammatory effect was shown to dramatically reduce pro-inflammatory 
cytokine secretion by peripheral mononuclear and monocyte cells of murine colitis model 
which was TLR-2 independent. It has been shown that gut mucosal barrier integrity can also 
be protected by probiotic  against the damaging effects of enteropathogenic E. coli in a TLR-
independent way (Zyrek et al. 2007). This study provided evidence that E. coli Nissle 1917 
(EcN) can induce a principal signaling effect leading to the renewal of a disrupted epithelial 
barrier. This is conveyed via silencing of PKCzeta and the redistribution of ZO-2. The authors 
suggested that these properties may contribute to the reported efficacy in the treatment of 
inflammatory bowel diseases and in part justify the probiotic nature of EcN. Moreover E. coli 
Nissle 1917 (EcN) has been suggested to secrete a factor which suppresses the TNFα-induced 
IL-8 transactivation through mechanisms different from NF-kappaB inhibition when cultured 
with human colonic epithelial cell line HCT15 (Kamada et al. 2008). 
While genomic DNA of pathogenic bacteria induces systemic inflammatory effects, probiotics 
genomic DNA has been shown to have systemic anti-inflammatory activity (Rachmilewitz et 
al. 2004).  The reason for such differences is unknown. Anti-inflammatory probiotic effects 
can encompass the induction of Treg cells as well. It has been observed that subcutaneously 
administered probiotics exerted anti-inflammatory effects not only in colitis model but in 
arthritis treatment as well (Sheil et al. 2004). An in vitro study which was carried out by Takeda 
et al. (2006) revealed that L. casei Shirota induced IL-12 production which subsequently 
causes an increase in natural killer (NK) cells activity. Although these are examples of strain-
specific activity, the molecular basis and clinical significance are required to be extensively 
investigated especially in vivo.  
 
1.7.4 Colonisation and safety of probiotics in the oral cavity 
Despite their positive intestinal activities, the effects of most intestinal probiotics on the oral 
tissue and microbiota remain insufficiently identified. Some of them are known to have 
positive effects on the oral health. Many in-vitro and in-vivo studies have indicated that the 
probiotics ability to colonise the oral cavity is variable and dependent on the probiotic strains, 
products, and also host (Busscher, Mulder, et al. 1999; Krasse et al. 2005; Haukioja, Yli‐
Knuuttila, et al. 2006; Yli‐Knuuttila et al. 2006; Maukonen et al. 2008).  
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Some probiotic species such as Lactobacillus and Streptococcus appear to be able to inhabit 
the oral cavity of certain people so long as the products containing them are regularly used. 
It has been found that S. salivarius K12 can colonise the oral cavity for a short time after use 
and may have the potential to control oral bacterial infections only when the uptake is 
repeated regularly (Horz et al. 2007). A number of studies have reported that L. rhamnosus 
GG and two other L. reuteri strains can colonise the mouth of 48-100% of the study subjects 
consuming probiotic-containing products (Meurman et al. 1994; Yli‐Knuuttila et al. 2006; Horz 
et al. 2007; Caglar et al. 2009) showing a variable colonising potential. It is assumed that 
probiotic bacteria would colonise the oral cavity only when they were used in products in 
contact with the mouth.  
It has been observed that administration of a mixture of different Lactobacillus strains in 
capsule form causes the salivary Lactobacillus count to rise (Montalto et al. 2004). As long 
term colonisation of probiotics is unlikely, though possible (Yli‐Knuuttila et al. 2006), potential 
adverse effects of probiotics in the oral cavity have not gained much intensive investigations. 
When probiotics are aimed to be used for oral health, the acidogenicity of lactobacilli and 
bifidobacteria cannot be ignored. For example, it has been noted that the probiotic L. 
salivarius strain is capable of inducing caries in an animal model (Matsumoto et al. 2005). 
Screening of probiotics for their effects on oral microbial communities has been 
recommended to allow selection of strains without a risk of oral health hazards. It has been 
observed that L. salivarius W24 has the potential to make a biofilm model more cariogenic 
(Pham et al. 2009). A significant number of studies have tested different activities of 
probiotics in respect of dental caries, periodontal diseases and cases of halitosis and some 
tumor disorders (Haukiojaa 2010; Chatterjee et al. 2011) showing promising results. However, 
most of these studies have been performed for a short time of period and, in some of them, 
the resulted differences were minimal, though significant in term of statistics, to build a 
conclusive statement for their effects. The same applied to dental caries, adding to the 
limitations of small samples size and short duration of follow up, it is of importance to know 
that the salivary level of caries associated microbes does not parallel to dental caries. 
Moreover, the microbiota of the whole saliva has been found to be most comparable to that 
of the dorsal and lateral surfaces of the tongue and microbiota of soft tissues resembles each 
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other more than that on the teeth and gingival margin (Mager et al. 2003). Therefore, no 
decisive declaration of the effect of probiotics on dental caries can be yet made. 
1.8 Biosurfactants 
Bacteria in general and probiotic in particular have the ability to produce a variety of 
molecules for different purposes. Numerous studies have been conducted on the properties 
of bacterial supernatants and their effects on other bacteria (Bermudez-Brito et al. 2013; 
Khodaii et al. 2017; Maslennikova et al. 2017). Surfactants are amphiphilic compounds that 
decrease the surface tension between two immiscible phases, when these substances are 
produced by living microorganisms such as bacteria, yeast and fungi, then they are called 
biosurfactants (Santos et al. 2016). Hence, biosurfactants are molecules of microbial origin 
with hydrophilic (water-soluble) and hydrophobic (oil-soluble) moieties that partition at 
liquid/liquid, liquid/gas or liquid/solid interfaces.  
Biosurfactants have recently been used in a wide range of applications such as industrial, 
bioremediation, food processing, pharmaceutical, medical and oil recovery industries and 
others to be described  as a “multifunctional biomolecules” of the 21st century (Santos et al. 
2016). Compared to synthetic surfactants, biosurfactants have several merits such as 
biodegradability and lower toxicity, better environmental compatibility, higher foaming 
ability, higher selectivity and certain activity under hostile conditions such as extremes of 
temperature, pH and salinity (Shekhar et al. 2015).  
Moreover, certain biosurfactants have been found to cause pores, destabilise biological 
membranes or modulate certain surface enzymes activity which make them candidates as 
antimicrobial, haemolytic, antiviral, antitumor, and insecticide agents. They have also been 
observed to regulate microbial attachment/removal from the surfaces (Vijayakumar and 
Saravanan 2015).  
1.8.1 Biosurfactant producing microorganisms 
Different microorganisms are able to produce tensioactive substances with different 
molecular structures and surface activities (Campos et al. 2013). The interest in the isolation 
of these biosurfactant-producing microorganisms has been increasing recently to get 
biological substances with good surfactant properties such as low critical micelle 
concentration (CMC), low toxicity and high adequate emulsifying potential.  Bacteria of the 
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genera Pseudomonas and Bacillus have been described as great biosurfactant producers (Silva 
et al. 2014).  However, due to their probable pathogenic nature, most bacteria-originated 
biosurfactants are not suitable and predominantly objectionable for use in food industrial 
formulations (Shepherd et al. 1995; Toribio et al. 2010; Saharan et al. 2011). On the other 
hand, nature does contain probiotics derived from microorganisms that generally regarded 
as safe (GRAS) and are recognised to manufacture a variety of biomolecules of different 
activities, including biosurfactants (Merk et al. 2005; Ceresa et al. 2015).  
Many researchers have focussed on the future of the probiotic lactic acid bacteria (LAB) as 
biosurfactant-producers and their significant protagonist in term of health and industry 
(Sharma et al. 2016). For instance, the animal pathogenicity (acute oral toxicity and dermal 
sensitisation) test of novel xylolipid biosurfactant from L. lactis was performed on mice. The 
given doses of the biosurfactant were followed for adverse effect or lethality. No observed or 
measured illnesses or death were reported during the study duration and hence, the tested 
biosurfactant samples were placed in the toxicity category IV (i.e. safe to consume and for 
dermal applications) according to the FDA standards (Saravanakumari and Mani 2010). 
 
1.8.2 Classification of biosurfactants based on the chemical nature 
Biosurfactants are primarily classified based on their chemical structures. The hydrophilic 
moiety is usually amino acid, peptide, mono-, di-, or polysaccharide. The multiple range of 
properties are conferred by the structural orientation of the biosurfactants on the surfaces 
and inter phases which give rise to the surface and interfacial lowering ability and the 
formation of micelles and microemulsion (Chen et al. 2010; Chen et al. 2010a). Surface active 
molecules of microbial origin can be either low molecular weight which can powerfully lower 
the surface and interfacial tension (biosurfactant) or high molecular weight polymers that do 
not reduce the surface tension as much but can stabilise emulsions (bioemulsans or 
bioemulsifier) (Neu 1996 Rosenberg and Ron 1997; Rosenberg 2006). 
1.8.2.1 Low molecular weight compounds 
1.8.2.1.1 Lipopeptides 
Lipopeptides are low molecular weight biosurfactant compounds. Lipopeptides can be 
different in the fatty acid chain and their peptide moiety and are mainly produced by Bacillus 
species (Thavasi et al. 2008; Soberón-Chávez 2010; Thavasi et al. 2011). Lipopeptides have 
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shown potential as antibiotics, antiviral and antitumor agents, immune-modulators or specific 
toxins and enzyme inhibitors.  
Surfactin, a cyclic lipopeptide, is an example of a lipopeptide biosurfactant produced by 
Bacillus subtilis (Ron & Rosenberg, 2001) and is named such because of its exceptional 
surfactant activity (Peypoux et al. 1999). Surfactin has been found to lyse mammalian 
erythrocytes and to form spheroplasts (Bernheimer and Avigad 1970). Many bacterial species 
produce these biologic substances, surfactin and subtilisin are produced by Bacillus subtilis. 
Bacillus licheniformis and Bacillus subtilis synthesise Peptide-lipid and lichenysin (Yakimov et 
al. 1997; Begley et al. 2009), viscosin is synthesised by Pseudomonas fluorescens (Banat et al. 
2010), and gramicidin is synthesised by Bacillus brevis, Brevibacterium brevis (Krauss and 
Chan, 1983) and many others (Shekhar et al. 2015). Propionibacterium freudenreichii subsp. 
freudenreichii, a probiotic type strain, produces a lipopeptide biosurfactant with a wide range 
of antimicrobial and antiadhesive potentials (Hajfarajollah et al. 2014)  
 
1.8.2.1.2 Glycolipids 
Biosurfactants of the glycolipid type are the most common and readily available. These are 
usually mono or disaccharides compounds acylated with long chain or hydroxyl fatty acids 
(Fracchia et al. 2012; Shekhar et al. 2015). Rhamnolipids, mannosylerythritol lipids (MELs), 
sophorolipids and trehalolipids are among the best studied glycolipids subclasses. 
Rhamnolipids biosurfactants are produced mainly by P. aeruginosa and Burkholderia. Mono-
rhamnolipids are composed of one rhamnose sugar moieties and di-rhamnolipids are 
composed of two, these rhamnose moiety are linked to one or two β-hydroxyfatty acid chains 
(Perfumo et al. 2006; Raza et al. 2009). These substances have many potential applications in 
the biomedical field as they display antibacterial, antifungal, antiviral and also antiadhesive 
effects (Remichkova et al. 2008; Sotirova et al. 2008) and have been applied in the 
formulation of nanoparticules (Xie et al. 2006; Palanisamy and Raichur 2009) and 
microemulsions (Xie et al. 2007; Nguyen and Sabatini 2009). Mannosylerythriol lipids (MELs) 
are synthesised by Pseudozyma antarctica and have recently attained interest due to their 
environmental compatibility, structural diversity and important variable applications in the 
biomedical fields. Moreover, they have been utilised in the biotechnological field for gene and 
drug delivery and as skin moisturisers in cosmetics (Arutchelvi and Doble 2011). S. 
thermophilus synthesises glycolipid biosurfactants with reported anti-adhesive activity 
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against several bacterial and yeast strains isolated from voice box prostheses (Busscher et al. 
1997; Busscher et al. 1999; Rodrigues et al. 2004; Rodrigues et al. 2006). Biosurfactants 
produced by the probiotic L. casei MRTL3 and E. faecium have been characterised as glycolipid 
compound (Sharma and Singh Saharan 2014; Sharma et al. 2015). 
 
1.8.2.1.3 Fatty Acids, Phospholipids and Neutral Lipids 
Many yeasts, bacteria and fungi secret large quantities of phospholipids, fatty acids or neutral 
lipids to ease the uptake of the carbon source from the hydrophobic substrates such as 
alkanes (Cirigliano and Carman 1985). The hydrophilic and lipophilic balance (HLB) is directly 
proportional to the length of the hydrocarbon chain in their constructions. Clear 
microemulsions of alkanes in water were formed due to the production of 
phosphatidylethanolamine rich vesicles by Acinetobacter species (Käppeli and Finnerty 1979). 
Interficial tension between hexadecane and water was found to be reduced to less than 1 
mN/m by bile salt synthesised by Myroides species (Desai and Banat 1997) and 
phosphatidylethanolamine synthesised by Rhodococcus erythropolis grown on n-alkane 
(Kretschmer et al. 1982).  
 
1.8.2.1.4 Other biosurfactants  
Viscosinamide, a cyclic depsipeptide produced by P.  fluorescens has been reported by Nielsen 
and his colleagues (Nielsen et al. 1999) to have antifungal and surface active properties. In-
vitro antimicrobial activity against Mycobacterium tuberculosis and Mycobacterium avium-
intracellulare was attributed to two massetolides A–H, which are also cyclic depsipeptides  
isolated from the Pseudomonas spp., obtained from a marine habitat (Gerard et al. 1997). 
Sphingolipid biosurfactants degradation products have been shown to hinder the interaction 
of S. mitis with buccal epithelial cells and of S. aureus with nasal mucosal cells (Bibel et al. 
1992).  
 
1.8.2.2 High molecular weight biosurfactants 
High molecular weight biosurfctants are mainly polymeric and composed of lipoproteins, 
proteins, polysaccharides, lipopolysaccharides or complexes containing several of these 
structural types  (Rosenberg and Ron 1997; Rosenberg and Ron 1999; Ron and Rosenberg 
41 
 
2001). Alasan, liposan, lipomanan, emulsan, and some other polysaccharide–protein 
complexes are among the best studied polymeric biosurfactants. Emulsan has been 
considered as an effective emulsifying agent, even at low concentrations of 0.001 % to 0.01 
%, for hydrocarbons in water (Zosim et al. 1982). Candida lipolytica has been shown to 
synthesise liposan as an extracellular emulsifier and Candida tropicalis produces mannan lipo-
protein (Cirigliano and Carman 1984). L. plantarum has been studied for biosurfactant 
production and characterisation and has been documented to produce glycoprotein 
biosurfactant of antimicrobial activity (Madhu and Prapulla 2014). 
 
1.8.3 Factors affecting biosurfactant production 
There are many factors, beside the producer strain, that should be considered during 
biosurfactant production. These factors may act at the genetic, nutritional and 
physiochemical environment levels and can influence not only the quantity of biosurfactants 
produced but also the type of polymer manufactured  (Hatha et al. 2007; Salihu et al. 2009).  
 
1.8.3.1 Growth conditions  
Growth conditioned media should be optimised for maximum possible gains as the 
production of the biosurfactants may affect by the changes of temperature, pH, and aeration 
or agitation status. The probiotic strain L. lactis CECT-4434 has been shown to produce cell-
bound biosurfactants and bacteriocins when fermentation was carried out under 
uncontrolled pH (Rodríguez et al. 2010) which further emphasises the significance of pH in 
biosurfactants production. Extremophile-derived biosurfactants production has received 
interest recently for their considerable commercial opportunities. Certain biosurfactants, 
such as those produced by Serratia marcescens, are found to be able to maintain their 
properties at high temperature of up to 100 °C, high salt concentration (up to 12 % NaCl) and 
a wide pH range offering interesting and useful properties for many environmental and 
industrial applications. (Anyanwu et al. 2011). The degree of aeration and agitation is also a 
potential element in biosurfactant synthesis as both enable oxygen transfer from the gas 
phase to the aqueous phase. For instance, it has been observed that the optimum production 
level of the surfactant (45.5 g/L) was when the aeration was 1 vvm and the dissolved oxygen 
concentration was maintained at 50 % of saturation (Adamczak and Odzimierz Bednarski 
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2000). When aeration applied to P. aeruginosa LBI in a batch feed culture, the product yield 
increased to 70 % (Maneerat 2005). Wei et al. (2005) noticed increased rhamnolipid 
production up to 80 % when agitation increased from 50 to 250 rpm (Wei et al. 2005). 
Conversely, maximum biosurfactant production of the probiotic L. plantarum CFR occurred 
under stationary conditions (Madhu and Prapulla 2014). Different incubation periods of 
biosurfactant-producer microorganisms also have an effect on the biosurfactant production. 
The impact of incubation time can be assessed by monitoring the values of emulsification 
activity, surface tension, biomass concentration after a regular interval of time. Pseudomonas 
species, for instance, displaced the optimum rhamnolipid production of 5.86 g/L at 72 h 
(Soniyamby et a.l  2011). Other Pseudomonas species, P. fluorescence, maximised yield after 
56 h (Abouseoud et al. 2007).  
 
1.8.3.2 Nutritional factors 
1.8.3.2.1 The effect of carbon source 
Microorganisms have been shown to prefer hydrocarbons substrates over carbohydrates for 
biosurfactants synthesis. When microbes grow at the expense of water immiscible substrates, 
a burst of biosurfactant yield enhances the solubilisation of water insoluble substrates and 
thus assist nutrient passage to the microbes. It has also been observed that when microbes 
grow in media with readily available carbon source, then biosurfactant production is limited, 
and when the available carbon is consumed with the presence of water-immiscible 
hydrocarbon then biosurfactant production is triggered (Banat 1995). Rhamnolipid synthesis 
is regulated by the presence of n-alkane in the medium while other Pseudomonas species 
prefer vegetable oil for higher biosurfactant yield (Kosaric and sukan 2000). Diesel, crude oil, 
glucose, sucrose, glycerol have been reported to be a good source of carbon substrate for 
biosurfactant production (Garima Bhardwaj et al. 2013).  
1.8.3.2.2 The effect of nitrogen source 
Rhamnolipids and sophorose lipids production was enhanced when there is a limitation of the 
nitrogen supply in the media (Reis et al. 2013). However, because nitrogen is essential for cell 
growth and protein and enzyme synthesis, it is considered an important element for 
biosurfactant manufacturing. Different nitrogen compounds have been used for the 
production of biosurfactants including urea peptone, yeast extract, ammonium sulphate, 
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ammonium nitrate, sodium nitrate, meat extract and malt extracts. Nitrate has been reported 
to support supreme surfactant production in P. aeruginosa whereas ammonium salts and 
urea were the preferred nitrogen sources for biosurfactant production by Arthrobacter 
paraffineus (Adamczak and odzimierz Bednarski 2000).  
1.8.4 Biosurfactants in biomedicine and pharmaceutics 
Biosurfactants have been proposed and used in a variety of applications in medicine and 
pharmaceutical formulation. The ability to form pores and destabilise biological membranes 
permit their use as antimicrobial, haemolytic, antiviral, antitumor, and insecticide agents 
(Carrillo et al. 2003; Scott et al. 2007; Ortiz et al. 2009). In addition, they have shown the 
tendency to modulate enzyme activity permitting enhancement of the activity of certain 
enzymes ameliorating microbial process or the inhibition of certain other enzymes permitting 
their use as antifungal agents (Mnif and Ghribi 2015). In addition, biosurfactants may be 
utilised in the field of gene therapy and gene transfection (Liu et al. 2010; Zhang et al. 2010)  
and respiratory failure due to the deficiency of surfactant in premature infants (Muthusamy 
et al. 2008). Biosurfactants displayed ability to aid in the recovery of intracellular products, as 
immunological adjuvants, in the area of tumour management as anticancer agents (Zhao et 
al. 1999) and as agents for the stimulation of skin fibroblast metabolism (Shekhar et al. 2015). 
Despite the wealth of publications concerning the biological activity of biosurfactants, their 
actual clinical application in the field of medicine and pharmaceuticals is still fairly narrow 
(Fracchia et al. 2015). Daptomycin, branched cyclic lipopeptide isolated from Streptomyces 
roseosporus, has been approved and commercially used as antibiotics against skin infection, 
endocarditis and bacteraemia caused by methicillin-resistant Staphylococcus aureus and 
other Gram-positive pathogens (Tally et al. 1999; Robbel and Marahiel 2010). Its mechanism 
of antibiotic activity was supposed to be due to membrane conformational changes and 
membrane pore formation (Scott et al. 2007). 
1.8.4.1 Oral related application 
The reported antimicrobial activity combined with the ability to alter substrate’s surface 
energy and area (Busscher and Van Der Mei 1997; Lígia R. Rodrigues et al. 2006) for several 
biosurfactants would identify them as an effective candidates for oral health use. However, 
application of biosurfactants in oral-related health is still at an early stage. Uncharacterised 
glycoprotein-type biosurfactants derived from L. casei (ATCC39392) (Savabi et al. 2014), L. 
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acidophilus DSM 20079 (Tahmourespour et al. 2011a), L. reuteri (DSM20016) (Salehi et al. 
2014) and L. fermentum ATCC 9338 (Tahmourespour et al. 2011b) have shown to intensely 
knockdown S. mutans gene expression of glucosyltransferase (gtfB and gtfC) and 
fructosyltransferase (ftf) genes. These genes play an important role in S. mutans attachment 
to the tooth surface which is the initial step in biofilm production and in dental caries. Gene 
expression down regulation in response to treatment with the biosurfactant might suggest a 
promising application in prophylaxis of dental caries. A partially characterised lipopeptide 
biosurfactant was extracted form Bacillus tequilensis CH and demonstrated an ability to 
inhibit pathogenic S. mutans biofilm formation on hydrophilic and hydrophobic surfaces at 
50 μg/mL (Pradhan et al. 2013). However, the lack of evidence of complete purity or 
characterisation of the tested biosurfactants should be considered cautiously in interpreting 
these results. Though not directly involved in oral health but closely related, a glycoprotein 
biosurfactant was isolated from the probiotic bacteria L. lactis 53 and S. thermophilus A. 
Fractionation was attained by hydrophobic interaction chromatography which allowed the 
isolation of a fraction rich in glycoproteins. Molecular (by Fourier transform infrared 
spectroscopy) and elemental compositions (by X-ray photoelectron spectroscopy) were also 
determined. Antimicrobial activity was reported for the active fraction of the biosurfactant 
against orally related pathogen S. salivarius GB 24/9. The biosurfactant also demonstrated 
antiadhesive/antibiofilm properties. When artificial model voice prosthesis was 
preconditioned with the biosurfactant, the tested microorganisms showed a lower potential 
to form biofilm (Rodrigues et al. 2004). The finding of this study was considered promising in 
innovating a new strategy of prolonging the lifespan of voice prostheses. Similarly, 
antiadhesive activity was reported for biosurfactants (unidentified chemical structure) from 
Robinia Pseudoacacia (AC5 and AC7) and Nerium oleander (OC5) (Cochis et al. 2012) against 
Candida albicans biofilm on resins and silicon denture materials for dental prosthetic devices.  
Rufino and his team (2011) described the production of the biosurfactant Rufisan from the 
yeast C. lipolytica UCP 0988. This biosurfactant showed efficacy as an antimicrobial and 
antibiofilm agent for a wide spectrum of pathogens, including orally related microorganisms 
such as S. agalactiae, S. mutans, S. mutans NS, S. mutans HG, S. sanguis 12, S. oralis J22 at a 
concentration superior to the biosurfactant critical micelle concentration. Although the 
chemical characterisation of Rufisan has not been provided in this study, the results obtained 
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showed that the biosurfactant from C. lipolytica is a potential antimicrobial and/or anti-
adhesive agent for several biomedical applications (Rufino et al. 2011). Moreover, around 50 
% and 67 % inhibition of fungal Yarrowia lipolytica biofilm formation on in-vitro 96 well plate 
surface and glass surface respectively, was reported when rhamnolipid was used in a pre-
coating experiment. This antibiofilm potential against the opportunistic oral pathogen Y. 
lipolytica is another finding adding to the orally-related biosurfactants benefits which can 
further investigated to clinical application stages (Dusane et al. 2012). In the same framework, 
it has also concluded that the rhamnolipid-like biosurfactant released by the naturally oral 
cavity dwelling S. mitis can significantly discourage adhesion of S. mutans to a glass surface 
(van Hoogmoed et al. 2000). Using atomic force microscopy, the same research group found 
that coating a dental surface with S. mitis biosurfactant resulted in a remarkable increase in 
repulsion when S. mutans bacterial cells came close to the dental surface (van Hoogmoed et 
al. 2006). Emulsan (usually produced by Acinetobacter calcoaceticus) was patented as an 
effective antiplaque agent.  Dispersion of emulsan in water and allowing it to come in contact 
with dental surface was shown to inhibit plaque and reduce caries. It was supposed that 
emulsan inhibited the adhesion of S. mutans through lectin-specific interaction with galactose 
or galactosamine on S. mutans cell surface. This finding suggested a possible emulsan 
containing toothpaste or mouthwash (Eigen et al. 1986), though have not been reviewed 
scientifically. Against these published findings related to biosurfactants effect on oral health, 
it has been clearly demonstrated that the application of biosurfactants in oral-related health 
is still at an early stage and therefore more studies are needed.  
 
1.9 Aims and objectives 
The aim of this thesis was to identify a bacteria-derived material with antimicrobial properties 
demonstrating a potential use in endodontics to control pulpitis and root canal infection. 
Bacteria-derived biosurfactants have been broadly investigated for use in a wide range of 
biomedical applications, however their role in endodontic infection has not been studied yet.  
Therefore, the main focus of this project was to investigate the potential of probiotic-derived 
and commercial rhamnolipid biosurfactants in the control of pulp infection.  
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This was achieved by: 
 
 Investigating probiotic strains for potential antimicrobial effect against SAG and E. 
faecalis  
 
 Determine the presence of and subsequent extracting biosurfactants. 
 
 The physico-chemical characterisation of extracted biosurfactants.  
 
 The proteomic analysis by mass-spectrometry to identify potential proteins of the 
adhesin-like type contributing to adhesion/antiadhesion effect of the biosurfactant.  
 
 Partial purification of the extracted biosurfactant by size-exclusion chromatography.   
 
 Evaluation of the antimicrobial/antiadhesive effects of the extracted and the 
commercial biosurfactants against SAG and E. faecalis using in-vitro standard 
antimicrobial assay and evaluating the effect of biosurfactant-coating in hampering 
bacterial attachment. This was enabled through the development of a method to 
characterise biosurfactants surface-coating.  
 
 Elucidating the cytotoxic and apoptotic effect of the biosurfactants using pulpal 
fibroblasts and ex-vivo tooth sections alongside with quantitatively assessing their 
immunogenic potential on pulp tissue. 
 
 Develop an infective co-culture tooth model to assess the ex-vivo antimicrobial and 
immune-modulatory effect of the biosurfactant.  
 
The objective of this thesis was to introduce biosurfactants for the first time into the 
field of endodontic and vital pulp therapy. This will provide a substantial foundation 
for further investigations and development of biosurfactant-coated/containing 
materials to improve bacterial elimination from the infected pulp and root canal. 
Consequently, infections of the pulp by pathogenic bacteria are less likely to result in 
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the formation of abscesses and their associated complications ensuring a higher 
success rate of vital pulp therapy and endodontic procedure.  
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2 Chapter 2 Assessment of SAG/E. faecalis biofilm forming ability 
and screening of potential probiotics for antimicrobial activity 
against SAG/E. faecalis 
2.1 Introduction  
Dental pulp is a soft tissue enclosed within a hard rigid chamber of dentine. This protective 
environment is essential to keep the pulp sterile in the microbial rich niche of the oral cavity. 
If this secure system is disrupted for any reason, then the pulp will be in contact with 
pathogens directly or indirectly through bacterial toxins diffusing through dentinal tubules. 
Either way, the pulp responds by inflammation which is initially reversible, but which if left 
untreated progresses to  “irreversible pulpitis” and eventually necrosis (Yu and Abbott 2007).  
Pulpitis is a common clinical problem and has been reported as the most frequent  reason  for 
patients seeking emergency dental care (Keenan et al. 2005). In cases of failure to rescue the 
pulp, endodontic or root canal therapy is required. These interventions attempt to eradicate 
bacteria from the tooth, thereby preventing further progression of infection to the deeper 
tissue (Levin et al. 2009). In general, endodontic treatment is a difficult and challenging 
procedure with a success rate ranging from around 65 % to over 90 % depending on clinical 
considerations (Levin et al. 2009) such as the quality of treatment and the clinical stage of 
pulpitis (Mukhaimer et al. 2012). In addition, endodontic procedures are costly and time 
consuming. The prevention of pulp infection and subsequent root canal treatment is 
therefore beneficial (Burke et al. 2009).  
Pulpotomy involves the removal of part of the pulp which is in proximity to the stimuli while 
maintaining the radicular pulp. Pulpotomy procedures in both primary and permanent 
dentitions have variable clinical, radiological and histological success rates (Burke et al. 2009). 
The major challenge of such procedures is preventing further bacterial colonisation of the 
pulp. 
Endogenous oral commensal bacteria have been established as the main causative agents of 
dental infection and pulpitis (Sundqvist 1976). A number of different  microbial species have 
been implicated in endodontic pathology (Featherstone 2000). Members of the Streptococcus 
anginosus group (SAG) and Enterococcus faecalis are frequently isolated species (Molander 
et al. 1998; Pinheiro et al. 2003; Robertson and Smith 2009; Ledezma-Rasillo et al. 2010). 
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Whilst present in only low numbers in dental plaque, it has been proposed that SAG are 
important early in the pathogenic process and may actually initiate infection, thereafter 
preparing the environment for subsequent colonisation by anaerobic species. Interestingly, 
in this context, members of the SAG are often isolated in pure culture from early cases of 
endodontic infection (Ruviére et al. 2007; Robertson and Smith 2009).  
Bacteriotherapy – purposeful use of bacteria or their products for the treatment of illness - 
(Sanders 1984) - has been studied widely as alternatives to the use of antibiotics as a response 
to the emergence of antibiotic resistant pathogens and the slow and expensive path of 
commercialising new antibiotics. Probiotics- living microorganisms that confer health benefit 
to the host- form the cornerstone of bacteriotherapy. The number of probiotic products 
entering the global market is expanding (Sanders et al. 2018). The majority of the probiotic 
health benefits have been associated with gastrointestinal diseases. More recently, 
considerable investigation has focussed on diverse applications of probiotics in other human 
body systems, mainly as antimicrobial for prevention and treatment of respiratory and 
urogenital infections, and as immune-modulatory agents to alleviate allergic inflammatory 
diseases (Della Riccia et al. 2007; De Vrese and Schrezenmeir 2008; Gilad et al. 2011; Yan et 
al. 2011). Probiotics in dental products have been proposed and studied by many. A number 
of studies have demonstrated the effect of probiotics on S. mutans in saliva as a cariogenic 
species (Näse et al. 2001; Ahola et al. 2002; Nikawa et al. 2004; Çaglar et al. 2005; Caglar et 
al. 2006; Caglar et al. 2007; Çaglar et al. 2008; Cildir et al. 2009). These studies provided 
promising results, however, they need to be confirmed in randomised double blind placebo 
studies employing larger sample populations with specific target sites in the oral cavity.   
Although the mechanism of probiotics action is still not fully understood, their activities on 
the oral cavity can be summarised into three main mechanisms: 1- antagonising pathogens, 
2- accumulation with oral microbiome and 3- modulation of the composition and 
consequently reduction of the pathogenicity, cariogenicity and microbial burden of the oral 
biofilm (Samot and Badet 2013; Schwendicke et al. 2014; Taheur et al. 2016). The other 
mechanism of probiotics mode of action involves interactions with the oral host tissue notably 
the epithelium. This interaction could enhance the defending barrier and modulate the 
immune response which can be utilised to competitively exclude pathogenic bacteria from 
their tissue binding site (Anusha et al. 2015; Manning et al. 2016).  
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Bacteriotherapy use in endodontics is still in its infancy. A preliminary study (Bohora and 
Kokate 2017) tested the in-vitro antagonistic efficacy of probiotic products containing species 
of Lactobacillus and Bifidobacterium against E. faecalis and Candida albicans as root canal 
pathogens. Promising antagonism was reported for the probiotics although further 
investigation is essential before confirming the success of application in endodontic therapy.   
The number of probiotics investigated for clinical applications is expanding and broad 
screening may be required to select among the numerous strains. To date, no study has 
looked at the antimicrobial activity of probiotics against SAG as a “pioneer pathogenic 
bacteria” and E. faecalis, and possible application of probiotics or their by-products in pulp 
and root canal therapy. The aim of this chapter was firstly to evaluate the in-vitro biofilm 
forming capacity of the four endodontic pathogens to abiotic surface and secondly to screen 
five probiotic stains for their potential to inhibit the growth of the four clinical isolates. The 
probiotic strain with the maximum inhibitory effect would be selected for further 
investigation on the potential biofilm forming pathogens.  
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2.2 Materials and methods 
2.2.1 Microbial culture conditions   
Table 2.1 summarises the stock microbial isolates and media used in this study.  
2.2.2 Pathogenic strains  
The bacterial species used in this study (Table 2.1) were taken from the culture collection of 
the Oral Microbiology Unit, Cardiff School of Dentistry. These strains had been genotypically 
and phenotypically characterised in previous work (Everett 2018). Bacteria were grown on 
fastidious anaerobe agar (FAA) (Lab M™ International Diagnostic Group pic, Bury, UK) 
supplemented with 5 % (v/v) defibrinated horse blood (TCS Bioscience Ltd., Buckingham, UK). 
Brain-heart infusion (BHI) broth (Oxoid Ltd., Basingstoke, UK) was inoculated from colonies 
on FAA plates to prepare bacterial suspensions. Streptococcus spp. and E. faecalis were 
incubated in a CO2 cabinet (5 % v/v CO2, 20 % v/v H2 , 70 % v/v N2) at 37 °C (Don Whitley 
Scientific Ltd., Shipley, UK). Staphylococcus aureus NCTC8325 and Escherichia coli NCTC10418 
were incubated aerobically at 37 °C (LTE scientific LTD, UK). 
2.2.3 Probiotics  
Lactococcus lactis NCTC8033, Streptococcus thermophilus NCTC10353 and Lactobacillus 
acidophilus NCTC12980 strains were purchased from Public Health England/NCTC and revived 
according to the suppliers’ instructions. Briefly five mL of BHI broth was used to reconstitute 
the dried bacterial powder from the freeze-dried ampoule and after 5 min, a loopful was 
inoculated on to FAA plates and incubated at 37 °C and 5 % CO2 for 24 h. The plates were then 
checked for purity and morphology of the colonies. Lactobacillus plantarum NCIMB8826 and 
Lactobacillus fermentum DSM20055 were kindly provided by the School of 
Biosciences/Cardiff University (Table 2.1).  
2.2.4 Standardisation of inoculum 
Overnight broth cultures of Streptococcus spp., E. faecalis RB17 and the five probiotic strains 
in their appropriate broth (Table 2.1) were adjusted by optical density (OD) measurements 
using a spectrophotometer (254 Colorimeter, Sherwood Scientific, Cambridge, UK). The 
equipment was calibrated at 600 nm to zero (blank) by using sterile un-inoculated broth 
medium. Subsequent sample readings were performed and diluted as necessary with sterile 
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appropriate broth to achieve a final OD (600 nm) of 0.08 – 0.1 which was found, by plating 
and enumeration, equivalent to approximately 1.5 x 108 CFU/mL.  
 
Table 2.1 Stock microbial isolates used and their media 
 
 
 
2.2.5 Bacterial growth curves  
Bacterial suspensions were prepared as previously described (Section 2.2.4) in the 
appropriate broth for each strain (Table 2.1) to an OD600 of 0.08-0.1 (equivalent to 1.5 x 108 
CFU/mL). Suspensions were then diluted 1:10 to give an approximate 1 x 107 CFU/mL. Two 
hundred µL of this bacterial suspension was then added to each well of a 96-well plate 
(SARSTEDT, Germany). Un-inoculated broth was used as a negative control. Plates were 
incubated within the plate reader (FLUOstar Omega, BMG Labtech, Ortenberg, Germany) at 
37 °C, 5 % CO2 for 24 h or 48 h depending on the strain. Growth curves were analysed 
according to Widdel (Widdel 2007) for the length of the lag phase (λ), the maximum growth 
(Amax) and the doubling time (Td) as illustrated in figure 2.1.  
Strains Reference source  Reference ID Agar medium Broth  
Probiotic strains     
Lactococcus lactis subsp lactis NCTC 8033 FAA + BHI 
Streptococcus thermophilus NCTC 10353 M17 M17 
Lactobacillus acidophilus NCTC 12980 MRS MRS 
Lactobacillus fermentum  DSM 20055 MRS MRS 
Lactobacillus plantarum NCIMB 8826 MRS MRS 
Pathogenic strains     
Streptococcus anginosus Dento-alveolar abscess 670/95 FAA + BHI 
Streptococcus constellatus Oral mucosal carcinoma S08-07 FAA + BHI 
Streptococcus intermedius Dento-alveolar abscess HW13 FAA + BHI 
Enterococcus faecalis Faecal sample RB17 FAA + BHI 
Escherichia coli  NCTC 10418 FAA + BHI 
Staphylococcus aureus NCTC 8325 FAA + BHI 
NCTC: National Collection of Type Cultures, DSM: German Collection of Microorganisms and Cell Cultures, 
NCIMB: National Collection of Industrial, Food and Marine Bacteria.  FAA+: fastidious anaerobic agar 
supplemented with 5% defibrinated horse blood, MRS:  de Man, Rogosa, Sharpe, BHI: brain heart infusion. 
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Doubling time was calculated according to the following equation:                                              
                                                                     Td = In2/µ          
 where Td is the doubling time and µ is the specific growth rate.  
To find µ using excel, the log absorbance (600nm) was plotted versus time (h), and a growth 
curve generated. Points were selected on the exponential phase where a straight line could 
be drawn. A best fit equation using exponential trendline was obtained in the formula:  
                                                       
                                                                  Y=A*Exp^ (µ*t) 
 
2.2.6 Biofilm formation 
This assay was performed to investigate the innate adherence and biofilm formation potential 
of the bacterial strains included in this study. Streptococcus spp., E. faecalis isolates and the 
five probiotic strains were investigated individually for adherence and biofilm formation to 
un-conditioned polystyrene well plate (SARSTEDT, Germany).  
Overnight broth cultures of the pathogenic or probiotic strains were diluted in the 
appropriate broth (Table 2.1) to achieve an optical density of 0.08-0.1 at 600 nm. One further 
(λ
) Amax 
Y=A*e^ (µ*t) 
Figure 2.1 Illustration of bacterial growth phases. Parameters obtained from growth curves 
include length of lag phase (λ), maximum growth (Amax) and specific growth rate (µ). The 
latter was obtained from the best fit exponential equation (red dotted line). Adopted and 
modified from Friedrich Widdel (2007). 
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10-fold dilution was performed. The resulting bacterial suspension was pipetted into a 6-well 
plate (1 mL/well). Sterile un-inoculated broth was used as a control. The lid was replaced 
immediately after inoculation to avoid aerial contamination and the plates were incubated at 
37 °C and 5% CO2 for 90 min to allow bacterial cells to attach. After the 90 min incubation, 
medium was replaced with an equal volume of new un-inoculated broth. Plates were 
incubated (37 °C and 5 % CO2) for 24, 48 and 72 h with a change of medium every 24 h to 
remove the loosely or non-adhered bacterial cells and replenish nutrients.  
At 24, 48 and 72 h incubation, the well liquid contents were aspirated gently and the wells 
washed gently twice with sterile phosphate-buffered saline (PBS, 1 mL/well) to remove any 
additional unattached bacteria. Attached bacteria were harvested with a cell scraper (25 cm, 
Sarstedt, USA). Crystal violet was used to stain and microscopically visualise the plate surface 
afterward to confirm maximal detachment of the bacterial cells from the surface. Collected 
bacteria were resuspended in 1mL sterile PBS in 1.5 mL centrifuge tube, vortex mixed for 10 
seconds at 2500 rev/min, and diluted in 10-fold serial dilutions to 10-4 in sterile PBS. Four 10 
μL drops of each dilution (including the original vortex mixed sample as the zero dilution) 
were plated according to Miles and Misra plate method (Miles et al. 1938) onto agar plates 
appropriate for the microorganism (Table 2.1). The inoculated agar plates were incubated at 
5 % CO2 and 37 °C until colonies had grown sufficiently (24-48 h) to allow visual counting of 
individual colonies per drop. The average count of the four drops was calculated, multiplied 
by the dilution factor, and then by 100 to obtain a total recovered cell count.  
2.2.7 Assessing antimicrobial activity of probiotic strains 
2.2.7.1 Cross streak assay 
The method used by Yoshida et al. (2009) was adopted with minor modifications. Probiotic 
suspensions from overnight cultures in the appropriate broth (Table 2.1) were prepared and 
diluted to an OD600 of 0.08-0.1. Thick, full strength (46 g/L FAA agar and 5 % horse blood) and 
half strength (23 g/L FAA agar and 2.5 % defibrinated horse blood) FAA plates were prepared 
with the aim of representing  two possible in-vivo conditions; nutrient rich and nutrient 
limited. The plates were inoculated with the prepared probiotic suspension by placing a single 
streak on the centre of the agar plate (the master streak) using 1 µL sterile microbiology loop 
(NUNCTM, DENMARK). The inoculated plates were then incubated for 1, 3, 5, 7, 9 and 10 days 
at 37 °C and 5 % CO2. Overnight broth of the pathogenic stains was prepared in BHI to an 
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OD600 of 0.08-0.1. These were further diluted to 1:10 in BHI. After each pre-incubation period 
of the streaked plates (1, 3, 5, 7, 9 and 10 days), plates were seeded with the pathogenic 
strains (SAG and E. faecalis) by a single streak at a 90° angle to the probiotic strains (but not 
touching the central probiotic streak) so there were 4 inhibition points with four pathogenic 
species examined per plate (Figure 2.2). The plates were further incubated at 37 °C and 5 % 
CO2 and inspected on a daily basis for 7 days to determine the pattern of growth or interaction 
of the test pathogens in relation to the master streak. Negative controls were prepared using 
a central streak of sterile distilled water on the full and half strength FAA plates incubated at 
the same pre-incubation periods and inoculated with the pathogens in the same manner as 
the test samples. Controls were treated in exactly the same way as the test samples. Because 
of the difficulty to control each bacterial inoculum inoculation distance, percentage of 
inhibition to the total streak length was calculated: 
 
                   
 
 
 
 
 
 
 
           
 
 
 
 
 
 
Distance of inhibition (mm) 
Total cross-streak distance (mm) 
% Inhibition = X 100 
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2.2.7.2 Broth inhibition assay  
According to a published broth assay method (Chapman et al. 2013), 20 mL of 24 h broth 
cultures of probiotics in their appropriate broths (Table 2.1), incubated at 37 °C and 5 % CO2 
were centrifuged at 2000 g for 15 min (Thermo IEC CL10, UK). The resulting supernatants 
were filter sterilised using 0.22 µm filters (Elkay Laboratory Product LTD, UK) and their pH was 
measured using a pH-meter (HI2210 pH meter, ROMANIA). To account for possible acid effect, 
half of each supernatant was neutralised to pH 7.0 using 1 M sodium hydroxide. Neutralised 
and non-neutralised supernatants were filtered through 0.22 µm filter (Elkay Laboratory 
Product LTD, UK) and frozen in 5 mL aliquots until use. Supernatants were then defrosted at 
room temperature before use. SAG and E. faecalis were cultured overnight at 37 °C and 5 % 
CO2 in BHI broth. An aliquot (5 µL) of adjusted (OD600= 0.08-0.1) bacterial culture was added 
to 9 mL of fresh BHI broth and 1 mL of the cell-free probiotic supernatant was added to each 
pathogen culture. This was carried out for the pH-neutralised and the non pH-neutralised 
supernatants for each probiotic treatment. Growth controls were prepared by the addition 
of 1 mL sterile fresh probiotic broths (Table 2.1) to 9 mL sterile BHI plus 5 µL bacterial 
suspension aliquots. OD600 was measured at zero-time and the inoculated tubes were 
incubated immediately at 37 °C and 5 % CO2 for 24 h. One mL of each sample was taken at 4, 
Figure 2.2 Detection of probiotic-inhibitory effect in cross-streak experiment. a- Line-
inoculation of the antibiotic-producer strain onto the FAA Petri plate. b- Inoculation of the 
test organisms with cross-streak method just near the producer microorganism. c- 
Measurement of the inhibition distance and the total streak length after the incubation period 
(adopted from Tóth et al. 2013). 
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8 and 24 h for OD600 reading, to determine inhibition of pathogen growth compared to the 
growth control. Gentamicin (0.1 mg/mL) was used as a positive control.  
2.2.8  Statistical analysis 
All experiments were performed in triplicate and each experiment repeated independently 
three times. Tukey’s One-way analysis of variance (ANOVA) with post-hoc correction 
(GraphPad InStat 3 (v3.06)) was used to analyse statistical difference between test groups’ 
means of biofilm assay. Dunnett's mean comparison one-way ANOVA was used with the broth 
inhibitory assay. A p value of ≤ 0.05 was considered significant (*, p < 0.05), very significant 
(**, p < 0.01) or highly significant (***, p < 0.001).  
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2.3 Results 
2.3.1 Bacterial growth in various culture media 
The growth curves of probiotic strains and pathogenic clinical isolates in the appropriate 
culture media are presented in figure 2.3 and figure 2.4. Table 2.2 depicts growth curve 
parameters for the pathogenic strains and the probiotic strains.     
All clinical isolates were grown in BHI at 37 °C and 5 % CO2. Their growth curves (Figure 2.3) 
followed a typical bacterial growth pattern demonstrated by the initial lag phase, followed by 
exponential growth and stationery phase when the nutrients may be inadequate. Although 
the starting inoculum concentration was the same for all strains, parameters (Table 2.2) of 
the growth phase for the different strains were shown to differ. The shortest lag phase was 
observed for E. faecalis (λ = 1.34 ± 0.5) and it reached the stationary phase earlier than the 
other stains (5 h compared to 9, 8 and 15 h for S. anginosus, S. intermedius and S. constellatus 
respectively) with a short duplication time (Td) of 0.63 ± 0.3 h. S. anginosus had a maximum 
absorbance (Amax) comparable to that of E. faecalis (0.83 ± 0.015 and 0.84 ± 0.03 
respectively), however it appeared to replicate more slowly  than E. faecalis (Td = 1.34 ± 0.16 
h). S. constellatus demonstrated the longest lag phase of 4 ± 1 h and the longest Td of 2.3 ± 
0.24 h. S. intermedius required less time to enter the exponential growth phase (λ = 2.6 ± 0.5 
h) and was faster to duplicate (Td= 0.82 ± 0.15 h) in comparison to S. constellatus: However, 
the Amax of these strains was comparable (0.65 ± 0.07 and 0.56 ± 0.03 respectively).  
Regarding the probiotic strains (Figure 2.4, Table 2.2), L. lactis grew well in BHI broth and on 
FAA plate but did not grow well on de Man, Rogosa, and Sharp (MRS) agar medium; the 
former two media were selected for growth of  L. lactis in broth and agar culture,  respectively. 
L. plantarum demonstrated the highest Amax of 1.85 ± 0.065 followed by L. fermentum (Amax 
= 1.37 ± 0.09) and L. lactis (0.74 ± 0.035). Although L. plantarum and S. thermophilus entered 
exponential growth at comparable times (λ= 4.16 ± 0.28 and 4.5 ± 1.8 respectively) and had 
comparable growth rates (Td = 1.45 ± 0.18 and 1.57 ± 0.25 respectively), L. plantarum showed 
the highest Amax (1.85 ± 0.065) while S. thermophilus showed the lowest Amax (0.29 ± 0.05). 
L. acidophilus required 8 ± 1 h for signs of replication to be detected (Td= 4.2 ± 1.66) and 
appeared to reach stationary phase after around 30 h, therefore incubation was continued 
for 48 h.  
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Figure 2.3 SAG and E. faecalis isolates growth curve. Absorbance of bacterial suspension 
grown in BHI broth, showing bacterial growth phases for 24 hours incubation at 37°C, 5% CO2. 
Error bars represent the standard error of the mean (SEM) of three independent experiments. 
 
 
 
 
 
 
 
 
 
Figure 2.4 Probiotic strains growth curve. Absorbance of bacterial suspension grown in MRS 
broth for L. plantarum, L. fermentum and L. acidophilus, BHI broth for L. lactis and M17 broth 
for S. thermophilus, showing bacterial growth phases and total growth of isolates after 24 
hours incubation at 37°C, 5% CO2. Error bars represent standard error of the mean.  
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Table 2.2 Pathogenic and probiotic growth parameters. 
Strains  Amax length of lag 
phase (λ) 
doubling time  
Td (h) 
S. anginosus 0.83 ± 0.015 3 ± 0.2 1.34 ± 0.16 
S. constellatus 0.56 ± 0.03 4 ± 1 2.3 ± 0.24 
S. intermedius 0.65 ± 0.07 2.6 ± 0.5 0.82 ± 0.15 
E. faecalis 0.84 ± 0.03 1.34 ± 0.5 0.63 ± 0.3 
 
L. lactis 0.74 ± 0.035 2 ± 0.3 0.84± 0.10 
L. plantarum 1.85 ± 0.065 4.16 ± 0.28     1.45 ± 0.18 
L. fermentum 1.37 ± 0.09 2. 4 ± 0.28 0.95 ± 0.20 
L. acidophilus 24h 0.63 ± 0.10 - - 
L. acidophilus 48h 1.05 ± 0.23 8 ± 1  4.2 ± 1.66 
S. thermophilus 0.29 ± 0.05 4.5 ± 1.8 1.57 ± 0.25 
 
 
 
2.3.2 Biofilm Assay  
The potential of the pathogenic and probiotic strains to adhere to and maintain viability on 
microtitre plates was determined and used to infer the potential of these strains to develop 
into biofilms (Figure 2.5 and Figure 2.6 respectively). Recovery and subsequent plating and 
enumeration of the attached viable cell after 24, 48 and 72 h was performed. This method 
was used to quantify the bacterial cells (CFU/mL) in the biofilm biomass (Djordjevic et al. 
2002; Azeredo et al. 2017).   
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Figure 2.5 Comparison of biofilm forming-capacity between the four pathogenic strains. The 
propensity of each pathogen to form biofilms was measured after 24 h, 48 h and 72 h culture 
in a 6-well polystyrene plates by plating and enumeration on FAA plate. Data are expressed 
as the mean ± SEM. * = p ≤ 0.05 versus all strains was considered significant using Tukey’s one 
way ANOVA.  
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Figure 2.6 Comparison of biofilm forming-capacity between the five probiotic strains. The 
propensity of each probiotic strain to form biofilms was measured after 24, 48 and 72h culture 
in a 6-well polystyrene plates by enumeration on appropriate media. Data are expressed as 
the mean ± SEM. * = p ≤ 0.05 versus all strains was considered significant using Tukey’s one 
way ANOVA. 
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Each strain of the four pathogenic strains demonstrated the ability to form consistent biofilm 
over 24, 48 and 72 h as shown statistically by no significant difference (p ≥ 0.05) of the 
recovered viable cells over these time periods (Figure 2.5). No significant difference was 
encountered in the number of viable cells recovered from E. faecalis and S. intermedius 
biofilm over 24, 48 and 72 h (p > 0.05) but significantly (p ≤ 0.05) more viable bacterial cells 
were recovered from both of these strains in comparison to  S. anginosus and S. constellatus 
biofilm. The two latter strains formed 24, 48 and 72 h-old biofilms with comparable (p > 0.05) 
biomass (as measured by the recovered viable cells count).   
Figure 2.6 compares the biofilm propensity of the five probiotic strains over period of 24, 48 
and 72 h. As with the pathogenic strains, plating and counting of the detached bacterial 
population was used to assess biofilm formation. No significant difference (p > 0.05) was 
detected between 24, 48 and 72 h-old biofilm of each of the probiotic strains. However, the 
number of viable cells recovered from L. plantarum biofilm grown for 24, 48 and 72 h was 
significantly (p ≤ 0.05) higher than that of the other probiotic strains biofilms grown for the 
corresponding time period. S. thermophilus, on the other hand, formed a 24 h-old biofilm 
with the least number of viable cells (log10 = 5.07 ± 0.54) and increased slightly but not 
significantly over the following  24 h (log10 = 6.2 ± 1.5) to drop again in the 72 h biofilm culture 
(log10 5.6 ± 0.50).  
  
2.3.3 In-vitro screening probiotics for their antimicrobial effects 
2.3.3.1 Cross streak assay 
The indicator strains were pre-incubated for 1, 3, 5, 7, 9, and 10 days. However, only three 
time periods (1, 7 and 10 days) are  presented here as they showed the most marked and 
typical  differences. As shown in figure 2.7 and table 2.3, out of the five probiotic culture 
streaked as indicator strains, L. acidophilus and S. thermophilus did not affect the growth of 
any of SAG or E. faecalis (% of inhibition = 0) at any of the pre-incubation periods inspected.  
Pre-incubation period was found to have a substantial effect on the appearance of the 
inhibitory effect of the other three probiotic strains (L. plantarum, L. fermentum and L. lactis). 
Using full strength FAA plate, a pre-incubation period of 7 days was required for L. plantarum 
to inhibit the growth of S. anginosus by 27.1 ± 1.4 %, S. constellatus by 37.2 ± 5.7 and S. 
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intermedius by 69.84 ± 3.9 % (Figure 2.7, Table 2.3). A longer L. plantarum pre-incubation of 
10 days resulted in 100 % inhibition of the three SAG members indicating a concentration-
dependent effect (Figure 2.7, Table 2.3). Although E. faecalis did not demonstrate any zone 
of inhibition, its growth was remarkably constricted when grown with the 10 d pre-incubated 
L. plantarum (Figure 2.8) when compared to the negative control plate.  Comparable results 
were obtained when L. plantarum was inoculated on half-strength FAA plates (Figure 2.7, 
Table 2.3). 100 % SAG growth inhibition was observed at 10 d pre-incubation. However, 7 d 
pre-incubation caused inhibition of only S. constellatus (35.5 % ± 3.6) and S. intermedius 
(32.39 % ± 3.45) but not of S. anginosus. No inhibition of E. faecalis was recorded at any time 
on the half-strength FAA plate (Figure 2.7, Table 2.3).   
L. fermentum did not show any antimicrobial effect when cultured on half-strength FAA plates 
even after prolonged pre-incubation of 10 d. However, a profound anti-SAG activity (100 % 
inhibition) was found when L. fermentum was incubated for 10 d on full-strength FAA plates 
before SAG were cross streaked on. A shorter pre-incubation period of 7 d caused 15.05 % ± 
4.06 inhibition of S. constellatus and 11.17 % ± 4.74 inhibition of S. intermedius but not of S. 
anginosus. E. faecalis was found resistant to the antimicrobial effect of L. fermentum.  
As with L. fermentum, L. lactis was not able to impede bacterial growth of the tester strains 
on half-strength FAA plates, however, 100 % inhibition of S. constellatus and S. intermedius 
was reported on full-strength 10 d pre-incubation plate. A shorter pre-incubation of 7 d 
resulted in much less inhibition of S. constellatus and S. intermedius (14.46 % ± 3.53 and 13.12 
± 3.09 respectively).  
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Figure 2.7 Cross streak assay. Centrally streaked probiotic stain (sterile distilled water was 
used as the control) was pre-incubated for 1, 7, and 10 days on full and half-strength FAA 
plates. After co-culturing and incubation, inhibition and total streak distance was measured 
by ruler. Ef, Sa, Si and Sc stand for E. faecalis, S. anginosus, S. intermedius and S. constellatus 
respectively. PP: pre-incubation period. Note: all plates were at the same orientation of the 
Ef, Sa, Sc, Si-labelled top left corner one.  The experiment was performed in triplicate on three 
different occasions.  
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Figure 2.8 E. faecalis growth difference between the negative control (left red 
arrow) and L. plantarum pre-incubated for 10 days (right red arrow). Note: the 
plates were left 3 days after co-culturing.  
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Table 2.3 Percentage zone of inhibition in cross streak assay. Data presented as mean ± SEM (n=3). Zero indicates there was no observed 
inhibition of the pathogenic streaks. 100% represents a complete inhibition of the total pathogenic streaks.  
 
% inhibited distance to the total streak distance 
Full strength FAA plate Half strength FAA plate 
1d 7d 10d 1d 7d 10d 
probiotic 
strain 
pathogen 
strain mean SEM mean SEM mean SEM mean SEM mean SEM mean SEM 
L. plantarum 
Ef 0  ± 0 0  ± 0 0  ± 0 0  ± 0 0  ± 0 0  ± 0 
Sa 0  ± 0 27.1 ± 1.43 100  ± 0 0  ± 0 0 ± 0 100  ± 0 
Sc 0  ± 0 37.26 ± 5.71 100  ± 0 0  ± 0 35.5 ± 3.6 100  ± 0 
Si 0  ± 0 69.84 ± 3.96 100  ± 0 0  ± 0 32.39 ± 3.45 100  ± 0 
 
L. fermentum 
Ef 0  ± 0 0  ± 0 0  ± 0 0  ± 0 0  ± 0 0  ± 0 
Sa 0  ± 0 0  ± 0 100  ± 0 0  ± 0 0  ± 0 0  ± 0 
Sc 0  ± 0 15.05 ± 4.06 100  ± 0 0  ± 0 0  ± 0 0  ± 0 
Si 0  ± 0 11.17 ± 4.74 100  ± 0 0  ± 0 0  ± 0 0  ± 0 
 
L. lactis 
Ef 0  ± 0 0  ± 0 0  ± 0 0  ± 0 0  ± 0 0  ± 0 
Sa 0  ± 0 0  ± 0 0  ± 0 0  ± 0 0  ± 0 0  ± 0 
Sc 0  ± 0 14.46  ± 3.53 100  ± 0 0  ± 0 0  ± 0 0  ± 0 
Si 0  ± 0 13.12  ± 3.09 100  ± 0 0  ± 0 0  ± 0 0  ± 0 
 
L. acidophilus 
Ef 0  ± 0 0  ± 0 0  ± 0 0  ± 0 0  ± 0 0  ± 0 
Sa 0  ± 0 0  ± 0 0  ± 0 0  ± 0 0  ± 0 0  ± 0 
Sc 0  ± 0 0  ± 0 0  ± 0 0  ± 0 0  ± 0 0  ± 0 
Si 0  ± 0 0  ± 0 0  ± 0 0  ± 0 0  ± 0 0  ± 0 
 
S. 
thermophilus 
Ef 0  ± 0 0  ± 0 0  ± 0 0  ± 0 0  ± 0 0  ± 0 
Sa 0  ± 0 0  ± 0 0  ± 0 0  ± 0 0  ± 0 0  ± 0 
Sc 0  ± 0 0  ± 0 0  ± 0 0  ± 0 0  ± 0 0  ± 0 
Si 0  ± 0 0  ± 0 0  ± 0 0  ± 0 0  ± 0 0  ± 0 
Ef, E. faecalis; Sa, S. anginosus; Sc, S. constellatus; Si, S. intermedius; d, day; SEM, standard error of the mean.  
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2.3.3.2 Broth inhibition assay 
To determine whether there was inhibitory activity of the excreted by-products from the 
probiotic strains against the tested endodontic pathogens, a broth inhibitory assay was 
undertaken. Test samples growth patterns were followed for 0, 4, 8 and 24 h by measuring 
the absorbance (600 nm) at each time point and comparing it to the untreated growth 
control. It was found that all the probiotic supernatants were acidic (Table 2.4). While L. 
plantarum supernatant was the most acidic (pH = 4.0 ± 0.3), S. thermophilus supernatant was 
found to produce the least acidic supernatant (pH = 6.5 ± 0.1) so did not need pH adjustment. 
The lactobacilli strains were grown in MRS broth, L. lactis in BHI and S. thermophilus in M17. 
2.3.3.2.1 Testing against E. faecalis growth  
It was observed, from the turbidity reading, that E. faecalis growth was significantly (p ≤ 0.05) 
reduced at 8 and 24 h time points when mixed with non-pH-controlled supernatants of L. 
acidophilus, L. fermentum and L. plantarum. However, upon pH neutralisation of the three 
probiotic supernatants to pH 7.0, no significant (p > 0.05) growth reduction (as measured by 
the absorbance reading) was reported for E. faecalis at 8 and 24 h incubation (Figure 2.9a). L. 
lactis and S. thermophilus supernatants were found to have no effect on the Enterococcus 
growth demonstrated by no significant (p > 0.05) difference in the absorbance of the test 
samples and the control (Figure 2.9b and Figure 2.9c). These comparisons were undertaken 
against the untreated growth control (negative control).   
2.3.3.2.2 Testing against S. anginosus growth 
As shown in figure 2.10a, b and c, only L. fermentum and L. plantarum supernatants (pH-
controlled and non-pH-controlled) at 24 h caused a significant (p ≤ 0.01) S. anginosus growth 
reduction in comparison to the untreated growth control (negative control).  
2.3.3.2.3 Testing against S. constellatus growth  
Although statistically not-significant (p > 0.05), the non-pH-controlled supernatants of the 
three probiotic lactobacilli appeared to reduce the growth of S. constellatus at 24 h 
incubation. Upon pH adjustment L. plantarum and L. acidophilus supernatants inhibited S. 
constellatus growth though again not significantly (p > 0.05) as shown in figure 2.11a. No 
effect (p > 0.05) was noticed in co-culture with L. lactis and S. thermophilus supernatants 
(Figure 2.11b and Figure 2.11c).  
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2.3.3.2.4 Testing against S. intermedius growth  
After 24 h incubation, significant reduction (p ≤ 0.05) of S. intermedius growth was observed 
following treatment with the pH-controlled and non-pH-controlled supernatants of L. 
acidophilus, L. fermentum and L. plantarum (Figure 2.12a) in comparison to the untreated 
negative growth control. No inhibitory effect of L. lactis supernatant (Figure 2.12b) and S. 
thermophilus (Figure 2.12c) were observed against S. intermedius.  
 
 
 
Table 2.4 pH reading of 24 h-probiotic supernatant indicating acid production. Data is 
expressed as mean ± standard deviation (n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Probiotic  Culture 
broth/pH 
24 h-probiotic 
supernatant pH  
L. acidophilus MRS/6.2 ± 0.3 
 
4.3 ± 0.2 
L. plantarum 4.0 ± 0.3 
L. fermentum 4.3 ± 0.4 
L. lactis BHI/7.4 ± 0.2 5.0 ± 0.2 
S. thermophilus M17/6.9 ± 0.2 6.5 ± 0.1 
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Figure 2.9 E. faecalis growth patterns following treatment with a- pH-controlled and 
non-pH controlled L. acidophilus, L. fermentum and L. plantarum supernatants using 
MRS broth supernatant. b. pH-controlled and non-pH controlled L. lactis supernatant 
in BHI broth, c. S. thermophilus supernatant using M17 broth. Data are expressed as 
mean ± SEM. n, pH-neutralised; non, non-pH neutralised; negative control, untreated 
growth control. * p < 0.05; ** p < 0.01; *** p < 0.001 using Dunnett's one-way 
ANOVA.  
MRS medium 
BHI medium 
M17 medium 
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Figure 2.10 S. anginosus growth patterns following treatment with a- pH-controlled 
and non-pH controlled L. acidophilus, L. fermentum and L. plantarum supernatants 
using MRS broth supernatant. b. pH-controlled and non-pH controlled L. lactis 
supernatant in BHI broth, c. S. thermophius supernatant using M17 broth. Data are 
expressed as mean ± SEM. n, pH-neutralised; non, non-pH neutralised; negative 
control, untreated growth control. * p < 0.05; ** p < 0.01; *** p < 0.001 using 
Dunnett's one way ANOVA. 
MRS medium 
BHI medium 
M17 medium 
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Figure 2.11 S. constellatus growth curve patterns following treatment with a- pH-
controlled and non-pH controlled L. acidophilus, L. fermentum and L. plantarum 
supernatants using MRS broth supernatant. b. pH-controlled and non-pH controlled 
L. lactis supernatant in BHI broth, c. S. thermophius supernatant using M17 broth. 
Data are expressed as mean ± SEM. n, pH-neutralised; non, non-pH neutralised; 
negative control, untreated growth control. * p < 0.05; ** p < 0.01; *** p < 0.001 
using Dunnett's one-way ANOVA. 
M17 medium 
BHI medium 
MRS medium 
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Figure 2.12 S. intermedius growth curve patterns following treatment with a- pH-
controlled and non-pH controlled L. acidophilus, L. fermentum and L. plantarum 
supernatants using MRS broth supernatant. b. pH-controlled and non-pH 
controlled L. lactis supernatant in BHI broth, c. S. thermophius supernatant using 
M17 broth. Data are expressed as mean ± SEM. n, pH-neutralised; non, non-pH 
neutralised; negative control, untreated growth control. * p < 0.05; ** p < 0.01; *** 
p < 0.001 using Dunnett's one-way ANOVA. 
MRS medium 
BHI medium 
M17 medium 
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2.4 Discussion  
This chapter presents a novel in-vitro comparison of the antimicrobial capacity of five 
probiotic bacterial strains against four potential endodontic pathogens. Overall, L. plantarum 
showed the most inhibitory activity against SAG members and E. faecalis; activity was 
demonstrated both for cells growing on solid agar and within broth culture.  L. fermentum 
exhibited comparable anti-SAG activity to that of L. plantarum but only on full strength FAA 
medium. S. thermophilus, on the other hand, did not show any antimicrobial ability. These 
results led to the selection of L. plantarum from the five studied probiotics as the most 
promising species for further investigation in the following chapters.  The results also 
highlighted that the E. faecalis strain studied was the most resistant to inhibition by the 
current study methods.  
Additional analysis revealed that the four pathogenic strains showed the ability to adhere and 
increase in cell number on the plastic surface of the well plate; a widely employed indicator 
of good biofilm forming capacity. E. faecalis and S. intermedius both demonstrated a good 
biofilm forming capacity with the two highest recovered viable cell count (Figure 2.5). These 
findings will be employed later to study the antiadhesive effect of L. plantarum extracts on 
SAG and E. faecalis attachment.  
Despite the wide range of currently available endodontic and vital pulp therapies, there are 
still considerable high failure rates (Bernstein et al. 2012) which necessitates further clinic 
visits and costs and may lead to more invasive therapy or ultimately tooth extraction. One  
important factor associated with failure is the continued presence of bacteria within the pulp 
and root canal system (Siqueira 2001; Nair 2006). According to one review (Jhajharia et al. 
2015), endodontic infection is mostly a surface-associated microbial invasion and the term 
“biofilm” should be considered when dealing with such infection. Eradication of this form of 
bacterial burden is a crucial requirement of successful treatment (Sundqvist et al. 1998).  
Probiotic bacteria and their by-products have been studied widely for their antimicrobial and 
immune-modulatory effects in different human body systems (Kechagia et al. 2013). It has 
been hypothesised in the current study that these activities can be harnessed for dental 
application to treat or prevent pulpitis and subsequent endodontic infection.   
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The three “anginosus” group members (S. anginosus, S. constellatus and S. intermedius) and 
E. faecalis were selected for the current study as they are considered part of the commensal 
oral microbiota but also associated with pulpitis and endodontic infections. The “anginosus” 
group has been reported to associated with about one third of endodontic infections (Siqueira 
and Rôças 2009) and E. faecalis has been frequently isolated from failed endodontic and 
apical periodontitis (Portenier et al. 2003; Ozbek et al. 2009).  
Although the studied strains belong to the same group, their biofilm formation potential was 
found here to be different confirming previous reports of considerable phenotypic and 
genotypic heterogeneity within the group. S. intermedius and E. faecalis appeared to show 
the greatest biofilm forming potential, as measured by the recovered viable cells followed by 
S. anginosus and S. constellatus. This might be attributed to the biofilm-phenotypic 
characterisation. Only a  limited number of publications are available regarding SAG biofilm-
phenotypic characterisation (Eick et al. 2004; Fernanda Petersen et al. 2004; Landrygan-Bakri 
et al. 2012; Takeshi Yamanaka 2013).  By employing the matrix proteoglycans of decorin and 
biglycan of soft gingival and alveolar bone to assess real-time SAGs adherence and biofilm 
formation, Landrygan-Bakri et al. (2012) found a significant ability of S. constellatus and S. 
intermedius strains to adhere to the glycosaminoglycan (GAG) moiety of the extracellular 
matrix proteoglycans decorin and biglycan. The possession of high chondroitinase activity by 
selected isolates of S. constellatus and S. intermedius (322/95, 34C, 127/95, 30C) and its 
absence from the more poorly-adhering isolates of S. anginosus was proposed by the author 
to be critical for the release of the GAG chain from the mother molecule and for subsequent 
interactions. The phenotype/genotype characteristic of the bacterial cell may be influenced 
by such interaction thus determining whether or not “commensal” organisms initiate an 
infective process. Moreover, S. constellatus and S. intermedius adherence to such surface 
proteins of alveolar bone may enhance their survival and potential virulence in the periapical 
region lending the tissue susceptible to infective biofilm and abscess formation.  
Petersen et al. (2004) emphasised the role of quorum sensing in encouraging a biofilm mode 
of growth of S. intermedius NCTC 11324. They reported that a 24 h incubation of S. 
intermedius with the addition of synthetic competence-stimulating signalling peptide (CSP) at 
5 % CO2 and 37 ◦C, resulted in a 100 % increase in biofilm formation without affecting growth 
rate when compared to CSP-untreated growth.  
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In contrast, a study conducted by Yamanaka et al. (2013) examined the in-vitro biofilm 
forming capacity of one clinical S. constellatus strain (designated as H39) isolated from a 
lesion resulting from infection of the root canal and three reference SAG strains (S. 
constellatus ATCC 27823, S. intermedius ATCC 27335 and S. anginosus ATCC 33397). Biofilm 
phenotype of the clinical strain H39 and the type strains of SAG was assayed via a crystal violet 
staining microtiter plate method. S. constellatus strain H39 succeeded in forming consistent 
biofilm which was comparable to that of the species reference strain followed by S. 
intermedius ATCC 27335. While S. anginosus ATCC 33397 failed to grow as biofilm. Scanning 
electron microscopy (SEM) images of the grown biofilms showed that the clinical and 
reference strains of S. constellatus were able to produce a dense meshwork-like structure 
around the cell surface but other strains of S. anginosus ATCC 33397 and S. intermedius ATCC 
27335 lacked this phenotype. Moreover, the two strains of S. constellatus were found to 
produce a highly viscous material in the spent culture medium compared to the un-inoculated 
broth. However, no change in the viscosity was reported for S. intermedius and S. anginosus 
spent culture medium. These findings might explain, to some extent, the different biofilm 
potential amongst the different strains of the same group. Of further consideration, biofilm 
formation is considered an important step in initiating host response to infection and may 
contribute to pathogenicity of that phenotype (Parsek and Singh 2003). Hence, the current 
finding that different SAG members differ in their biofilm forming potential might affect their 
pathogenicity and tropism in pulp and endodontic infections.  In 2001, Claridge and colleagues 
conducted a study that aimed to assess the clinical importance of individual species of the 
"Streptococcus milleri group" (SMG) and abscess formation. SMG isolates had been identified 
to species level in 118 clinical cases using 16S rRNA sequence analysis. Of these isolates, only 
19 % of the S. anginosus but almost all isolates of S. intermedius and most S. constellatus 
isolates were found to associate with purulent infection, in comparison to otherwise healthy 
subjects. This lower virulence potential reported for S. anginosus might be explained, in part, 
by the poor adherence/biofilm potential reported for S. anginosus in the above mentioned 
studies (Eick et al. 2004; Fernanda Petersen et al. 2004; Landrygan-Bakri et al. 2012; Takeshi 
Yamanaka 2013). 
Alongside  SAG, we tested the biofilm potential of  E. faecalis which is frequently isolated from 
root canals of teeth following failure of  endodontic procedures (Portenier et al. 2003; Ozbek 
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et al. 2009).  Occasionally E. faecalis has been isolated from primary pulpitis (Ozbek et al. 
2009).  This means that this species is closely associated with the pathogenesis of endodontic 
infection and persistence of apical periodontitis. Herein, the results revealed the ability of this 
strain to grow and form consistent biofilm on polystyrene well plate. The number of viable 
bacterial cells recovered from E. faecalis biofilm was comparable to that of S. intermedius. 
This outcome is in accordance with the finding of Foley and Gilbert (1997), who demonstrated 
the growth of an  immature E. faecalis biofilm after  12 h incubation that yielded  variable cell 
counts whilst a mature consistent biofilm was obtained between 12 and 96 h incubation. Lima 
et al. (2001) showed that one day old biofilm contained  more viable cells than 3 days-old one.  
Enterococcal adhesiveness and biofilm potential have been studied and a number of 
molecules identified as being involved in biofilm formation. For instance, aggregation 
substance (AS) is a surface adhesin that has been found to involve in the adhesion of E. 
faecalis to intestinal and renal epithelium and to components of the extracellular matrix ( 
Süßmuth et al. 2000; Wells et al. 2000; Rozdzinski et al. 2001). Microbial surface components 
recognising adhesive matrix molecules (MSCRAMMs) have been documented to facilitate the 
colonisation of host tissues and binding of bacterial cells to indwelling abiotic surfaces that 
become coated with host-derived extracellular matrix components. E. faecalis has been 
examined for the presence of such molecules and shown to have more than a dozen 
MSCRAMMs which may be involved in  adherence (Sillanpää et al. 2008). Moreover, an E. 
faecalis polysaccharide antigen locus (epa) has been labelled as being involved in the 
synthesis of cell wall-associated polysaccharides, which contribute to biofilm formation, 
among other virulence properties (Teng et al. 2002).  
Adhesiveness and biofilm formation is an important characteristic required for probiotics to 
be used in the oral cavity so they can resist the normal oral transit.  L. plantarum followed by 
L. fermentum were able to form the most robust consistent biofilm as measured by the 
recovery of viable cells grown on polystyrene well plate for 24, 48 and 72 h (Figure 2.6). There 
is no conclusive statement regarding the probiotic species biofilm potential. This might be 
due to the wide variety of probiotic strains tested, different experimental conditions for each 
study and different abiotic or cell-line surfaces. The differences in probiotic-binding capacity 
in-vitro may indicate that there are also differences in the persistence of the different 
probiotic strains in the oral cavity (Haukioja et al. 2006). The mechanism of L. plantarum 
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adherence has not been well documented. One study (Ramírez et al. 2015) demonstrated a 
high L. plantarum biofilm sensitivity to treatment with proteinase K suggesting a role of 
proteins and/or proteinaceous molecules in surface colonisation. Two further studies (Kubota 
et al. 2008; Samot et al. 2011) reported that L. plantarum produces certain polysaccharides 
which might contribute to its high adherence and good biofilm formation. L. plantarum strains 
were found to form biofilm with the highest cultivable cell count within 24 h; the cell count 
remained constant for 48 h but decreased after 72 h by 1 to 3 log10 per well (Ramírez et al. 
2015). This finding is in accordance with the current study observations. In contrast, Jalilsood 
et al. (2015) reported that L. plantarum PA21 cell counts analysis (CFU/cm2) revealed the 
highest biofilm cell density on the fourth day of culture. 
The probiotic species that showed the least capacity to adhere and remain viable over the 
time course and was therefore regarded as the species with the lowest biofilm forming 
capacity was S. thermophilus NCTC 10353. This poor ability of S. thermophilus to grow in dense 
biofilm has been found, in one study, to be correlated to the poor initial adherence to the 
surface and to the lack of the activity of biofilm genes which are involved in surface 
polysaccharide production and exposed surface protein. This has been proposed to be due to 
the genetic domestication of S. thermophilus and adaptation to milk environment where it is 
used mostly (Couvigny et al. 2015).  
It may be worth highlighting that in the microtiter plate biofilm assay method used herein, all 
adherent biomass was used to evaluate biofilm. However, bacterial cells that sedimented to 
the bottom surface of the wells and become embedded by the extracellular biofilm matrix 
might constitute part of the biofilm biomass. Therefore, the resultant biofilm biomass is not 
necessarily generated entirely as a result of biofilm formation (Azeredo et al. 2017). 
Probiotics have been shown to play a beneficial role to the oral health via a number of 
proposed mechanisms. In this study, five probiotic strains; L. plantarum, L. fermentum, L. 
acidophilus, L. lactis and S. thermophilus were screened for their antimicrobial activity against 
SAG and E. faecalis. Extraction of new molecules from natural sources, such as probiotics, 
have proven to be a promising and interesting niche in the antimicrobial  field, as most of 
these natural components may be difficult to synthesise and may prove safer than synthetic 
products (Kamat and Velho-Pereira 2012). As living microorganisms, probiotics produce 
several primary and secondary metabolites. Some of them may have antimicrobial activity, 
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which can be tested with different methods. Here, the antimicrobial activity of the probiotic 
strains was tested both during growth on solid agar in proximity to target species and in broth 
culture in co-culture of their supernatants with SAG and E. faecalis. Results demonstrated 
that all Lactobacillus treatments inhibited the growth of the tested bacteria but to a variable 
extent. L. plantarum demonstrated the most inhibitory activity against SAG members and E. 
faecalis followed by L. fermentum. At the time of writing this chapter, there have been no 
previous studies assessing the antimicrobial efficacy of this strain of L. plantarum against SAG/ 
E. faecalis as a Gram positive endodontic infection causative agent.   
The cross streak assay was employed herein to screen for the antimicrobial potential of living 
probiotics cells. It has been shown previously that the cross streak assay resulted in higher 
inhibition zones on indicator bacteria than those obtained by the method of agar well 
diffusion (Lertcanawanichakul and Sawangnop 2011). It may be the case that some bacteria 
may only produce certain substances when growing on solid media, in comparison to the 
liquid state.  For instance, the production of some bacteriocins from Gram positive bacteria 
has been found to occur preferentially in solid media, as in the case of the bacteriocin from 
Actinomyces odontolyticus (Franker et al. 1977). Pre-incubation was performed at different 
time periods from 1 to 10 days. This was done to provide enough time for the live organism 
to produce antimicrobial substances which might diffuse into the agar medium (Velho-Pereira 
and Kamat 2011). 
L. plantarum showed the most inhibitory effect against SAG members and caused notable 
restriction of E. faecalis growth on full strength FAA plates. This antagonistic activity was 
prominent after prolonged (> 7 days) pre-incubation of the probiotic strains tested. L. 
fermentum also showed anti-SAG effect at prolonged pre-incubation. This may be attributed, 
in part, to the stress of nutrition limitation after this prolonged incubation period which 
caused the microorganism to produce inhibitory competitive molecules for their own survival 
This suggestion is supported by the finding of Tong et al. (2012). They observed an antagonism 
between L. lactis and S. mutans under in-vitro nutrition deficiency while this effect was lost 
when the two bacteria were grown in nutrition rich media. They proposed that, under 
nutrition limitation, quorum sensing system may be activated, which plays a key role in 
bacterial stress responses causing the bacteria to produce molecules, such as nisin, with 
inhibitory activity against other competing counterparts (Tong et al. 2012).  
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S. thermophilus NCTC 10353 did not demonstrate any inhibitory effects against any of the 
pathogenic strains tested in the current study, even after prolonged pre-incubation of 10 
days. This may result from the unsuitability of FAA as a supporting medium for this species 
especially as it was noticed to grow poorly on FAA. However, Letort and Juillard (2001) stated 
that S. thermophilus appeared to be less nutrient-demanding than other lactic acid bacteria 
(Letort and Juillard 2001).  This S. thermophilus NCTC 10353 strain may have no inhibitory 
effect against SAG and E. faecalis. Similarly, S. thermophilus M37 was tested for its 
antimicrobial activity against a number of pathogens, although no SAG or E. faecalis were 
included in the study, and no antimicrobial activity was demonstrated against any of the 
tested pathogens (Hladíková et al. 2012). Contrary to the current finding, S. thermophilus A 
has been shown to produce a glycolipid biosurfactant with antimicrobial/antiadhesive activity 
against several bacterial and yeast strains isolated from explanted voice prostheses 
(Rodrigues et al. 2006). Another study, conducted in 2011 on S. thermophilus strains isolated 
from a Turkish yogurt, demonstrated that all these strains showed inhibitive activity against 
at least one of the tested pathogens, although nutrient agar was used as a test medium 
(Akpinar et al. 2011).  
A more selective/specific inhibitory effect of L. lactis NCTC 10353 was noticed herein. L. lactis 
inhibited S. intermedius and S. constellatus growth but only after prolonged pre-incubation of 
9-10 days. This inhibitory activity was observed only when the bacteria grew on full-strength 
FAA plates. This may be due to the production of specific inhibitory substances which were 
synthesised in response to stress and might reflect as well the different antimicrobial 
susceptibility of the SAG members to different antimicrobial agents (Jacobs and Stobberingh 
1996; Rams et al. 2014). In a study conducted in 2012, a selective antimicrobial activity was 
reported for two strains of L. lactis (ZS25 and LM25). L. lactis ZS25 inhibited the growth of E. 
coli (1.75 %) and S. aureus (5.25 %), while L. lactis LM25 inhibited the growth of P. aeruginosa 
(3.06 %) and S. aureus (3.75 %) among other tested pathogens (Hladíková et al. 2012). L. 
acidophilus did not show any inhibitory effect against any of SAG or E. faecalis. Contrary to 
the finding of current study, Chapman (2013) reported L. acidophilus as the most inhibitory 
amongst four probiotic strains against E. faecalis showing zone of inhibition of around 9 mm 
using agar spot assay (Chapman 2013). A study conducted in 2014 on L. acidophilus strains 
isolated form yogurt revealed antimicrobial activity against B. subtilis, P. aeruginosa, S. 
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pyogenes, Proteus vulgaris, S. aureus and Aeromonas hydrophila using the cell-free 
supernatant in a well diffusion method. PCR analysis revealed that these stains harbour the 
gene encoded for bacteriocin which might contribute to the observed inhibitory effect 
(Abdulla 2014). Moreover, antimicrobial activity was documented for three L. acidophilus 
strains against a number of foodborne pathogens. However, the diameter of inhibition zone 
varied between the three L. acidophilus strains against the different foodborne pathogens 
included in this study. This inhibitory activity was associated with the production of a 
bacteriocin-like substance (Abo-Amer 2013). 
FAA agar was used in the cross streak assay because it supported the growth of both the 
fastidious probiotic (Liew et al. 2005) and the pathogenic strains. As bacterial production of 
certain molecules is correlated with the medium composition (Lin and Pan 2015) hence, FAA 
medium might have influenced, by enhancing or attenuating, the production of potential 
compounds from the probiotics. Two concentrations of FAA (full strength and half-strength) 
were used here as a try to mimic the situation in the progressed endodontic infection of 
deficient nutritional status so the activity of the bacteria (probiotics and pathogens) under 
this condition can be evaluated. L. fermentum, L. acidophilus and L. lactis but not L. plantarum, 
demonstrated a reduced antimicrobial activity when grow on half-strength FAA plates. This 
might indicate the requirement of specific elements at enough concentration for probiotics 
to synthesise their antimicrobial substance. Or it might be due to the increased resistance of 
the pathogenic strains of SAG and E. faecalis to the inhibitory effect of the probiotics when 
grow on deprived medium.   
To measure the inhibitory effect of the probiotic cell-free supernatant on planktonic growth 
of the pathogens, a broth inhibition assay was conducted. Results indicated that cell-free 
supernatant of certain probiotics reduced the growth of certain pathogens, when there was 
no adjustment of pH (acidic pH). This inhibitory effect might be attributed to the pH-lowering 
potential of acid production. This is emphasised by the disappearance of some of the 
observed antimicrobial effect upon neutralisation of the pH (by addition of 1 M NaOH) to pH 
7.0). It was proposed that one of the probiotic antimicrobial mechanisms is acid production 
(O’Hanlon et al. 2011) as a result of fermentation process such as lactic and acetic acid 
(Alakomi et al. 2000; De Keersmaecker et al. 2006; Makras et al. 2006). Lactic acid has been 
shown to inhibit the growth of many pathogens including species of 
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Enterobacteriaceae and Pseudomonadaceae (Davidson et al. 2005). Lactic acid can penetrate 
the bacterial cytoplasmic membrane and cause a reduction in the internal pH. This, in turn, 
leads to the disruption of the transmembrane proton motive force (Ray 1992). Alakomi and 
colleagues (Alakomi et al. 2000) proposed an additional (or alternate)  mechanism of lactic 
acid effect, which was its ability to disintegrate the outer membrane of Gram negative 
bacteria at low pH (3-4). This permeabilisation has been proved by the release of 
lipopolysaccharide (LPS) and sensitisation of the bacteria to detergent or lysozyme effects. 
Hence, lactic acid, in addition to its antimicrobial effect by the low pH, can work as adjuvant 
to enhance the bacterial penetration of other antimicrobials.  
The acid-related antimicrobial activity noticed in the current study was emphasised by the 
partial abrogation of the observed effect upon neutralisation of the pH as mentioned earlier. 
This was documented particularly against E. faecalis; its significant growth suppression by the 
crude lactobacilli supernatants was absent when the pH was adjusted to 7 (Figure 2.9a). This 
result is in agreement with the finding of a previous research study (Chapman et al. 2013) 
that assessed the crude supernatant effect of four probiotic lactobacilli (L. acidophilus NCIMB 
30184 (PXN 35), L. fermentum NCIMB 30226 (PXN 44), L. plantarum NCIMB 30187 (PXN 47) 
and L. rhamnosus NCIMB 30188 (PXN 54) against two urinary tract pathogens (E. coli NCTC 
9001 and E. faecalis NCTC 00775). The crude supernatants of the lactobacilli (except for L. 
rhamnosus) significantly reduced the growth of E. faecalis (measured by absorbance at 650 
nm), nonetheless this effect was lost when pH adjusted to 7 indicating an acid-induced 
inhibitory activity (Chapman et al. 2013).   
Interestingly, the current study demonstrated that not all neutralised supernatants lost their 
growth antagonist effect upon pH neutralisation, as in the case of L. plantarum, L. fermentum 
and L. acidophilus, which may be attributed to the production of other compounds with 
antibacterial activity. These results are supported by the previous study of Terai et al. (2015) 
who screened a number of probiotics for their potential against a number of periodontal and 
cariogenic oral pathogens. Antimicrobial activity of 3 lactobacilli cell culture supernatants 
against two pathogens (Porphyromonas gingivalis ATCC 33277, Aggregatibacter 
actinomycetemcomitans ATCC 43718) was reported even after pH adjustment (Terai et al. 
2015). The different organic acids of lactic acid bacteria, in general, have been reported to 
contribute to about 50 % of the reported antimicrobial effect (Olivares et al. 2006). The 
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remaining antagonistic effects may be due to the synthesis and excretion of other 
antimicrobial compounds such as hydrogen peroxide, bacteriocins and/or biosurfactants 
(Piard and Desmazeaud 1991; Piard and Desmazeaud 1992; Delgado et al. 2001; Madhu and 
Prapulla 2014). According to Piard and Desmazeaud (1991) the production levels and the 
proportions among these compounds depend largely on the strain, medium composition and 
other physical parameters.  
The probiotic supernatants tested in this chapter were filter-sterilised. This excludes the 
possible probiotic-pathogen bacterial cells competition for nutrients which is a potential 
mechanism of antimicrobial effect in the agar streak assay. Instead, it could be that during 
their overnight incubation, the probiotics produced bacteriocins, a small antimicrobial 
peptides which can act towards other bacterial species with greater potency via such 
mechanisms as pore formation and inhibition of cell wall synthesis (Coman et al. 2014).  
Although S. thermophilus is considered a lactic acid bacterium, its cell-free supernatant was 
found to be only slightly acidic (pH = 6.5 ± 0.1). A study has demonstrated that the levels of 
lactic acid production by S. thermophilus isolates from traditional yogurt varied depending on 
the strain and the growth conditions used. By using HPLC, lactic acid production was 
measured and found to range between 0 and 77.9 mg/kg for the different S. thermophilus 
strains studied, which suggested a strain specific property (Gezginc et al. 2015).  
Collectively, the inhibitory activity of L. plantarum both in cross streak assay and broth 
inhibition assay strongly suggests the ability of this bacterium to produce inhibitory 
substances in solid and liquid media.  The differences in the results between cross streak and 
broth inhibition may be due in part to the different testing protocols. In the cross-streak assay, 
viable cells were used and incubated for long period of time until the significant inhibitory 
effects were noticed which may be due to factors other than acid production such as 
competition for nutrients and production of other antimicrobial compounds. However, the 
antimicrobial activity in liquid media is favoured by rapidly diffusing antimicrobial compounds 
such as organic acids and bacteriocins (Coman et al. 2014). The broth inhibition assay is based 
on using cell free supernatant of 24 h probiotic broth which may contain higher 
concentrations of acids than that produced by the cells growing on solid media.   
83 
 
2.5 Conclusion 
Of the species tested, L. plantarum showed the broadest antimicrobial effect both in solid and 
liquid media together with the highest biofilm forming potential and therefore was 
considered to be a good candidate for further investigation. L. fermentum also revealed a 
biofilm formation potential and inhibitory effects comparable to that of L. plantarum, but 
mainly in full-strength medium. SAG and E. faecalis showed differences in response to 
probiotic treatment with the E. faecalis being less susceptible. E. faecalis was one of the more 
successful biofilm forming species, in addition to S. intermedius.  
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3 Chapter 3 L. plantarum biosurfactant extraction, characterisation 
and purification 
3.1 Introduction                             
Probiotic agents including lactobacilli have been studied extensively for their beneficial health 
properties (Santos et al. 2009; Bermudez-Brito et al. 2012) including an ability to interfere 
with pathogenic infections via a variety of mechanisms (see Chapter 1, General introduction). 
Production of biosurfactants by probiotics is found to be one of these interfering mechanisms 
(Rodrigues et al. 2006; Sharma and Saharan 2016; Morais et al. 2017).  Biosurfactants are a 
structurally diverse group of amphiphilic compounds with both hydrophilic and hydrophobic 
moieties (mostly hydrocarbons) which can affect surfaces, lower surface and interfacial 
tensions, form micelles, and exert emulsifying effects on immiscible materials (Chen et al. 
2007; Franzetti et al. 2010; Pacwa-Płociniczak et al. 2011; Souza et al. 2014; Varjani and 
Upasani 2016). Biosurfactants have been under extensive investigation to be used as  
replacements for synthetic surfactants and have shown promise in a variety of industrial and 
environmental applications (Varjani and Upasani 2017). Chemically, biosurfactants can be 
grouped either as low or high molecular weight; the former consisting of glycolipids and 
lipopeptides and the latter of high molecular weight polymeric biosurfactants (Yu and Huang 
2011; Hosková et al. 2013; Ramírez et al. 2015). Microorganisms can synthesise biosurfactants 
as nonpolar hydrocarbons, as well as in water-miscible medium, and the produced 
biosurfactants have been shown to  be released into the growth medium or remain attached 
to the cell wall (Mukherjee et al. 2006). Lactobacilli have been documented in a number of 
studies as “biosurfactant producers” (Gudiña et al. 2011; Satpute et al. 2016; Morais et al. 
2017). However their biosurfactants are found to be less effective in reducing surface tension 
(reducing surface tension of water to 36-40 mN/m) and are synthesised in lower biomasses 
(20-100 mg/L). Despite the increasing interest in Lactobacillus biosurfactants, there is minimal 
information available about their chemical composition and this impact on their commercial 
production. Only few studies have examined the Lactobacillus biosurfactants in depth,  
characterising them partially as multipotent complex of proteins, polysaccharides and/or 
lipids (Velraeds et al. 1996;  Velraeds et al. 1996; Busscher et al. 1997; Gudina et al. 2010; 
Shokouhfard et al. 2015). A wide range of analytical, extraction, purification and 
characterisation methods, including precipitation, filtration, solvent extraction, 
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centrifugation, foam fractionation and chromatographic techniques have been employed for 
biosurfactants production (Heyd et al. 2008; Pornsunthorntawee et al. 2008; Banat et al. 
2010; Varjani and Upasani 2016). In addition to these techniques, more sophisticated 
methods such as ion exchange, adsorption and desorption can be used for biosurfactants 
purification (Satpute et al. 2010; Varjani and Upasani 2017). To characterise the extracted 
biosurfactants, a number of techniques including thin layer chromatography (TLC), gas 
chromatography (GC), fourier transform infrared spectroscopy (FT-IR), gas chromatography–
mass spectrometry (GC–MS), electrospray ionisation mass spectrometry (ESI-MS), high-
performance thin layer chromatography (HP-TLC), high performance liquid chromatography 
(HPLC), liquid chromatography–mass spectrometry (LC–MS), fast atom bombardment–mass 
spectrometry (FAB-MS) and nuclear magnetic resonance (NMR) have been used (Benincasa 
et al. 2004; Abdel-Mawgoud et al. 2009; Raza et al. 2009; Lotfabad et al. 2010; Satpute et al. 
2010; HoŠková et al. 2013; Varjani and Upasani 2016). Light scattering and microscopic 
hydrodynamic protocols have been used to obtain micelles characteristics (Satpute et al. 
2010).  
As previously shown in Chapter 2, L. plantarum demonstrated the broadest antimicrobial 
activity against the four endodontic isolates and was chosen as the potential probiotic for 
biosurfactants production and extraction. To our knowledge, no other studies have assessed 
the antimicrobial/antiadhesive activity of L. plantarum biosurfactants against SAG and E. 
faecalis. The aim of this chapter was to screen for the best growth phase of L. plantarum strain 
for biosurfactant production and to determine the biosurfactant production profile. 
Biosurfactant physical characterisation including surface tension and emulsifying activity 
determination was also undertaken. To provide an insight into the chemical composition of 
the extracted biosurfactants, partial chemical characterisation has been also performed.  
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3.2 Materials and methods 
3.2.1 Biosurfactant extraction 
3.2.1.1 Growth of L. plantarum for biosurfactant production and extraction 
Biosurfactant production by L. plantarum was conducted in 500 mL flasks containing 400 mL 
of MRS medium. Each flask was inoculated with a pre-culture grown overnight at 37 °C and in 
5 % CO2 and adjusted to an OD600 of 0.08-0.1 (108 CFU/mL) and diluted 1:10 to get a bacterial 
suspension of around 1x107 CFU/mL. The later was then incubated at 37 °C and 5 % CO2. To 
determine the best time for biosurfactant production, four time points during the standard 
growth curve of L. plantarum (see Section 2.2.5) were selected which represented the mid-
exponential phase (8.5 h), the early stationary phase (16 h) and two points of the late 
stationary phase at 24 h and 48 h.  
At the end of each time point, the 400 mL sample was collected and ultracentrifuged at 10,000 
g at 10 °C for 10 min (SORVALL RC +6 centrifuge Thermo Scientific USA). The bacterial pellet 
was used for cell-bound PBS-extract recovery (see Section 3.2.1.2). The supernatant (MRS-
extract) was collected and filtered through 0.22 µm filter unit (Whatman, GE Healthcare, UK) 
and used for surface tension measurements looking at the released biosurfactant (see Section 
3.2.1.3).   
3.2.1.2 Cell-bound PBS-extract recovery  
The bacterial pellet was washed twice with the 400 mL of sterile double distilled water, and 
resuspended in the same volume of phosphate-buffered saline (PBS: 10 mM 
KH2PO4/K2HPO4, pH adjusted to 7.0) (Vecino et al. 2015). The bacterial-suspension was left 
at room temperature (20-25 °C) for 18 h with gentle stirring for cell-bound biosurfactants 
release. Subsequently, bacteria were removed by centrifugation (10000 g, 10 °C for 10 min) 
and the remaining supernatant was filtered through a 0.22 µm filter unit (Whatman, GE 
Healthcare, UK). To confirm biosurfactant production, the surface tension was measured 
(Section 3.2.1.3) during the extraction process at each time point.  
3.2.1.3 Surface-activity determination 
The surface tension of the bacterial supernatants (MRS-extract) and the cell bound PBS-
extracts were evaluated using the Du-Nouy-Ring method based on measuring the force 
required to detach a ring or loop of wire from an interface or surface (Tadros 2005). Dynamic 
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contact angle analyser (KR USS GmbH, Germany) equipped with a 1.9 cm De Nouy platinum 
ring (Thermal exchange Ltd, Germany) was used. The machine was equilibrated with distilled 
water twice before use. Sterile PBS was used as a negative control for cell-bound PBS-extract. 
Sterile MRS medium was used as the negative control for the broth extract. All the 
measurements were performed at room temperature (20-25 °C) in triplicates.  
3.2.1.4 Biomass determination 
For biomass determination, 400 mL samples of the MRS-extract or the cell-bound PBS-extract 
were freeze-dried and the resulted powder was weighed. The yield was expressed as 
milligram of the sample per millilitre of the culturing medium (mg/mL). 
3.2.1.5 Dialysis 
To remove PBS, the freeze-dry cell-bound PBS-extract product collected at the mid-
exponential phase was dissolved in 5 mL of sterile distilled water and then dialysed against 
distilled water at 4 °C using dialysis membrane of molecular weight cut-off 1000 Da 
(Spectra/Por 6 Membranes; Cole-Parmer instrument Ltd. UK) for 48 h with three changes of 
the dialysis solution. The dialysate was further filter sterilised and freeze-dried. The crude 
dialysed biosurfactant (termed Lp-BS from here forth) was weighed and stored at -20 °C for 
subsequent studies.  
3.2.2 Physicochemical characterisation of Lp-BS 
3.2.2.1 Physical characterisation: Surface tension and emulsifying activity determination 
Surface tension was determined as discussed in section 3.2.1.3.                                               
Emulsifying activity was determined by the addition of 2 mL of either kerosene (Sigma 
Aldrich), heptane (Sigma Aldrich), hexane (Sigma Aldrich), xylene (Fisher Scientific), motor oil 
or sunflower oil to the same volume of distilled water and 1 mL of Lp-BS solution ( at a 
concentration of 1 mg/mL in distilled water) in glass test tubes. The mixtures were mixed by 
vortexing at high speed for 2 min and subsequently incubated at 25 °C for 24 h. The 
emulsification indexes (EI24) were calculated as the percentage of the height of the 
emulsified layer (mm) divided by the total height of the liquid column (mm) as follows:  
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EI24 (%) = α / β ×100                        
, where α and β represent the height of the emulsified layer and the total height, respectively. 
All measurements to determine the emulsification indexes were performed in triplicate. 
3.2.2.2 Biochemical characterisation of Lp-BS 
3.2.2.2.1 Fourier transform infrared spectroscopy (FT-IR)  
Fourier transform infrared spectroscopy using Nicolet 380 FT-IR (Fisher Scientific) was used 
to study the molecular composition of Lp-BS. The spectra were recorded on FT-IR-4100 
Spectrometer and were obtained from 64 scans with a resolution of 8 cm in the range of 600–
4000 cm−1. Samples were prepared via homogeneous dispersal of 30 mg of Lp-BS sample in 
pellets of potassium bromide (KBr) powder at a ratio of 1:100 and pressed under 7,500 kg of 
pressure to gain translucent pellet. IR spectra were collected over the 600 and 4000 cm−1 
range.  A pellet of KBr was used as a background reference. 
3.2.2.2.2 Lipid detection by thin layer chromatography (TLC) 
To detect for lipid presence in the Lp-BS sample, 100 µL aliquot of Lp-BS (prepared at 
concentration of 1 mg/mL in distilled water) was spotted using a pipette on a precoated 
5cm×10cm silica gel plate (Sigma Aldrich). Alongside the sample, rhamnolipid (1 mg/mL) 
(Sigma Aldrich) was also spotted onto the plate as a positive control. The mobile phase used 
for the separation of the biosurfactants composed of chloroform (Fisher Scientific, UK)/ 
methanol (Fisher Scientific, UK)/acetic acid (Fisher Scientific, UK) at a ratio of 65:15:2 v/v 
respectively. The developing jar was allowed to be saturated with the mobile solvent system 
for 20-30 min. The spotted plate was then place in the jar and monitored by eye until the 
mobile phase reached near the top end of the plate. After the separation of lipid mobile 
components, the plate was then sprayed with the detection agent consisting of ammonium 
molybdate/cerium sulphate (0.42 % w/v ammonium molybdate and 0.2 % w/v cerium (IV) 
sulphate in 6.2 % v/v sulphuric acid). The plate was then heated in the oven at 120 °C for 10 
min. The chromatogram of Lp-BS was compared with the TLC pattern of a standard mixture 
of rhamnolipids (mono and di-rhamnolipid). Brown staining bands indicated the presence of 
lipid in the tested solutions. 
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3.2.2.2.3 Protein assay, SDS-PAGE and silver staining  
3.2.2.2.3.1 Bicinchoninic Acid Protein Assay (BCA) 
To determine total protein concentration in the bacterial extracts (PBS-extracts and MRS-
extracts) obtained at the four time points selected, a Pierce® BCA Protein Assay Kit (Thermo 
Fisher Scientific, USA) was used. This assay involved the addition of BCA reagent (composed 
of bicinchoninic acid and cupric sulphate) to the protein-containing solution. Copper ions in 
the cupric sulphate are reduced by the peptide bonds in the protein molecules. The reduced 
ions are then chelated by the bicinchoninic acid which causes the formation of a purple 
product which can be measured colorimetrically. The more protein in the sample, the more 
ions are reduced and this is proportional to the colour change and the absorbance reading.  
A standard curve was generated according to the manufacturer’s instructions, by the addition 
of 25 µL of a range of concentrations from 25 μg/mL to 2,000 μg/mL of known bovine serum 
albumin (BSA) standards to the corresponding wells of a 96 well plate (SARSTEDT, Germany) 
in triplicate.  On the same plate in triplicate, 25 μL of the PBS-extracts or MRS-extracts (1 
mg/mL in distilled water) for the four time points selected for the extraction of the 
biosurfactant were included. Sterile MRS or PBS were also placed into triplicate wells as 
control. Two hundred microliters of BCA reagent [reagent A: bicinchoninic acid in 0.1M 
sodium hydroxide and reagent B: 4 % (w/v) cupric sulphate, (50:1, reagent A: B)] was then 
added to each of the standards and samples. The plate was shaken for 30 s using a plate 
shaker and then incubated at 37 °C for 30 min. At the end of incubation period, the plate was 
left to cool down to ambient temperature. Absorbance was read at 562 nm using a 
SPECTROstar Omega Plate Reader (BMG Labtech, Germany). By plotting the absorbance 
values from the BSA standards vs. the concentrations, a standard curve was generated and a 
best-fit equation line was obtained with Microsoft® Excel®2013 which allowed the calculation 
of the test samples concentrations. 
3.2.2.2.3.2 Gel electrophoresis using SDS-PAGE and sliver staining  
Double concentration (2x) Laemmli Sample Buffer (BioRad Laboratories, USA) was 
supplemented with 2-mercaptoethanol (Sigma-Aldrich) at 5 % (v/v) and diluted 1:1 with 
distilled water to generate 1x Laemmli Sample Buffer. Twenty µg of protein samples 
(determined previously in Section 3.2.2.2.3.1) was diluted 1:1 with 1x Laemmli buffer (Bio-
Rad, USA). The resultant mixture was heated to 95 °C for 5 min and 18 µL were loaded on 4-
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15 % Mini- Protean® TGX™ Precast Gels (Bio-Rad) along with 8 μL Kaleidoscope™ Pre-stained 
Standard Markers (Bio-Rad). Gels were placed into a Mini-PROTEAN® Tetra Vertical 
Electrophoresis Cell (BioRad Laboratories, UK) in 1x sodium dodecyl sulphate-polyacrylamide 
gel-electrophoresis (SDS-PAGE) running buffer [1.92 M glycine (Thermo Fisher Scientific), 250 
mM tris-base (Sigma-Aldrich), 1% SDS, pH 8.3). Separation of proteins was performed by 
electrophoresis at 200 V/cm2 for 35-40 min, until the migration front reached the bottom of 
the gel.  
To visualise the separated protein bands in the gel, silver staining was performed using a Silver 
Stain Plus™ kit (BioRad Laboratories). The SDS-PAGE gel was removed from the casts and, 
according to the manufacturer’s protocol, placed in the fixative solution [(50 % v/v methanol 
(Fisher Scientific), 10 % v/v acetic acid (Fisher Scientific), 1% v/v Fixative Enhancer 
Concentrate, 30 % v/v distilled water)] with gentle agitation for 20 min. A 10 min wash of the 
fixed gel was performed twice with 400 mL double distilled water. Staining solution was 
prepared fresh by adding 5 mL Silver Complex Solution, 5 mL Reduction Moderator Solution 
and 5 mL Image Development Reagent to 35 mL double distilled water, with gentle stirring 
followed by the addition of 50 mL Development Accelerator Solution to the staining solution. 
The washed gel was then placed in the staining solution for approximately 20 min with gentle 
agitation until the required staining intensity was obtained. Immediately after, the staining 
reaction was stopped by decanting the staining solution and adding 5 % v/v acetic acid for 15 
min with a final wash in double distilled water for 5 min. The gel was imaged using a Gel Doc 
EZ System (BioRad Laboratories). 
3.2.2.2.4 Quantitative assessment of carbohydrate content by anthrone assay 
To quantify carbohydrate content in Lp-BS, an anthrone test was performed. Anthrone 
reagent was prepared by dissolving 0.2 g of crystalloid anthrone (Fisher Scientific, UK) in 71 
mL concentrated > 99.7 % sulphuric acid (Fisher Scientific, UK) in an ice bath. After complete 
dissolution, the acid solution was added to 29 mL cold double distilled water with gentle 
agitation allowing minimal heat generation. A range of glucose standard concentrations (10-
50 µg/mL) were prepared. Two and a half mL of anthrone reagent was added to each of the 
test or standard samples in glass tubes in an ice bath. A 0.5 mL volume of the crude 
biosurfactant solution at a concentration of 1 mg/mL in double distilled water, the standards 
and the water blank was layered on top of the anthrone reagent tubes. The tubes were then 
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heated at 95 °C in a water bath for 10 min. The formation of a bluish green coloured complex 
indicated the presence of carbohydrate and the absorbance at 620 nm was measured. 
Standard equation was generated from the best fit line and total carbohydrate was drawn 
using glucose as substrate.  
3.2.3 Fractionation by size exclusion chromatography 
For purified fractionation of the biosurfactant components, a Sephacryl gel filtration column 
(HiPrep™ 16/60 Sephacryl® S-100 HR, Sigma Aldrich) of fractionation range 1KDa-100KDa, was 
used. Lp-BS was dissolved in phosphate buffer (0.01 M sodium phosphate buffer, 0.15 M NaCl, 
pH 7.0) at a concentration of 4 mg/mL and filtered through a 0.22 μm filter unit to remove of 
any insoluble matter. Size exclusion chromatography was performed, using AKTA Purifier 
apparatus controlled by Unicorn Software (GE Healthcare, v5.2). The system, into which was 
connected the Sephacryl® S-100 HR column, was washed in 20 % (v/v) ethanol and pumped 
with 18.2 MΩ water and then equilibrated with 0.01 M sodium phosphate buffer, 0.15 M NaCl 
(pH 7.0).  Two mL of Lp-BS solution was loaded into the column and eluted out with phosphate 
buffer at a flow rate of 30 mL/h. The absorbance of the eluent from the column was 
continually monitored at 210 nm, 254 nm and 280 nm. Eluent from the column was collected 
in 5 mL fractions and subsequently pooled into five elution pools labelled as F1, F2, F3, F4 and 
F5. The collected five elution pools were transferred to dialysis tubing (Spectra/Por 6 
Membranes; Cole-Parmer instrument Ltd. UK, MWCO 1000Da) and dialysed against double 
distilled water for 48 h at 4 °C, with continuous agitation and with the dialysis solution being 
changed thrice daily. Dialysed fraction pools were frozen at -80°C and lyophilised for 
subsequent analysis. 
3.2.3.1 Characterisation of elution pools fractionated by chromatography 
3.2.3.1.1 Detection of carbohydrate  
To determine carbohydrate presence of the five fractions, anthrone assay was employed as 
described previously in section 3.2.2.2.4.  
3.2.3.1.2  SDS-PAGE and colloidal coomassie blue stain of proteins in the FPLC fractions 
One milligram of each elution pools was dissolved in 1 mL distilled water and was 
electrophoretically separated by SDS-PAGE as described previously (Section 3.2.2.2.3.2). The 
gel was then stained with colloidal coomassie stain according to the manufacture’s instruction 
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(Colloidal Blue Staining Kit, Thermo Fisher Scientific). The gel was gently shaken in the fixing 
solution [(40 mL distilled water, 50 mL methanol 99.9 % v/v (Fisher Scientific, UK), 10 mL acetic 
acid 99.9 % v/v (Fisher Scientific, UK)] for 10 min at room temperature. The gel was then 
transferred into the staining solution (55 mL distilled water, 20 mL methanol 99.9 % v/v 
(Fisher Scientific, UK), 20 mL stainer A) for 10 min at room temperature. Five mL stainer B 
were then added to the existing staining solution and the gel was shaken gently in the latter 
mixture for a minimum of 3 h. The staining solution was decanted and the gel was washed in 
200 mL distilled water overnight at room temperature. For storage until analysis, the gel was 
kept in 1% v/v acetic acid at 4 °C.   
3.2.3.1.3 Assessment of the emulsifying activity  
Fraction 1 and 2 were analysed for emulsifying activity by employing emulsification index 24 
assay against xylene (described in Section 3.2.2.1). 
3.2.4 Mass spectrometric analysis of Lp-BS 
In-gel proteomic analysis was performed at the Proteomics Facility, University of Bristol. Fifty 
µg of Lp-BS was electrophoretically separated by SDS-PAGE and the gel was stained with 
colloidal coomassie stain as described in section 3.2.3.1.2 and kept hydrated in distilled water 
whilst transported to Bristol Proteomic Facility centre. Ten major bands were selected (most 
intense ones), cut and placed in labelled microcentrifuge tubes. Each gel slice was subjected 
to in-gel tryptic digestion using a DigestPro automated digestion unit (Intavis Ltd.). The 
resulting peptides were dried down in a speedvac and then resuspended in 1% formic acid and 
fractionated using an Ultimate 3000 nano-LC system in line with an LTQ-Orbitrap Velos mass 
spectrometer (Thermo Scientific). In brief, peptides in 1 % (v/v) formic acid were injected onto 
an Acclaim PepMap C18 nano-trap column (Thermo Scientific) which binds all peptides. After 
washing the nano-trap column with 0.5 % (v/v) acetonitrile 0.1 % (v/v) formic acid to remove 
any residual salts, peptides were loaded on a 250 mm × 75 μm Acclaim PepMap C18 reverse 
phase analytical column (Thermo Scientific). Then, an organic gradient was applied over a 60 
min starting with 1 % solvent B/ 99 % solvent A. Over the next 39 min the % of solvent B 
increased (and the % of solvent A decreased) until a 50 % B/50 % A was reached, then % of 
solvent B was stepped up to 90 % (and the % of solvent A was dropped to 10 %) over the next 
0.5 min and remained at this level for the next 4.5 min. After that, % of solvent B was dropped 
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back to 1 % (and % of solvent A was increased to 99%) with a flow rate of 300 nL/min. Solvent 
A was 0.1 % formic acid and Solvent B was aqueous 80 % acetonitrile in 0.1 % formic acid. 
Peptides were ionised by nano-electrospray ionisation at 2.1 kV using a stainless-steel emitter 
with an internal diameter of 30 μm (Thermo Scientific) and a capillary temperature of 250 °C. 
Tandem mass spectra were acquired using an LTQ- Orbitrap Velos mass spectrometer 
controlled by Xcalibur 2.1 software (Thermo Scientific) and operated in data-dependent 
acquisition mode. The Orbitrap was set to analyse the survey scans at 60,000 resolution (at 
m/z 400) in the mass range m/z 300 to 2000 and the top twenty multiply charged ions in each 
duty cycle selected for MS/MS in the LTQ linear ion trap. Charge state filtering, where 
unassigned precursor ions were not selected for fragmentation, and dynamic exclusion 
(repeat count, 1; repeat duration, 30s; exclusion list size, 500) were used. Fragmentation 
conditions in the LTQ were as follows: normalised collision energy, 40 %; activation q, 0.25; 
activation time 10ms; and minimum ion selection intensity, 500 counts. 
The raw data files were processed and quantified using Proteome Discoverer software v1.4 
(Thermo Scientific) and searched against the UniProt Lactobacillus plantarum database 
(28578 sequences) using the SEQUEST algorithm. Peptide precursor mass tolerance was set 
at 10ppm, and MS/MS tolerance was set at 0.8Da. Search criteria included 
carbamidomethylation of cysteine (+57.0214) as a fixed modification and oxidation of 
methionine (+15.9949) as a variable modification. Searches were performed with full tryptic 
digestion and a maximum of 1 missed cleavage was allowed. The reverse database search 
option was enabled and all peptide data was filtered to satisfy false discovery rate (FDR) of 1 
%. 
3.2.5 Statistical analysis 
Results were represented as mean ± standard deviation (SD) of three independent 
experiments. No statistical analysis was required in this chapter.  
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3.3  Results 
3.3.1 Biosurfactant production   
A growth curve was produced for L. plantarum and four time points for sample collection 
were selected in order to investigate biosurfactant production (Figure 3.1). The reduction in 
surface tension of the culture broth for samples collected at the four time points was minimal 
(2 mN/m - 0mN/m) (Table 3.1). This finding indicates that culture supernatant is not a good 
source of biosurfactant at any point in the growth phase. However, biosurfactant activity was 
detected from the cell pellet based PBS extraction procedure; over a period of 15 h at room 
temperature with gentle stirring, cell bound biosurfactant appeared to be released into the 
PBS medium.  
Cell-bound PBS extract samples collected at the mid (8.5 h), early (16 h) and the late stationary 
phase (24 and 48 h) exhibited a reduction in surface tension at varying degree (17.3 ± 0.5, 
11.8 ± 1, 16.6 ± 0.6 and 9.3 ± 0.6 mN/m respectively) when compared to PBS as a negative 
control. Although the 16 h-extract was found to produce the highest yield of the cell-bound 
biosurfactant (1.19 ± 0.3 mg per mL culture broth), the maximum surface tension lowering 
effect was observed for the mid-exponential phase sample together with a high yield of 1.0 ± 
0.1 mg/mL (Table 3.1). In view of these results, the mid-exponential time point was selected 
for ongoing biosurfactant extraction and characterisation and is referred to as Lp-BS 
henceforward. Upon dialysis, the biomass of the obtained Lp-BS was reduced to 40 mg per 
litre of culture medium. 
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Table 3.1 Comparison of the surface activity and yield of the MRS-extract and PBS-extract 
among different time points of L. plantarum growth. Surface tension measured by means of 
Du Nouy ring. PBS-extract samples collected at the four time points reduced the surface 
tension of PBS. Negligible surface activity was monitored for the MRS-extract collected at any 
time. Data expressed as the mean ± SD of three separate experiments. The downward arrows 
represent the reduction in surface tension compared to the corresponding control.  
 
 
 
 Cell-bound PBS-extract  Extra-cellular MRS-extract 
Time of sample 
collection 
Yield 
(mg/mL) 
ST 
(mN/m) 
Yield 
(mg/mL) 
ST 
(mN/m) 
Mid-exponential 
(8.5 h incubation) 
1.00 ± 0.10 ↓17.3 ± 0.50 15.0 ± 0.30 ↓2.0 ± 0.03 
Early stationary (16 
h incubation) 
1.19 ± 0.30 ↓11.8 ± 1.00 15.0 ± 0.15 ↓0.0 ± 0.00 
Late stationary (24 
h incubation) 
0.60 ± 0.15 ↓16.6 ± 0.60 15.0 ± 0.10 ↓1.0 ± 0.50 
Late stationary (48 
h incubation) 
0.80 ± 0.05 ↓9.30 ± 0.60 16.0 ± 1.10 ↓0.0 ± 0.00 
Rhamnolipid was used as a positive control. It lowered surface tension of distilled water by 40 mN/m. MRS 
and PBS were used as negative controls with ST of 44 mN/m and 72 mN/m respectively. 
Figure 3.1 L. plantarum growth curve. Red arrows represent the four time 
points for sample collection and subsequent biosurfactant extraction. 
These time points represent the different phases of L. plantarum growth.  
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3.3.2 Emulsification activity  
The surface activity of the Lp-BS was additionally assayed for emulsification effect against four 
hydrocarbon compounds and one vegetable oil and motor oil (Figure 3.2). Comparative 
analysis demonstrated that Lp-BS and rhamnolipid were able to emulsify kerosene, heptane 
and xylene to the same extent (EI24 % = 28.5 %) (Figure 3.3). A higher emulsifying index of 
heptane was recorded when mixed with Lp-BS or rhamnolipid than the synthetic surfactant 
tween80 (EI24 % = 28.5 % vs. 14.5 % respectively) (Figure 3.3). Tween80 was shown able to 
completely emulsify xylene (EI24 % = 100 %) while Lp-BS and rhamnolipid had an emulsifying 
activity of only 28.5 %. Rhamnolipid, on the other hand, showed a higher emulsifying activity 
(EI24% = 57.14%) against hexane than tween80 (EI24 % = 28.5 %) while Lp-BS failed to 
emulsify this hydrocarbon (Figure 3.3). The vegetable oil tested was shown to be emulsified 
by rhamnolipid and tween80 to the same extent (EI24 % = 28.5 %) while only the latter was 
shown to emulsify motor oil (EI24 % = 28.5 %). The control (distilled water) had an expected 
activity close to zero against the assayed hydrocarbons (Figure 3.3).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Emulsification index 24 (EI24) of Lp-BS. Six different hydrocarbons 
were used. Rhamnolipid was used as biosurfactant control and tween80 was 
used as a synthetic surfactant control. Distilled water (DW) employed as a 
negative control.  EI24 (%) = α / β ×100, where α and β represent the height of 
the emulsified layer and the total height, respectively as represented in the 
figure. The figure is a representative of three independent repeats. 
α 
β 
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3.3.3 Partial chemical characterisation 
3.3.3.1 Fourier transform infrared spectroscopy (FT-IR)  
To acquire a preliminary characterisation of the biosurfactant mixture, fourier transform 
infrared spectroscopy (FT-IR) was used to characterise the molecular composition of the cell-
bound biosurfactant of L. plantarum (Lp-BS). The IR spectrum can be divided into two main 
regions, the functional group region and the fingerprint region. The former lays between 4000 
cm-1 and 1000 cm-1 and it is where most of the functional groups show absorption bands. The 
right-hand third fingerprint region (about 1000 cm-1 -400 cm-1) is characteristic of the 
compound as a whole and each compound shows a unique pattern in this region even if it 
shares a similar absorption bands in the functional region with other compound. Different 
functional groups were identified here and the most relevant peaks obtained are identified in 
figure 3.4.  
The broad peak at 3350 cm-1 indicated the presence of OH and NH groups, characteristic of 
proteins. The strong and well defined peak at 1660.5 cm-1 corresponded to C=O stretching 
Figure 3.3 Comparative emulsification activity of the cell-bound BS on 
different hydrocarbons (kerosene, hexane, heptane and xylene), sun 
flower and motor oil. Rhamnolipid was used as a positive control for the 
biosurfactant and tween80 for the synthetic surfactant. The extracted Lp-
BS showed rhamnolipid-comparable activity on kerosene, heptane and 
xylene. The error bars represent the mean ± SD (n=3). 
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(AMI protein band). The other peak at 1530 cm-1 was typical of N-H bending (AMII protein 
band). The identification of these groups suggests the presence of proteins in the examined 
sample. C-H stretching was detected at the small peak of the transmittance range 2948 cm-1 
and the very small peak at 1461 cm-1, corresponding to C-H bending (scissor) indicated the 
presence of bonds of aliphatic chains. The large well defined peak demonstrated at 1062 cm-
1 was equivalent to the PII polysaccharide band typical of bond vibrations in the C-O-C group. 
Furthermore, another small but well defined peak was detected at 1232c m-1 which was a 
corresponding to C-O stretching in sugars.  
A similar FT-IR spectrum (Figure 3.5) was evident for cell-bound biosurfactant of L. agilis  
(Gudiña et al. 2015) and was proposed by the authors to be a glycoprotein. The spectra of Lp-
BS and L. agilis cell-bound biosurfactant had similar functional group region but different 
fingerprint regions.   
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Figure 3.4 FT-IR spectrum of Lp-BS. Fourier transform infrared spectroscopy (FT-IR) was used 
to elucidate the chemical structure of the cell-bound Lp-BS by identifying type of functional 
groups. The spectrum indicates a glycoprotein nature for the biosurfactant. 
Figure 3.5 FT-IR spectrum of cell-bound biosurfactant produced by L. agilis CCUG31450 
published in the Royal Society of Chemistry journal (Gudiña et al. 2015) and supposed to be a 
glycoprotein. The functional group region highly matches with that of Lp-BS but not the 
fingerprint region.  
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3.3.3.2 Protein assay, SDS-PAGE and silver staining 
3.3.3.2.1 BCA Assay  
An equation was generated from a standard curve that related absorbance (y) against protein 
concentration (x) (Figure 3.6). The protein content of the freeze-dried PBS- and broth-extracts 
was calculated. The cell-bound extract sample collected at the mid-exponential phase showed 
the highest protein concentration of 32.6 ± 7.4 µg per 1 mg of the crude sample (Figure 3.7). 
The three cell-bound extract samples collected at the stationary phase time points 
demonstrated lower protein contents compared to the log phase sample ( 12.1 ± 3.7, 15.3 ± 
5.1, 11.9 ± 2.4 µg/mg respectively). Protein biomasses of the broth extracts obtained at the 
four time points (206.16 ± 38.43, 187.24 ± 55.21, 199.5 ± 34.98, 182.3 ± 48.22 µg/mg 
respectively) were found to be less than the broth control (227.47 ± 44.9 µg/mg) (Figure 3.7).    
After dialysis, protein content of the selected cell-bound mid-exponential time point extract 
(Lp-BS) increased to 538 ± 160 µg/mg (Table 3.2) as a result of concentrating the sample.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 Standard curve generated from BCA assay relating protein 
concentration to absorbance. The equation of the line allowed calculation of 
protein concentration in the supernatants of a known absorbance. 
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3.3.3.2.2 Protein Separation with Sodium Dodecyl Sulphate-Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) and silver staining  
The protein separation profile of the cell-bound extracts obtained at the four time points 
indicated the presence of a wide variety of protein components. The sample collected at the 
mid-exponential phase (8.5 h) showed more intense bands than samples from the other three 
time points (16 h, 24 h and 48 h). These results are in accordance with the BCA protein 
concentration result. The identified bands had a molecular weight ranging from as low as 10 
KDa to high molecular weight of around 250 KDa (Figure 3.8 Left panel).  
Analysing the mid-exponential cell-bound extract (Lp-BS) after dialysis revealed three distinct 
protein bands of 10, 15 and 30 kDa and a smear band at 100-250 kDa (Figure 3.8 Right panel).    
 
 
 
Figure 3.7 Protein concentration of the PBS and MRS-extracts at the four 
time points selected for extraction. Among the PBS-extracts, the 8.5h 
sample (mid-exponential one) showed approximately two-fold higher 
content of protein than the other three stationary phase time points. Data 
expressed as mean ± SD (n=3). The protein contents of the broth extracts 
were lower than the broth control which might be due to consumption 
during growth. 
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3.3.3.3 Thin layer chromatography (TLC) 
No lipid residues were detected when the biosurfactant developed silica plate was sprayed 
with ammonium molybedate/serium sulphate mixture (Figure 3.9). This result indicated the 
absence of lipid moiety in the examined cell-bound biosurfactant (Lp-BS). However, 
rhamnolipid which was used as a positive control, gave two distinctive spots, indicative of the 
presence of mono and di- rhamnolipid mixture (Figure 3.9 red arrows). 
 
 
 
 
 
 
 
 
 
Figure 3.8 Left: SDS-PAGE of L. plantarum PBS-extracts at four time points 
(8.5, 16, 24 and 48h) showing that the 8.5 h sample contained more protein 
bands of different molecular weight compared to the samples collected at 
stationary phase. Right: SDS-PAGE of the mid-exponential biosurfactant 
(Lp-BS) after dialysis. 
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3.3.3.4 Anthrone assay 
Anthrone assay for carbohydrate content of the crude biosurfactant extract (Lp-BS) was 
employed using glucose as a standard to generate the standard curve (Figure 3.10). The 
presence of carbohydrate by indicated with the development of a bluish-green colour 
observed following the incubation of the crude biosurfactant solution with anthrone reagent. 
The amount of the carbohydrate present was estimated using the standard graph (Figure 
3.10) and a concentration of 0.186 ± 0.07 mg per 1mg of the crude sample was calculated 
(Table 3.2).   
 
 
 
 
 
 
 
Figure 3.9 Thin layer chromatography of Lp-BS. The extracted biosurfactant Lp-BS 
demonstrated no lipid spot following staining with ammonium molybdate/cerium IV 
sulphate stain while the two lipid moieties of the mono- and di-rhamnolipid (RL) 
positive control are shown as brown spots (red arrows). 
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3.3.4 Fractionation by size exclusion and chemical analysis 
The crude Lp-BS was fractionated by size using a fast protein liquid chromatography (FPLC). 
Five absorption peaks were detected (Figure 3.11). A sharp tall peak was detected for 
fractions A6-A9 followed by short but broad peak between A10-B14. Three small sharp peaks 
were observed from fractions B13-B1. Based on the chromatogram profile (Figure 3.11), 
fractions A6-A9, A10-B14, B13-B10, B9-B7 and B6-B1 were pooled and denoted fraction 1 (F1), 
Table 3.2 Summary of the chemical composition of the crude biosurfactant 
extract (Lp-BS) 
Compound mg of the compound /1 mg of dialysed cell-bound BS 
(Lp-BS) 
Carbohydrate 0.186 ± 0.07 
Protein 0.538 ± 0.16  
Lipid -  
Figure 3.10 Standard curve generated from anthrone assay relating glucose 
concentration to absorbance at 620 nm. The equation from the curve y = 0.0027x 
+ 0.0495 allowed to calculate carbohydrate concentration in the dialysed cell-
bound extract.  
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fraction 2 (F2), fraction 3 (F3), fraction 4 (F4), and fraction 5 (F5) respectively. Low yield was 
obtained for fractions 3-5 (1 mg/20 mg of loaded Lp-BS). Dialysed freeze-dried fractions were 
subjected to anthrone assay for the detection of carbohydrate presence. Fraction 1 (F1) and 
fraction 2 (F2) were positive for carbohydrate while no sugar was detected for the other three 
fractions (F3, F4 and F5). Analysis for protein was performed via SDS-PAGE and the gel was 
stained with colloidal coomassie stain (Figure 3.12). No protein bands were observed for 
fraction 3, 4 and 5. Conversely, many protein bands of different intensity and molecular 
weights were visible for fraction 1 and 2. Fraction 1 was the most abundant of protein bands 
of molecular weight of 10-110 KDa. Fraction 2 also revealed many protein bands of molecular 
weights between 10-73 KDa.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        High molecular weight                                                                                                                           Low molecular weight 
        F1                 F2               F3      F4 F5 
Figure 3.11 Representative chromatogram of crude Lp-BS fractionation via size 
exclusion FPLC. Five peaks were eluted through Sephacryl HR-100 (fractionation 
range 1-100 KDa). Additional FPLC runs yielded identical chromatogram profiles. 
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3.3.5 Detection of biosurfactant fractions by EI24  
By running an emulsification index 24h assay on the first two fractions (F1 and F2), it was 
shown that only fraction 1 demonstrated emulsifying activity on xylene indicating that this 
fraction contained the biosurfactant compound. However, fraction 2 showed similar result to 
the water negative control indicative of the absence of biosurfactant (Figure 3.13).  
 
 
Figure 3.12 Protein separation of the crude Lp-BS and its size exclusion 
fractions by Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE). The gel was stained with colloidal coomassie stain. No bands of 
fractions 3, 4, and 5 (denoted F3, F4 and F5) were visible. Fractions 1 (F1) and 
2 (F2) showed many bands of different molecular weights and intensity. CHO 
stands for carbohydrate examined by anthrone assay for the five Lp-BS 
fractions; + indicates positive for sugar, - indicates the absence of sugar. 
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3.3.6 Liquid chromatography-mass spectrometry (LC-MS) 
Protein separation profile of Lp-BS by means of SDS-PAGE and coomassie stain revealed that 
numerous protein bands of different intensities were detected (Figure 3.14). Their molecular 
weights ranged from 10-150 KDa. Ten bands (most intense ones) were cut and sent for LC-MS 
analysis. The reports from Bristol proteometry centre showed the results of a Sequest search 
against the Uniprot L. plantarum database. The data were filtered at 1 % FDR and also any 
proteins that were only matched by a single peptide were removed. The identification was 
performed twice and consistent results were obtained. Numerous different proteins (>100) 
were detected for each band (see Appendix I). A score cut-off of ≥ 100 of the identified 
proteins was selected to narrow down the search and the search was done using Uniprot 
(https://www.google.co.uk/search?q = uniprot&rlz=1C1JZAP_arGB700GB710&oq = 
uniprot&aqs = chrome.69i57j0l5.6499j1j4&sourceid = chrome&ie=UTF-8, 27/ Nov / 2018) and 
other publications of similar proteins of Lactobacillus spp. Bands 9 and 10 (Figure 3.14) were 
not included in the search because their maximum proteins scores were below the selected 
cut-off.  
 
 
Figure 3.13 Emulsification index 24 (EI24) of the freeze-dried FPLC fractions. Only fraction 
1 showed emulsifying activity against xylene demonstrated as a creamy white top layer. No 
difference between the negative water control (DW) and F2 in their emulsifying effect when 
mixed with xylene indicative of the absence of biosurfactant. DW, distilled water.  
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A search for Lactobacillus surface proteins that contribute to cell adhesion was undertaken. 
Only three proteins were found to be involved in L. plantarum adhesion (Table 3.3). Bands 2, 
3, 4, and 5 (Figure 3.14) were found to contain the protein “Elongation factor Tu 
OS=Lactobacillus plantarum (strain ATCC BAA biosynthesis (Uniprot), this protein was 
identified as a mucin adhesion factor of L. plantarum CS23 and L. plantarum CS24·2 (Dhanani 
and Bagchi 2013) (Table 3.3). Likewise, Glyceraldehyde 3-phosphate dehydrogenase 
OS=Lactobacillus plantarum (strain ATCC BAA-793 / NCIMB 8826 / WCFS1) OX=220668 
GN=gapB PE=3 SV=1 - [F9UM10_LACPL] (Swiss-Prot accession number F9UM10) was 
identified in bands 3, 4, 6, 8 (Figure 3.14) and was found to function as mucin binding protein 
(Kinoshita et al. 2008) (Table 3.3). Enolase 1 OS=Lactobacillus plantarum (strain ATCC BAA-
793 / NCIMB 8826 / WCFS1) OX=220668 GN=eno1 PE=3 SV=1 - [ENO1_LACPL] of an accession 
number Q88YH3 (Swiss-Prot) was identified in band number 3 only (Figure 3.14). This protein 
functions as fibronectin-binding protein (Uniprot, 27/Nov/2018) and a collagen-binding 
protein (Castaldo et al. 2009; Kainulainen and Korhonen 2014; Salzillo et al. 2015) (Table 3.3).  
Figure 3.14 Protein separation profile of crude Lp-BS in preparation for mass spectrometry. 
Gel stained with colloidal coomassie stain. Ten bands (red arrows) were cut and subjected to 
the process of digestion in preparation of LC-MS analysis. 1, standard; 2, Lp-BS. 
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Table 3.3 Lp-BS mass spectrometric identification of adhesin-like proteins 
 
 
 
 
Protein Uniprot 
Accession 
no.  
Band no. Score  
in each band 
respectively 
% coverage 
in each band 
respectively 
Function* Reference 
Elongation factor Tu Q88VE0 2, 3, 4, 5 104.6, 894.0,  
136.5,  158.7 
 
64.5,  74.4,  
64.3,  64.5  
Mucin adhesion 
factor 
Dhanani and Bagchi 2013 
Enolase 1 Q88YH3 3 252.6 69.2 Fibronectin and 
collagen-binding 
protein 
Uniprot; Castaldo et al. 2009; 
Kainulainen and Korhonen 
2014; Salzillo et al. 2015. 
Glyceraldehyde 3-
phosphate 
dehydrogenase (GAPDH) 
F9UM10 3, 4, 6, 8 110.8,  776.2,  
311.7,  106.0 
63.8,  80.2,  
69.7,  63.5 
Mucin-binding 
protein 
Kinoshita et al. 2008 
*, adhesin-like function is stated here only, other metabolic and catalytic functions are not included; Score, The sum of the ion scores of all 
peptides that were identified; % Coverage, The percentage of the protein sequence covered by identified peptides. 
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3.4 Discussion  
As previously reported (Chapter 2), L. plantarum showed potential antimicrobial activity 
against SAG and E. faecalis growth in-vitro justifying further investigations. Biosurfactant 
production has been proposed as one of the  antimicrobial mechanisms of lactic acid bacteria 
(Reid and Bruce 2001; Sharma et al. 2016). In this chapter, L. plantarum was assayed for 
biosurfactant production as a possible antimicrobial.  
In this work and for the first time, a high molecular weight cell-bound biosurfactant was 
successfully extracted from L. plantarum NCIMB8826 strain at the mid-log phase by passive 
release into PBS. The extracted crude biosurfactant showed good surface tension and 
emulsifying activity comparable to that of the commercial rhamnolipid. A preliminary 
characterisation by FT-IR together with conventional protein, carbohydrate and lipid analysis 
was found to be effective in providing a rapid, but partial, chemical picture of the crude Lp-
BS as a glycoprotein. Mass spectrometric analysis revealed a complex proteomic composition 
of Lp-BS and successfully enabled the identification of three of the adhesin-like proteins which 
might suggest an antiadhesive effect of this biosurfactant (Rams et al. 2014). Importantly, 
chromatographic fractionation based on size exclusion was shown to be suitable to partially 
purify the biosurfactant utilising its propensity to aggregate into micelle.   
To account for the kinetics of L. plantarum biosurfactant production and its relation to 
bacterial growth, samples were collected at different time points of L. plantarum growth 
curve. As biosurfactant can be either cell-bound or excreted into the culture medium, L. 
plantarum production of cell-bound and excreted biosurfactants was assessed using MRS as 
a culture medium. No reduction in surface tension of the culture broth was observed for any 
of the four MRS-extracts suggesting that L. plantarum does not produce extra cellular 
biosurfactant under the conditions studied. Contrary to that, the four cell bound samples 
showed the ability to reduce surface tension (Table 3.1).    
Biosurfactants synthesis can be either spontaneous to increase the bioavailability of nutrients 
for actively growing bacteria or triggered by various physical and chemical stresses as an 
ecological strategy to survive such as growth under condition of low concentration of nitrogen 
or carbon source; for example, when bacteria reach stationary phase with limitation of the 
nutrients and activation of quorum sensing (QS) system (Desai and Banat 1997; Bhardwaj et 
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al. 2013; Ocampo 2016; Santos et al. 2016). Different biosurfactants production kinetics, 
though not fully characterised as yet, have been reported for various bacteria (Desai and 
Banat 1997; Rodrigues et al. 2006; Gudiña et al. 2011). This can be classified as (a) growth-
associated production; (b) production under growth-limiting conditions; (c) production by 
resting or immobilised cells; and (d) production with precursor supplementation (Desai and 
Banat 1997; Santos et al. 2016). The fact that Lp-BS was produced over the four time points 
of growth phases might indicate that its production followed these kinetics mentioned earlier 
(except d). Since Lp-BS was produced when L. plantarum grew in MRS broth in the absence of 
a continuous nutritional supply (such as would be provided in a bioreactor system), it might 
be that it was produced impulsively during the log phase and then tapered over time due to 
the limitation of nutrients which are essential and determinative of biosurfactant production. 
Cell density has been associated with biosurfactant production (Adebusoye et al. 2008; 
Ocampo 2016) and it might be that L. plantarum biomass reached a critical cell density which 
resulted in a negative feed-back reduction to biosurfactant production.  
No satisfactory information is available to explain why certain bacteria produce cell-bound 
and others, extracellular biosurfactants. Nevertheless, it has been proposed that extracellular 
biosurfactants facilitate the emulsification of substrates that are insoluble in water 
(hydrophobic) and make them accessible for bacterial utilisation while the cell bound 
biosurfactants might have a role in the bacterial cell adhesion to different surfaces (Desai and 
Banat 1997; Tan and Kong 2000; Ocampo 2016). Accordingly, the lack of hydrocarbons in the 
MRS medium might explain why a cell-bound biosurfactant was produced by L. plantarum 
rather than a released extracellular one. However, given that a recent review of lactic acid 
bacterial species demonstrated that a majority (40 out of 46) produced cell-bound 
biosurfactants (Satpute et al. 2016) and that lactic acid bacteria (LAB) are frequently reported 
to play a beneficial role in preventing tissue attachment by pathogens and colonisation 
(Blomberg et al. 1993; Satpute et al. 2016), it seems plausible that cell-bound biosurfactant 
production is a species-specific phenomenon contributing to the native antiadhesive role of 
LAB in their natural environment. This may explain why the focus for cell associated 
biosurfactant usage appears to be related to anti-adhesive rather than antimicrobial effects. 
Similarly, a strain of L. plantarum isolated from the vagina of healthy Nigerian women showed 
the potential to produce large amounts of cell-bound biosurfactant after 18 h incubation in 
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MRS medium. This strain was proposed as a good anti-infective candidate since it 
demonstrated inhibitory effect against urogenital pathogens (Anukam and Reid 2007). In 
another study (Madhu and Prapulla 2014), L. plantarum CFR 2194, an isolate from kanjika, a 
rice-based Ayurveda fermented product was tested for biosurfactant production over 24, 48 
and 72 h in MRS. The three cell-bound samples (24, 48 and 72 h) demonstrated a reduction 
in surface tension with the maximum effect observed for the sample collected late at 72 h 
with significant antiadhesive activity against food-borne pathogens. Moreover, two L. 
plantarum strains (L26 and L35) isolated from Romanian traditional fermented food products 
grown in MRS medium were found to produce cell-bound biosurfactants during the 
exponential growth phase, but production continued to increase significantly in the stationary 
phase, and reached highest value after 48 h of incubation (Cornea et al. 2016).  
Although Lp-BS was produced at a relatively low biomass of 40 mg/L of culture medium, it is 
in accordance with the biomass of cell-bound biosurfactants extracted from other lactic acid 
bacteria (20-100 mg/L) (Velraeds et al. 1996; Velraeds et al. 1996; Busscher et al. 1997; 
Rodrigues et al. 2006b; Rodrigues et al. 2006; Gudiña et al. 2015). 
Lp-BS was shown to exert surface tension and emulsifying activity and therefore can be 
considered as a biosurfactant and bioemulsifier (Willumsen and Karlson 1996; Batista et al. 
2006). A reduction of surface tension of > 8 mN/m has been considered as an indicator for 
biosurfactant-producing bacteria (Busscher et al. 1994; Velraeds et al. 1996). A reduction of 
surface tension between 12-33 mN/m by cell-bound biosurfactants extracted from different 
Lactobacillus spp (Velraeds et al. 1996; Meylheuc et al. 2006; Rodrigues, et al. 2006b; Goŀek 
et al. 2009; Brzozowski et al. 2011; Gudiña et al. 2011; Madhu and Prapulla 2014) has been 
reported, and this is in accordance with the results obtained herein with Lp-BS (17.3 ± 0.5 
mN/m). Comparable emulsifying activity (28 %) was reported for Lp-BS to that of other 
lactobacilli. For instance, L. plantarum CFR2194 was documented to produce a biosurfactant 
with emulsifying effect on different hydrocarbon substrates of around 13-38 % (Madhu and 
Prapulla 2014). Another Lactobacillus, L. pentosus CECT4023, was reported to produce 
biosurfactant which emulsified gasoline, kerosene and octane to a higher extent (EI24 > 40%) 
(Moldes et al. 2013). An even more powerful bioemulsifier was extracted from L. agilis 
CCUG31450 with emulsifying index of 60 % against n-hexadecane (Gudiña et al. 2015). In 
industry, particularly pharmaceutical, surfactants are extensively utilised. The use of these 
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synthetic products may present concerns with regard to environmental pollution and noxious 
hazards. Hence, biosurfactants have been studied as an alternative (Desai and Banat 1997) 
offering the advantages of higher environmental sustainability, better foaming properties and 
stability at pH, salinity and temperature extremities (Mukherjee et al. 2006). Since Lp-BS was 
found able to demonstrate these two surface activities, a promising application of this agent 
might be achieved in the pharmaceutical formulations such as the preparation and 
stabilisation of emulsion, the antimicrobial activity via detergent-like effect on cell membrane 
permeability (Tahzibi et al. 2004; Tabatabaee et al. 2005; Techaoei et al. 2007; Rahman and 
Takashi 2009) and in the cosmetic industry (Vecino et al. 2017). 
Only limited information is available regarding the biochemical composition of the reported 
Lactobacillus biosurfactants which may be due, in part to their complex structure. Only 50 % 
of the publications regarding the cell-associated Lactobacillus biosurfactants have provided 
reports on their chemical composition (Satpute et al. 2016). Protein, carbohydrate and lipid 
analysis of Lp-BS were shown positive but not for lipid. This finding is further supported by 
FT-IR analysis of Lp-BS with functional groups which indicated the identification of a 
glycoprotein compound. Similarly, glycoprotein biosurfactants were identified from a number 
of lactobacilli; L. plantarum CFR2194 (Madhu and Prapulla 2014), L. pentosus CECT4023 
(Moldes et al. 2013),  Lactococcus lactis 53 (Rodrigues et al. 2006), L. casei 8/4 (Goŀek et al. 
2009), L. agilis CCUG31450 (Gudiña et al. 2015),  L. acidophiles (Ismaeel et al. 2013) and L. 
acidophilus ATCC 4356 (Shokouhfard et al. 2015). Of particular interest, biosurfactants 
isolated from L. agilis CCUG31450 (Gudiña et al. 2015) and L. plantarum CFR2194 (Madhu and 
Prapulla 2014) had FT-IR spectra of functional regions almost identical to that of Lp-BS, 
sharing the same functional groups of protein and carbohydrate. However, their fingerprint 
regions were not the same, indicating they are different compounds. It has been reported 
that the composition of protein and carbohydrate fractions of lactobacilli glycoproteins 
biosurfactants are affected by many factors such as the composition of the growing medium, 
duration, pH, temperature of incubation, inoculum volume and the growth phase of bacteria 
(Ch and Khanaqa 2010; Satpute et al. 2016). To the best of knowledge, no previous reports 
on biosurfactants have highlighted the value of the FT-IR fingerprint region as a differentiating 
tool to compare the biosurfactants of the same constituents.  
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The protein profile obtained via SDS-PAGE and silver staining indicated that the mid-
exponential phase time point demonstrated  more protein bands than in samples collected 
from the other time points (16, 24 and 84 h), which may be due to the physiology of the log 
phase when actively growing cells undergo DNA synthesis, transcription and translation to 
synthesise the required molecules (Faith et al. 2007). The abundance of protein bands reflects 
the heterogeneity of the proteins of the crude Lp-BS. Though not common, a number of 
studies used electrophoresis for biosurfactant identification. For instance, the Toren research 
group (Toren et al. 2001) successfully purified three Alasan bioemulsifier proteins and 
identified them by means of SDS-PAGE and coomassie stain. Their molecular weights were 
found to be 16, 31, and 45 kDa; the 45 KDa protein was the most surface active one. 
Moreover, SDS-PAGE analysis of a semi-purified biosurfactant extracted from the marine 
Vibrio spp. designated strain 3B-2 revealed the presence of miscellaneous proteins bands. 
Following its purification by chromatography, the electrophoresis revealed a pure product 
with single protein band gel (Hu et al. 2015). These findings suggest the usefulness of protein 
electrophoresis as an indication of purity and content of the investigated biosurfactants. In a 
study conducted by Shokouhfard and co-workers (Shokouhfard et al. 2015), a crude cell-
bound biosurfactant was extracted from L. acidophilus ATCC 4356. Its FT-IR analysis appeared 
to be mostly protein. Interestingly, its protein profile obtained from SDS-PAGE and staining 
with coomassie blue G250 revealed the presence of a single band with approximate size of 10 
kDa. Although the biosurfactant was extracted in the same way used in our study with Lp-BS 
(i.e. by suspending the cells in buffer and allow the biosurfactant to be released by gentle 
stirring), there was no details on the electrophoresis and staining procedures. The use of 
different procedures might impact on the separation of biosurfactant proteins.   
Further analysis of the crude Lp-BS by in-gel mass spectrometry identified a large number of 
proteins, of which, three (enolase, glyceraldehyde-3-phosphate dehydrogenase and 
elongation factor) have been identified as adhesin-like proteins in addition to having other 
metabolic or catalytic activities, thus can be termed as “moonlighting” proteins (Kainulainen 
and Korhonen 2014). Host tissue extracellular matrix proteins can act as a target for pathogen 
interaction and subsequent tissue colonisation via specific bacterial surface molecules 
(Chagnot et al. 2012; Singh et al. 2012). Likewise, probiotics can display cell surface molecules 
that specifically interact with the host tissue receptors and competitively exclude the  
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pathogens from binding to the same receptor sties thereby exerting their beneficial effects 
(Remus et al. 2013; Salzillo et al. 2015). Such host tissue surface molecules include collagen, 
laminin, fibronectin, mucin and fibrinogen (Castaldo et al. 2009; Sengupta et al. 2013; Yadav 
et al. 2013; Vastano et al. 2014). A number of Lactobacillus adhesion proteins have been 
identified and considered as a critical element contributing to the beneficial effects exerted 
by the bacteria (Nishiyama et al. 2016).  
A surface displaced alfa‐enolase of L. plantarum LM3 has been characterised as a fibronectin 
binding protein (Castaldo et al. 2009). Another study revealed the involvement of EnoA1 alfa‐
enolase of L. plantarum LM3 in type I collagen (CnI) binding (Salzillo et al. 2015). Similarly, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) has been found to be involved in the 
probiotic L. plantarum LA 318 adhesion to human colonic mucin. Possessing GAPDH adhesin 
similar to that of many pathogens makes it possible for the Lactobacillus to compete 
specifically with pathogenic bacteria for adhesion sites in the mouth or intestine host tissue. 
The author suggested the usefulness of L. plantarum LA 318 for the development of probiotic 
anti-infective therapy (Kinoshita et al. 2008). In a study that investigated the role of 
elongation factor-Tu in Lactobacillus adhesion, L. plantarum CS23  and L. plantarum CS24.2 
have shown the potential to adhere to mucin in-vitro and competitively block the adhesion of 
E. coli and Salmonella enterica serovar Typhi to mucin (Dhanani and Bagchi 2013). The authors 
also demonstrated an up-regulation of Lactobacillus EF-Tu gene upon exposure to mucin. This 
adhesin EF-Tu was found to significantly hinder the adhesion of enteropathogens to mucin 
(Dhanani and Bagchi 2013). Accordingly, the identification of these three surface adhesins in 
Lp-BS mixture might suggest a potential role of Lp-BS as antiadhesive biomolecules of 
therapeutic significance.   
Due to the complex, heterogeneous protein rich nature of Lp-BS, an attempt to purify it was 
performed via FPLC. Five elution fractions were obtained (Figure 3.11). Fraction 1 and 2 were 
assessed for emulsifying activity and only fraction 1 was found to have emulsifying potential 
against xylene indicating that the crude Lp-BS was successfully partially purified with the aid 
of size exclusion chromatography. It is known for biosurfactants to form molecular aggregates 
termed as “micelles” above a certain concentration known as the critical micelle 
concentration (CMC) (Liu et al. 2013). This phenomenon has been utilised for biosurfactant 
purification based on size exclusion. Although the CMC of Lp-BS has not been recorded in the 
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current study, it is possible that Lp-BS formed micelles and that, due to their bulky structure, 
they were eluted in the first column elution fraction (F1). While other small molecular 
contaminants were obtained in later column fractions due to their smaller size and failure to 
form aggregated macromolecules. Similarly, a lipopeptide biosurfactant, extracted from the 
cell-free broth of a marine Bacillus circulans culture, was successfully purified from other 
contaminants via size exclusion chromatography utilising the micelles-forming nature by 
loading the lipopeptide biosurfactant at a concentration higher than its CMC (Mukherjee et 
al. 2009). A study conducted by Sen and Swaminathan, 2005 (Sen and Swaminathan 2005) 
also exploited the micelle-forming behaviour of biosurfactants to purify surfactin. However, 
instead of using size exclusion chromatography, they performed trans-membrane separation. 
Basically, under nitrogen pressure, the surfactin-containing solution was poured into a cell 
and a magnetic bar was continuously stirred driving the solvent and other contaminants out 
through the cell membrane leaving behind the supramolecular surfactin micelle.  
The coomassie stained gel of the obtained Lp-BS FPLC fractions demonstrated the presence 
of considerable number of proteins for F1 indicating that the collected biosurfactant-
containing fraction was only partially purified and further purification by other techniques 
may be required. It might be worth mentioning here that colloidal coomassie stain of the SDS-
PAGE gel resulted in better resolution and highlighting of bands of the separated crude Lp-BS 
proteins than silver staining. This might be due to the glycoprotein nature of Lp-BS. Although 
silver stain can be used for protein with limited degree of glycosylation especially when extra 
sensitivity is required, however this stain might lose its sensitivity when applied for the 
detection of highly glycosylated proteins (protein-glycosaminoglycans or glycoproteins). This 
is presumably due the steric intervention with silver ions binding caused by the carbohydrates 
resulting in weak or even no detection giving a smear rather than a definite band (Møller and 
Poulsen 2009).  
3.5 Conclusion 
In summary, the work reported in this chapter was successful in the characterisation of a cell-
bound glycoprotein biosurfactant extracted from the potential probiotic L. plantarum during 
its exponential growth. This biosurfactant, besides reducing surface tension of PBS, 
demonstrated emulsifying activity against a number of hydrocarbons making it suitable for 
future pharmaceutical applications. Partial purification has been achieved by performing size-
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exclusion chromatography with the biosurfactant eluted in the early column fraction 
indicating the formation of bulky biosurfactants molecules. The heterogeneity of proteins 
obtained in the biosurfactant fraction signifies the need for further purification. Purification 
of the crude sample should be carefully analysed as each purification step will increase the 
costs and decreases the amounts of biosurfactants recovered. Proteins identification of Lp-BS 
by means of mass spectrometry revealed the presence of three potential moonlighting 
adhesins which might be involved in the biosurfactant antiadhesive activity. However, further 
investigations are needed to assess their role in adhesion and subsequent biotherapeutic 
application.  
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4 Chapter 4 Antimicrobial and antiadhesive activity of Lp-BS and 
rhamnolipid 
4.1 Introduction  
Initial screening of five probiotic stains for their antimicrobial effects against SAG and E. 
faecalis (Chapter 2) demonstrated L. plantarum as the potential one showing significant 
growth inhibitory effect against the four endodontic pathogens. L. plantarum was further 
investigated for biosurfactant production (Chapter 3) and was shown able to produce a cell-
bound biosurfactant (Lp-BS), which was partially purified and characterised as a mixture of 
glycoproteins. Three proteins of adhesin-like effect were also identified in the biosurfactant 
mixture proposing for possible antiadhesive potential. Before translation into clinical use 
becomes possible, this biosurfactant compound needs to be studied further for its in-vitro 
antimicrobial and antiadhesive effect against the endodontic pathogens.  
Microbial decontamination is a crucial key element for the success of vital pulp therapy and 
for the preparation of root canals prior to filling (Ghoddusi et al. 2014). This can be achieved 
not only by providing direct antimicrobial effect but also via prophylactic protection against 
microbial pulp and root canal colonisation. Such properties may be an inherent property of 
biosurfactants. The expanding problem of antibiotic resistance necessitates the investigation 
of alternative approaches to fight pathogenic infections. Generally, microbial biosurfactants 
have been studied for their medical and industrial applications (Singh and Cameotra 2004; 
Rodrigues et al. 2006; Oelschlaeger 2010) and their structure-related characteristics have 
been a field of increasing interest in exploring their biomedical applications such as antiviral, 
antimicrobial, antifungal and anticancer properties (Fiechter 1992; Singh and Cameotra 2004; 
Kosaric and Sukan 2014; Fracchia et al. 2015; Callaghan et al. 2016). A number of 
biosurfactants have been documented with known antimicrobial activity including surfactin 
and iturin produced by B. subtilis strains (Ahimou et al. 2000), mannosylerythritol lipids 
from Candida antarctica (Rufino et al. 2011), rhamnolipids from P. aeruginosa (Maier and 
Soberon-Chavez 2000), and biosurfactants isolated from S. thermophilus A and Lactococcus 
lactis 53 (Rodrigues et al. 2006). The specific mechanisms of biosurfactants antimicrobial 
activity have not been fully elucidated yet. Studies have suggested that biosurfactants have 
comparable mechanisms to the conventional antibiotics (Banat et al. 2010), for instance, they 
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can directly integrate into and disrupt the integrity of the pathogens cell membrane or by 
interfering with protein synthesis resulting in cell death (Abalos et al. 2001; Das et al. 2008; 
Sang and Blecha 2008; Yount and Yeaman 2013).  
The ability of microorganisms to adhere to distinct host tissue surface components via 
binding-proteins has been considered an important virulence factor that participates in 
initiating infections (Flock 1999) and biofilm formation (Huang et al. 2011). Biosurfactants 
have been shown to provide another valuable application as antiadhesive agents. These 
molecules can adsorb to the substratum surfaces or infection sites and the process appears 
to result in change in hydrophobicity and/or to interfere with the microbial adhesion process 
(Rodrigues et al. 2006).  
Often present as  part of the normal human microbiota , probiotic bacterial species and their 
biosurfactants might offer the advantage of being innocuous to humans and can be effectively 
medically applied (Sharma et al. 2016). Moreover, because of their proteinaceous nature, 
most biosurfactants produced by strains of Lactobacillus are commonly supposed to be 
surlactin type with high potential toward hampering pathogen adherence. Researchers have 
recently focused on the antiadhesive and antibiofilm properties of lactobacilli-derived 
biosurfactants which have provided promising results (Gudiña et al. 2010; Satpute et al. 
2016).  
Several well-known and widely used antimicrobial activity bioassays can be employed such as 
disk-diffusion, well diffusion and broth or agar dilution. More sophisticated techniques that 
provide rapid results such as flow cytofluorometric and bioluminescent methods are also 
applicable but not commonly used due to the need of specific equipment and protocol 
optimisation (Balouiri et al. 2016). Regarding antiadhesive assay protocols, pre-adhesion 
treatment of surfaces to be studied with the biosurfactant solution and crystal violet staining 
is the most commonly used method (Ahimou et al. 2000; Gudiña et al. 2010; Rufino et al. 
2011; Janek et al. 2012; Gudiña et al. 2015). Confocal laser scanning microscopy and SEM 
have been also used for visualising the attached bacterial layer in the absence or presence of 
the biosurfactant preconditioning (Janek et al. 2012; do Valle Gomes and Nitschke 2012; 
Sambanthamoorthy et al. 2014; Silva et al. 2017; Ceresa et al. 2018).  
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In light of these and other observations and considering there are no previous studies on the 
effectiveness of L. plantarum NCIMB 8826 biosurfactant and rhamnolipid on SAG and E. 
faecalis growth or adhesion, the aim of this work presented in this chapter was to assess the 
in-vitro antimicrobial and antiadhesive efficacy of the two biosurfactants. In doing so, their 
use as a model antimicrobial for future application as pulp and/or root canal therapy could 
be considered.  
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4.2 Material and methods 
4.2.1 Antimicrobial activity determination 
4.2.1.1 Growth inhibition on agar plates by well diffusion assay 
Overnight broth cultures of S. anginosus, S. constellatus, S. intermedius and E. faecalis isolates 
in BHI were prepared and adjusted to OD 600 of 0.08-0.1 (1.5 x 108 CFU/mL). Bacterial lawn 
plates of each studied strain were prepared by evenly swabbing the adjusted bacterial culture 
over the surface of an FAA plate using a sterile cotton swab. Wells were then punched into 
the agar using a sterile 6 mm biopsy punch. Two hundred microliter of pH 7.0 Lp-BS solution 
in PBS (50 mg/mL) or rhamnolipid (Sigma 90% purity) (50, 25 and 12.5 mg/mL in PBS) were 
then pipetted into the wells and the plates were incubated at 37 °C in 5 % CO2 for 24 h. Growth 
of bacteria was considered to be inhibited where a clear area of agar was observed around 
the inoculation site, in contrast to the bacterial growth covering the rest of the plate. For the 
purpose of comparison with the literatures regarding the activity of the studied 
biosurfactants, E. coli NCTC 10418 and S. aureus NCTC 8325 were also included herein as 
reference strains for the Gram negative and Gram positive bacteria respectively. Their lawn 
plates were prepared in the same way as with the test strains. Vancomycin (1 mg/mL) was 
used as a positive control against the Gram positive stains and gentamicin (1 mg/mL) against 
the Gram negative stain, while PBS was inoculated as a vehicle control. Three plates were 
inoculated for each strain a time and the whole experiment was repeated on three separate 
occasion.  
4.2.1.2 Determination of the minimum inhibitory concentration (MIC) of Lp-BS and 
rhamnolipid   
The minimum inhibitory concentration of Lp-BS and rhamnolipid against the endodontic 
pathogens (SAG and E. faecalis RB17) and against the reference strains (S. aureus NCTC 8325 
and E. coli NCTC 10418) was determined by broth microdilution susceptibility assay 
(Magalhães and Nitschke 2013) in 96-well plastic tissue culture plates (SARSTEDT, Germany). 
The biosurfactant was dissolved in BHI medium at a starting concentration of 50 mg/mL (pH 
7.0) and sterilised by filtration through a 0.22 µm pore-size filter (Whatman, GE Healthcare, 
UK). Subsequently, 200 µL of BHI medium containing the biosurfactant were placed into the 
first column of the 96-well microplate, and 100 µL of un-inoculated BHI medium in the 
remaining wells. After that, 100 µL from the first column were transferred to the second 
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column and mixed. Serially, 100 µL was transferred to the subsequent wells, discarding 100 
µL of the mixture in the final column. This process resulted in two-fold serial dilutions of the 
biosurfactant, with the biosurfactant concentration ranging from 50-0.01 mg/mL. The last two 
columns did not contain biosurfactant and served as growth and negative controls. All the 
wells (except for the broth negative control column) were inoculated with 10 µL of a pre-
culture of the corresponding microorganism grown overnight in BHI medium at 37 °C and 5 % 
CO2 and diluted to an optical density (600 nm) of 0.08-0.1 (corresponding to 1x108 CFU/mL) 
and further diluted 1:10 in BHI (ESCMID) 2003). The absorbance (at 600 nm) of the wells was 
measured at time zero (T0) using a microplate reader (FLUOstar Omega, BMG Labtech, 
Ortenberg, Germany). The microplate was then immediately covered and incubated for 24 h 
at 37 °C and 5 % CO2. After 24 h of incubation, the absorbance of each well plate (at 600 nm) 
was measured (T24). The MIC was determined at the concentration where the percentage of 
inhibition was > 90 % (Kolarević et al. 2016) according to the following formula: 
% Growth Inhibition c = [1 − (Ac / AO)] × 100 
, where Ac represents the absorbance of the well with a biosurfactant concentration c, and 
AO the absorbance of the growth control well (without biosurfactant). 
  Triplicate assays were performed for each microorganism and biosurfactant concentration. 
4.2.2 Pre-coating treatment characterisation 
To investigate for biosurfactant antiadhesive activity, three different surfaces were first 
examined to select for the one which could be successfully coated. These surfaces included 
glass slide, acrylic discs and dentine discs.  
4.2.2.1 Glass surface 
4.2.2.1.1 Coating glass slide with Lp-BS solution  
Briefly, 200 µL of Lp-BS at a concentration of 50 mg/mL and 20 mg/mL in PBS was added to 
the corresponding well of an 8-well chamber soda-lime glass slide (8 Well Falcon Culture Slide, 
Corning Incorporated Life Sciences, USA) and the same volume of PBS buffer were added to 
the control wells in triplicate. The slide was then wrapped in parafin foil and incubated at 37 
°C for 24 h and subsequently washed twice with PBS buffer for subsequent characterisation. 
The experiment was repeated three times.  
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4.2.2.1.2 Fluorescent characterisation of Lp-BS coating 
After coating the glass slide with the biosurfactant solution and washing twice with PBS (as 
described in Section 4.2.2.1.1), its plastic chamber was removed according to the 
manufacturer’s instructions (Falcon 8 Well Culture Slide, Corning Incorporated Life Sciences, 
USA) by means of the provided Chamber Removal Key and Safety Removal Fixture (Figure 
4.1). The coated and the uncoated control wells were then prepared for microscopy analysis 
by staining with 20 µL/well of the ready to use fluorescent SYPRO Ruby Protein Gel Stain 
(Thermo Fisher Scientific, UK) for 1 min. The stained slide was then overlaid with a glass cover 
slip and visualised using Olympus Provis AX 70 fluorescence microscope. The Live/Dead filter 
cube was used with the fluorescent microscope because it has emission spectrum similar to 
that of SYPRO Ruby Protein Gel Stain so it can be used to visualise the stain and the bacteria 
during subsequent antiadhesive assay. A low magnification of 20x was used to get a complete 
view over the entire well surface area. The slides were protected from exposure to light 
between imaging by foiling with aluminium foil.  
 
 
 
 
 
 
 
 
 
 
1                                                                2                                                              3 
Figure 4.1 Representative diagram of 8-well glass slide chamber removal. Adopted from the 
manufacturer’s instruction leaflet (Falcon 8 Well Culture Slide, Corning Incorporated Life 
Sciences, USA). 
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4.2.2.2  Acrylic (poly (methyl-methacrylate), PMMA) coupon 
4.2.2.2.1 Acrylic (poly (methyl-methacrylate), PMMA) coupon preparation  
To provide cheap and easy to prepare surface for coating characterisation, disc shaped poly 
(methyl methacrylate) (PMMA) coupons were prepared according to the manufacturer’s 
instructions. Briefly, self-cure acrylic polymer (Bracon Ltd., Etchingham, UK) was added to self-
cure acrylic monomer (Bracon Ltd.) at a 2:1 ratio and mixed by hand until homogenous. The 
mixture was then carefully poured into a plastic mould (with pre-cut circular sections of 
approximately 10 mm diameter and 2 mm thickness) and compressed between two thick and 
smooth glass plates. The mixture was allowed to cure under ambient conditions overnight. 
The coupons were sanded to remove rough edges, if present. The coupons were allowed to 
soak in filtered sterilised water for a minimum of 7 d to allow excess monomer to leech out, 
before being sterilised by autoclaving at 121 °C for 15 min. Coupons were stored in sterile 
distilled water prior to use, and as they were intended for single use only, used coupons were 
discarded after experimentation.  
4.2.2.2.2 Coating acrylic coupons with rhamnolipid and Lp-BS solutions 
Solutions of rhamnolipid (0.048, 0.097 and 50mg/mL) and Lp-BS (50 mg/mL) in PBS were 
prepared. An appropriate number of sterile acrylic coupons prepared (as described above) 
were placed in each bijoux bottle containing the rhamnolipid, Lp-BS solution or PBS buffer as 
a negative control and incubated at 37 °C with continuous agitation for 24 h. Subsequently 
the coupons were removed from the biosurfactant solution and PBS and washed twice with 
PBS for subsequent characterisation.   
4.2.2.2.3 Characterisation of rhamnolipid and Lp-BS-acrylic coupon coating with scanning 
electron microscopy (SEM)  
Scanning electron microscopy was used to further characterise the biosurfactant-coating of 
acrylic coupons. The pre-coated coupons were coated (as described above) and allowed to 
air-dry for 15 min. The coupons were sputter coated with gold (2-20 nm thick) using 
sputter coaters with rotary pump and gold-palladium target (DSR1 desk sputter coater; 
VacTechniche- East Sussex, UK), and imaged on a Tescan VAGA SEM system, at 5-10 kV.   
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4.2.2.2.4 Characterisation of rhamnolipid-acrylic coupons coating with crystal violet 
staining 
Crystal violet stain binds to the carbohydrates and peptidoglycans in bacterial cell walls 
(Beveridge 2001).  This property was utilised here for the characterisation of rhamnolipid 
coating where it can bind the rhamnose moiety. Briefly acrylic coupons were coated with 50 
mg/mL rhamnolipid as previously outlined in section 4.2.2.2.2. The discs were then allowed 
to air-dry and then stained with Gram’s stain crystal violet (Thermo Scientific™ Remel™, Gram 
Stain Kit) for 5 min. The coupons were then removed from the stain and washed once with 
running tap water and examined by eye in comparison to the uncoated discs.  
4.2.2.3 Dentine discs 
4.2.2.3.1 Dentine discs coating with rhamnolipid and Lp-BS solutions  
Solution of rhamnolipid and Lp-BS in PBS were prepared at concentrations of 50 mg/mL and 
20 mg/mL respectively. Three dentine discs (5mm diameter wafers of devitalised dentine, IDS, 
immunodiagnostic systems) were placed in each bijoux bottles containing the rhamnolipid 
solution, Lp-BS solution or PBS buffer as a negative control and incubated at 37 °C with 
continuous agitation for 24 h. Subsequently the discs were removed from the biosurfactants 
solutions or PBS and washed twice with PBS for subsequent characterisation.   
4.2.2.3.2 Characterisation of rhamnolipid and Lp-BS coating with scanning electron 
microscopy (SEM) 
 To characterise the biosurfactant coating, the coated dentine discs (described above) were 
allowed to air-dry for 15 min. The discs were then sputter coated with gold, and imaged on a 
Tescan VAGA SEM system, at 5-10 kV as previously described (Section 4.2.2.2.3).  
4.2.3 Antiadhesive activity  
4.2.3.1 Lp-BS-coated glass slides 
4.2.3.1.1 Evaluation of Lp-BS antiadhesive effect via microscopic imaging  
To investigate for the potential of the biosurfactant coating to interfere with the attachment 
of endodontic pathogens SAG and E. faecalis to glass surface, an antiadhesive assay was 
performed. An overnight bacterial culture was prepared in BHI, pelleted and adjusted to an 
optical density (600 nm) of 0.6. An aliquot of 200 µL of the adjusted bacterial suspension was 
added to each well precoated with 20 mg/mL Lp-BS (as previously outlined in Section 
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4.2.2.1.1) and the same volume of PBS was added to the control wells. The slide was then 
incubated for 2 h at 4 °C. At the end of the incubation period, each well content was discarded 
and unattached microorganisms were removed by washing the wells once with 200 µL PBS. 
The adherent microorganisms were then fixed with 200 µL 4 % (v/v) formalin (Fisher, UK) for 
24 h for subsequent imaging. Propidium iodide stain (BacLight™ Bacterial Viability Kit, Life 
Technologies) was prepared according to the supplier’s instructions at a ratio of 1 µL in 1 mL 
PBS and protected from light. The slide chamber was removed (as discussed in Section 
4.2.2.1.2, Figure 4.1) and the fixed cells were then stained with 10 µL of propidium iodide per 
well and overlaid into a glass cover slip. The slide was then examined by CLSM (Leica SP5, 
AOBS spectral confocal microscope, Leica, Heidelberg, Germany) using the appropriate 
excitation and emission spectra of the Live/Dead stain (excitation 470 nm, emission 490–700 
nm) (BacLight™ Bacterial Viability Kit, Life Technologies) at 40x objective lens. Images of 5 
areas on each well were obtained.  
4.2.3.1.2 Semi-quantification of CLSM microscopic images using COMSTAT 
The surface area covered by the fluorescent bacteria was determined using the image analysis 
program comstat2. Leica image files (.LIF) were converted to OME-TIFF files for analysis by 
COMSTAT using the BIOSTAT macro provided with the software, in ImageJ. The software splits 
files by colour, generating an image for the red (dead) channel. These images are converted 
to greyscale, and any pixel above the threshold value was included for analysis. The area 
covered by the fluorescent bacteria was then measured and calculated.  
4.2.3.1.3 Evaluation of Lp-BS antiadhesive effect via viable cell count 
In addition to microscopical analysis, a viable cell count of the recovered cells from coated 
wells was also performed. Ten and 20 mg/mL concentration of Lp-BS was used for glass 
surface coating as described earlier (see Section 4.2.2.1.1). An aliquot of 200 µL bacterial 
suspension in PBS adjusted to an optical density (600 nm) of 0.6 was added to each well 
precoated with either 10 or 20 mg/mL Lp-BS and the same volume of PBS was added to the 
control wells. The slide was then incubated for 2 h at 4 °C. At the end of the incubation period, 
each well content was discarded and the unattached microorganisms were removed by 
washing the wells once with 200 µL PBS. The slide chamber was removed carefully according 
to the manufacturer’s instructions (as explained in Section 4.2.2.1.2, Figure 4.1) and a 25 cm 
cell scraper (Sarstedt, USA) was used to harvest attached bacterial cells into centrifuge tubes 
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containing 1 mL sterile PBS. The bacterial suspension was then vortex mixed and 10-fold 
serially diluted to 10-4 in sterile PBS. Fifty µL of each bacterial dilution were spirally plated 
onto FAA plates using a spiral plater (Don Whitley Scientiﬁc Limited, Shipley, UK). The 
inoculated agar plates were incubated at 5 % CO2 and 37 °C for 24 h until colonies had grown 
sufficiently to allow visual counting of individual colonies.     
4.2.3.2 Rhamnolipid-coated acrylic coupons 
4.2.3.2.1 Evaluation of rhamnolipid antiadhesive effect via microscopic imaging  
The antiadhesive propensity of rhamnolipid-coating of acrylic coupons was assayed. Briefly, 
coupons were coated with different concentrations (50, 0.097 and 0.048 mg/mL) of 
rhamnolipid solution and uncoated coupons were served as negative controls (as described 
in Section 4.2.2.2.2). Each of the coated or uncoated coupon was gently transferred into 
individual wells of 24-well plate (Sarstedt, USA) and 1 mL of bacterial suspension in PBS 
(adjusted to OD600=0.6) was added to each well. The plate was then incubated for 2 h at 4 °C. 
At the end of the incubation period, the coupons were then transferred into individual wells 
of 24-well plate containing 1 mL PBS for washing and then into wells containing 1 mL of 4 % 
formalin (Fisher) for fixation for 24 h. Each of the fixed coupon was then inverted into a glass 
cover slip containing 10 µL propidium iodide (1 µL propidium iodide in 1 mL PBS). The coupon 
surface was examined by CLSM (Leica SP5, AOBS spectral confocal microscope, Leica, 
Heidelberg, Germany) using the excitation and emission spectra of the Live/Dead stain 
(excitation 470 nm, emission 490-700 nm) (BacLight™ Bacterial Viability Kit, Life Technologies) 
at 40x objective lens. Images of 5 areas on each coupon were obtained and analysed by 
Comstat software as outlined in section 4.2.3.1.2 
4.2.3.2.2 Evaluation of rhamnolipid antiadhesive effect via viable cell count  
Viable cell counts of the recovered bacterial cells was performed alongside microscopic 
analysis. The effect of 50, 0.097 and 0.048 mg/mL rhamnolipid-acrylic coupons coating on 
SAG and E. faecalis adhesion on acrylic discs was assessed by determining the viable bacterial 
cell counts. The same procedure as explained earlier in section 4.2.3.2.1 was followed, but 
instead of fixation in formalin, the coupons were transferred into sterile plastic bijoux bottles 
containing 5 mL PBS and subjected to vortex at 2500 rev/min for 30 sec to detach bacteria. 
The resulting bacterial suspension was then 10-fold serially diluted in PBS to 10-4. For each 
dilution, 50 µL were spirally plated (Don Whitley Scientiﬁc Limited, Shipley, UK) on FAA plates 
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and incubated for 24-48 h at 5 % CO2 and 37 °C and colonies counted. Results were expressed 
as log10 CFU per mL for three independent experiments. 
4.2.4 Statistical analysis 
All experiments were subjected to three repeats on separate occasions. Un-paired t-test 
(GraphPad InStat 3 (v3.06)) was used to evaluate statistical difference between tests’ means 
to the untreated control of COMSTAT images of Lp-BS antiadhesive assay. Dunnett’s one way 
ANOVA (GraphPad InStat 3 (v3.06)) was used to assess statistical difference between the 
tests’ means to the untreated control of viable count antiadhesive assay of Lp-BS and 
rhamnolipid and for COMSTAT images of rhamnolipid antiadhesive assay. A p value of ≤ 0.05 
was considered significant (*, p ≤ 0.05), very significant (**, p ≤ 0.01) or highly significant (***, 
p ≤ 0.001).   
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4.3 Results 
4.3.1 Antimicrobial activity of Lp-BS and rhamnolipid 
4.3.1.1  Zones of inhibition on agar well diffusion assay 
Figure 4.2 shows representative images of the results obtained, which were comparable for 
all 3 independent experiments. Wells that had been inoculated with the three rhamnolipid 
concentrations (50, 25 and 12.5 mg/mL) showed a zone of inhibition against the three SAG 
members and S. aureus growth. E. faecalis and E. coli growth was not affected by the 
rhamnolipid demonstrated by no zone of inhibition after 24 h incubation (Figure 4.2). 
Yellowish zones indicated the haemolysis of red blood cells of the FAA agar medium caused 
by rhamnolipid. Lp-BS on the other hand, did not show any antimicrobial activity against any 
of the tested pathogens indicated by no zone of inhibition at the high concentration of 50 
mg/mL (Figure 4.2).  
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Figure 4.2 Agar well diffusion assay with rhamnolipid and Lp-BS. FAA plates were 
swabbed with culture of SAG members, E. faecalis, S. aureus or E. coli. Wells were 
inoculated with the corresponding material and cultured for 24 h. No antimicrobial 
activity was detected for Lp-BS (50 mg/mL) against any of the tested pathogens. 
Rhamnolipid (RL) demonstrated zone of inhibition against SAG members, S. aureus 
but not E. faecalis and E. coli. PBS, phosphate buffer, RL; rhamnolipid. Images are 
representative of three independent repeats.  
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4.3.1.2 Minimum inhibitory concentration determination 
4.3.1.2.1 Rhamnolipid minimum inhibitory concentration (MIC)  
Bacteria were incubated for 24 h with rhamnolipid solutions in order to assess the 
antimicrobial efficacy of rhamnolipid against these bacterial strains. Table 4.1 represents the 
determined MIC values of rhamnolipid against the tested strains. The lowest rhamnolipid MIC 
value of 0.048 mg/mL was reported against S. constellatus and S. intermedius. S. anginosus 
and S. aureus cultures demonstrated no growth compared to their untreated control cultures 
at rhamnolipid concentration of 0.097 mg/mL. A high MIC value of 50 mg/mL was reported 
for rhamnolipid against E. faecalis but at 0.097 mg/mL E. faecalis growth was inhibited by > 
60 %. No growth inhibitory effect of rhamnolipid solutions was monitored against E. coli 
growth when compared to the untreated control (Table 4.1).  
4.3.1.2.2 Lp-BS minimum inhibitory concentration 
The four endodontic pathogens and the two reference strains (S. aureus NCTC 8325 and E. 
coli NCTC 10418) were cultured with Lp-BS solutions to account for the antimicrobial effect 
of Lp-BS against these bacterial strains. No antimicrobial activity of Lp-BS solutions was 
reported against any of the tested pathogens (Table 4.1).  The lack of antimicrobial effect was 
indicated by no difference in the 24 h-absorbance reading of the Lp-BS treated bacterial 
cultures compared to the untreated growth controls. 
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Table 4.1 Minimum inhibitory concentration (MIC) of Lp-BS and rhamnolipid against SAG, S. 
aureus, E. faecalis and E. coli. No antimicrobial activity of Lp-BS was demonstrated against any 
of the tested pathogens at the highest concentration tested. MICs of rhamnolipid range from 
0.048 mg/mL against S. constellatus and S. intermedius and 0.097 mg/mL against S. anginosus 
and S. aureus. E. coli was found resistant to rhamnolipid while E. faecalis required an MIC of 
50 mg/mL. Data expressed as mean ± SEM. 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.2 Surface coating characterisation  
4.3.2.1 Dentine discs 
No difference in surface morphology or appearance between the uncoated plain dentine discs 
and those coated with 50 mg/mL rhamnolipid was noticed when examined by SEM (Figure 
4.3a and b respectively). Coating discs with 50 mg/mL Lp-BS resulted in clumpy inconsistent 
layer and uneven distribution over the disc surface (Figure 4.3 c1 and c2).   
 
 
 
Bacterial strain MIC (mg/mL) 
 Rhamnolipid Lp-BS 
S. anginosus 670/95 0.097 ± 0.050 ND 
S. constellatus S08‐07 0.048 ± 0.020 ND 
S. intermedius HW13 0.048 ± 0.024 ND 
E. faecalis RB17 50.00 ± 0.00 ND 
S. aureus NCTC 8325 0.097 ± 0.020 ND 
E. coli NCTC 10418 > 50.00 ± 0.00 ND 
MIC; minimum inhibitory concentration, ND; not detected. 
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Figure 4.3 Scanning electron microscopy of dentine discs coated with Lp-BS (50 mg/mL) and 
rhamnolipid (50 mg/mL). No difference in surface appearance between uncoated control disc 
(a) and disc coated with rhamnolipid was observed (b) while disc coated with Lp-BS shows 
clumps or aggregates and uneven distribution (c1 and c2).  
 
4.3.2.2 Acrylic discs                                            
To provide simple, affordable and easy to visualise surface as a coating model, acrylic discs 
were used. The discs were coated with either of the two biosurfactants (Lp-BS or rhamnolipid) 
at 50 mg/mL as an initial concentration and visualised by SEM. As shown by the SEM images, 
surface coated with rhamnolipid (Figure 4.4 b1) displayed no difference in appearance to the 
plain uncoated control (Figure 4.4 a1). Scratching the surface of the coated and uncoated 
discs as an attempt to reveal any difference in surface texture also resulted in no difference 
between rhamnolipid treated surface and the uncoated control (Figure 4.4 b2 and a2 
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respectively). Coupons coated with 50 mg/mL Lp-BS showed inconsistent coating of non-
homogenous and incomplete layer when examined by SEM (Figure 4.4 c1 and c2).   
Following staining with crystal violet, rhamnolipid coating was demonstrated as a light purple 
colour layer when compared to the uncoated control coupons (Figure 4.5) indicating a 
successful coating by rhamnolipid. Hence, acrylic coupons were chosen to assess antiadhesive 
effect of rhamnolipid.   
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a-1 uncoated control b-1 rhamnolipid 50mg/mL c-1 Lp-BS 50mg/mL                    
 
1 
a-2  b-1  c-2  
 
1 
Figure 4.4 Scanning electron microscopy of acrylic discs coated with Lp-BS (50 mg/mL) and rhamnolipid (50 mg/mL). To study antiadhesive 
activity of the two biosurfactants, acrylic coupons were used to provide a simple and economic model for the coating which can be visualised 
under microscope. Discs coated with rhamnolipid (b) show no difference in surface texture  to the uncoated control (a) even after scratching the 
surface as shown in the lower two images (b2 and a2 respectively). Discs coated with Lp-BS show non homogenous coverage over the disc surface 
(c1 and c2). 
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Rhamnolipid-coated coupon                              Uncoated control coupon 
Figure 4.5 Crystal violet staining of acrylic discs coated with 
rhamnolipid 50 mg/mL. Crystal violet binds to the mannose moiety of 
the rhamnolipid molecules. Therefore rhamnolipid coating can be 
detected with crystal violet. The image is a representative of three 
independent repeats.  
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4.3.2.3 Glass slides  
SYPRO Ruby fluorescent stain was used to visualise 8-well chamber glass slide coated with 50 
mg/mL and 20 mg/mL of Lp-BS (Figure 4.6). At the high concentration, the coating was shown 
to be densely accumulated at the well corners due to sloughing and failure to form continuous 
coating (Figure 4.6c). However, a lower concentration of 20 mg/mL showed the ability to form 
a complete homogenous layer of coating over the entire well surface (Figure 4.6b). Therefore 
an 8-well glass slide surface coated with 20 mg/mL Lp-BS was selected for subsequent 
assessment of the antiadhesive activity of the L. plantarum biosurfactant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 SYPRO Ruby stain for imaging Lp-BS coating of 8-well chamber glass slide using 
fluorescent microscopy. a- uncoated control glass slide. b- at 20 mg/mL, continuous layer of 
Lp-BS is shown over the whole well surface compared to the control un-coated well (a).  c- at 
50 mg/mL Lp-BS, non-continuous coating layer is shown with accumulation at the corners 
only. 20x magnification was used. Scale bar represents 10 µm.   
138 
 
4.3.3 Antiadhesive effect  
4.3.3.1 Antiadhesive effect of Lp-BS pre-coating of glass slides 
4.3.3.1.1 Confocal laser scanning electron microscopy (CLSM) 
The antiadhesive activity of the crude Lp-BS (20 mg/mL in PBS) was investigated at the 
bacterial adhesion phase (2 h). Figure 4.7a demonstrates a representation of three 
independent experimental repeats of the confocal imaging of fixed samples. Pre-treatment 
of the glass slides with 20 mg/mL Lp-BS resulted in a significant (p < 0.001) reduction of SAG 
and E. faecalis attachment to the surface when compared to the untreated glass slides as 
measured by the log10 bacterial covered surface (µm2) / field (Figure 4.7b).   
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Figure 4.7 Attachment of SAG and E. faecalis to 20 mg/mL Lp-BS-coated 8 well chamber glass 
slide and to un-coated 8 well chamber glass slide; a- surfaces visualised by confocal laser 
scanning microscopy after fixation and staining with propidium iodide dye using a 40x 
objectives. Scale bars represent 10 µm, b- statistically analysed graph of the bacterial covered 
surface area.  *** p < 0.001 using unpaired t-test and error bars represent SEM.  
 
a- 
b- 
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4.3.3.1.2 Recovery of viable bacterial cells  
The antiadhesive activity of the crude Lp-BS (20 and 10 mg/mL) was further analysed by 
plating and enumeration of the recovered viable cells after attachment for 2 h to coated and 
uncoated glass slide surface (Figure 4.8). At 20 mg/mL, S. anginosus attachment was 
significantly reduced (p < 0.01) by the effect of biosurfactant coating when compared to the 
untreated control. Similarly, S. constellatus and S. intermedius adherence potential to BS-
coated surface was found to be significantly lower than that of the plain uncoated surface (p 
< 0.05). Enterococcus attachment to the Lp-BS-coated surface was also significantly reduced 
(p < 0.01) as demonstrated by lower numbers of viable bacteria recovered. Coating the glass 
surface with the lower concentration of Lp-BS (10 mg/mL) did not significantly reduced SAG 
and E. faecalis adhesion to the coated surface when compared to the uncoated control 
indicating a concentration-dependent antiadhesive activity of the crude biosurfactant.    
 
 
 
 
 
 
 
 
 
 
Figure 4.8 Bacterial cell recovery of SAG and E. faecalis. 8 well chamber glass slides were 
coated with 10 and 20 mg/mL of Lp-BS and bacterial attachment were evaluated by recovery 
of viable cells and enumeration. Error bars represent SEM; ** p < 0.005, * p < 0.05 using 
Dunnett’s one way ANOVA to the corresponding untreated control.    
 
141 
 
4.3.3.2 Antiadhesive effect of rhamnolipid 
4.3.3.2.1 Confocal laser scanning electron microscopy (CLSM) 
Figure 4.9a represents the confocal images of fixed uncoated acrylic coupon controls and 
coupons pre-coated with different concentrations of rhamnolipid and co-cultured with either 
member of SAG or E. faecalis for 2 h. Figure 4.9b is a statistically analysed graph of the covered 
surface area of the treated vs. untreated control. S. anginosus attachment to discs pre-coated 
with 50, 0.097 or 0.048 mg/mL rhamnolipid solutions was found to be significantly reduced 
(p < 0.001) compared to the uncoated control coupons. S. intermedius adhesion to discs 
coated with 50 and 0.097 mg/mL was also significantly lowered when compared to the 
uncoated control (p < 0.05) while coating with the lower concentration of 0.048 mg/mL 
resulted in no significant decrease in attachment (p > 0.05). Conversely, no difference (p > 
0.05) in E. faecalis and S. constellatus attachment to coated or uncoated coupons was 
reported at any of the three tested rhamnolipid concentrations.  
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Figure 4.9 Attachment of SAG and E. faecalis to rhamnolipid-coated acrylic discs (50 mg/mL, 
0.097 mg/mL and 0.048 mg/mL) and un-coated acrylic discs. a- visualised by confocal laser 
scanning microscopy after fixation and staining with propidium iodide dye using a 40x 
objectives. Scale bars represent 10 µm. b- statistically analysed graph of the bacterial covered 
surface area.  Error bars represent SEM; *, p < 0.05; ***, p < 0.001 using Dunnett’s one way 
ANOVA comparing each of the treated group to the untreated control.
b- 
a- 
143 
 
4.3.3.2.2 Recovery of viable bacterial cells  
Enumeration of the viable cells detached from acrylic coupons coated with rhamnolipid (50, 
0.097 and 0.048 mg/mL) revealed a significant reduction (p < 0.01) in viability ( CFU/mL) of 
the recovered S. anginosus compared to untreated control (Figure 4.10) at the three 
concentrations tested. S. intermedius bacterial cells recovered from discs precoated with 
rhamnolipid 50 mg/mL failed to be cultured on FAA plates (CFU/mL = 0.0) while the log10 of 
the bacterial cells recovered from discs precoated with 0.097 and 0.048 mg/mL was 
significantly (p < 0.001) lower than the uncoated control discs (Figure 4.10). S. constellatus 
did not show a significant reduction in attachment to discs coated with 0.097 and 0.048 
mg/mL (p > 0.05) while no viable cells were recovered from discs coated with the high 
concentration of 50 mg/mL rhamnolipid. Enumeration of the plated E. faecalis bacterial cells 
recovered from discs coated with rhamnolipid (50, 0.097 and 0.048 mg/mL) and the uncoated 
control discs showed no significant difference (p > 0.05) (Figure 4.10). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10 Bacterial cell recovery of SAG and E. faecalis from rhamnolipid coated and 
uncoated acrylic coupons.  Acrylic coupons were coated with 50, 0.097 and 0.048 mg/mL of 
rhamnolipid solutions and bacterial attachment were evaluated by recovery and enumeration 
of viable cells. Error bars represent SEM; **, p < 0.01;  ***, p < 0.001 using Dunnett’s one way 
ANOVA comparing each of the treated group to the untreated control group. 
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4.4 Discussion 
Downstream processing of biosurfactants, particularly high molecular weight ones, is 
probably a very expensive and time consuming process. The production of high yield with low 
purifying cost is a critical element for commercialisation of powerful biosurfactants (Smyth et 
al. 2010). Therefore there is a trend towards using biosurfactants of partial,  but clinically 
acceptable, purity (Piljac 2012). Accordingly, Lp-BS was tested for its 
antimicrobial/antiadhesive activity in its crude form at this stage of partial purification. 
Although no antimicrobial effect was observed, surface coating with Lp-BS was found to have 
significant activity in reducing SAG and E. faecalis attachment to artificial surfaces. The results 
obtained herein open future prospects for possible application of this biosurfactant to reduce 
or inhibit the adhesion of pathogenic microorganisms in several biomedical dental 
applications for example in prophylaxis and treatment of caries and pulpitis. 
Rhamnolipid, a commercially available P. aeruginosa derived biosurfactant of 90 % purity was 
also included in the study to examine its antimicrobial and antiadhesive effect against the 
above mentioned endodontic pathogens. Rhamnolipid demonstrated a significant 
antimicrobial activity with MIC values of 50 mg/mL against E. faecalis, 0.097 mg/mL against 
S. anginosus, and 0.048 mg/mL for S. constellatus and S. intermedius. As an antiadhesive 
agent, rhamnolipid showed the potential to significantly reduce the attachment of S. 
anginosus and S. intermedius to in-vitro acrylic surfaces whilst E. faecalis and S. constellatus 
were not affected by rhamnolipid coating.  
Several publications explain the importance of biosurfactants as antimicrobial/antiadhesive 
agents against various infectious bacteria (Gudiña et al. 2010; Rufino et al. 2011; Gomaa 2013; 
Sambanthamoorthy et al. 2014; Ndlovu et al. 2017; Garg and Chatterjee 2018). However,   no 
previous studies have been published regarding L. plantarum NCIMB 8826 biosurfactant 
antimicrobial/antiadhesive activity against the endodontic infective bacteria SAG and E. 
faecalis. Therefore, experiments were performed to determine whether Lp-BS demonstrated 
any antimicrobial activity against these pathogens. It has been reported that several 
biosurfactants possess variable degrees of antimicrobial activity including lactic acid bacteria 
biosurfactants (Banat et al. 2000; Rodrigues et al. 2004; Moryl et  al. 2015; Yan et al. 2019). 
However, not all biosurfactants have been documented  to exert antimicrobial activity in all 
cases (Walencka et al. 2008; Ciandrini et al. 2016; Ndlovu et al. 2017). Supporting  the current 
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findings, a recent study by Yan and colleagues (Yan et al. 2019) reported a lack of antimicrobial 
activity of crude cell-bound L. plantarum biosurfactant against S. aureus at 100 mg/mL. The 
biosurfactant was extracted by the same method employed herein for Lp-BS but no details of 
the extracted biosurfactant chemical structure were provided by the authors.  Conversely, 
two L. plantarum strains isolated from Romanian traditional fermented food products were 
identified and shown to produce biosurfactants with  antimicrobial activity against a number 
of food-borne contaminants (Cornea et al. 2016).  Microbial biosurfactants encompass a wide 
spectrum of chemically diverse compounds such as glycolipids, lipopeptides, polysaccharide–
protein complexes, phospholipids, fatty acids and neutral lipids. Therefore, it is reasonable to 
expect a diversity of their biological properties including antimicrobial effect against the 
different pathogenic strains (Santos et al. 2016). For instance, L. plantarum CFR 2194 was 
shown to produce a glycoprotein cell-bound biosurfactant with significant antimicrobial 
activity (Madhu and Prapulla 2014). As revealed from the FT-IR spectrum, this glycoprotein 
biosurfactant shared the same chemical functional groups with Lp-BS. However their FT-IR 
fingerprint regions are not the same indicating they are glycoproteins of different chemical 
structures. Similar findings have been reported for L. agilis; its cell-bound glycoprotein 
biosurfactant exhibited considerable antimicrobial activity but shared different chemical 
structures (as indicated by non-identical FT-IR fingerprint region) (Gudiña et al. 2015) to that 
of Lp-BS which lacks antimicrobial activity.  There would appear to be a degree of strain-
specificity for activity, in that some probiotics affect only some strains of a given species. 
Therefore it is likely that each strain needs to be verified individually for the health benefit in 
demand (De Vrese and Schrezenmeir 2008; Rastogi et al. 2011).  
The antimicrobial activity of the glycolipid, rhamnolipids, has been reported against a wide 
range of pathogens with significantly variable MIC values (Table 4.2) (Haba et al. 2003; 
Benincasa et al. 2004; Magalhães and Nitschke 2013; de Freitas Ferreira et al. 2018). However, 
to the best of our knowledge, the activity against SAG endodontic pathogens has not been 
studied. The commercial 90 % pure rhamnolipid tested herein exhibited a significant 
antimicrobial effect particularly against SAG, but inhibited 60 % of E. faecalis at the MIC 
required to inhibit S. anginosus (0.097 mg/mL). It has been reported that rhamnolipids act on 
the cell membrane and the variability of its effect on bacteria  may be related to the difference 
in lipid composition of the cells (Verheul et al. 1997; Sotirova et al. 2008). Moreover, the 
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glycolipid rhamnolipids can exist in several isoforms and analogues resulting in significant 
structural heterogeneity (Benincasa et al. 2004). Such structural diversity might be 
responsible for the variability in reported antimicrobial activity of the rhamnolipids. Strain-
specificity is an additional consideration;  there is evidence that  rhamnolipids produced from 
different strains have different structures which in turn influence their antimicrobial activity 
(Déziel et al. 1999; HoŠková et al. 2013). When compared to the SAG members, E. faecalis 
was found to be less susceptible to the rhamnolipid inhibitory effect (MIC = 0.097 and 50 
mg/mL for S. anginosus and E. faecalis respectively). The ability of Enterococcus species to 
resist many  clinically useful antibiotics has been reported as a growing issue in contemporary 
medicine (Hollenbeck and Rice 2012) and in the context of  endodontic infection (John et al. 
2015). Studies have reported a wide range of MIC values of rhamnolipid against the different 
E. faecalis strains tested. For instance, rhamnolipid extracted from P. aeruginosa MR01 did 
not show antimicrobial activity against clinical and reference E. faecalis strains at 512 µg/mL 
whilst another stain (P. aeruginosa MASH1) produced rhamnolipid with antimicrobial activity 
against the two E. faecalis strains at lower concentration (MIC = 64 µg/mL) (Lotfabad et al. 
2012). Kristoffersen and his group (Kristoffersen et al. 2018) extracted rhamnolipid from a 
strain of the P. fluorescence Group which could inhibit > 50 % of E. faecalis growth at 50 
µg/mL. Another study revealed that rhamnolipid extracted from P. aeruginosa LBI 
demonstrated a much lower MIC value of 4 µg/mL against E. faecalis (Benincasa et al. 2004) 
than that stated earlier in the previous example.  
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Table 4.2 Review of a number of publications reporting MICs of rhamnolipid of different sources against a range of microorganisms. 
Bacterial strain Method used MIC value Rhamnolipid origin Reference 
S. aureus  ATCC 2921 micro-broth dilution 128 µg/mL P. aeruginosa MR01         (Shahcheraghi et al. 2013) 
micro-broth dilution 512 µg/mL P. aeruginosa MASH1         (Shahcheraghi et al. 2013) 
E. faecalis ATCC 29212 micro-broth dilution >512 µg/mL P. aeruginosa MR01         (Shahcheraghi et al. 2013) 
micro-broth dilution 64 µg/mL P. aeruginosa MASH1         (Shahcheraghi et al. 2013) 
E. faecalis (Clinical sample) micro-broth dilution >512 µg/mL P. aeruginosa MR01         (Shahcheraghi et al. 2013) 
micro-broth dilution 64 µg/mL P. aeruginosa MASH1         (Shahcheraghi et al. 2013) 
E. coli (Clinical sample) micro-broth dilution >512 µg/mL P. aeruginosa MR01         (Shahcheraghi et al. 2013) 
micro-broth dilution >512 µg/mL P. aeruginosa MASH1         (Shahcheraghi et al. 2013) 
E. coli ATCC 25922 micro-broth dilution >512 µg/mL P. aeruginosa MR01         (Shahcheraghi et al. 2013) 
micro-broth dilution >512 µg/mL P. aeruginosa MASH1         (Shahcheraghi et al. 2013) 
S. aureus    Disc diffusion  17 mm at 10  
µg/mL 
P. flourescences (Govindammal and Parthasarathi 2013) 
E. coli  Disc diffusion 10 mm at 10  
µg/mL 
P. flourescences (Govindammal and Parthasarathi 2013) 
S. aureus ATCC 6538 micro-broth dilution 32 µg/mL P. aeruginosa 47T2 NCIB 
40044 
(Haba et al. 2003) 
32 strains of Listeria 
monocytogenes 
micro-broth dilution  78.1-2500 
μg/mL 
- (Magalhães and Nitschke 2013) 
Burkholderia cepacia micro-broth dilution  1000 g/mL P. aeruginosa  BTN 1 (Tedesco et al. 2016) 
E. coli micro-broth dilution 32  μg/mL P. aeruginosa AT10 (Abalos et al. 2001) 
S. aureus micro-broth dilution 128  μg/mL P. aeruginosa AT10 (Abalos et al. 2001) 
S. faecalis micro-broth dilution 64  μg/mL P. aeruginosa AT10 (Abalos et al. 2001) 
C. albicans micro-broth dilution >256  μg/mL P. aeruginosa AT10 (Abalos et al. 2001) 
S. anginosus 670/95 micro-broth dilution 0.097 mg/mL P. aeruginosa (commercial) Current study 
S. constellatus S08-07 micro-broth dilution 0.048 mg/mL P. aeruginosa (commercial) Current study 
S. intermedius HW13 micro-broth dilution 0.048 mg/mL P. aeruginosa (commercial) Current study 
E. faecalis RB17 micro-broth dilution 50 mg/mL P. aeruginosa (commercial) Current study 
S. aureus NCTC 8325 micro-broth dilution 0.097 mg/mL P. aeruginosa (commercial) Current study 
E. coli NCTC 10418 micro-broth dilution > 50 mg/mL P. aeruginosa (commercial) Current study 
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In addition to their antimicrobial activity, biosurfactants have been widely reported to 
effectively impede bacterial attachment and colonisation. Coating surfaces with 
biosurfactants has shown promise as an alternative non-pharmacological anti-infective 
therapy particularly in the context of  increasingly antibiotic resistant pathogens (Gudiña et 
al. 2010; Rufino et al. 2011; Gomaa 2013; Satpute et al. 2018; Yan et al. 2019). It has been 
reported that Lactobacillus spp. biosurfactants, rich in unspecified proteins, possess strong 
binding affinity to different surfaces (Velraeds et al. 1996; Velraeds et al. 1996; Satpute et al. 
2016). However, there is a lack of information regarding the biosurfactants’ surface coating 
characterisation. In the present study, and for the first time, a fluorescent staining with SYPRO 
Ruby stain was found to be efficient in characterising surface coating with Lp-BS. Crystal violet 
staining was found successful in assessing rhamnolipid coating. Crystal violet staining has 
been used mainly as an indirect approach for assessing the antiadhesive efficacy of 
biosurfactants coating (Janek et al. 2012) by measuring the amount of bacteria attach to the 
coated surface. This stain binds to the sugar moiety of bacteria cell wall and biosurfactant 
coating and therefore might give incorrect reading. Therefore, fluorescent microscopy and 
viable bacterial cell count were employed herein to assess the antiadhesive activity of Lp-BS 
and rhamnolipid. Lp-BS demonstrated a significant antiadhesive activity against SAG and E. 
faecalis attachment to glass surface at 20 mg/mL as revealed by the confocal fluorescent 
images and the recovered viable bacterial cell counts but not at 10 mg/mL as evident from 
the recovered viable cell count indicating a concentration-dependent effect. A number of 
researchers have  documented the effectiveness of cell-associated lactobacilli proteinaceous 
biosurfactants as antiadhesive agents to impede bacterial surface colonisation (Velraeds et 
al. 1996; Velraeds et al. 1998; Satpute et al. 2016). For instance, L. plantarum CFR 2194 
glycoprotein biosurfactant was found to effectively inhibit the in-vitro attachment of food-
borne pathogens (Escherichia coli ATCC 31705, E. coli MTCC 108, Salmonella typhi, Yersinia 
enterocolitica MTCC 859 and Staphylococcus aureus F 722) to 96-well ELISA plates via crystal 
violet method (Madhu and Prapulla 2014). Cell-bound biosurfactant of L. plantarum 27172 
inhibited S. aureus CMCC 26003 adhesion by 50 % at 50 mg/mL with no antimicrobial activity 
demonstrated at this concentration (Yan et al. 2019). Although little information about the 
mechanism of such antiadhesiveness has been provided by these studies, it is possible that  
biosurfactants change surface properties such as hydrophobicity making the surface more 
averse to bacterial attachment  (Fischer 1996; Hua et al. 2003; Pacwa-Płociniczak et al. 2011). 
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Interestingly, biosurfactants have been proposed to function as antiadhesive agents via 
manipulating gene expression of different virulent bacterial genes. It has been shown that 
Lactobacillus-derived cell-bound biosurfactant caused down regulation of essential dental-
adhesion genes; glucosyltransferases and fructosyltransferase (gtfB, gtfC and ftf) in S. mutans 
strains, a major cariogenic pathogen, and therefore hindered its biofilm formation potential 
(Tahmourespour et al. 2011a; Tahmourespour et al 2011b; Salehi et al. 2014). In addition, a 
rhamnolipid-like biosurfactant of S. mitis was shown to reduce S. mutans adherence to glass 
surface by the dynamic shear forces that occur in the oral cavity (Van Hoogmoed et al. 2000). 
The identification of ECM-binding proteins in the biosurfactant mixtures has been shown to 
be involved in the antiadhesion potential of the biosurfactants. These binding proteins may 
compete with pathogenic bacteria for the protein binding site and hence interfere with their 
attachment. A 29 KDa protein (p29) possessing antiadhesive activity against a well-known 
virulent uropathogen, E. faecalis 1131 was successfully purified from L. fermentum RC-14 
biosurfactant mixture. This protein showed 100 % identity to a 29 KDa collagen-binding 
protein previously isolated from L. reuteri NCIB 11951 (Heinemann et al. 2000). Later, the 
same team successfully identified collagen-binding proteins from L. fermentum RC-14, L. 
rhamnosus GR-1 and L. casei Shirota biosurfactant mixtures using surface-enhanced laser 
desorption/ionisation (SELDI)-time of flight mass spectrometry as a rapid mean to 
characterise ECM-binding proteins in the complex but clinically significant biosurfactant 
mixtures (Howard et al. 2000). In the Lp-BS mixture, three ECM-binding proteins (elongation 
factor Tu, enolase 1 and glyceraldehyde 3-phosphate dehydrogenase) have been identified 
(see Chapter 3). These proteins have not been previously recognised in biosurfactant 
compounds with antiadhesive activity. However, their involvement in protein-binding 
(Dhanani and Bagchi 2013, Castaldo et al. 2009; Kainulainen and Korhonen 2014; Salzillo et 
al. 2015; Kinoshita et al. 2008) could explain the observed significant antiadhesive effect of 
Lp-BS. Nonetheless, further investigations are required to confirm the relationship between 
the antiadhesive effect of Lp-BS and these identified adhesion proteins.  
The glycolipid rhamnolipid demonstrated a selective potential to reduce the adhesion of S. 
anginosus and S. intermedius but not S. constellatus and E. faecalis which might be due to a 
higher adhesion tendency of the two latter strains to the acrylic surface. At 50 mg/mL, a 
significant lower number of viable cells of S. anginosus and no cells of S. constellatus and S. 
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intermedius were recovered from the coated coupons. This might be due to the antimicrobial 
activity of rhamnolipid coating layer on attached SAG bacterial cells.   
4.5 Conclusion  
This study represents the first description of the antimicrobial/antiadhesive activity of L. 
plantarum NCIMB 8826 biosurfactant (Lp-BS) and rhamnolipid against the endodontic 
pathogens, SAG and E. faecalis. Moreover, Lp-BS biosurfactant coating was successfully 
detected, for the first time by means of conventional stains. The antiadhesive propensity 
reported for Lp-BS and the antimicrobial activity reported for rhamnolipid seems to be 
particularly promising in laying the foundation for a new therapies in the field of endodontics 
which is particularly welcome, given the growing problem of antimicrobial resistance.  
However, further investigations are required to assess the cytotoxic effect of these two 
substances to viable pulp cells and tissues.  
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5 Chapter 5 Ex-vivo application of Lp-BS and rhamnolipid 
5.1 Introduction   
The preceding chapters (Chapter 3 and Chapter 4), characterised and assessed for the in-vitro 
antimicrobial/antiadhesive activity of the two biosurfactants Lp-BS and rhamnolipid. 
However, to demonstrate further translational potential before clinical use, the two 
biosurfactants were required to be tested on mammalian tissue. Pulpal tissue healing and 
formation of reparative dentine is the goal of treating exposed pulp in order to preserve pulp 
vitality and health. The recently introduced concept of vital pulp therapy (VPT) encompasses 
irritant debridement and application of a protective material over the pulp (Aguilar and 
Linsuwanont 2011). To minimise bacterial leakage, this procedure must be followed by an 
overlying tight-sealed restoration. Although successful outcomes of VPT procedures in vital 
teeth with cariously exposed pulp has been documented in  several studies (Mejare and Cvek 
1993; Calişkan 1995; Matsuo et al. 1996; Demarco et al. 2005), another set of studies (Amini 
and Parirokh 2008; Dammaschke et al. 2010a; Akhlaghi and Khademi 2015; Hargreaves and 
Berman 2015) demonstrated a decreased success rate with time. These unfavourable 
outcomes were shown to be mainly due to infection caused by either residual bacteria or new 
ones leaked through the restoration margins (Neelakantan et al. 2012; Akhlaghi and Khademi 
2015). This observation suggests the need for the use of pulp-capping agents with 
antimicrobial activity underneath permanent restorations (Neelakantan et al. 2012). The 
currently available pulp capping materials such as calcium hydroxide, polyantibiotic paste, 
light-cured fluoride-releasing hydroxyapatite-based liner and mineral trioxide aggregates 
have been shown to exert antimicrobial activity to a varying extent (Lu et al. 2008; Reston and 
de Souza Costa 2009; Pereira-Cenci et al. 2013; Shivakumar et al. 2009) although these cavity 
sterilising agents may induce pulp damage themselves (Neelakantan et al. 2012). 
Biosurfactants, microbial-derived compounds with surface activity containing both hydrophilic 
and hydrophobic moieties (Costa et al. 2011) are the focus of recent interests due to their 
biodegradable and environment friendly nature, biocompatibility, stability in extreme conditions 
of temperature, pH and salinity (Banat et al. 2000). Alongside these physicochemical properties, 
biosurfactants have potential applications in medical and pharmaceutical fields for their microbial 
growth inhibitory and antiadhesive properties (Rodrigues et al. 2007). In addition, biosurfactants 
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have been shown to exert healing and immune-modulatory effects on tissues (Stipcevic et al. 2013; 
Sana et al. 2017; Sen et al. 2019). 
Therefore, the introduction of such multifunctional molecules as a novel endodontic material 
can potentially provide a protection to the pulp not only through antimicrobial activity but 
also by preventing bacterial colonisation of the pulp ECM. Lp-BS with its significant SAG-
antiadhesive activity obtained herein, as a probiotic-derived biosurfactant, might offer the 
advantage of being non-toxic to the tissue. Although derived from Pseudomonas sp., 
rhamnolipids are accepted for in-vivo safety according to tests results on animals (Sekhon 
Randhawa and Rahman 2014). Owing to their amphiphilic nature and diverse chemical 
structure, rhamnolipids have found a wide range of applicability in the fields of environment 
bioremediation, foods, cosmetics, and biomedicines (Abdel-Mawgoud et al. 2010). The 
relatively cost effective commercial rhamnolipid tested herein has been shown to effectively 
inhibit SAG members’ growth. 
A previously developed ex-vivo rodent dental model (Roberts et al. 2013), provides a way to 
study the cellular and molecular response to treatment with new endodontic antimicrobial 
agents. Hence, the aim of this chapter was to investigate the ex-vivo effect of Lp-BS and 
rhamnolipid as antimicrobial and antiadhesive agents. In addition, the viability of the pulp 
cells and tissues in response to such treatment was assessed. As bacterial derived products, 
the immunogenicity of the two biosurfactants was also evaluated.  
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5.2 Materials and methods 
5.2.1 Rat dental pulp extraction  
Rat dental pulp was extracted according to a previously developed protocol (Harrington et al. 
2014). Male Wistar rats (28-day-old) were sacrificed by a qualified technician at the Joint 
Biological Services Unit, Cardiff University for harvesting of tissue under schedule 1 of the UK 
Animals Scientific Procedures Act, 1986. Four rats were bathed for 30 s in 70 % IMS for 
sterilisation. Incisions were made along the soft mucosa of the mouth to allow easier access 
to the teeth, then the connective tissue surrounding incisors was cut using a scalpel and the 
incisors extracted using forceps. Pulp tissue was obtained by teasing out the contents from 
the exposed end of the incisors or by dividing the incisor longitudinally to reveal the pulp 
tissue. All pulp tissue was pooled and kept hydrated in antibiotic treated α-modified Minimum 
Essential Medium (αMEM) containing ribonucleosides, deoxyribonucleosides, L-glutamine 
and phenol red, in addition to antibiotics (100 units/ml penicillin G sodium, 0.1 µg/ml 
streptomycin sulphate and 0.25 µg/ml amphotericin; Invitrogen, Paisley, UK). 
5.2.2 Production of a single cell suspension from dental pulp tissues 
Rat dental pulp cells were obtained according to a previously developed protocol (Harrington 
et al. 2014). The extracted pulp tissue was quickly shredded using a scalpel and immediately 
treated with pre-warmed 4 mg/mL collagenase/dispase (Roche Applied Science, UK) at 37 °C 
for 1 h with periodic shaking. The swift processing minimises potential inflammatory 
responses by the pulp tissue. The dissociated cells were passed through a 70 µm cell strainer 
(BD Falcon, UK) and a 5-10 mL medium containing serum were also passed through the 
strainer to produce a single cell suspension. The cells were centrifuged at 400 g for 5 min 
before the supernatant was discarded and the cell pellet resuspended with fresh medium, 
then centrifuged again to ensure complete removal of the enzymes. The cells were then 
resuspended in culture medium.   
5.2.3 General culturing medium 
Working medium for cell culture consisted of α-modified Minimum Essential Medium 
(αMEM) containing ribonucleosides, deoxyribonucleosides, L-glutamine and phenol red, in 
addition to antibiotics (100 units/ml penicillin G sodium, 0.1 µg/ml streptomycin sulphate and 
0.25 µg/ml amphotericin; Invitrogen, Paisley, UK) with 20 % heat inactivated foetal bovine 
serum (FBS) (Invitrogen, UK). The rodent tooth sections were cultured in Dulbecco’s Modified 
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Eagle’s Medium (DMEM) with phenol red (Sigma 41965-047) with/without antibiotics (100 
units/ml penicillin G sodium, 0.1 µg/ml streptomycin sulphate and 0.25 µg/ml amphotericin; 
Invitrogen, Paisley, UK) supplemented with 10 % heat inactivated FBS and 0.15 mg/ml vitamin 
C.   
5.2.4 Cell Culture  
Cell culture was performed under sterile conditions, using tissue culture plates and flasks 
(Sarstedt, Leicester, UK). Cells were cultured in 5 % CO2 in a humidified chamber at 37 °C. 
Medium was pre-warmed to 37 °C in a water bath, prior to administering to the cells. When 
the cells were approximately 80 % confluent in T-75 flask, they were washed with 0.1M 
phosphate buffered saline (PBS, pH 7.4) before being treated with 2 ml of pre-warmed 
accutase (Accutase® solution. Sigma Aldrich). Incubation was performed at 37 °C until the 
cells had become detached from the culture vessel (approximately 5 min). Accutase was 
subsequently inactivated by the addition of serum-containing in the culture medium before 
centrifugation at 1800 rpm. The resulting pellet was resuspended in the culture medium 
before cell counting and reseeding as described before. 
5.2.5 Freezing and Thawing Cells  
Cells were centrifuged, stained with trypan blue and counted (Sigma, UK) and resuspended in 
1 mL freezing mix containing 10 % Dimethyl Sulfoxide (DMSO) (Sigma, UK) and 90 % FBS. 
Freezing mix was added to the cryovials placed in freezing pot at -70°C. After 24 h, cryovials 
were transferred to liquid nitrogen for long term storage. When cells were required, cells 
were rapidly thawed by transferring to a 37 °C water bath. The cells were immediately 
resuspended in 5 mL medium and centrifuged as stated above. Cells were rewashed with 
medium and expanded in culture.  
5.2.6 Lp-BS and rhamnolipid cytotoxicity on rat dental pulp cells  
The possible toxic effect of the two biosurfactants (Lp-BS and rhamnolipid) on extracted 
rodent dental pulp cells was assessed by trypan blue staining. Trypan blue is taken up by the 
cells, however, only viable cells are able to subsequently exclude the dye out (Strober 2001). 
The stain, therefore, is only present in non-viable cells. From confluent culture, 6-well plates 
were seeded at 4000 cell/cm2 density and incubated in for 24 h. At the end of incubation, 
medium was aspirated and cells washed with PBS. Different concentrations of Lp-BS (20, 10 
and 5 mg/mL) and rhamnolipid (50, 25, 12.5, 6.25, 3.125, 1.56, 0.78, 0.39, 0.195 and 0.097 
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mg/mL) in αMEM culture medium (Section 5.2.3) were prepared. Two mL of each treatment 
solution was added to the corresponding wells in triplicate. Medium with 0 mg/mL of either 
biosurfactants was served as the negative control. The plates were incubated in 5 % CO2 in a 
humidified chamber at 37 °C for another 24 h. After 24 h incubation, the medium was 
removed, cells were washed three times with PBS and incubated with 0.5 mL 0.4 % trypan 
blue stain for 1 min. The stain was removed and the cells were washed once with PBS. The 
numbers of blue stained and non-stained cells were immediately counted under light 
microscopy. Viability greater than 90 % was deemed to be acceptable.  
5.2.7 Detection of apoptosis induced by Lp-BS and rhamnolipid by TUNEL assay 
Terminal deoxynucleotidyl transferase (TdT) dUTP Nick End Labeling (TUNEL) assay has been 
designed to detect apoptotic cells that undergo extensive DNA degradation during the late 
stages of apoptosis (Kyrylkova et al. 2012). The  method  is  based  on  the  ability  of  TdT to  
label  blunt  ends  of  double-stranded DNA breaks (Kyrylkova et al. 2012). From confluent cell 
culture (Section 5.2.4), cells were seeded at 4000 cell/cm2 density using eight well chamber 
glass slide. Chamber slides were incubated in 5 % CO2 at 37 °C for 24 h. At the end of the 
incubation period, the medium was discarded and attached cells washed with PBS. Three 
hundred microliters of rhamnolipid solution of 0.097 and 0.195 mg/mL concentration or Lp-
BS solution of 5 and 10 mg/mL in αMEM + 20 % FBS were added to the corresponding wells 
in triplicates. Control wells (negative and positive) were incubated in αMEM + 20 % FBS only. 
The test and control chamber slides were incubated in 5 % CO2 at 37 C for 24, 48 and 72 h. At 
the end of each incubation period, wells were treated according to the manufacturer’s 
protocol (DeadEnd™ Fluorometric TUNEL System, Promega, UK). Briefly, cells were fixed with 
4 % formaldehyde in PBS for 25 min at 4 °C. The slide chambers were removed and then 
washed twice by immersing the slides twice in PBS, 5 min each time. Cells were then 
permeabilised by immersing the slides in 0.2 % Triton® X-100 in PBS for 5 min to allow 
penetration of the TUNEL reaction reagents into the cell nucleus followed by washing by 
immersing the slides twice in PBS, 5 min each time. A positive control was prepared by 
treating cells, cultured in the medium only with no biosurfactants, with 100 µL (5 unit/mL) 
DNase (Promega) per well for 5 min at room temperature to induce DNA strand breaks, prior 
to labelling. One hundred µL of equilibration buffer was added to the cells at room 
temperature for 5-10 min. While cells were equilibrating, rTdT incubation buffer was 
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prepared by addition of 45 µL equilibration buffer to 5 µL nucleotide mix and 1 µL rTdT 
enzyme. Fifty µL of rTdT incubation buffer was added to the cells of the experimental and 
positive control. Incorporation of biotinylated-dUTP onto the 3′ ends of fragmented DNA is 
facilitated in the reaction containing TdT enzyme. The slides were then covered with plastic 
coverslips to ensure even distribution of the mixture and incubated for 60 min at 37 °C in a 
humidified chamber protected from light exposure by wrapping the slide container with 
aluminium foil. The slides were kept protected from light to the end of the experiment. The 
reaction was stopped by immersing the slides in 2X SSC for 15 min followed by washing three 
times in PBS, 5 min each time. To visualise all nuclei, 10 µL Vectashield® with DAPI was added 
to the wells. Detection of localised green fluorescence of apoptotic cells was performed by 
imaging the slides under fluorescence microscopy–equipped with fluorescein isothiocyanate 
(FITC) filter where they appeared green (TUNEL positive). DAPI-stained nuclei were stained 
blue. The percentage of TUNEL-positive cells was calculated as the number of TUNEL-positive 
cells divided by the number of cells stained blue.   
5.2.8 Tooth slice culture under standard conditions 
Tooth slices were prepared as previously described (Roberts et al. 2013). Male Wistar rats 
(28-day-old) were sacrificed under schedule 1 of the UK Animals Scientific Procedures Act, 
1986 by a qualified technician at the Joint Biological Services Unit, Cardiff University for 
harvesting of tissue. Upper and lower incisor teeth were dissected from the freshly sacrificed 
rats by removing the bone from around the teeth using a sterile scalpel. The teeth were then 
placed in sterile DMEM (Section 5.2.3) prior to being cut into 2 mm thick transverse sections 
on a diamond edged rotary saw (TAAB, Berkshire, UK). The blade was sterilised using 70 % 
ethanol and was kept cool with sterile PBS in a well at the base of the blade. The cut sections 
were immediately transferred to fresh sterile DMEM + 20 % FBS for no more than 20 min 
before being cultured in 2 mL of DMEM + 20 % FBS at 37 °C, 5 % CO2. Storage of the dissected 
incisors and resulting tooth slices in supplemented DMEM before culture is vital to maintain 
maximum viability of the cells within the slices. Figure 5.1 demonstrates the orientation of 
the tooth slice from which the section is cut, relative to its position in the incisor.  
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5.2.9 Viability of rat pulp tissue follow treatment with Lp-BS solutions 
5.2.9.1 Incubation of tooth section in Lp-BS solutions 
Tooth sections were prepared as discussed above (Section 5.2.8) and pre-incubated for 24 h 
in DMEM + 10 % FBS (Section 5.2.3) at 37 °C, in 5 % CO2. Lp-BS solutions in DMEM + 10 % FBS 
were prepared by dissolving 10 mg per mL of the medium and then serially 1:1 diluted four 
times to reach 0.625 mg/mL ending up with Lp-BS of 10, 5, 2.5, 1.25 and 0.625 mg/mL 
concentrations. At the end of the 24 h pre-incubation, the medium was discarded and wells 
were washed with 2 mL PBS. Two mL of Lp-BS solutions were added to the corresponding 
wells in triplicate for each dilution. Negative control tooth sections were incubated in DMEM 
+ 20 % FBS only. The plates then incubated for another 24 h at 37 °C, in 5 % CO2. Another 
plate was prepared as above but the tooth sections were treated with Lp-BS 10 and 0.625 
mg/mL for 48 h at 37 °C, in 5 % CO2.  
5.2.9.2 Histological, fixation, processing and staining methods  
5.2.9.2.1 Fixation and demineralisation 
Following culture, incisor slices were removed using sterile forceps and transferred to 10 % 
(v/v) neutral-buffered formalin solution for 24 h for fixation of tissues to occur. The slices 
Figure 5.1 Schematic diagram of rat skull showing position of incisors. Red areas 
on schematic represent 2 mm sections that are cut along the length of the 
incisors. The right-hand side of the diagram shows how the tooth slices appear 
after being cut and how the tooth slice is orientated in relation to its previous 
position in the tooth.  
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were then transferred to a minimum of 5 mL 10 % (v/v) formic acid for 48 - 72 h with constant 
agitation to allow for demineralisation.  
5.2.9.2.2 Processing of tissue  
Tooth slices were transferred to individual biopsy cassettes and processed through a series of 
graded ethanol on an automatic tissue processor (50 % v/v, 70 % v/v, 95 % v/v, and 100 % v/v 
ethanol) followed by 100 % v/v xylene for five minutes each. Following processing, the tissues 
were embedded in paraffin wax using a processing machine (Shandon Pathcentre, Thermo 
Scientific, Surrey, UK) and aligned so that transverse sections of the slice could be cut.  
5.2.9.2.3 Sectioning of tooth slices 
Sections of 5 μm thickness were cut from the wax blocks using a Leitz 1400 microtome (Leica, 
Buckinghamshire, UK). The cut sections were floated on warm water (40 °C) and mounted on 
glass slides. These were then placed in a slide drying oven (60 °C) before staining to improve 
adhesion of the section to the slide.  
5.2.9.2.4 Staining histological sections 
Histological sections were mounted on uncoated microscope slides and placed on an 
automated tissue stainer. The slides were taken through xylene, alcohol and water washes 
followed by haemotoxylin and eosin (H&E) stains. They were then taken through a further 
series of alcohol washes before finally being immersed in xylene. The slides were then 
removed and a coverslip glued by DPX over the stained section for viewing by an Olympus 
AX40 light microscope. 
5.2.9.2.5 Semi-quantification of cell viability by cell counts 
ImageJ software (National Institutes of Health, Maryland USA) was used to count the number 
of nuclei per pulp on stained histological sections. Images were captured at 20x magnification 
and five random 50 µm² areas were selected for each section with three sections being 
studied for each treatment and control group. The blue field was extracted from the images 
and the moment’s threshold method was applied to separate the pulp cells.  The watershed 
function was applied to split adjacent cell nuclei and the number of particles ranging in size 
from 3 to 100 μm2 were counted.   
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5.2.10 RT-qPCR of cytokines 
5.2.10.1 RT-qPCR of cytokines of Lp-BS treated tooth section 
To ensure enough mRNA is extracted from the pulp tissue (Ayre et al. 2018), 4 mm thick tooth 
slices were prepared and cultured as previously described (Section 5.2.8) for 24 h before being 
transferred to sterile DMEM+10 % FBS as a control or with Lp-BS (10 and 0.625 mg/mL 
prepared in DMEM+10 % FBS) and incubated for another 24 h. After incubation, the tooth 
slice was transferred to sterile PBS and the pulp removed by flushing the pulpal cavity with 
PBS using a 0.1 mm needle and syringe. mRNA was extracted using TRIzol® Reagent 
(ThermoFisher Scientific, Loughborough, UK) followed by DNAse treatment (Promega, 
Southampton, UK) according to the manufacturers’ instructions. Analysis of gene expression 
was performed in accordance to the Minimum Information for publication of Quantitative 
real-time PCR Experiments (MIQE) guidelines (Bustin et al. 2009). RNA concentrations were 
determined using a NanoVue Spectrophotometer (GE Healthcare Life Sciences, 
Buckinghamshire, UK). RNA purity was determined by ensuring the ratio of absorbance at 
260/280 nm was above 1.8. RNA was directly stored at -80°C for use in reverse transcription 
reactions.  
Complementary DNA (cDNA) was synthesised by reverse transcription using Promega 
reagents (Southampton, UK) in a G-Storm GS1 thermocycler (Somerton, UK).  One μg of the 
extracted mRNA was combined with 1 μL random primer in a 15 μL reaction in nuclease free 
water at 70 °C for 5 min.  This suspension was added to 5 μL Moloney Murine Leukemia Virus 
Reverse Transcriptase (MMLV) reaction buffer, 1.25 μL deoxyribonucleotide triphosphates 
(10mM stock dNTPSs), 0.6 μL RNasin, 1 μL MMLV enzyme and 2.15 μL nuclease free water 
and incubated at 37 °C for 1 h. The resultant cDNA was diluted 1:10 in nuclease free water 
(250 ng cDNA) and stored at -20 °C.  
A list of the genes that were examined in this study can be found in table 5.1 with the forward 
and reverse primers. The primers were designed and validated by Primerdesign Ltd 
(Primerdesign). Ten μL of PrecisionFAST qPCR SYBR Green MasterMix with low ROX 
(Primerdesign) was combined with 1 μL resuspended primer mix (Primerdesign) and 4 μL 
nuclease-free water (Primerdesign, Chandler’s Ford, UK) prior to addition of 5 μL cDNA in 
BrightWhite Real-time PCR FAST 96-well plates (Primerdesign).  Plates were covered with 
adhesive optical seals (Primer Design); and centrifuged at 500 g for 5 min. qPCR analysis was 
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conducted in a QuantStudio™ 6 Flex Real-Time PCR System machine (ThermoFisher Scientific, 
USA), using QuantStudio™ Real-Time PCR Software (v1.0). Reaction conditions were as 
follows: one initial denaturation at 95°C for 20s, forty cycles of denaturation for 1s and 
annealing for 20s. After cycling was completed, melt curve analysis was performed as follows: 
95 °C denaturation for 15s, 60 °C dissociation for 1min and 95 °C denaturation for 15s. Relative 
gene expression was calculated with beta-2-microglobulin (B2M) was used as an internal 
reference control for data normalisation and negative control samples as the control using 
the Livak method (Livak and Schmittgen 2001) (i.e. ΔCt method).  
5.2.10.2 RT-qPCR of cytokines of rhamnolipid treated tooth section 
Four mm thick tooth slices were cultured as previously described (Section 5.2.8) for 24 h 
before being transferred to sterile DMEM + 10 % FBS as a control or with 0.097 mg/mL 
rhamnolipid prepared in DMEM + 10 % FBS. The negative control and the treated tooth 
sections were then incubated for 2, 4, 6, 24, 48 and 72 h at 37 °C in 5 % CO2. Medium was 
changed every 24 h. After each incubation time point, tooth sections were treated following 
the same procedure explained above (Section 5.2.10.1).  
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Table 5.1 Primer sequences and product sizes of selected markers for qPCR analysis used in 
this study. Note: all the genes used were designed and validated by Primerdesign Ltd, UK. For 
the reference gene B2M primer sequences refer to Primerdesign Ltd, UK.   
 
 
 
 
 
 
 
 
 
Gene Primer Sequence Forward (F) & Reverse 
(R) 
Product Length 
(b p) 
Annealing 
Temperature °C 
IL-1beta F:AGCACCTTCTTTTCCTTCATCTT 
R:CAGACAGCACGAGGCATTTT 
145 57.2 
IL-6 F:AGAGCAATACTGAAACCCTAGTTC 
R:GTCCTTAGCCACTCCTTCTGT 
133 57.3 
TNF-alpha F:GCTCCCTCTCATCAGTTCCA 
R:CTCCTCTGCTTGGTGGTTTG 
109 56.8 
Defensin beta 2 
(Defb2) 
F:TGCTGGAATTCTAGGACCTCTTC 
R:GCAACAGTAGAACTTGTATGGGAAA 
139 57.6 
TGF-beta1 F:CGCAACAACGCAATCTATGAC 
R:GGACAGCAATGGGGGTTCT 
108 57.3 
IL-4 F:CACTTTGAACCAGGTCACAGA 
R:CTCGTTCTCCGTGGTGTTC 
94 56 
IL-10 F:CTGGACAACATACTGCTGACA 
R:GGCATCACTTCTACCAGGTAAA 
107 56.3 
Fas F:GCACAACAGCCCCCAAGAT 
R:GCTTTTCTGAGACCCTGGATTAAA 
114 57.9 
Casp3 F:AGAGTTTGGTGCCACTATGAAT 
R:CTTGACATTATCGTTCCTATGCTTAA 
116 57 
Casp8 F:TCCACAGTTGTCTTTACGATATTGC 
R:GGTCCAAGCACAGGAACTTGA 
78 57.7 
Bcl2 F:CATGAAATAAAAAGCTGAAAGGAATT 
R:GGATGAAGGGGTGTCTTTAGTTA 
109 56.3 
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5.2.11 Bacterial growth under modified culture medium (DMEM+10 % BHI) 
A previously validated (Roberts et al. 2013), modified co-culture medium was used to account 
for the viability of the study bacterial isolates in this medium. Bacterial suspensions of SAG 
and E. faecalis at 102 CFU/mL were prepared by the inoculation of DMEM (Invitrogen) 
supplemented with 10 % heat-inactivated FBS, 0.15 mg/mL vitamin C and 10 % BHI broth 
(DMEM-BHI). Bacterial suspensions were also prepared in BHI alone. Two hundred µL of each 
bacterial isolate suspension (102 CFU/mL) in DMEM-BHI and BHI were added to the wells of 
96-well plate in triplicate, un-inoculated BHI was served as the negative control. The plate 
was incubated in a plate reader (FLUOstar Omega, BMG Labtech, Ortenberg, Germany) at 37 
°C in 5 % CO2 and the absorbance (600 nm) was recorded for 24 h. Viable cell count was 
performed for the first 8 h incubation of the four isolates in DMEM-BHI. Hourly and for 8 h, 
50 µL of each bacterial isolate grown in the modified culture medium were plated on FAA 
plate using spiral platter. The plates were then incubated at 37 °C in 5 % CO2 for 24 h and the 
resulting colonies were counted.    
 
5.2.12 Ex-vivo rhamnolipid antimicrobial activity 
5.2.12.1 Co-culture tooth section with bacteria and rhamnolipid 
Two mm tooth sections were prepared as described in section 5.2.8 and pre-incubated for 24 
h in supplemented DMEM with antibiotic (Section 5.2.3). Tooth sections were then washed 
in 2 mL of PBS, transferred into supplemented DMEM without antibiotics and incubated 
overnight to remove traces of antibiotic. Rhamnolipid solution was prepared at 0.097 mg/mL 
in serum-free DMEM-BHI with no antibiotic and 1.98 mL of this solution was added to each 
of the test sections. The same volume of serum-free DMEM-BHI medium with no antibiotic 
was added to the untreated infection control samples. S. anginosus and S. constellatus were 
cultured to the log phase in BHI for 8-12 hours and adjusted to OD (600nm) of 0.08-0.1 
equivalent to 108 CFU/mL. Twenty µL of this bacterial suspension were added to each of the 
rhamnolipid treated and the infection control. The tooth sections were then incubated at 37 
°C and 5 % CO2 for 24 h under constant agitation at 60 rpm. At the end of the incubation 
period, tooth section samples were collected for histology (Section 5.2.12.2) while their 
culture supernatants were collected for cytokines quantification by ELISA (Section 5.2.13).  
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5.2.12.2 Tooth slices fixation, processing and sectioning 
Tooth sections cultured with the bacterial isolates and rhamnolipid were fixed and processed 
as described previously in section 5.2.9.2.  
5.2.12.3 Histological sections staining with a modified Gram stain 
Gram staining of the histological sections was performed using a modified Brown and Brenn 
method (Ayre et al. 2018). Paraffin-embedded tooth slices were cut using a microtome into 5 
μm sections mounted on slides and rehydrated through a series of xylene, 100, 95 and 70 % 
v/v ethanol for five minutes each then into distilled water. After ﬂushing with crystal violet 
solution for 60 s, samples were rinsed with tap water and then ﬂushed with Lugoli’s iodine 
solution for 60 s. Acetone was used to rinse the slide until the acetone ran clear and then the 
slide was rinsed with tap water. The slide was then counterstained by quickly dipping and 
removing the slide in eosin solution followed by immediate washing under running tap water 
to avoid overstraining that affects visualising the Gram stained bacterium. The stained slides 
were then left to air-dry, and then submerged in xylene for 5 min before a cover slip was 
applied with DPX mountant. Light microscopy images were captured using a Nikon digital 
camera and ACT-1 imaging software (Nikon UK Ltd, Surrey, UK). 
5.2.13 Enzyme Linked-Immunosorbent Assay (ELISA) quantification of cytokines in 
supernatant culture media 
To assess the immunogenic effects of rhamnolipid and bacteria on pulp tissue, a number of 
pro-inflammatory, anti-inflammatory and growth factor cytokines were analysed in spent 
culture supernatant by ELISA. Tooth sections were cultured with bacterial isolates and 
rhamnolipid as described in section 5.2.12.1 for 24 h. At the end of the incubation period, 
supernatants were collected, frozen down at -20 °C and allowed to thaw at room temperature 
when used as below: 
5.2.13.1 ELISA quantification of pro-inflammatory cytokines  
5.2.13.1.1 TNF-alpha 
Secreted TNF-alpha in the collected supernatant was quantified using a sandwich rat Tumour 
necrosis factor alpha ELISA kit (amsbio, UK). The 96-well plate provided with the kit was pre-
coated with rat TNF-alpha antibody. Following the manufacturer’s instructions, 50 µL of the 
cytokine standard were loaded into nominated wells in duplicate in a descending way (640 – 
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40 ng/L). Forty µL of the sample supernatant was added to the sample wells followed by the 
addition of 10 µL anti-TNF-alpha biotinylated antibody to the same sample wells. Then, 50 µL 
streptavidin-HRP were added to the sample wells and standard wells but not to the blank 
well. The plate was then mixed on a plate mixer, covered with a sealer and incubated for 60 
min at 37 °C. At the end of the incubation period, the sealer was removed and the plate was 
washed 5 times with the wash buffer by soaking the wells with 350 µL wash buffer for 30 s 
for each wash and blotting the plate onto paper towels after each washing. The plate was 
then loaded with 50 µL of substrate solution A to each well and then with 50 µL substrate 
solution B to each well (substrate solutions contain tetramethylbenzidine (TMB)). A new 
sealer was applied and the plate was incubated for 10 min at 37 °C in the dark. Fifty µL stop 
solution was added to each well with a change of colour from blue into yellow was evident 
immediately. Soon (not more than 10 min) after adding the stop solution, the plate optical 
density was determined at 450 nm using a microplate reader (FLUOstar Omega, BMG Labtech, 
Ortenberg, Germany). The amount of TNF-alpha was quantified by plotting the standard 
samples as a reference standard curve. The experiment was performed in triplicate and the 
results was expressed in ng/L.   
5.2.13.1.2 IL-1beta 
The rat IL-1beta sandwich ELISA kit (eBioscience™ Rat IL-1 beta Platinum ELISA Kit) was used 
to detect and quantify IL-1beta in culture supernatant. The 96-well plate provided with the 
kit was pre-coated with rat IL-1beta polyclonal antibody. Each sample, blank and standard 
was assayed in duplicate. According to the manufacturer’s instructions, the plate was washed 
twice with approximately 400 µL wash buffer per well for 10 s each time with thorough 
aspiration of the microwell contents between washes. Excess wash buffer was removed from 
the wells by tapping the plate onto an absorbent paper towel. One hundred µL of each 
standard dilution was added to the corresponding wells in descending manner (2000-31.3 
pg/mL). Fifty µL sample diluent was added to the sample wells followed by the addition of 
another 50 µL of each sample to the sample wells. Biotin-conjugate anti-rat IL-1beta antibody 
was loaded at 50 µL into each well. The plate was covered with adhesive film and incubated 
at room temperature for 2 h. The adhesive film was then removed, the wells were emptied 
and washed 3 times as before. After that, 100 µL of the diluted streptavidin-HRP to all wells 
including the blank wells. The plate was then covered with a new adhesive film and incubated 
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for 1 h at room temperature. At the end of the incubation, the film was removed, the wells 
contents were discarded and wells were washed 3 times as before. One hundred µL of TMB 
substrate solution were added to all wells and the plate was incubated for 10 min at room 
temperature protected from direct light exposure. To stop the enzyme reaction, 100 µL stop 
solution was added just when the highest standard developed a dark blue colour. Absorbance 
was read at 450 nm immediately after the addition of the stop solution. Standard curve was 
generated by plotting the absorbance vs. the concentration and a best fit equation was 
obtained. The concentration read from the curve was multiplied by the dilution factor (x 2) 
and expressed as pg/mL.  
5.2.13.1.3 IL-6 
The quantity of the produced IL-6 by the tooth sections into their collected supernatant was 
quantified using rat IL-6 sandwich ELISA kit (amsbio, UK). The plate provided within the kit 
was pre-coated with rat IL-6 antibody with 96 wells. Following the manufacturer’s 
instructions, 50 µL of the standard were loaded into the standard designated wells in 
duplicate in a descending way (24-1.5 ng/L). From this step on to the end of the experiment, 
the same procedure was followed as in section 5.2.13.1.1.  
5.2.13.1.4 IL-18 
Rat IL-18 sandwich ELISA kit (amsbio, UK) was used to detect and quantify IL-18 cytokine 
released into the collected supernatants. A pre-coated 96-well plate with rat IL-18 antibody 
provided with the kit was employed. The standard dilutions were prepared according to the 
manufacturer’s instructions and 50 µL of each dilution were pipetted into the designated 
standards wells (400-25 pg/mL). The same steps described in section 5.2.13.1.1 were followed 
from this step on.  
5.2.13.2 ELISA quantification of anti-inflammatory cytokine, transforming growth factor 
(TGF-beta) and antimicrobial peptide defensin-beta2 
5.2.13.2.1 IL-10 
IL-10 levels in the collected samples supernatants were determined using a sandwich IL-10 
ELISA kit (amsbio, UK). According to the manufacturer’s protocol, the rat IL-10 antibody pre-
coated plate standards wells were loaded with 50 µL standard dilutions (480-30 pg/mL) in 
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duplicate.  After the addition of the standard dilutions, the same steps were followed as 
described previously in section 5.2.13.1.1.  
5.2.13.2.2 TGF-beta 
For accurate detection and quantification of the growth factor TGF-beta in culture 
supernatants, a rat TGF-beta sandwich ELISA kit (amsbio, UK) was used in this study. The kit 
was provided with a 96-well microplate pre-coated with rat TGF-beta antibody. The 
designated standard wells were loaded with 50 µL of the prepared standards dilutions (1200-
75 ng/L). The experiment was completed as described in section 5.2.13.1.1.   
5.2.13.2.3 Defensin-beta2 
The antimicrobial peptide defensin-beta2 was detected in culture supernatants by means of 
the competitive rat defensin-beta2 ELISA kit (amsbio, UK). Fifty µL of standard dilutions (1200-
75 ng/L) and samples were added to the corresponding monoclonal antibody pre-coated 
wells. Fifty µL biotinylated antigen was added to each well except the blank ones. The plate 
was covered with a sealer and incubated at 37 °C for 30 min. The wells were then washed off 
with 300 µL wash buffer five times with decanting the contents and tapping the plate on 
absorbent paper towel each washing time. Fifty µL of concentrated avidin-HRP were added 
to the standard and sample wells and the plate was covered and incubated for 30 min at 37 
°C. The sealer was removed and the wells were washed as described earlier. Fifty µL of 
substrate solution A were added to each well and then 50 µL of substrate solution B were 
added to each well (substrate solutions contain tetramethylbenzidine (TMB)). The plate was 
covered with a new sealer and incubated for 10 min at 37 c in the dark. Stop solution was 
added at 50 µL volume to each well and a colour change from blue into yellow was monitored. 
Immediately after that, the optical density was recorded using a plate reader at 450 nm. 
Standard curve was generated by plotting the mean absorbance for each standard on the Y-
axis against the target antigen concentration on the X-axis. A best fit curve was drawn and 
the sample defensin-beta2 concentration was obtained.  
5.2.14 Effect of serum on rhamnolipid activity on pulp cells  
Following culturing rhamnolipid with 20 % serum containg DMEM medium, no rhamnolipid 
antimicrobial effect was observed indicating a possible serum-binding inactivation. To 
determine the concentration of foetal bovine serum that can be used in culture medium 
without binding to and inactivating rhamnolipid, trypan blue viability assay at different FBS % 
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was performed. Rat dental pulp cells were extracted and cultured as described in section 5.2.1 
and 5.2.2. From a frozen vial, cells were cultured at 5000 cell/cm2 density. From confluent 
culture flask, cells were harvested, counted and two sets of cells were seeded at 4000 cell/cm2 
density in 12-well plate (SARSTEDT, Germany) using αMEM + 1 % antibiotic + 20, 10, 5, 2 or 0 
% FBS for 24 h as shown in table 5.2. At the end of the first incubation period, medium was 
aspirated. The first set of cells were cultured in αMEM + 1 % antibiotic supplemented with 
the same concentration of FBS as in the first incubation period and treated with rhamnolipid 
0.097 mg/mL (test sample) or without rhamnolipid (control sample) for another 24 h. To 
account for the residual effect of serum, the second set of cells were cultured in serum-free 
αMEM + 1 % antibiotic and treated with rhamnolipid 0.097 mg/mL (test sample) or without 
rhamnolipid (control sample) for another 24 h. Then, the medium was removed, cells were 
washed with PBS three times and incubated with 200 µL 0.4 % trypan blue stain for 1 min. 
The stain was removed and the cells were washed once with PBS. The numbers of blue stained 
and non-stained cells were immediately counted under light microscope. Viability greater 
than 90 % deemed to be acceptable.  
 
Table 5.2 Representative table of the two set of cells  
 
 
 
First 24 h Second 24 h 
 
Cells cultured with αMEM + 1 % 
antibiotic and FBS 
Control sample 
Cells cultured in 
αMEM + 1 % 
antibiotic and FBS 
Rhamnolipid 
treatment 
Cells cultured in 
αMEM + 1 % 
antibiotic and FBS 
First 
set of 
cells 
20 % 20 % 20 % 
10 % 10 % 10 % 
5 % 5 % 5 % 
2 % 2 % 2 % 
0 % 0 % 0 % 
Second 
set of 
cells 
20 % 0 % 0 % 
10 % 0 % 0 % 
5 % 0 % 0 % 
2 % 0 % 0 % 
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5.2.15 Statistical analysis 
All experiments were subjected to three repeats on separate occasions. Comparison among 
the different treatment groups was made using Tukey’s one way ANOVA multiple 
comparisons test with post-hoc correction (GraphPad InStat 3 (v3.06)). For DAPI-stained 
nuclei count, comparison was made to the untreated control of each time point using 
Dunnett's multiple comparisons one way ANOVA test (GraphPad InStat 3 (v3.06)). A p value 
of ≤ 0.05 was considered significant (*, p ≤ 0.05), very significant (**, p ≤ 0.01) or highly 
significant (***, p ≤ 0.001).   
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5.3 Results 
5.3.1 Section a: Lp-BS 
5.3.1.1 Lp-BS cytotoxicity to rat dental pulp cells 
Trypan blue viability assay was carried out on extracted rat dental pulp cells following 24 h 
exposure to Lp-BS at three concentrations (20, 10 and 5 mg/mL). At 20 mg/mL, only few cells 
remained attached to the well surface after 24 h and they all picked up the dye and stained 
blue indicating their mortality in response to the treatment when compared to the control 
group (Figure 5.2). Cells treated with the lower concentrations of 10 and 5 mg/mL did not 
retain the stain fully resulting in difficulty of distinguishing the dead from the living cells when 
examined at 10x magnification (Figure 5.2). At higher magnification (20x), some of these cells 
demonstrated intra-cellular bodies or structures (Figure 5.2, red arrows) which might be a 
cytoplasmic vacuolation or chromatin condensation characteristics of apoptotic cells (Korsnes 
2012).   
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Figure Lp-BS cytotoxicity on rat dental pulp cells 
 
 
 
 
50 µm  50 µm  
100 µm  100 µm  
100 µm  100 µm  
Figure 5.2 Lp-BS in-vitro cytotoxic effect on rat dental pulp cells. Trypan blue staining was 
employed to determine viability at 24 h post-treatment. 20 mg/mL Lp-BS was found toxic (no 
viable cells were noticed). At 10 mg/mL and 5 mg/mL, cells did not stain properly by trypan 
blue and it was difficult to distinguish life and dead cells based on colour using power 10x 
magnification. At higher magnification 20x, cells showed intra-cellular structures or bodies 
(red arrows) which might be apoptotic bodies. The images are representative of three 
independent experiments.  
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5.3.1.2 Apoptotic effect of Lp-BS on rat dental pulp cells 
To account for the apoptotic potential of Lp-BS, a TUNEL assay was performed on rat dental 
pulp cells grown with 10 and 5 mg/mL Lp-BS for 24, 48 and 72 h (Figure 5.3). Subsequent to 
incubation with 10 mg/mL Lp-BS for 24 h, a high percentage (> 30 %) of the pulp cells was 
found to be TUNEL-positive. This was significantly (p < 0.001) higher than the counterpart 
untreated control (Figure 5.4). The total number of DAPI-stained nuclei was significantly (p < 
0.001) lower than the untreated control of the 24 h time point (Figure 5.5). Treatment with 5 
mg/mL of Lp-BS for 24 h did not show significant (p > 0.05) high percentage of apoptotic cells 
when compared to the untreated control (Figure 5.4) and the number of DAPI-nuclei was 
found comparable to the untreated control (p > 0.05) (Figure 5.5). Further incubation of cells 
with 10 and 5 mg/mL for 48 and 72 h did not induce significant (p > 0.05) percentage of 
apoptotic TUNEL-positive cells compared to the untreated controls (Figure 5.4). However, 
total cell number of DAPI-stained nuclei treated with 5 and 10 mg/mL for 48 and 72 h 
decreased dramatically (p < 0.001) over time to approach close to zero after 72 h (Figure 5.5). 
See appendix II for magnified photomicrographs.  
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Figure 5.3 Apoptotic effect of Lp-BS. To determine the apoptotic potential of Lp-BS, 
TUNEL assay was performed on pulp cells grown in-vitro following treatment with 10 and 
5 mg/mL for 24, 48 and 72 h. The images are representative of 3 independent 
experiments. See appendix II for magnified photomicrographs. 
100 µm 
100 µm 
173 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*** 
Figure 5.4 Percentage of apoptotic cells to the total cells number 
following treatment with Lp-BS 5 and 10 mg/mL. Comparison was made 
using Tukey’s one way ANOVA multiple comparisons test. ***; p < 0.001. 
Error bar represent SEM of three independent experiments. N=3. 
Figure 5.5 Rat dental pulp cells count following treatment with Lp-BS for 24, 
48 and 72 h.  The DAPI-stained nuclei were counted. Comparison was made to 
the untreated control of each time point using Dunnett's multiple comparisons 
one way ANOVA test. ***; p < 0.001. Error bar represent SEM of three 
independent experiments. N=3.  
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5.3.1.3 Viability of rat pulp tissue following treatment with Lp-BS solutions 
Tooth slices were cultured with a series of Lp-BS concentrations (10, 5, 2.5, 1.25 and 0.625 
mg/mL) for 24 h and with 0.625 and 10 mg/mL Lp-BS for 48 h. These sections were processed 
automatically and stained with H&E stain. As was seen under standard culture conditions, 
tissue architecture and morphology was maintained for the first 24 h culture with the Lp-BS 
five concentrations (Figure 5.6). Areas of both dentine and pre-dentine could be observed 
with odontoblasts remaining as tall columnar cells, the viability of which can be seen from the 
darkly stained purple nuclei. Healthy pulp fibroblasts were seen as spindle shaped cells with 
dark purple nuclei. Staining of the matrix was seen between the cells, all of which were 
indicators that the tooth slices were surviving in the biosurfactant solutions with no 
deleterious effects (Figure 5.6a). This was confirmed using cell counts on the pulp layer which 
were performed using ImageJ software. One-way Tukey’s ANOVA test showed no significant 
decrease (p > 0.05) in cell number at 24 h incubation with any of the tested Lp-BS solutions 
compared to the untreated control (Figure 5.6b).  
Stained sections which were treated with 0.0625 mg/mL Lp-BS for 48 h demonstrated no 
change to the untreated control sections in tissue architecture and morphology of the 
dentine, pre-dentine, odontoblasts and pulp fibroblast cells (Figure 5.7). Cell counts on the 
pulp area also revealed no significant difference (p > 0.05) to the untreated 48 h-old control 
section (Figure 5.9).  
Incubation of the tooth sections with 10 mg/mL for 48 h appeared to be associated with a 
breakdown of the surrounding extracellular matrix (Figure 5.8 red arrows). This matrix 
degradation was seen in the photomicrographs as a decrease in the structural integrity of the 
tissues as there was less staining seen surrounding the cells where there had previously been 
staining. The odontoblasts layer seemed to be affected by the toxic effect of biosurfactant as 
demonstrated in the photomicrographs as loss and fading of the nuclei—karyolysis of the 
majority of the odontoblast cells following 48 h culture with 10 mg/mL Lp-BS (Figure 5.8 black 
arrows). Cellular toxicity was also obvious in the pulp region. The majority of the pulp tissue 
cells underwent karyolysis evident in the photomicrographs by loss and fading of nuclei 
(Figure 5.8 blue arrows). Apoptotic cell death was also noticed as fragmented basophilic 
nuclei-karyorrhexis in the pulp tissue region (Figure 5.8 green circle) (Elmore 2007). The 
observed changes in cell number which were seen in the histological sections was confirmed 
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using average cell counts over a 50 µm² area. These counts demonstrated that there was a 
significant (p < 0.001) decrease in pulpal cell number after 48 h culture with 10 mg/mL when 
compared to the untreated control sections (Figure 5.9).  
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b- 
a- 
Figure 5.6 Viability of rat pulp tissue follow treatment with Lp-BS. Although Lp-BS was 
shown to be toxic against cells, the viability of pulp tissue was assayed in the presence 
of different concentrations (10, 5, 2.5, 1.25 and 0.625 mg/mL) of Lp-BS for 24 h. a- 
Tooth slices fixed, processed and histological sections stained with H&E stain. Nuclei 
of the pulp area excluding the odontoblast layer were counted automatically using 
ImageJ software divided by the surface area. b- Using Tukey’s one-way ANOVA, no 
significant difference was obtained among the different concentrations and the 
untreated control (p > 0.05).  Images were obtained at 20x magnification. Error bars 
represent SEM of three independent experiments. Scale bar=100 µm. 
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10 mg/mL Lp-BS 
100 µm 
Figure 5.7 Viability of rat pulp tissue follow treatment with Lp-BS for 48 h. 
Although Lp-BS was shown to be toxic against cells, the viability of pulp tissue was 
assayed in the presence of 10 and 0.625 mg/mL of Lp-BS for 48 h. Tooth slices 
were fixed and processed and histological sections stained with H&E stain. Images 
obtained at 20x magnification. N=3. 
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Figure 5.8 Photomicrograph representation of tooth section treated with Lp-BS 10 mg/mL 
for 48 h. Circle #1 represents the breakdown of the surrounding extracellular matrix and the 
loss and fading of the nuclei—karyolysis of the majority of the pulp tissue cells. Circle #2 
represents fragmented basophilic nuclei-karyorrhexis characteristic of apoptosis. Circle #3 
represents the loss and fading of the nuclei—karyolysis of the majority of the odontoblast 
cells. 
1 
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5.3.1.4 RT-qPCR of cytokines 
5.3.1.4.1 Concentration of mRNA   
Lp-BS treated pulp tissue was extirpated and mRNA was extracted.  mRNA concentration and 
purity were determined using a NanoVue 463 Spectrophotometer (GE Healthcare Life 
Sciences, Buckinghamshire, UK).  mRNA concentrations extracted from tooth sections treated 
with 10 mg/mL Lp-BS showed a trend of significant decline with time from > 100 ng/µL after 
2 and 6 h incubation to about 40 ng/µL after 24 h incubation (Figure 5.10). Statistical analysis 
using Tukey’s one-way ANOVA revealed that the mRNA yield obtained from the untreated 
control tooth sections and those treated with 0.625 mg/mL Lp-BS at the three time points 
was significantly (p < 0.05) higher than that of the samples treated with the high 
concentration of 10 mg/mL Lp-BS (Figure 5.10). 
 
 
 
Figure 5.9 Cells count of the pulp tissue following treatment with Lp-BS for 
48 h. Statistical analysis was performed using Tukey’s one-way ANOVA 
comparisons test. ***; p < 0.001. Error bar represent SEM of three 
independent experiments. 
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5.3.1.4.2 Inflammatory markers 
For further characterisation of Lp-BS inflammatory potential on pulp tissue cells, mRNA gene 
expression of a series of inflammatory cytokines was assayed over 2, 6 and 24 h incubation 
with 0.625 or 10 mg/mL Lp-BS.  
5.3.1.4.2.1 Gene expression profile of pro-inflammatory cytokines (TNF-alpha, IL-1beta, 
IL-6)  
5.3.1.4.2.1.1 TNF-alpha 
Tooth sections co-incubated with 10 mg/mL for 2 h demonstrated a significant (p < 0.05) down 
regulation of TNF-alpha mRNA expression when compared to the untreated control. Further 
incubation for 6 and 24 h also resulted in down regulated expression of TNF-alpha though not 
significantly in comparison to the control (p > 0.05) (Figure 5.11). Co-culture with the low 
concentration of Lp-BS (0.625 mg/mL) brought TNF-alpha gene expression below the control 
level 2 and 6 h. Continuing treatment with 0.625 mg/mL for 24 h caused a significant (p < 
Figure 5.10 mRNA concentration of samples treated with Lp-BS. 
Tukey’s one-way ANOVA revealed a significant reduction of the 
obtained mRNA level over time when the pulp tissue was treated 
with 10 mg/mL Lp-BS. Error bar represent SEM of three independent 
experiments. 
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0.05) 1.7 fold increase in the expression of TNF-alpha when compared to the untreated 
control (Figure 5.11).   
5.3.1.4.2.1.2 IL-1beta 
IL-1beta gene expression was elevated in response to treatment for 2, 6 and 24 h with the 
low concentration of 0.625 mg/mL but not at 10 mg/mL Lp-BS in comparison to the untreated 
control (p < 0.001). Although the mRNA expression of the pro-inflammatory cytokine IL-1beta 
underwent significant (p < 0.001) up-regulation in response to treatment with 0.625 mg/mL 
Lp-BS, the fold change decreased over time from 8.1 and 6.3 after 2 h and 6 h respectively to 
reach 3.6 at the end of incubation (24 h) (Figure 5.11). Treatment with 10 mg/mL did not show 
a significant effect on gene expression of the target cytokine. After 2 h culture of the tooth 
slice with 10 mg/mL Lp-BS, there was a non-significant (p > 0.05) down regulation of IL-1beta 
mRNA expression when compared to the untreated control. The expression up-regulated 
slightly (p > 0.05) in the following 6 h in co-culture with Lp-BS (1.4 fold) to be tapered down 
again at the end of the experiment (24 h), though insignificantly (p > 0.05).  
5.3.1.4.2.1.3 IL-6  
Lp-BS treatment at 0.625 mg/mL of tooth section resulted in up-regulation of mRNA IL-6 
expression by 2.6 fold after 2 h incubation, maximised after 6 h to 6.1 fold and then declined 
to 4.1 fold of the control. It was statistically significant at 6 and 24 h (p < 0.001) in comparison 
to the untreated control (Figure 5.11). Of the samples treated with 10 mg/mL, IL-6 gene 
expression maximised significantly only after 6 h incubation (p < 0.001 in comparison to the 
control) reaching a comparable level to that induced by 0.625 mg/mL (i.e. 6.8 fold increase). 
The expression then declined significantly (p < 0.001 in comparison to 6 h time point) after 24 
h while no expression was reported at 2 h incubation when compared to the untreated 
control (Figure 5.11).  
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Figure 5.11 Pro-inflammatory genes expression in response to Lp-BS treatment. Tukey’s one 
way ANOVA was used to determine significant difference among the different groups. *; p < 
0.05, **; p < 0.01, ***; p < 0.001. Error bars represent SEM of three independent experiments. 
Note: B2M was used as reference gene. 
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5.3.1.4.2.2 Gene expression profile of anti-inflammatory cytokines (IL-4 and IL-10)  
5.3.1.4.2.2.1 IL-4  
Only 0.625 mg/mL Lp-BS demonstrated the potential to significantly (p < 0.001) induce IL-4 
mRNA up-regulation by 3.5 fold after 24 h incubation with the tooth section when compared 
to the untreated control. However, at 2 and 6 h, the target gene was knocked down by the 
effect of Lp-BS at the two concentrations tested (0.625 and 10 mg/mL) (Figure 5.12). 
5.3.1.4.2.2.2 IL-10 
Statistically significant (p < 0.001) inductions of IL-10 mRNA expression by 11.6, 18.2 and 10.3 
folds to the control were observed in tooth section cultured with 0.625 mg/mL Lp-BS at 2, 6 
and 24 h, respectively (Figure 5.12). In comparison, tissue treated with 10 mg/mL induced up-
regulation of the IL-10 gene by only 2.9 and 1.7 folds after 6 and 24 h incubation respectively, 
though this induction was not statistically significant (p > 0.05) when compared to the 
untreated controls (Figure 5.12).   
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Figure 5.12 Anti-inflammatory genes expression (IL-4 and IL-10) in response to 
treatment with Lp-BS. Tukey’s one way ANOVA was used to determine significant 
difference among the different groups. *; p < 0.05, **; p < 0.01, ***; p < 0.001. Error 
bars represent SEM of three independent experiments. Note: B2M was used as 
reference gene 
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5.3.1.4.2.3 Gene expression profile of TGF-beta and beta defensin cytokines  
5.3.1.4.2.3.1 TGF-beta1 
A down regulation of the mRNA expression of TGF-beta1 was evident for the samples treated 
with 0.625 and 10 mg/mL at 2, 6 and 24 h (Figure 5.13). Co-culture of the tooth slice with 10 
mg/mL Lp-BS down regulated TGF-beta1 gene expression significantly by 0.2, 0.2 and 0.06 
folds at 2, 6 and 24 h incubation respectively (p < 0.05, 0.01, 0.001 respectively) as shown in 
figure 5.12. Co-culture of the tooth slice with 0.625 mg/mL knocked down TGF-beta1 gene 
expression which was statistically significant (p < 0.01) at 6 h incubation (Figure 5.13) but not 
at 2 or 24 h (p > 0.05). 
 
5.3.1.4.2.3.2 Defensin beta2 
Treatment with 10 mg/mL caused down regulation of the antimicrobial defensin beta2 mRNA 
expression at all of the time points (2, 6 and 24 h) though insignificantly (p > 0.05) (Figure 
5.13). Similarly, co-culture of the tooth slices with 0.625 mg/mL down regulated the target 
gene expression at 2 and 6 h but the reduction was insignificant (p > 0.05). Interestingly, a 
significant up-regulation by 5.4 fold (p < 0.001) of the defensin beta2 mRNA expression was 
induced by treatment with 0.625 mg/mL after 24 h incubation (Figure 5.13).  
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Figure 5.13 TGF-beta1 and defensin beta2 gene expression in response to 
treatment with Lp-BS. Tukey’s one way ANOVA was used to determine 
significant difference among the different groups. *; p < 0.05, **; p < 0.01, 
***; p < 0.001. Error bars represent SEM of three independent experiments. 
Note: B2M was used as the reference gene. 
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5.3.1.4.3 Apoptotic marker gene expression in response to treatment with Lp-BS 
Figure 5.14 highlights Lp-BS-induced alterations in the mRNA expression of markers 
associated with apoptosis after 24 h. The overall picture of Lp-BS induced apoptotic effect 
demonstrated a linearity in pulp tissue response to the low and high Lp-BS concentrations 
tested. Of the pro-apoptotic genes tested (casp3, casp8 and FAS), casp8 and FAS were up-
regulated significantly in response to treatment with Lp-BS when compared to the untreated 
control. Casp8 gene expression was up-regulated by 2.5 and 3.1 fold when co-cultured for 24 
h with 0.625 and 10 mg/mL respectively (p < 0.05 and 0.01 respectively) relative to the 
untreated control sample. A relative fold change increase of 2.3 and 4.5 was reported for FAS 
gene in response to treatment of the tooth slices with 0.625 and 10 mg/mL respectively (p < 
0.05 and 0.001 respectively in comparison to the control). The gene expression of casp3 was 
not affected by Lp-BS 0.625 and 10 mg/mL (p > 0.05). Lp-BS demonstrated the potential to 
induce the expression of the anti-apoptotic Bcl2 gene by 1.5 and 3.7 folds at 0.625 and 10 
mg/mL Lp-BS respectively (p < 0.05 and 0.001 respectively) when compared to the untreated 
control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14 Apoptosis markers mRNA expression in response to 
treatment with Lp-BS for 24 h. Tukey’s one way ANOVA was used to 
determine significant difference among the different groups. *; P < 0.05, 
**; p < 0.01, ***; p < 0.001. Error bars represent SEM of three independent 
experiments. Note: B2M was used as the reference gene. 
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5.3.2 Section b: rhamnolipid  
5.3.2.1 Rhamnolipid cytotoxicity on rat dental pulp cells in 10% serum-containing 
medium 
To determine the viability of extracted rat dental pulp cells when exposed to rhamnolipid, 
trypan blue viability assay was performed. Different concentrations of rhamnolipids were 
tested (50, 25, 12.5, 6.25, 3.125, 1.56, 0.78, 0.625, 0.39, 0.195 and 0.097 mg/mL) as 
demonstrated in figure 5.15a. Percentages of viable cells to the total cells count are presented 
in figure 5.15b. Concentrations from 0.39 up to 50 mg/mL showed 100 % toxicity (i.e. no viable 
cell remained). More than 90 % cell viability was reported when cells exposed to rhamnolipid 
0.195 mg/mL. The morphology of the cells treated with 0.195 mg/mL rhamnolipid did not 
seem normal in comparison to the untreated control cells. At 20x magnification using light 
microscopy, these cells demonstrated intra-cellular vesicles or bodies which might be a pre-
apoptotic bodies (Figure 5.15a). Cells grown at 0.097 mg/mL showed more than 95 % viability 
and no intracellular bodies were detected (Figure 5.15b).  
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Figure 5.15 Viability of rat dental pulp cells in response to treatment with rhamnolipid. a- 
Photomicrographs are representative of three independent repeats. b- Percentage of cell 
viability. Error bars represent SEM of three independent repeats. 
a- 
b- 
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5.3.2.2 Apoptotic effect of rhamnolipid on rat dental pulp cells 
To determine if rhamnolipid at 0.097 and 0.195 mg/mL had the ability to induce apoptosis in 
dental pulp cells, a TUNEL assay was employed. Cells were cultured with either 0 mg/mL 
(control), 0.097 mg/mL or 0.195 mg/mL rhamnolipid for 24, 48 and 72 h as depicted in the 
micro-images of figure 5.16.   
At the lower rhamnolipid concentration (0.097 mg/mL), a significantly (p < 0.001) high 
percentage (> 16 %) of TUNEL-positive cells were reported after 24 h incubation with the 
treatment (Figure 5.17) in comparison to the untreated control. More than 6 % of the cells 
treated with 0.195 mg/mL rhamnolipid for 24 h was found TUNEL-positive compared to the 
untreated control cell sample (p < 0.001)(Figure 5.17). DAPI-positive nuclei count of the 0.195 
mg/mL rhamnolipid treated cells was lower than the untreated control but the difference was 
not significant (p > 0.05). Counts of DAPI-positive nuclei of cells treated with 0.097 mg/mL 
demonstrated no difference to the untreated control (p > 0.05) (Figure 5.18). Incubation for 
48 h with the treatment (0.097 and 0.195 mg/mL), the percentage of apoptotic cells dropped 
dramatically showing no significant difference (p > 0.05) to the untreated control (Figure 
5.17).  
The number of DAPI-positive nuclei of 0.097 and 0.195 mg/mL rhamnolipid-treated cells 
decreased significantly (p < 0.05) at 48 h post treatment (Figure 5.18). Further incubation of 
the cells with rhamnolipid solutions of 0.097 and 0.195 mg/mL for 72 h resulted in less than 
1 % apoptosis (Figure 5.17) which was comparable to the untreated control (p > 0.05). Cells 
treated with 0.097 mg/mL showed the potential to regenerate and at the end of the 72 h 
incubation their DAPI count was close to the untreated control, though the difference was 
still significant (p < 0.05) (Figure 5.18). DAPI-positive cells grown with 0.195 mg/mL for 72 h 
continued to decrease reaching a significant low level (p < 0.001) in comparison to the control 
sample (Figure 5.18). See appendix II for magnified photomicrographs.  
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Figure 5.16 TUNEL assay on rat dental pulp cells treated with rhamnolipid. The photographs 
are representative of three independent experiments. RL; rhamnolipid. See appendix II for 
magnified photomicrographs. 
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Figure 5.17 Percentage of apoptotic cells number to the total DAPI-stained nuclei number 
following treatment with rhamnolipid. Comparison was made using Tukey’s one way ANOVA 
multiple comparisons test. ***; p < 0.001. Error bar represent SEM of three independent 
experiments. 
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Figure 5.18 Rat dental pulp cells count following treatment with rhamnolipid for 24, 48 and 
72 h.  DAPI-stained nuclei were counted. Comparison was made to the untreated control of 
each time point using Dunnett's multiple comparisons one way ANOVA test. *; P<0.05, **; 
P<0.01, ***; p< 0.001. Error bar represent SEM of three independent experiments. 
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5.3.2.3 RT-qPCR for cytokines 
5.3.2.3.1 Inflammatory markers 
For further characterisation of rhamnolipid 0.097 mg/mL inflammatory potential on pulp 
tissue cells, mRNA gene expression of a series of inflammatory cytokines (below) were 
assayed over 2, 4, 6, 24, 48 and 72 h incubation with 0.097 mg/mL rhamnolipid.  
5.3.2.3.1.1 Gene expression profile of pro-inflammatory cytokines (TNF-alpha, IL-1beta, 
IL-6)  
5.3.2.3.1.1.1 TNF-alpha 
The overall TNF-alpha expression profile (Figure 5.19) suggested a prompt significant (p < 
0.01) up-regulation by 7.9 fold of the target gene after 2 h incubation of the tooth section 
with rhamnolipid 0.097 mg/mL relative to the untreated control.  
In response to subsequent incubation for 4, 6, 24, 48 and 72 h, TNF-alpha mRNA expression 
declined significantly (p < 0.001). Gene expression dropped from 7.9 folds at 2 h to 2.5 folds 
at 4 h. At 6 h post incubation, a knocking down of the gene was reported while after 24 and 
48 h the gene showed slight but insignificant up-regulation (1.28 and 1.17 folds respectively) 
to decline again at 72 h (0.59 folds) relative to the control.   
5.3.2.3.1.1.2 IL-1beta 
A bar chart representation of IL-1beta expression profile is provided in figure 5.19. An up 
regulation by 3.7 folds of the IL-1beta gene was reported early after 2 h incubation of tooth 
section with 0.097 mg/mL rhamnolipid (p < 0.01) relative to the untreated control sample. 
Four and 6 h post incubation with the treatment, the pulp tissue expression of IL-1beta mRNA 
was down regulated significantly (p < 0.001). Further incubation of the tooth slice with 
rhamnolipid solution for 24 and 48 h resulted in insignificant (p > 0.05) re-induction of the 
target gene expression by 2.1 and 2.8 folds respectively which declined again toward the end 
of the incubation period (72 h) in relation to the untreated control. 
5.3.2.3.1.1.3 IL-6 
No significant up-regulation of IL-6 mRNA expression was monitored between 2 and 24 h co-
culture of the tooth sections with 0.097 mg/mL rhamnolipid solution (p > 0.05) (Figure 5.19). 
At 48 h incubation, a 16.7 folds increase (p < 0.001) of IL-6 mRNA expression was reported 
followed by a decline to 1.9 folds after 72 h relative to the control (Figure 5.19). 
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Figure 5.19 Pro-inflammatory gene expression in response to 
treatment with rhamnolipid. Tukey’s one way ANOVA was used to 
determine significant difference among the different groups. *; P < 
0.05, **; p < 0.01, ***; p < 0.001. Error bars represent SEM of three 
independent experiments. Note: B2M was used as the reference gene. 
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5.3.2.3.1.2 Gene expression profile of anti-inflammatory cytokines (IL-4 and IL-10)  
5.3.2.3.1.2.1 IL-4 
IL-4 mRNA expression by the cells of the tooth section co-cultured with 0.097 mg/mL 
rhamnolipid was up-regulated significantly (p < 0.001) by 6.2 folds 2 h post incubation (Figure 
5.20). A significant (p < 0.001) decline in the expression was followed the subsequent time 
points between 4 and 24 h. After 48 h culture, the gene expression was induced again by 2.1 
folds and then knocked down significantly (p < 0.001) at 72 h time point (Figure 5.20). The 
comparison was made relative to the negative control.    
 
5.3.2.3.1.2.2 IL-10 
A significant (p < 0.001) up-regulation of IL-10 mRNA expression was induced at two time 
points; 2 and 48 h by 6.5 and 10.9 folds respectively relative to the untreated control (Figure 
5.20). At 4, 6 and 24 h the expression declined significantly (p < 0.001) by 1.5, 0.8 and 2.2 
folds, respectively. Following up-regulation at 48 h, the mRNA expression dropped 
significantly at 72 h by 1.3 folds (Figure 5.20).   
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Figure 5.20 Anti-inflammatory gene expression in response to 
treatment with rhamnolipid. Tukey’s one way ANOVA was used to 
determine significant difference among the different groups. *; P < 
0.05, **; p < 0.01, ***; p < 0.001. Error bars represent SEM of three 
independent experiments. Note: B2M was used as the reference 
gene. 
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5.3.2.3.1.3 Gene expression profile of TGF-beta1 and beta defensin cytokines  
5.3.2.3.1.3.1 TGF-beta1 
A slight, but insignificant (p >  0.05) up-regulation of the TGF-beta1 mRNA expression was 
induced only at 2 h post incubation of the tooth section with 0.097 mg/mL rhamnolipid 
relative to the untreated control (Figure 5.21). Subsequent incubation of the samples with 
rhamnolipid for 4, 6, 24, 48 and 72 h resulted in down-regulation of the growth factor cytokine 
mRNA expression which was significant ( p < 0.001) for the 4, 6 48 and 72 h samples but not 
for the 24 h sample (p > 0.05) when compared to the untreated counterpart controls (Figure 
5.21).   
 
5.3.2.3.1.3.2 Defensin beta2 
The expression of the antimicrobial peptide defensin beta2 mRNA was up-regulated 2 h post 
incubation with rhamnolipid by 7.0 fold which was significantly (p < 0.001) higher than 
expression at any other time points (Figure 5.21). At 4 h incubation, the expression was 
reduced to 4.2 fold and further down regulated the following 6 and 24 h to slightly (p > 0.05) 
up-regulated at 48 h (1.7 fold increase).  At the end of the incubation period (72 h), the gene 
expression was down regulated (0.4 fold) relative to the untreated control (Figure 5.21).  
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Figure 5.21 TGF-beta1 and defensin beta2 gene expression 
in response to treatment with rhamnolipid. Tukey’s one way 
ANOVA was used to determine significant difference among 
the different groups. *; p < 0.05, **; p < 0.01, ***; p < 0.001. 
Error bars represent SEM of three independent experiments. 
Note: B2M was used as the reference gene. 
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5.3.2.3.2 Apoptotic markers 
Treatment with rhamnolipid 0.097 mg/mL for 24 h did not show the potential to induce any 
of the tested pro- or anti-apoptotic markers (Figure 5.22). Conversely, a down regulation of 
these markers was the observed trend. However, this down regulation of the apoptotic 
markers genes expression was not significant (p > 0.05) (Figure 5.22).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.22 Apoptosis markers mRNA expression in response to 
treatment with rhamnolipid for 24 h. Tukey’s one way ANOVA was used 
to determine significant difference among the different groups. Error 
bars represent SEM of three independent experiments. Note: B2M was 
used as the reference gene. 
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5.3.2.4 Bacterial growth under modified culture medium (DMEM + 10% BHI) 
SAG and E. faecalis isolates were grown in modified culture medium (DMEM + 10% FBS + 10% 
BHI) to 102 CFU/mL. Figure 5.23a depicts the bacterial growth curves based on the measured 
absorbance hourly for 24 h as an indication of the change in turbidity relative to bacterial 
growth. S. intermedius did not grow in BHI nor in the modified medium with no measurable 
growth at 24 h (Figure 5.23a). Similarly, S. anginosus was unable to grow in the modified 
medium. Conversely, it grew in BHI but demonstrated a delayed lag phase (10 h) followed by 
log phase which continued to the end of the incubation period (24 h). S. constellatus growth 
was further impaired when grown in DMEM + BHI with no measurable growth after 16 h. The 
maximum absorbance recorded at 600 nm was 0.16 compared to 0.5 when S. constellatus 
grew in BHI medium. E. faecalis survived and showed typical growth curve both in BHI and 
the modified medium. A longer lag phase of 9 h was required for this bacterium before 
starting the exponential phase when it was cultured in DMEM + BHI than when it grew in BHI 
(lag phage length = 7 h). Its growth occurred at a slower rate in the modified medium and its 
maximum absorbance at 600 nm (0.43 ± 0.08) was lower than that in BHI (0.74 ± 0.07) (Figure 
5.23a).  
Since the tooth section was aimed to be co-cultured with SAG and E. faecalis and the 
rhamnolipid treatment for 8 h and since none of the tested isolates were able to show active 
growth during the first 8 h of incubation in the modified medium, then a viable cell count of 
the bacteria was carried out hourly for 8 h as shown in figure 5.23b. S. intermedius could be 
cultured on FAA plates and gave rise to viable colonies only up to 4 h; beyond that no viable 
cells were recovered. S. anginosus cells were cultured on FAA plates and a slight increase in 
number was evident between zero time (log10 = 1.80 ± 0.12) and 8 h (log10 = 2.40 ± 0.03). 
Similarly, S. constellatus was able to be cultured from the modified medium onto FAA plates 
with the bacterial yield increased from 1.70 ± 0.15 log10 at zero time to 2.80 ± 0.03 log10 at 8 
h. Comparable to its absorbance reading based growth pattern (Figure 5.23a), E. faecalis 
demonstrated viability in the modified medium when cultured on FAA plates. The log10 of the 
recovered E. faecalis increased steadily from 1.20 ± 1.06 at zero time to 5.40 ± 0.04 at 8 h 
incubation.    
However, upon application of this bacterial concentration (102 CFU/mL) of S. anginosus and 
S. constellatus to the tooth section in the modified culture medium, no supernatant change 
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in colour was observed, indicative of no growth. No bacterial attachment in the histologically 
prepared sections was noticed (data not shown). Thus, a higher concentration of the bacterial 
inoculum (106 CFU/mL) were applied to infect the tooth section for 24 h (below).  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b- 
a- 
Figure 5.23 SAG and E. faecalis growth and viability in the modified 
culture medium (DMEM containing 10 % FBS + 10% BHI). a- Optical 
density (600 nm) based bacterial growth pattern for 24 h. b- Viable 
bacterial cell count over 8 h culture in the modified culture medium. Error 
bars represented the SEM of three independent experiments. 
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5.3.2.5 Ex-vivo rhamnolipid antimicrobial activity 
Preliminary experiments (data not shown) involved culturing tooth section with S. anginosus 
or S. constellatus (106 CFU/mL) and rhamnolipid in serum containing modified culture medium 
and demonstrated no inhibitory effect of rhamnolipid. The culture supernatants of the 
infected control and rhamnolipid treatment were turbid and yellowish indicating bacterial 
growth. Serum inactivation of the rhamnolipid was suggested and a serum-free modified 
culture medium was employed. 
 
5.3.2.5.1 Histology sections: Gram staining 
Sections were treated with modified Gram stain (Brown and Brenn stain), which stains Gram 
positive bacteria purple (crystal violet), and Gram negative bacteria pink (fuchsin).  
Following co-culture of the tooth section with 106 S. constellatus for 24 h, bacterial cells 
stained purple were visualised attached to the exposed pulp tissue (Figure 5.24a, red arrows).  
A zone of cell infiltration (Figure 5.24a, blue arrows) can be seen surrounding the infected 
area. Subsequent to co-culturing the tooth section with the same bacterial concentration and 
0.097 mg/mL rhamnolipid solution, only few S. constellatus cocci could be detected in the 
area between the odontoblasts and the pre-dentine layer (Figure 5.24a, red circles) which 
might be dead bacterial cells of the infecting inoculum.  
Gram staining of the histological sections of tooth slices inoculated with S. anginosus at the 
same concentration (106 CFU/mL) for 24 h showed small bacterial aggregates attached to the 
exposed pulp layer (Figure 5.24b, red arrows). No bacterial invasion deep into the pulp tissue 
was noticed. Bacterial cocci were also found attached to the periodontal ligament (Figure 
5.24b, red arrows). In response to co-culture with rhamnolipid solution at 0.097 mg/mL 
concentration, only few singular cocci were found attached to the pulp exposed area which 
might be from the original bacterial inoculum. These findings indicated a successful 
antimicrobial activity of the rhamnolipid treatment against the two SAG isolates tested.  
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a- S. constellatus  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sc RL 20x Sc control 20x 
Sc RL 40x Sc control 40x 
100 µm 100 µm 
50 µm 50 µm 
Figure 5.24 Ex-vivo rhamnolipid antimicrobial activity.  
a- S. constellatus-infected tooth section was co-cultured with 0.097 mg/mL rhamnolipid for 
24 h. Top two microphotographs were taken at 20x magnification. Bottom two 
microphotographs were taken at 40x magnification. Red arrows represented the Gram 
stained bacteria and blue arrows represent cell infiltration in the absence of rhamnolipid 
(negative control sample). Red circles represent the Gram stained bacteria in the presence of 
rhamnolipid (test sample). The photographs are representative of three independent 
experiments. Sc; S. constellatus, RL; rhamnolipid. 
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b- S. anginosus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b- S. anginosus-infected tooth section co-cultured with 0.097 mg/mL rhamnolipid for 24 h. Top two 
microphotographs taken at 20x magnification. Middle two microphotographs taken at 40x 
magnification. Right bottom image taken at 60x magnification. Left bottom micrograph showed 
bacteria attached to periodontal and surrounding tissue (40x mag). Red arrows represented Gram-
stained bacteria in the absence of rhamnolipid (negative control sample). Red circles represent the 
Gram stained bacteria in the presence of rhamnolipid (test sample). The photographs are 
representative of three independent experiments. Sa; S. anginosus, RL; rhamnolipid.  
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5.3.2.6 ELISA quantification of cytokines in tissue culture supernatant 
5.3.2.6.1 ELISA quantification of pro-inflammatory cytokines  
5.3.2.6.1.1 TNF-alpha 
ELISA quantification of tooth slice culture supernatant revealed a substantial release of TNF-
alpha in all of the treatment groups tested for 24 h in serum free medium (Figure 5.25). A 
level of more than 300 ng/L TNF-alpha was quantified in the supernatant of the negative 
control sample. A slightly higher level was detected in the spent culture sample of tooth 
section treated with the rhamnolipid solution only at 0.097 mg/mL. Tooth sections infected 
with S. anginosus or S. constellatus also triggered the release of this inflammatory cytokine at 
levels (293.5 ± 13.3 ng/L and 317.7 ± 44.2 ng/L respectively) comparable to the control sample 
(323.0 ± 15.3 ng/L). TNF-alpha quantities released by S. anginosus and S. constellatus-infected 
sections treated with rhamnolipid were also in linearity with the untreated negative control 
(317.4 ± 16.7 and 287.04 ± 13.2 ng/L vs. 323.0 ± 15.3 ng/L respectively). Despite these 
variations in the levels of TNF-alpha, no statistical significance (p > 0.05) was encountered 
among the different groups using Tukey’s one way ANOVA test.   
 
5.3.2.6.1.2 IL-1beta 
The levels of IL-1beta cytokine quantified in the supernatant collected for the different tested 
groups demonstrated significant variations (Figure 5.25). Rhamnolipid-treated tooth section 
released a significantly higher level (93.2 ± 25.4 pg/mL) of IL-1beta than the untreated 
negative control (59.2 ± 5.6 pg/mL; p < 0.05) and the bacteria infected samples (37 ± 3.1 
pg/mL by S. anginosus infected sample; p < 0.001 and 47.2 ± 11.3 pg/mL by S. constellatus 
infected sample; p < 0.01). Subsequent to the co-culture of the tooth section with S. anginosus 
and rhamnolipid for 24 h, a strikingly high level of the target inflammatory protein was 
excreted (141.2 ± 19.7 pg/mL) which was significantly higher (p < 0.001) than the pathogen-
infected tooth section alone. Similarly, though not significant (p > 0.05), an enhanced release 
of IL-1beta (68.9 ± 3.2 pg/mL) was reported for S. constellatus-infected tooth section co-
cultured with rhamnolipid for 24 h when compared to S. constellatus-infected sample. 
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5.3.2.6.1.3 IL-6  
The release of IL-6 (Figure 5.25) followed the same trend as TNF-alpha. No statistical 
significant variation (p > 0.05) in the levels of IL-6 was measured among the different groups 
assayed. S. anginosus-infected tooth section demonstrated the highest level of excreted IL-6 
(20.0 ± 1.7 ng/L). Rhamnolipid only treated tooth section released the least quantity of this 
inflammatory cytokine (15.2 ± 1.9 ng/L) into the culture supernatant. A lower level of IL-6 was 
detected for sections co-cultured with the S. anginosus isolate and rhamnolipid (16.5 ± 
2.1ng/L) than for sections co-incubated with the pathogen alone (20.09 ± 1.7 ng/L). Similarly, 
S. constellatus infected sample treated with rhamnolipid was found to release less IL-6 (17.2 
± 1.7 ng/L) than the infected sample with no rhamnolipid treatment (19.01 ± 1.09 ng/L) but 
the difference was insignificant (p > 0.05).   
 
5.3.2.6.1.4 IL-18 
The release of the pro-inflammatory protein IL-18 into the culture supernatant did not show 
any significant difference (p > 0.05) among the tested groups (Figure 5.25). Similar to IL-6, IL-
18 was produced at the least level (178.6 ± 12.4 pg/mL) by rhamnolipid-treated tooth slice in 
comparison to other groups. Other treated group samples excreted comparable levels of the 
tested cytokine into their spent culture supernatant (p > 0.05).  
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Figure 5.25 Pattern of pro-inflammatory cytokines release from infected tooth section treated with rhamnolipid for 24 h. Bar charts represent 
TNF-alpha, IL-1beta, IL-6 and IL-18 levels in the culture medium of bacterially infected tooth sections treated with rhamnolipid 0.097 mg/mL by 
ELISA. Error bar represents SEM of three independent experiments. *; p < 0.05, **; p < 0.01 and ***; p < 0.001 using Tukey’s one way ANOVA. 
RL; rhamnolipid, sa; S. anginosus, sc; S. constellatus.   
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5.3.2.6.2 ELISA quantification of anti-inflammatory cytokine IL-10, transforming growth 
factor TGF-beta and antimicrobial peptide defensin-beta2 
5.3.2.6.2.1 IL-10 
The collective data obtained from ELISA assay result did not show large variations in the IL-10 
levels among the different treatment groups (Figure 5.26). Rhamnolipid treated sample 
supernatant released the least quantity of IL-10 (174.5 ± 22.0 pg/mL) which was significantly 
(p < 0.05) lower than the untreated negative control. S. anginosus infected sample 
supernatant was found to contain comparable amount of IL-10 to that of the negative control 
and the rhamnolipid treated infected sample supernatants (p > 0.05). S. constellatus-treated 
sample produced significantly higher quantity of IL-10 than that produced by the rhamnolipid 
treated sample (p < 0.05).     
 
5.3.2.6.2.2 TGF-beta 
The pattern of TGF-beta release into the culture supernatant did not express significant 
variation among the different treated groups (Figure 5.26). Rhamnolipid treated tooth section 
was found to release the lowest quantity of the growth factor into the supernatant (477.1 ± 
61.5 ng/L) when compared to the other group (p > 0.05). Although not significant (p > 0.05), 
rhamnolipid treated S. anginosus infected sample showed a slight increase of TGF-beta 
release compared to the S. anginosus infected sample (677.1 ± 50.5 vs. 629.3 ± 37.1 ng/L, 
respectively). Conversely, tooth section cultured with S. constellatus alone produced a higher 
level of TGF-beta than the section co-cultured with S. constellatus and rhamnolipid (676.3 ± 
68.09 ng/L vs. 608.2 ± 78.2 ng/L respectively). However, this difference was not significant (p 
> 0.05).  
 
5.3.2.6.2.3 Defensin-beta2 
The profile of defensin-beta2 excretion into the culture medium demonstrated significant 
variation among the different treatment groups collected 24 h post incubation (Figure 5.26). 
ELISA assay revealed that the negative control sample produced the highest level of defensin-
beta2 (198.2 ± 78.1 ng/L) which was statistically significantly (p < 0.01) higher than other 
treatment groups except that of the S. anginosus-treated tooth section (p > 0.05). Treating S. 
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anginosus and S. constellatus-infected tooth sections with rhamnolipid 0.097 mg/mL caused 
a significant (p < 0.01) reduction of the level of the excreted densin-beta2 released into the 
medium when compared to the untreated negative control. 
Interestingly, S. anginosus infected tooth section demonstrated the ability to release 
significantly (p < 0.01) higher quantity (166.5 ± 30.9 ng/L) of the antimicrobial peptide into 
the culture medium than the pathogen infected tooth section treated with rhamnolipid (14.6 
± 5.6 ng/L).  No significant difference (p > 0.05) of the peptide levels in the culture medium 
collected was calculated between S. constellatus infected tooth slices and their counterparts 
treated with rhamnolipid.  
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Figure 5.26 Pattern of anti-inflammatory cytokine IL-10, transforming growth factor TGF-
beta and antimicrobial peptide defensin-beta2 release from tooth section treated with 
rhamnolipid for 24 h. Bar charts represent IL-10, TGF-beta and Defensin beta2 levels in the 
culture media of bacterially infected tooth sections treated with rhamnolipid 0.097 mg/mL 
by ELISA. Error bar represents SEM of three independent experiments. *; p < 0.05, **; p < 
0.01 and ***; p < 0.001 using Tukey’s one way ANOVA. RL; rhamnolipid, sa; S. anginosus, sc; 
S. constellatus. 
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5.3.2.7 Serum effect on rhamnolipid activity on pulp cells  
Cells that were cultured in 0 % FBS αMEM medium for 24 h did not grow properly as only 2-3 
cells were counted per field (Figure 5.27a). In the presence of 2-20 % FBS, cells were able to 
grow and demonstrated normal morphology (Figure 5.27a). Treating cells that had been 
growing in medium containing 0-5 % FBS with 0.097 mg/mL rhamnolipid resulted in a 
significant toxicity (Figure 5.28a) indicated by few dead cells remaining attached to the well 
surface that stained blue with trypan blue (Figure 5.27a). At 10 and 20 % FBS, introducing 
rhamnolipid treatment did not cause toxic effect on cells and showed no difference (p > 0.05) 
to the untreated control cells (Figure 5.27a and 5.28a).  
With cells were grown in 2-20 % FEB for the first 24 h and then in 0 % FBS for the second 24 
h (Figure 5.27b), rhamnolipid treatment during the second 24 h caused significant cytotoxic 
effect on cells in comparison to the untreated control in all serum concentrations tested 
(Figure 5.28b) indicating a negligible residual serum effect on rhamnolipid activity.   
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a 
b 
Figure 5.27 Effect of serum on rhamnolipid cytotoxicity. Cells were grown for 24 h in αMEM 
medium containing different concentrations of FBS (0-20%) then divided into two sets. One 
set was cultured for 24 h in the same concentration of FBS (a) and the other set cultured for 
the second 24 h in medium containing 0 % FBS (b). The two groups were then treated with 
rhamnolipid 0.097 mg/mL. The microphotographs (10x magnification) are representative of 
three independent experiments. Scale bar=100µm.  
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Figure 5.28 Percentage of viable pulp cells treated with 0.097 mg/mL at different serum 
concentrations. The Serum concentration between 0 and 5 % caused 100% toxicity of pulp 
cells while 10 % and 20 % FBS inactivated rhamnolipid inhibiting its cytotoxic effect (a). 
Residual serum was found to have no effect on rhamnolipid activity indicated by cell toxicity 
(b). Error bars represent SEM of three independent experiments.    
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5.4 Discussion  
Preserving vital pulp tissue and minimising the need for root canal therapy is gaining 
increasing importance in contemporary endodontics. One of the most crucial steps of 
successful regenerative endodontic is the complete elimination of residual infection 
(Albuquerque et al. 2014; Kamocki et al. 2015). 
The current chapter aimed to assess the applicability of Lp-BS and rhamnolipid as pulp 
antimicrobial agents in an ex-vivo relevant setting employing a previously developed and 
characterised rodent dental model (Roberts et al. 2013). Biosurfactant toxicity and 
immunogenicity to the pulp tissue cells were also investigated.  
5.4.1 Lp-BS 
The data obtained suggests that Lp-BS at 10 mg/mL was significantly toxic to the pulp cells 
and tissue. This was evident by the significantly lower count of cells treated with the 
biosurfactant and lower mRNA yield collected from tooth sections co-cultured with the 
biosurfactant (Figure 5.10). This toxicity might impact the obtained immune response by 
causing death to certain cells that contribute in pulp immunity. Down regulation of the 
expression of most of the tested inflammatory, growth factor and antimicrobial peptide genes 
in tissue treated with 10 mg/mL Lp-BS in comparison to tissue treated with the non-toxic 
0.625 mg/mL Lp-BS might be related  to such toxicity (Figures 5.11-5.13). Although it has been 
previously suggested that dental pulp can tolerate the toxic effect of restorative materials if 
bacteria and/or their toxins can be omitted from the pulp, the failure rate of the pulp therapy 
reported (Akhlaghi and Khademi 2015) might indeed be due to such restorative materials 
toxicity. Therefore, because of its toxicity and likelihood to account for failure, Lp-BS might be 
inappropriate to be used in pulp therapy. Thus, a decision of not to precede with further 
investigating the crude Lp-BS application to the ex-vivo model was made. The successfully 
partially purified fraction devoid of the contaminants of Lp-BS achieved by FPLC (Chapter 3) 
might show less or no toxicity and thus could be assessed for such application in the future. 
Although apoptosis-induced toxicity was reported for Lp-BS, demonstrated by TUNEL assay 
positivity, cell morphology and apoptotic markers gene expression up-regulation, this 
property has been reported advantageous for a number of biosurfactants as antitumor 
agents. This opens future prospects for possible investigation of Lp-BS as antitumor agent. 
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For instance, lipopeptide biosurfactants produced by Bacillus subtilis (Kim et al. 2007) and 
Bacillus natto T-2 (Wang et al. 2007) have been proposed as promising antitumor agents via 
induction of apoptotic effect on LoVo cells and human leukaemia K562 cells respectively. 
Candida antarctica-derived glycolipids biosurfactants have also been reported to contribute 
to growth arrest, apoptosis, and differentiation of mouse malignant melanoma and human 
HL60 cells (Sudo et al. 2000; Zhao et al. 2000). The molecular mechanism of biosurfactant-
induced apoptosis is still not well clarified. An increase in Ca2+ which evoked Extracellular 
Signal-regulated Kinases (ERK) phosphorylation has been proposed as a possible mechanism 
of Bacillus natto T-2-derived cyclic lipopeptide biosurfactant pro-apoptotic activity on K562 
cells (Wang et al. 2009). This ERK phosphorylation subsequently activated Bax, cytochrome c 
and caspase-3 leading to apoptosis in K562 cells. A membrane permeabilisation of melanoma 
A375 cells was proposed as a different mechanism of the lipopeptide biosurfactant 
pseudofactin II (PFII) pro-apoptotic activity (Janek et al. 2013). The interaction of PFII micelles 
with the plasma membrane impaired membrane integrity, evident by the release of LDH, 
leading to the observed Ca2+ influx which triggers further signalling cascades, like measured 
caspase-3 activation ending up with cell apoptosis.  
A concern that needs to be mention here is that Lp-BS may form an adhesive layer on top of 
the exposed ends of the tooth sections. In this case it might be that this adhesive layer 
prevented proper oxygenation of the pulp cells and thus resulted in cells toxicity.  
5.4.2 Rhamnolipid  
Rhamnolipid 0.097 mg/mL was established to exert the potential to inhibit in-vitro SAG 
growth (Chapter 4), thus a number of assessments were performed in this chapter to analyse 
its cytotoxic and immunogenic effects on pulp cells and tissue. An assessment of bacterial 
growth in the modified serum-containing tissue culture medium (DMEM+10 % FBS + 10% BHI) 
was also performed. S. anginosus and S. constellatus survived in the modified medium and 
thus were selected to infect the tissue to assess the antimicrobial activity of rhamnolipid. 
However, subsequent preliminary experiment of co-culturing S. anginosus and S. constellatus-
infected tooth sections with rhamnolipid 0.097 mg/mL in FBS-containing modified medium 
demonstrated no bacterial inhibitory effect of rhamnolipid. The lack of rhamnolipid 
antimicrobial effect might suggest inactivation of the biosurfactant antimicrobial effect 
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possibly via binding to serum protein/s. Therefore, serum-free culture medium was employed 
and as a result, rhamnolipid was shown to exert antimicrobial activity in this medium.  
Consequently, all results of rhamnolipid in serum-containing medium including viability assay, 
TUNEL assay for apoptosis and genes expression of inflammatory, TGF-beta1 and defensin-
beta2 might be unreliable. Moreover, it might be that the observed cytotoxicity and 
immunogenicity of the currently tested rhamnolipid on pulp cells and tissue was due to the 
unbound rhamnolipid molecules or to the 10 % contaminants of the 90 % pure commercial 
rhamnolipid used. Therefore, these findings are difficult to interpret with confidence.  
Earlier studies mainly focused on the serum effect on rhamnolipid cytotoxicity. To the best of 
our knowledge, there is no study discussing the serum effect on antimicrobial activity of 
rhamnolipid. Rhamnolipid could bind with high affinity to serum albumin at 1:1 to 1:2 ratio 
(Sánchez et al. 2008). Therefore, the concentration of free rhamnolipid, due to protein 
binding, might be reduced to a level below the MIC for SAG resulting in no antimicrobial 
effect.  
The presence of serum in DMEM culture medium severely attenuated rhamnolipid 
cytotoxicity on dental pulp cells particularly at concentration of ≥ 10 % FBS (Figure 5.27 and 
5.28). This finding correlated  with  previously reported  findings of rhamnolipid effects on 
macrophage cells (McClure and Schiller 1992; Häussler et al. 1998) and fibroblast cells 
(Stipcevic et al. 2005).  
It has been shown that the presence of FBS severely reduced rhamnolipid cytotoxicity 
(McClure and Schiller 1992; Häussler et al. 1998; Stipcevic et al. 2005). An interesting study 
conducted by Jian and colleagues (2014) reinvestigated the selective rhamnolipid antitumor 
effect against cancerous but not normal cells. Rhamnolipid was found to exert cytotoxic effect 
equally against cancer and normal cells due to a reduction in surface tension of the culture 
medium. The authors demonstrated that the presence of FBS in the culture medium 
significantly diminished rhamnolipid cytotoxicity which was proposed to be due to the 
inhibited surface activity. These findings corrected the misleading previous claim that 
rhamnolipid selectively kills cancer cells which was incorrectly made due to the error in 
experimental design  in which  cancer cells were cultured in the absence of serum while 
normal cells were grown in serum-containing medium (Thanomsub et al. 2006).  
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Rhamnolipids have been well accepted for in-vivo animal safety (Federal Register, 2004), 
though demonstrating cytotoxicity in serum-free medium. This safety can be due to serum-
protein binding (Jiang et al. 2014). On the other hand, serum protein binding can be reversible 
and the bound portion may behave as a depot or reservoir from which a continuous slow 
release of the drug can be maintained (Banker and Clark 2008). Further work need to be 
performed to utilise this propensity of rhamnolipid serum protein binding by adjusting the 
concentration for a controlled release pharmaceutical form.   
Although S. constellatus and S. anginosus were applied to infect the tooth section at the same 
concentration and although the two strains showed comparable in-vitro attachment and 
biofilm potential on plastic well surface (Chapter 2), the former was shown to have a higher 
affinity to bind to the tooth soft tissue, mainly to the pulp (Figure 5.24a). This highlighted the 
importance of such ex-vivo tooth model to further understand the bacterial attachment in a 
more relevant situation. S. anginosus demonstrated a higher affinity to adhere to the remnant 
of the periodontal ligament region and to a lesser extent to the exposed pulp tissue (Figure 
5.24b). However no statistical analysis on this observation was possible and estimation was 
done based only on visual basis. This difference in the pulpal affinity and possible infectivity 
of the two species belonging to the same SAG group sheds light on the importance of bacterial 
identification to the species level. Little information is available considering the differences in 
SAG members’ pathogenicity and adherence. In a study published 2011 (Japanese Society of 
Chemotherapy Committee on guidelines for treatment of anaerobic infections and Japanese 
Association for Anaerobic Infection Research 2011), among 39 Streptococcus spp. isolated 
from dental infection, 16 strains were found to be S. constellatus (35.6 %) while only 2 strains 
were identified as S. anginosus (4.4 %).  More recently, S. constellatus of the SAG group was 
identified among the most abundant microorganisms, found in highest numbers within 
individual dental abscesses (George et al. 2016). Interestingly, higher adherence to the PGs 
decorin and biglycan was generally noted for S. constellatus isolates over S. anginosus isolates 
(Landrygan-Bakri et al. 2012) which might explain the higher adherence potential of S. 
constellatus found herein.  
Hydrolytic enzymes are generally considered to be potential virulence factors (Homer et al. 
1993). In screening for a number of hydrolytic enzymes of SAG isolates in relation to infection, 
Jacobs and Stobberingh (1995) documented that a number of these enzymes were found 
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prominent in S. constellatus and S. intermedius strains but not in S. anginosus.  Specifically, 
among the three species of 518 SAG strains, ribonuclease activity was equally dispersed while 
hyaluronidase, deoxyribonuclease and chondroitin sulphatase activity was found to be allied 
mainly to S. intermedius and S. constellatus and was associated with infection-related strains 
(Jacobs and Stobberingh 1995). Based on these findings, it could be suggested that S. 
constellatus may bear a more potential ability for initiating dental infection. Yet, further 
investigation on a wide range of SAG species need to be done before uttering any conclusive 
statement.  
Although a high concentration of bacterial inoculum (106 CFU/mL) was applied to infect the 
tooth section for 24 h, no difference in tissue structure was noticed in comparison to the 
untreated control. Conversely, in a study conducted earlier (Roberts et al. 2013) employing 
the same rodent 3D-tooth model, a different infection pattern of SAG members was reported. 
The bacterial isolates inoculated at lower concentration of 102 CFU/mL were shown able to 
adhere directly to the central region of the pulpal matrix in small foci that were associated 
with a localised matrix breakdown. The different colonisation style obtained in this study can 
be due to the use of different strains of SAG isolates (S. constellatus 45386 and S. anginosus 
39/2/14A) and that visualising bacterial attachment was made by FDA fluorescent stain 
instead of Gram’s stain. FDA stain might be subjective to interpretation error and diffusion 
and artifacts especially with auto-fluorescing tissue like the tooth tissues taking into account 
the authors did not provide an FDA-stained bacterial positive control. Moreover, pre-culturing 
the tooth sections for 5 days prior to co-culturing with bacterial isolates (Roberts et al. 2013) 
might be an additional factor affected pulp tissue status making it weaker and more liable to 
the damaging effect of bacteria especially if it involved immune cells (Morotomi et al. 2019).   
In mammals, microbial associated molecular peptide (MAMP) sensitivity leads to the 
induction of the inflammatory response with the production of cytokines including 
interleukins and the tumour necrosis factor-alpha (TNF-alpha). Years ago, lipopeptides were 
shown to induce human innate immune responses through the pattern recognition receptor 
(PRR) Toll-like receptor TLR2 perception, by activating the transcriptional activator of multiple 
host defense genes NFkB, the production of interleukin (IL)-12 and the respiratory burst 
(Hauschildt et al. 1990; Aliprantis et al. 1999; Brightbill et al. 1999; Takeuchi et al. 2000; 
Gerold et al. 2008). Recently, it has been shown that rhamnolipids are involved in eliciting 
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animal defense responses and, like lipopeptides, can be thus classified as MAMPs (Vatsa et 
al. 2010). Rhamnolipids can play dual role: as antimicrobial and also can stimulate host 
defense immunity. This dual property is probably very important for the efficacy of new 
therapy. However, because a wide range of rhamnolipids congeners and homologues have 
been isolated and characterised, the biological effects obtained have been variable as well 
(Abdel-Mawgoud et al. 2010).  
Interestingly, all the markers tested in the current study by ELISA were detected in all the 
samples assayed including the untreated control and the infected sections with and without 
rhamnolipid treatment. This might be due to tissue response to the process of extraction and 
cutting, though the sections were pre-cultured for 24 h to allow for amelioration of such 
response.  
Among the four pro-inflammatory markers monitored 24 h post rhamnolipid application with 
the infected tooth section, only IL-1beta was at a significantly higher level in rhamnolipid 
treated sections (control or infected sections) in comparison to the uninfected or bacterially 
infected tooth sections where it was also detected but at lower levels. This finding is 
promising as it might indicate a moderate immune response to rhamnolipid treatment. 
Moderate inflammation is an expected first step of pulp tissue repair cascade in response to 
direct pulp capping followed by the commitment of adult reserve stem cells, their 
proliferation and terminal differentiation. For many years, inflammation in pulp healing has 
been considered as undesirable effect which can lead to necrosis. However, recent results 
highlighted the potentially beneficial impact of moderate balanced inflammation on tissue 
healing and regeneration (Goldberg et al. 2008), in part, through stimulating progenitor cells. 
Inflammation has been shown to appear 3-7 days after implantation of pulp capping 
molecules and resolves within 2 weeks (Goldberg et al. 2008). A long term follow up of 
rhamnolipid-induced inflammatory response may give more detailed information on the pulp 
response scenario. The tooth section model that was employed herein has its own limitation; 
only innate immune response can be investigated making it difficult to predict whether 
rhamnolipid can be implicated in adaptive immunity. Further study is also required to assess 
its ability to induce reparative dentine formation in the exposed pulp. 
IL-1beta is a double-edged sword inflammatory cytokine, i.e. it is essential to resist infections 
but also exacerbates damage during chronic disease and acute tissue injury (Dinarello 2010). 
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Beside innate immune cells, IL-1beta can be produced by pulp fibroblasts and vascular 
endothelial cells (Barkhordar et al. 2002) but not odontoblasts (Yumoto et al. 2018). Research 
has shown a higher level of IL-1beta in inflamed pulp tissue than in healthy controls (Silva et 
al. 2009) and the fold increase was comparable to the current finding. Similarly, pulp 
fibroblasts derived from infected tooth were found to contain 2.5 fold greater amount of IL-
1beta and showed the potential to synthesise around 80 % greater amounts of collagen 
compared to fibroblast cells of healthy pulp (Barkhordar et al. 2002).   
Contradicting with the current finding that rhamnolipid did not show significant potential to 
induce higher level of TNF-alpha, Rha-Rha-C14-C14, which is structurally quite similar to the 
rhamnolipid exotoxin from P. aeruginosa, exhibited strong stimulatory activity on human 
mononuclear cells to produce TNF-alpha, a pleiotropic inflammatory cytokine (Andrä et al. 
2006). Another study demonstrated that rhamnolipids induced copious release of IL-6, IL-8 
and granulocyte-macrophage colony-stimulating factor from epithelial cells at sub-cytotoxic 
levels (Bédard et al. 1993).  
The anti-inflammatory cytokine; IL-10 was detected in all of the samples tested showing a 
trend toward controlling the immune response. However, its level in the rhamnolipid treated 
section was slightly (p < 0.05) lower than the untreated control.  
The antimicrobial factor defensin-beta2 was suppressed in the presence of rhamnolipid 
including bacterially infected sections co-cultured with rhamnolipid. The expression and 
release of this antimicrobial peptide is crucial to neutralise pathogens (Chromek et al. 2006; 
Abdel-Mawgoud et al. 2010). It has been reported that rhamnolipids from P. aeruginosa 
supernatant are able to subvert a flagellin‐induced human defensin‐beta2 response in 
keratinocytes by interfering with host‐cell calcium signalling, targeting protein kinase C (PKC) 
and therefore can manipulate host innate immune response (Dössel et al. 2012).  
The role played by rhamnolipid in assessing wound healing and tissue regeneration (Stipcevic 
et al. 2006; Shen et al. 2016) encouraged looking at its effect on growth factor (TGF-beta). 
This signalling molecule plays a vital role in stem cell differentiation, chemotaxis and 
apoptosis in monocytes, epithelial, mesenchymal and neuronal cells (Gold et al. 2000; 
Kubiczkova et al. 2012; Niwa et al. 2018). TGF-beta induced myofibroblasts were selectively 
inhibited by rhamnolipid (Shen et al. 2016) suggesting rhamnolipid as a novel anti-scar 
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therapy, however the mechanism still needs to be clarified, which might involve TGF-beta-
rhamnolipid relationship. Specifically in pulp fibroblasts, TGF-beta2 has been reported to 
induce the synthesis of collagen matrix (Chan et al. 2005). Rhamnolipid treated section 
demonstrated a reduced, though non-significant, reduction in the TGF-beta level in 
comparison to the untreated control or the infected sections with or without rhamnolipid.  
 
5.5 Conclusion  
This study successfully employed an existing ex-vivo tooth model to assess the biosurfactant 
antimicrobial activity in co-culture with bacterially infected tooth sections. Rhamnolipid at 
0.097 mg/mL demonstrated powerful potential to prevent tooth section infection in co-
culture with S. anginosus and S. constellatus in serum-free medium. The resulting 
inflammatory response pattern showed a trend of moderate inflammation balanced by an 
induction of immunosuppressant cytokine. It was also demonstrated that rhamnolipid 
solution could tolerate serum concentration ≤ 5 % in culture medium without affecting its 
activity. This means that rhamnolipid can be further investigated as a pulp therapy 
antimicrobial adjuvant. 
Lp-BS was found to be potentially toxic eliciting cell apoptosis early (24 h) post incubation. Its 
effect on tissue was noxious particularly with prolonged incubation (48 h). Lp-BS fraction 
obtained from purification by FPLC can be assayed in the future for its toxicity and 
antiadhesive activity as endodontic agent.  
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6 Chapter 6 General summary and future direction 
6.1 General summary  
As an attempt to treat and preserve infected pulp, vital pulp therapy has been introduced and 
many agents have been in use. However, failure has been reported mainly due to microbial 
contamination. Developing new strategies to combat microbial infection is needed for a more 
successful outcomes. Hence the aim of this thesis was to investigate the possible use of 
probiotic bacteria in the control of dental infection; more specifically endodontic infection. In 
particular, the intention was to extract a biosurfactant compound from the potential 
probiotic, characterised and investigated it further as an antimicrobial/antiadhesive material 
that can be used in conjunction with vital pulp therapy. A commercially sourced biosurfactant, 
rhamnolipid was also included in this study to test its antimicrobial effect against endodontic 
pathogens.  
Five probiotic strains were selected because they have shown promising results in combating 
bacterial infections (Falagas and Makris 2009). Of the probiotic strains assayed in this project, 
L. plantarum demonstrated the most significant growth inhibitory effects against SAG and E. 
faecalis. Other strains also revealed some inhibitory effects against one or more of the tested 
pathogens. However L. plantarum was selected for further study because it affected the 
growth of all four test strains. Moreover, interesting promising therapeutic benefits for L. 
plantarum have been documented in the literature for non- endodontic infection which 
encouraged investigation for its use in clinical dental applications. For instance, L. plantarum 
has been shown to benefit host immune function via stimulation of gut-associated and other 
lymphoid tissues, creation of an acidic environment in the gut which is hostile to many 
pathogens, enhancement of mucosal barrier function, induction of T-cell apoptosis in the 
lamina propria and inhibition of inflammatory cytokines (Naruszewicz et al. 2002; Fedorak 
and Madsen 2004; Pathmakanthan et al. 2004; Ko et al. 2007; Wullt et al. 2007; Connelly 
2008). Moreover, L. plantarum has also been attributed with the potential to rapidly inhibit 
pathogens either by competing with pathogens for receptor space on epithelial tissue or 
depleting the space for pathogens to grow (Klarin et al. 2008). It was also reported to produce 
a bacteriocin which inhibits Listeria monocytogenes and to reduce Clostridium difficile-
associated diarrhoea by stimulating butyrate and short chain fatty acid production (Olasupo 
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1998; Niku‐Paavola et al. 1999; Hutt et al. 2006; Rokka et al. 2006). L. plantarum revealed, for 
the first time, the potential to inhibit endodontic isolates in this study, this effect was reported 
in-vitro. The in-vivo situation may differ particularly when biokinetics factors such as host 
serum effect are considered  (Li et al. 2017). Moreover, the pathogen biofilm phenotype, 
which can be 1000 time more resistant is an additional important factor that should be taken 
into account when considering the in-vivo situation (Hall and Mah 2017).  
It was hypothesised that the observed antimicrobial effect of L. plantarum against SAG and E. 
faecalis might be due to the production of biosurfactant. Therefore biosurfactant compounds 
were extracted at four different time points representing the different phases of L. plantarum 
growth. The sample collected at the mid-exponential phase (designated Lp-BS) demonstrated 
the maximum surface tension lowering effect and therefore it was decided to proceed with 
this time point for further biosurfactant production and extraction. Beside lowering surface 
tension, Lp-BS also revealed an emulsifying activity against a number of hydrocarbons 
(Gharaei-Fathabad 2011).  
The extraction was performed according to a previously optimised protocol (Gudina et al. 
2010) with minor modification. Among varieties of extraction protocols (Satpute et al. 2010; 
Varjani and Upasani 2017), this method was chosen because it did not involve the use of harsh 
chemicals like strong acid or alcoholic solvents (Das et al. 2014) which may affect the integrity 
and activity of the obtained product. However, this method of extraction was basic and the 
product obtained cannot be considered pure, even following dialysis to get rid of low 
molecular weight contaminants (> 1000 Da) including the extracting buffer (PBS). It is 
important to consider and appreciate that this project was developed from ‘the ground up’ 
and that working in biosurfactant research is a complex multidisciplinary area of effort. There 
is a significant requisite for analytical scheme development and production optimisation, 
which may be challenging and muddled by some research groups. This is something that has 
been highlighted and commented upon by other authors (Marchant et al. 2014; Elshikh et al. 
2016). Partial characterisation by means of FT-IR supported by anthrone and protein assays 
revealed a glycoprotein nature of Lp-BS and this correlated with the results obtained by other 
researchers (Tahmourespour et al. 2011a; Savabi et al. 2014). However, FT-IR as a standalone 
method is limited for the purpose of characterisation (Barth 2007). Nuclear magnetic 
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resonance (NMR) spectroscopy alongside other techniques such as HPLC-MS could be applied 
to more fully characterise such macromolecules (Elshikh et al. 2016).  
Proteomic analysis of Lp-BS revealed a rich and heterogeneous protein nature. Based on 
database comparisons, three moonlighting proteins were identified (Chapter 3) that had 
proposed roles for facilitating adhesin-like activity; namely elongation factor Tu, enolase 1, 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The detection of such protein-binding 
proteins in the Lp-BS mixture may suggest that there is a role that can be played by this 
compound in binding to pulp ECM proteins and thus probably blocking bacterial attachment 
and colonisation sites. In an in-vitro antiadhesive assay using glass surface coated with the 
biosurfactant, Lp-BS exerted significant antiadhesive effect against SAG and E. faecalis when 
applied as a surface coating at 20 mg/mL. This finding might indicate a novel and promising 
non-pharmacological antibacterial activity that can be played by this compound which has 
not been reported for any of the current pulp therapy agents. It further highlights the possible 
involvement of the identified adhesin-like proteins in the reported antiadhesive property. At 
lower concentration of 10 mg/mL, SAG attachment was reduced though not significantly 
indicating a dose-dependent response similar to that demonstrated with some other 
biosurfactants (Cao et al. 2009; Jemil et al. 2017). Glass surface Lp-BS coating was successfully 
characterised for the first time by staining with fluorescent stain (SYPRO Ruby stain) and this 
demonstrated a successful coating.  
Although a number of biosurfactants have been shown to possess antimicrobial activity 
(Santos et al. 2016), the  Lp-BS investigated herein did not demonstrate antimicrobial effect 
against SAG or E. faecalis at a wide range of concentrations between 0.1-50 mg/mL. This lack 
of antimicrobial activity might be due to the strain-specificity or to the biosurfactant 
extraction method used. It might be that the complex protein-carbohydrate nature of the 
glycoprotein Lp-BS blocks the biosurfactant functioning site and hence further purification of 
Lp-BS may be necessary. In addition, Lp-BS was obtained during the mid-exponential phase 
and it may be that this extract is less efficient as antimicrobial than samples that would be 
obtained later in the growth curve where the exhaustion of nutrient may encourage the 
production of competing molecules with antimicrobial activity.  
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Lp-BS was extracted from a “generally regarded as safe” (GRAS) probiotic, and therefore it 
could be hypothesised to be safe when applied to the biological tissue. However, Lp-BS 
demonstrated significant toxicity against rat pulp cells even at low concentration of 5 mg/mL 
after 72 h incubation. Cell apoptosis was shown to be induced early within the first 24 h 
incubation with Lp-BS at 10 and 5 mg/mL. It is possible that because cells were grown as a 
monolayer, they may be more sensitive to the toxic effect of the treatment. Therefore, Lp-BS 
was applied to  pulpal tissue utilising a previously developed and characterised ex-vivo tooth 
section model (Roberts et al. 2013). Co-culture of the tooth sections with Lp-BS 0.625-10 
mg/mL for 24 h resulted in no significant difference (p > 0.05) in the cell counts and 
histological appearance between the sections treated with the different Lp-BS concentration 
and the untreated control sections. This finding would tend to suggest an apparent lack of 
toxicity of Lp-BS to the pulp tissue. However, low mRNA yield and down regulation of most of 
the analysed inflammatory markers genes obtained at 10 mg/mL treatment suggested a cell 
abnormality which might be due to early apoptosis via induction of DNA damage and cell 
death (Thomas et al. 2015). Indeed, when the effect of treatment was examined for 48 h at 
10 mg/mL Lp-BS, significant toxicity was demonstrated, with obvious histological changes and 
low cell counts in comparison to the untreated control tooth sections. It is difficult to 
determine which specific component or components were responsible for the toxicity 
considering the complex composition and the crude nature of Lp-BS. It might be that certain 
Lp-BS components integrated with the cell membrane and this might have triggered  
molecular pathways that ultimately result in cellular toxicity (Zhang 2018). Alternatively, 
contaminant molecules of the crude Lp-BS may have led to cell-death. Because of the toxicity 
encountered with the use of Lp-BS, it was decided not to continue with this crude product. 
Further purification was therefore needed and was achieved partially by fractionation 
chromatography based on size which resulted in four elution pools. The first largest obtained 
fraction preserved the biosurfactant compound indicated by the emulsifying activity 
demonstrated by this fraction. It was supposed that  biosurfactant could form micelle 
macromolecules hat can be eluted early leaving the smaller contaminants to be collected later 
(Mukherjee et al. 2009). The successfully partially purified fraction containing the 
biosurfactant is available for further testing particularly in the context of toxicity. However, 
this was not possible within the confines current study. 
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Commercially available rhamnolipid, was initially employed in this research as a biosurfactant 
positive control. This glycolipid has been extensively studied in different biomedical fields 
(Irfan-Maqsood and Seddiq-Shams 2014; Chong and Li 2017). However, its application within 
endodontic therapy has never been explored. Rhamnolipid revealed powerful antimicrobial 
activity against the SAG members studied with MICs of 0.097 mg/mL against S. anginosus and 
0.048 mg/mL against S. constellatus and S. intermedius. E. faecalis was found difficult to be 
inhibited at the lower concentrations tested and required a high concentration of 50 mg/mL 
to be completely inhibited. Though rhamnolipid did not effectively inhibit E. faecalis growth 
at the lower concentration, its ability to inhibit the “pioneer” SAG strains is a significant 
finding in the context of the development of endodontic biotherapy and it may be that 
rhamnolipid could be used to reduce the levels of E. faecalis via an effect on the pioneer 
species. This would need to be investigated further.  In addition to antimicrobial activity, 
rhamnolipid showed the potential to reduce S. anginosus and S. intermedius attachment to 
acrylic discs coated with rhamnolipid at 50, 0.097 and 0.048 mg/mL. These promising results 
justified the further testing of rhamnolipid on pulp cells and tissue. Rhamnolipid cytotoxicity 
on rat pulp cells was tested in serum containing medium. Further investigations were 
performed on rhamnolipid immunogenicity on the pulp tissue also in serum containing 
medium. A further application of rhamnolipid on bacteria-infected tooth section was 
performed to assess its ex-vivo antimicrobial activity, again in serum containing culture 
medium. But, an inactivation of rhamnolipid antimicrobial activity was encountered which 
was proposed to be due to serum effect (Jiang et al. 2014). By omitting serum from the culture 
medium and co-culture S. anginosus and S. constellatus-infected tooth sections with 
rhamnolipid at 0.097 mg/mL, significant antimicrobial activity was observed. S. anginosus and 
S. constellatus were chosen for the tooth section co-culture experiments because they were 
shown to be capable of surviving in the modified culture medium (DMEM + 10 % BHI). 
The ex-vivo tooth model was also used to investigate the immune response of the dental pulp 
cells to rhamnolipid treatment. Of the four pro-inflammatory cytokines (IL-6, IL-1beta, TNF-
alpha and IL-18) tested using an ELISA method within 24 h-culture supernatants, only IL-1beta 
demonstrated higher levels (> 60 pg/mL) of the released cytokine in rhamnolipid-treated 
infected or non-infected tooth sections. There was no significant difference in the amount of 
the anti-inflammatory IL-10 when rhamnolipid-treated sections and the bacteria-infected 
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control sections were compared. These findings might suggest a mild controlled inflammatory 
pulp response to rhamnolipid treatment. Clinically, mild inflammatory response together with 
limited bacterial contamination is a requirement for pulp tissue repair (Goldberg et al. 2008), 
these two properties can be provided by rhamnolipid treatment. Furthermore cell 
differentiation in response to rhamnolipid treatment can be investigated.  The ex-vivo tooth 
model employed in this study provides limited capacity to explore the immune response due 
to the possible loss of some or all of the immune cells, no active blood supply and inability to 
follow the chronic immune response.   
Rhamnolipid treatment did not enhance the release of the growth factor TGF-beta or the 
antimicrobial peptide defensin-beta2. This finding is contrary to previous reports on the 
involvement of rhamnolipid in tissue regeneration and wound healing (Stipcevic et al. 2006). 
Regarding defensin-beta2, it has been reported that rhamnolipid released from P. aeruginosa 
was considered as a virulent factor and was demonstrated to suppress the release of the 
antimicrobial molecule (Dössel et al. 2012). However further studies are required to analyse 
the effect of rhamnolipid on this molecule at different time points (earlier to or later than 24 
h) and at the gene expression level.   
Although rhamnolipid was applied to the tooth section in serum-free medium, residual tooth 
section serum did not seem to inactivate rhamnolipid demonstrated by the prominent 
antimicrobial activity in the co-culture ex-vivo experiment. Rhamnolipid was shown to retain 
activity at FBS concentration up to 5 % in the culture medium. Higher concentrations of 10-
20 % FBS appeared to result in rhamnolipid inactivation as demonstrated by a dramatic 
attenuation of its cytotoxic effect. Serum protein binding is a crucial dilemma in  the context 
of the delivery and bioavailability of different medicaments (Vuignier et al. 2010). It can 
reduce the bioavailability of the drug to the target tissue but, at the same time, it can work as 
a reservoir allowing a controlled-release drug formulation.  
 Overall, a novel application of rhamnolipid as a potential endodontic antimicrobial agent was 
highlighted by the work reported in this thesis that showed promising results in the 
prevention of oral microbial infection particularly in case of Streptococcal pulpal infection. 
The further development of this material for optimum delivery may result in a new pulp 
therapy which could be effective in reducing the cases of failed pulp therapy due to bacterial 
contamination and therefore reducing the need for additionally extensive and invasive root 
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canal therapy, which results in irreversible loss of pulpal vitality and is associated with 
reduced tooth longevity.  In addition, non-antimicrobial pharmacotherapy targeted at specific 
virulence factors (such as antiadhesion) may play a preventative or therapeutic role in the 
management of endodontic infections. Therefore, future directions of research could focus 
on Lp-BS adhesion proteins and their possible involvement as an effective strategy to reduce 
microbial adhesion and combating colonisation by pathogenic microorganisms, not only in 
the pharmaceutical and biomedical field but also in other areas, such as food industry and 
cosmetics. Although probiotic Lactobacillus therapy has been widely investigated, their 
effects on SAG and E. faecalis is still not satisfactory and the result obtained in this thesis with 
L. plantarum is encouraging for ongoing further investigations.   
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6.2 Future directions  
1- To further investigate the role of L. plantarum and its products in the management of 
endodontic infections, work should be undertaken that more fully reflects the in-vivo 
situation. These may include assays for its adhesion potential to the dental/pulp 
tissues and studies of how the oral clearance mechanisms may be resisted.  Moreover, 
the antimicrobial activity of L. plantarum should be tested against pathogens attached 
to the host tissue; where their pathogenicity and virulence can be more prominent 
(Bauer and Shafer 2015).  
2- The applicability of L. plantarum biosurfactant as tensioactive bioemulsifier 
compound could be further investigated in the field of pharmaceutical technology and 
formulation and in the context of bioremediation. 
3- FPLC biosurfactant-containing fraction can be further studied in the future for its 
antimicrobial, antiadhesive and cytotoxic effects. It can be assayed for the presence 
of adhesion proteins by mean of Mass spectrometry. The target adhesin-like protein 
can be antibody-blocked and the antiadhesive activity can be compared. The obtained 
fraction also may offer less cytotoxicity due to the removal of the contaminants.  
4- The reported Lp-BS apoptotic effect could prove promising in controlling cancerous 
cells as has been reported for other similar biosurfactants (Zhao et al. 2000; Kim et al. 
2007). Therefore, further studies can be conducted considering the effect of the 
obtained biosurfactant on cancerous and healthy cell lines.  
5- A wider range of bacterial strains that involve in endodontic infection such as 
Prevotella intermedia, Fusobacterium nucleatum, S. mitis, S. sanguinis and others 
need also to be studied for their pattern of tooth infectivity and response to 
rhamnolipid treatment employing the ex-vivo model. Because of the heterogeneity of 
endodontic microbiology (Singh 2016) and difficulty to cover all possible infective 
strains, clinical samples obtained from primary pulpitis cases can be tested instead of 
testing individual strain separately.  
6- In-vivo application of rhamnolipid can be conducted on experimental animals to 
investigate its immune-modulatory effect. It can also be applied on individual immune 
cell line such as pulp extracted macrophages or fibroblasts and followed for gene 
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expression and release of inflammatory cytokines. Its effect on pulp stem cells 
differentiation should also be studied.  
7- The effect of serum concentration on rhamnolipid antimicrobial activity requests to 
be tested in the future. This can be achieved by culturing the bacterial isolates in 
rhamnolipid containing culture medium with different serum percentages and looking 
at bacterial growth curves in comparison to the control.  
8- The property of rhamnolipid binding to serum protein can be explored further which 
might provide a way of delivering rhamnolipid in a controlled slow release level 
especially its in-vivo administration into experimental animals has gained safety. 
Rhamnolipid has been also declared in a patent published in 1988 (Ishigami et al. 
1988) to be successfully formulated as liposome. The author suggested a wide range 
of applications for such formulation including drug-delivery. Taking the 
antimicrobial/antiadhesive and other immune effects of rhamnolipid obtained in this 
thesis into account, formulating rhamnolipid into liposome might be a promising way 
of delivering rhamnolipid. This might offer reducing rhamnolipid cytotoxicity, 
enhancing its antimicrobial property and achieving more stability (Sercombe et al. 
2015).  
9- Rhamnolipid could be incorporated into hydrogel for ease of application into the pulp 
or the root canal. This formulation can function as a mechanical matrix, a requirement 
for pulp capping material, supporting pulp cells adherence and multiplication 
therefore allows for normal pulp development (Klein‐Júnior et al. 2018). The potential 
probiotic can also be laden into a gel carrier. The loaded gel can further be applied to 
treat periodontitis (Stipcevic et al. 2000) where it may be placed in periodontal 
“pockets”, or voids between the tooth and the gingiva where periodontitis occurs 
(Vyas et al. 2000) and so the physical and antimicrobial properties of the gel could be 
assessed for this application with the potential to optimise the material properties for 
this oral location. 
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Appendix I: Mass spectrometric analysis data sheet of the Lp-BS 10 
proteins bands analysed 
 
Note: accession number obtained by search using Uniprot. Score, the sum of the ion scores of all 
peptides that were identified; Coverage, the percentage of the protein sequence covered by identified 
peptides; # Unique Peptides, the number of peptide sequences that are unique to a protein group; # 
Peptides, the total number of distinct peptide sequences identified in the protein group; # PSM's, the 
number of peptide spectrum matches; MW, molecular weight. 
 
Band # 1 
Accession 
 
Description Score Coverage # Unique 
Peptides 
# 
Peptides 
# 
PSMs 
MW 
[kDa] 
Q88XY8 Elongation factor G  369.24 60.89 36 36 150 77.0 
F9UMJ6 ATP-dependent Clp protease 224.88 50.66 39 40 82 92.6 
Q88U67 Probable phosphoketolase 1  175.75 35.03 23 24 68 88.7 
Q88YM5 60 kDa chaperonin  161.72 47.69 23 23 50 57.4 
F9UPA5 Transpeptidase-transglycosylase 
(Penicillin binding protein 1A)  
155.01 39.77 30 30 59 83.1 
Q88YL7 Protein translocase subunit SecA 149.68 35.32 25 25 56 89.5 
F9UPM3 Pyruvate kinase  129.83 41.98 20 20 45 62.8 
Q88VM0 Chaperone protein DnaK  119.02 42.12 24 24 39 66.7 
F9UPH5 DNA topoisomerase 4 subunit A  104.44 27.82 24 24 41 91.6 
F9UMB1 DNA helicase  102.79 33.07 23 23 40 87.9 
Q88XZ2 DNA-directed RNA polymerase subunit 
beta'  
95.63 28.85 32 32 43 135.2 
F9ULD9 ATP-dependent Clp protease, ATP-
binding subunit ClpL  
91.80 31.11 17 17 27 77.7 
Q88VK7 Translation initiation factor IF-2  90.84 29.60 22 22 36 93.6 
F9UMU5 ATP-dependent DNA helicase 85.38 33.91 24 24 33 85.0 
F9UU18 DNA helicase  83.83 27.31 19 19 30 87.8 
F9US38 DNA gyrase subunit A  74.47 18.76 16 16 28 94.5 
Q88V10 Alanine--tRNA ligase  73.48 25.00 19 19 26 97.2 
Q88V16 Endonuclease MutS2  71.34 22.36 15 15 24 87.2 
F9UN58 ATP-dependent Clp protease, ATP-
binding subunit ClpE  
69.37 28.55 19 19 26 81.7 
F9UQ86 Translation elongation factor, 
GTPase,TypA/BipA family  
68.95 25.33 12 12 24 68.4 
Q88VS3 Glycine--tRNA ligase beta subunit  66.68 29.11 20 20 29 78.5 
Q88S87 Probable phosphoketolase 2  64.09 25.88 21 22 33 89.6 
F9UPV0 GTP pyrophosphokinase / 
pyrophosphohydrolase  
63.47 25.70 21 21 29 86.2 
Q88YH3 Enolase 1  62.86 24.21 9 9 20 48.0 
Q88XA9 Leucine--tRNA ligase  60.56 21.91 19 19 26 92.6 
Q88YH5 Phosphoglycerate kinase  60.41 37.25 14 14 26 42.8 
F9UMD4 Aminopeptidase 60.31 20.62 16 16 24 93.9 
Q88VE1 Trigger factor  59.81 32.50 13 13 23 49.4 
F9UP85 Maltose phosphorylase  57.83 20.45 14 14 20 85.6 
Q88VJ5 Elongation factor Ts  57.23 40.07 10 10 17 31.6 
F9UN60 Phosphoenolpyruvate-protein 
phosphotransferase  
52.30 30.03 13 13 19 63.1 
Q88YC0 
 
Xaa-Pro dipeptidyl-peptidase  52.03 24.60 17 17 20 91.5 
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Q88VJ2 D-lactate dehydrogenase  51.06 44.88 14 14 23 37.2 
F9UPL0 30S ribosomal protein S1  49.88 34.03 15 15 20 47.1 
Q88UX7 Valine--tRNA ligase  49.67 20.92 19 19 25 101.5 
F9URD9 Cell wall hydrolase/muramidase  47.92 19.75 11 11 16 82.1 
F9ULZ0 Phosphoglucomutase  45.48 33.91 17 17 20 63.5 
F9UM10 Glyceraldehyde 3-phosphate 
dehydrogenase  
43.26 28.24 9 9 15 36.4 
Q88VX7 Chaperone protein ClpB  42.55 13.73 12 13 16 96.5 
Q88VE0 Elongation factor Tu  42.31 33.67 11 11 17 43.4 
F9UPI3 DNA topoisomerase 1  41.22 21.12 16 16 20 80.7 
F9UP05 Signal recognition particle receptor 
FtsY  
40.28 23.44 12 12 18 53.6 
Q88VJ4 30S ribosomal protein S2  39.86 37.83 10 10 14 30.2 
F9UTT2 Fructose-bisphosphate aldolase  39.72 22.30 5 5 11 30.9 
F9ULT0 Ribonucleoside-diphosphate reductase  38.38 14.29 11 11 15 82.1 
F9UNP5 DNA polymerase I  36.95 11.79 9 9 13 98.7 
P77886 Carbamoyl-phosphate synthase 
pyrimidine-specific large chain 
[CARB_LACPL] 
35.95 13.42 13 13 17 115.7 
Q88XZ3 DNA-directed RNA polymerase subunit 
beta  
35.80 14.49 16 16 16 134.4 
Q88WU9 Threonine--tRNA ligase  33.92 20.64 14 14 17 73.8 
Q88V89 Isoleucine--tRNA ligase  33.07 15.56 13 13 16 106.3 
Q88Z31 ATP-dependent zinc metalloprotease 
FtsH 
32.34 16.38 12 12 15 80.8 
Q88WR2 Phenylalanine--tRNA ligase beta 
subunit  
32.03 19.50 14 14 21 88.1 
Q88UW5 Glutathione biosynthesis bifunctional 
protein GshAB  
31.60 17.71 13 13 14 83.0 
F9UTA3 GMP reductase  31.22 29.24 9 9 13 39.9 
Q88YE7 Glutamine--fructose-6-phosphate 
aminotransferase [isomerizing]   
28.23 15.70 9 9 12 65.4 
Q88Z76 CTP synthase  27.64 14.71 8 8 12 59.7 
Q88Z97 Methionine--tRNA ligase  25.58 19.03 13 13 14 76.7 
F9UM19 Ribonuclease R  25.31 13.32 11 11 15 92.3 
F9URU9 Extracellular transglycosylase, with 
LysM peptidoglycan binding domain  
24.58 17.51 6 6 10 35.0 
P56512 L-lactate dehydrogenase 1  24.26 25.62 8 8 10 34.2 
Q88UI4 Glucose-6-phosphate isomerase  23.74 21.56 8 8 9 49.8 
Q88YH4 Triosephosphate isomerase  23.54 28.17 6 6 9 27.0 
Q88YW9 50S ribosomal protein L1 23.48 24.89 6 6 8 24.8 
F9UM05 Oligopeptide ABC transporter, substrate 
binding protein  
23.36 13.45 7 7 10 61.0 
F9UPD2 Carbamoyl-phosphate synthase 
(glutamine-hydrolyzing)  
22.87 12.19 10 10 10 94.3 
Q88UU3 ATP synthase subunit beta  22.39 12.63 5 5 8 50.8 
Q88VK1 Proline--tRNA ligase  22.09 15.29 9 9 10 63.5 
Q88XY9 30S ribosomal protein S7  21.83 26.28 3 3 7 17.8 
F9UL38 Cation transporting P-type ATPase  21.64 12.56 9 9 9 95.3 
F9UQZ0 Prophage P2a protein 6 endonuclease  21.55 24.36 9 9 10 40.6 
Q88W32 Probable manganese-dependent 
inorganic pyrophosphatase 
21.45 29.13 8 8 8 33.6 
F9US37 DNA gyrase subunit B  21.44 13.43 9 9 10 72.1 
Q88VQ8 Aspartate--tRNA ligase  21.11 15.72 10 10 13 67.6 
F9UUA0 Extracellular protein,gamma-D-
glutamate-meso-diaminopimelate 
muropeptidase  
19.49 13.24 4 4 7 36.8 
F9UNY9 Primosomal protein N' 19.48 11.43 10 10 11 90.0 
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F9UMH1 Asparagine synthase (Glutamine-
hydrolysing)  
19.47 14.53 9 9 12 73.1 
Q88T35 2,3-bisphosphoglycerate-dependent 
phosphoglycerate mutase 2  
19.22 30.87 5 5 7 26.1 
Q88WA8 Asparagine--tRNA ligase 2  18.84 10.88 4 4 7 49.8 
Q88YD2 Polyphosphate kinase 18.68 10.17 8 8 10 82.2 
F9UP39 3-oxoacyl-[acyl-carrier-protein] 
synthase 2 
18.64 11.95 4 4 6 42.4 
F9UNI1 GTP cyclohydrolase-2 18.53 12.38 4 4 6 43.6 
F9UL45 PTS system, mannose-specific EIIAB 
component  
17.69 12.96 4 4 7 35.3 
Q88XW0 DNA-directed RNA polymerase subunit 
alpha  
17.62 14.97 5 5 7 34.8 
F9ULY4 UTP--glucose-1-phosphate 
uridylyltransferase  
16.70 21.24 6 6 6 34.2 
Q88XX4 50S ribosomal protein L5  16.58 26.11 5 5 9 20.2 
Q88XY3 50S ribosomal protein L2  16.51 39.78 10 10 16 30.2 
F9UPK7 DNA-binding protein 16.39 40.66 3 3 5 9.6 
F9US12 Cell surface protein, LPXTG-motif cell 
wall anchor  
16.01 5.04 3 3 5 89.5 
Q88XY6 50S ribosomal protein L3  15.77 17.22 3 3 7 22.7 
F9UNZ9 Phosphatase, dihydroxyacetone kinase 
family  
15.74 8.80 5 5 6 60.7 
Q88YW7 50S ribosomal protein L7/L12  15.69 52.46 6 6 7 12.6 
Q88Y74 GMP synthase [glutamine-hydrolyzing]  15.63 14.67 8 8 9 57.4 
F9UQH9 Extracellular protein, DUF336 family  15.57 28.82 4 4 5 18.0 
Q88UU1 ATP synthase subunit alpha  15.38 9.33 4 4 5 54.5 
F9UP45 Enoyl-[acyl-carrier-protein] reductase 
[NADH]  
14.15 23.41 6 6 7 26.9 
F9UMJ0 Acetolactate synthase  14.03 9.29 4 4 6 61.2 
F9US18 Anaerobic ribonucleoside-triphosphate 
reductase   
13.83 8.24 6 6 7 83.7 
F9UT53 Cystathionine beta-lyase / cystathionine 
gamma-lyase  
13.70 13.91 5 5 6 40.8 
Q88X53 Arginine--tRNA ligase  13.44 11.57 6 6 7 62.9 
Q88XP7 Glutamyl-tRNA(Gln) amidotransferase 
subunit A 
13.19 12.53 6 6 6 52.1 
Q88XW9 30S ribosomal protein S5  13.06 30.72 6 6 6 17.3 
Q88UV8 D-alanine--D-alanine ligase  12.85 12.70 4 4 5 41.3 
F9URA6 Formate C-acetyltransferase  12.41 7.86 7 7 7 91.6 
Q88W26 ATP-dependent protease ATPase 
subunit HslU  
12.40 5.93 2 2 4 52.6 
Q88XY0 30S ribosomal protein S3  12.18 25.81 5 5 6 24.2 
Q88XZ7 Serine--tRNA ligase 2  12.15 11.29 4 4 4 48.1 
Q88WN5 50S ribosomal protein L21  11.84 27.45 2 2 4 11.0 
Q88VM1 Chaperone protein DnaJ  11.69 15.26 4 4 4 40.5 
Q88XP6 Aspartyl/glutamyl-tRNA(Asn/Gln) 
amidotransferase subunit B  
11.31 9.70 5 5 5 53.2 
F9UR64 NADH peroxidase  11.16 8.43 4 4 5 48.2 
F9UNV9 Glutamine synthetase  11.13 12.28 5 5 5 50.9 
F9UUC0 Endopeptidase PepO  10.81 6.90 5 5 6 71.9 
F9UP42 Acetyl-CoA carboxylase, biotin 
carboxylase subunit 
10.74 10.61 4 4 4 50.7 
F9UNV2 Bifunctional protein: transcription 
regulator sugar kinase, ROK family   
10.58 13.13 3 3 3 33.7 
Q88WG0 Acetyl-coenzyme A carboxylase 
carboxyl transferase subunit beta 2   
10.37 10.32 2 2 3 30.9 
Q88VE2 ATP-dependent Clp protease ATP-
binding subunit ClpX  
10.33 12.83 5 5 5 46.5 
F9UQC3 Cell division protein FtsZ  10.31 8.90 4 4 4 45.0 
F9ULV5 ABC transporter, ATP-binding protein  10.17 5.76 3 3 3 74.1 
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F9UMC8 Alkaline shock protein  10.09 23.57 2 2 3 15.8 
Q88XY5 50S ribosomal protein L4  10.06 15.94 3 3 4 22.6 
F9US03 Excinuclease ABC, subunit A  9.99 5.51 4 4 4 89.5 
F9UR85 Aspartate-semialdehyde 
dehydrogenase  
9.98 7.37 2 2 3 38.2 
F9UQA0 Extracellular protein, NlpC/P60 
family,gamma-D-glutamate-meso-
diaminopimelate muropeptidase  
9.88 5.65 2 2 3 48.3 
Q88XF3 Peptide chain release factor 3  9.81 8.76 4 4 4 59.5 
F9UNG7 Hypothetical membrane protein  9.66 3.64 3 3 4 91.9 
F9UNS5 6-phosphogluconate dehydrogenase, 
decarboxylating [F9UNS5_LACPL] 
9.62 5.02 2 2 3 52.9 
F9UN64 Serine-type D-Ala-D-Ala 
carboxypeptidase  
9.54 8.25 3 3 3 45.2 
F9UMX4 UDP-galactopyranose mutase  9.40 13.94 5 5 6 43.2 
F9UL33 N-acetylglucosamine-6-phosphate 
deacetylase  
9.34 10.85 4 4 5 41.4 
F9UL89 Prophage P1 protein 2, mitogenic 
factor, cell surface lipoprotein  
9.20 11.37 4 4 4 41.8 
F9UT87 Cyclopropane-fatty-acyl-phospholipid 
synthase  
9.00 8.56 3 3 3 45.3 
F9UNU7 Transpeptidase (Penicillin binding 
protein 2B)  
8.89 4.13 2 2 3 72.6 
F9USY7 Maltodextrin-binding protein  8.83 6.71 3 3 3 45.6 
F9UQ67 Ribonuclease J 8.77 6.10 3 3 3 63.9 
F9URG7 Glucose-6-phosphate 1-dehydrogenase  8.56 8.70 4 4 4 56.8 
Q88VQ7 Histidine--tRNA ligase  8.34 11.97 5 5 5 47.9 
F9UM84 Glutamine ABC transporter, ATP-
binding protein 
8.28 10.16 2 2 3 27.4 
F9UN93 Xaa-His dipeptidase  8.06 7.49 3 3 3 50.8 
F9UTG0 Glutathione reductase  7.88 4.95 2 2 3 48.2 
Q88YE8 Phosphoglucosamine mutase  7.80 6.87 3 3 4 48.3 
Q6LWD9 Nickase  7.79 4.08 3 3 3 80.0 
Q88XB8 S-adenosylmethionine synthase  7.68 8.61 3 3 3 42.7 
F9UL68 Aminopeptidase C  7.63 9.71 5 5 5 50.2 
F9UQ80 Pyruvate carboxylase  7.61 2.36 2 2 3 127.1 
F9UTJ5 Formate C-acetyltransferase  7.43 7.71 6 6 6 84.4 
Q88XX1 50S ribosomal protein L6 7.42 16.85 3 3 3 19.3 
Q88UT5 Serine hydroxymethyltransferase  7.30 7.04 3 3 3 44.4 
F9UL91 Prophage P1 protein 5, superinfection 
exclusion (Cell surface N-anchored)  
7.30 12.93 6 6 6 37.9 
Q88XV9 50S ribosomal protein L17  6.60 20.47 2 2 2 14.2 
Q88TV5 Tyrosine--tRNA ligase  6.20 5.74 2 2 2 47.0 
F9UMV3 Transcription regulator, TetR family  5.98 14.66 3 3 3 21.6 
F9UT66 CDP-glycerol 
glycerophosphotransferase / 
glycosyltransferase  
5.93 3.94 4 4 4 108.2 
F9UT98 Serine-type D-Ala-D-Ala 
carboxypeptidase 
5.90 7.88 3 3 3 46.9 
Q88VM6 D-alanine--D-alanyl carrier protein 
ligase  
5.79 5.31 3 3 4 56.0 
Q88V23 2,3,4,5-tetrahydropyridine-2,6-
dicarboxylate N-acetyltransferase  
5.66 14.41 3 3 3 24.5 
Q88VJ6 Uridylate kinase  5.51 9.58 2 2 2 25.9 
F9URQ9 Uncharacterized protein  5.41 4.04 3 3 4 76.2 
F9ULW6 Ribosome hibernation promoting 
factor  
5.40 11.17 2 2 2 21.7 
F9USZ3 Maltose phosphorylase  5.37 2.51 2 2 3 86.5 
Q88UU0 ATP synthase subunit delta  5.32 12.15 2 2 2 20.0 
Q06115 Choloylglycine hydrolase  5.31 6.79 2 2 2 37.0 
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F9UTR7 NADH dehydrogenase  5.31 4.00 2 2 3 43.8 
F9UPM8 Peptidase T  5.30 5.34 2 2 2 45.1 
Q88X05 Foldase protein PrsA 1  5.10 7.05 2 2 2 32.6 
F9UKZ6 DEAD-box ATP-dependent RNA helicase 
CshA  
5.07 8.14 4 4 4 59.0 
Q88V33 Probable transcriptional regulatory 
protein lp_2253  
5.05 11.98 3 3 3 26.4 
F9URK9 Protein-tyrosine phosphatase  5.04 8.99 2 2 2 30.0 
F9URZ3 Hypothetical membrane protein  4.94 3.98 4 4 4 115.2 
Q88UZ4 Protein RecA  4.92 6.84 2 2 2 40.6 
Q88V80 UDP-N-acetylmuramoylalanine--D-
glutamate ligase  
4.87 4.79 2 2 2 50.1 
Q88YI7 UvrABC system protein A  4.80 2.10 2 2 2 104.9 
F9UM27 Phosphate acetyltransferase  4.76 7.38 2 2 2 34.4 
F9UQH6 Catabolite control protein A  4.71 9.23 3 3 3 36.3 
Q88RX6 tRNA uridine 5-
carboxymethylaminomethyl 
modification enzyme MnmG  
4.65 4.87 3 3 3 70.7 
F9UQC4 Cell division protein FtsA  4.54 5.80 2 2 2 48.3 
F9UQS9 Mannose-6-phosphate isomerase  4.49 5.92 2 2 2 35.9 
F9URK6 NADPH-dependent FMN reductase 
family protein 
4.48 8.82 3 3 3 47.4 
Q88XX7 30S ribosomal protein S17  4.46 20.22 2 2 2 10.3 
F9UQH2 Ribokinase  4.42 6.54 2 2 2 31.7 
F9UNL2 ABC transporter component, iron-sulfur 
cluster assembly protein SufB, iron 
regulated  
4.27 4.06 2 2 2 52.6 
Q88Z28 Lysine--tRNA ligase  4.24 5.21 3 3 3 57.6 
Q88YY0 Glutamate--tRNA ligase  4.24 4.44 2 2 2 56.9 
F9UTA5 Ribosome-binding ATPase YchF  4.21 5.74 2 2 3 39.9 
F9UP94 Aminotransferase  4.19 4.99 2 2 2 43.8 
Q88YX0 50S ribosomal protein L11  4.08 16.31 2 2 2 14.8 
F9ULD3 Catalase  3.91 5.58 3 3 4 55.3 
Q88XX2 30S ribosomal protein S8 3.90 14.50 2 2 2 14.6 
F9US66 Serine protease HtrA  3.76 4.52 2 2 2 43.1 
Q9RE01 Uracil phosphoribosyltransferase  3.72 7.66 2 2 2 23.0 
F9UN23 Mannose-specific adhesin, LPXTG-motif 
cell wall anchor  
3.41 2.18 2 2 2 107.9 
F9UTV3 Multicopper oxidase  3.35 4.19 2 2 2 56.8 
Q88VL9 Protein GrpE  3.25 11.56 2 2 2 21.4 
F9UL42 Homoserine dehydrogenase  2.83 6.78 3 3 3 46.6 
P77885 Carbamoyl-phosphate synthase 
pyrimidine-specific small chain  
2.78 6.32 2 2 2 40.0 
F9UQB9 Cell division initiation protein DivIVA  2.74 8.19 2 2 2 26.2 
F9UP07 Signal recognition particle protein  2.70 3.72 2 2 2 53.9 
F9UPS7 RNA polymerase sigma factor SigA  2.60 5.43 2 2 2 41.4 
F9UQQ9 Cell shape determining protein MreB  2.03 4.80 2 2 2 35.8 
F9UMS0 Citrate lyase alpha chain  1.96 6.25 3 3 3 54.9 
Q88Z84 Ribose-phosphate pyrophosphokinase 1 1.91 4.29 2 2 2 35.9 
Q88XU8 50S ribosomal protein L13  1.69 10.20 2 2 2 16.2 
F9UPH6 DNA topoisomerase 4 subunit B 0.00 2.84 2 2 2 74.5 
 
Band # 2 
Accession Description Score Coverage # Unique 
Peptides 
# 
Peptides 
# 
PSMs 
MW 
[kDa] 
F9UPM3 Pyruvate kinase  324.72 86.52 40 40 114 62.8 
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Q88YM5 60 kDa chaperonin  254.78 79.11 38 38 80 57.4 
Q88YE7 Glutamine--fructose-6-phosphate 
aminotransferase [isomerizing]  
231.43 77.69 32 32 64 65.4 
F9ULZ0 Phosphoglucomutase  216.91 73.74 35 35 62 63.5 
Q88VE1 Trigger factor  158.23 60.91 26 26 51 49.4 
F9UMH1 Asparagine synthase (Glutamine-
hydrolysing)  
124.64 54.50 23 28 42 73.1 
Q88X53 Arginine--tRNA ligase  119.05 56.05 25 25 38 62.9 
F9UQE9 Oligoendopeptidase F  109.03 50.25 22 22 32 67.7 
Q88VE0 Elongation factor Tu  104.67 64.56 20 20 35 43.4 
Q88Z76 CTP synthase  96.84 48.23 21 21 31 59.7 
Q88YH3 Enolase 1 90.32 44.12 13 13 26 48.0 
Q88VK1 Proline--tRNA ligase  89.35 43.94 19 19 30 63.5 
F9UN60 Phosphoenolpyruvate-protein 
phosphotransferase  
88.81 44.62 20 20 31 63.1 
Q88WU9 Threonine--tRNA ligase  85.56 45.41 23 23 33 73.8 
Q88VM0 Chaperone protein DnaK  81.62 48.39 20 20 26 66.7 
F9UPL0 30S ribosomal protein S1  81.19 47.32 18 18 27 47.1 
F9USW0 Linoleic acid isomerase  79.39 42.02 18 18 27 64.2 
F9UM10 Glyceraldehyde 3-phosphate 
dehydrogenase  
73.79 56.76 16 16 22 36.4 
F9ULD9 ATP-dependent Clp protease, ATP-
binding subunit ClpL  
71.60 32.10 15 15 20 77.7 
F9UQ67 Ribonuclease J  66.29 39.90 19 19 24 63.9 
Q88YH5 Phosphoglycerate kinase  57.40 51.75 18 18 22 42.8 
Q88Y74 GMP synthase [glutamine-hydrolyzing]  57.19 36.10 15 15 22 57.4 
Q88XF3 Peptide chain release factor 3  56.66 32.00 12 12 17 59.5 
F9UTV3 Multicopper oxidase 53.81 42.32 15 15 19 56.8 
F9UPE1 Fibrinogen-binding family protein  53.09 35.74 15 15 18 64.4 
F9UNZ9 Phosphatase, dihydroxyacetone kinase 
family  
52.44 25.35 10 10 14 60.7 
Q88VJ4 30S ribosomal protein S2  50.29 46.82 11 11 16 30.2 
Q88XY8 Elongation factor G  48.99 28.37 15 15 19 77.0 
Q88VJ2 D-lactate dehydrogenase  45.66 46.99 15 15 17 37.2 
Q88UX2 Septation ring formation regulator EzrA  44.72 24.08 11 11 14 64.5 
F9UM65 Pyruvate oxidase  44.44 25.89 13 13 16 63.6 
F9UUC0 Endopeptidase PepO  41.66 27.43 14 14 15 71.9 
F9ULT4 DNA polymerase III subunit gamma/tau  39.28 23.01 8 8 12 62.7 
Q88Z28 Lysine--tRNA ligase 37.98 31.06 15 15 19 57.6 
F9UTT2 Fructose-bisphosphate aldolase  37.48 45.64 10 10 13 30.9 
F9UM05 Oligopeptide ABC transporter, substrate 
binding protein  
35.09 23.82 11 12 13 61.0 
Q88Z97 Methionine--tRNA ligase  35.02 21.52 12 12 13 76.7 
F9UNY0 DNA repair protein RecN  33.94 22.52 11 11 11 62.8 
F9USK0 Asparagine synthase (Glutamine-
hydrolysing) 
29.30 13.27 3 8 11 73.1 
F9UNS5 6-phosphogluconate dehydrogenase, 
decarboxylating  
28.76 19.46 8 8 9 52.9 
Q88YY0 Glutamate--tRNA ligase  27.33 26.61 12 12 12 56.9 
Q88XZ3 DNA-directed RNA polymerase subunit 
beta  
25.93 7.49 8 8 10 134.4 
F9URB5 1-deoxy-D-xylulose-5-phosphate 
synthase  
24.24 16.12 7 7 9 63.7 
Q88UI4 Glucose-6-phosphate isomerase  23.74 23.11 8 8 9 49.8 
Q88UU3 ATP synthase subunit beta  23.42 19.49 7 7 7 50.8 
Q88VQ8 Aspartate--tRNA ligase  23.17 22.91 13 13 14 67.6 
F9URG7 Glucose-6-phosphate 1-dehydrogenase  22.99 20.85 8 8 9 56.8 
Q88UU1 ATP synthase subunit alpha  22.13 17.86 8 8 9 54.5 
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Q88WA8 Asparagine--tRNA ligase 2  20.91 15.74 6 6 7 49.8 
Q88RX6 tRNA uridine 5-
carboxymethylaminomethyl 
modification enzyme MnmG 
20.37 13.99 9 9 9 70.7 
F9UN93 Xaa-His dipeptidase  19.84 13.49 5 5 7 50.8 
F9UU91 Cell surface protein, CscB family  19.39 6.34 5 5 5 118.7 
Q88W32 Probable manganese-dependent 
inorganic pyrophosphatase  
18.38 26.21 7 7 7 33.6 
F9UMD6 Type I restriction-modification 
system,methylation subunit  
18.33 10.04 4 4 5 59.9 
Q88YH4 Triosephosphate isomerase  17.12 25.40 5 5 5 27.0 
P37063 Pyruvate oxidase  16.88 10.61 5 5 5 66.1 
P56512 L-lactate dehydrogenase 1  16.84 31.87 9 9 9 34.2 
Q88U67 Probable phosphoketolase 1 16.65 9.39 6 6 6 88.7 
F9ULY4 UTP--glucose-1-phosphate 
uridylyltransferase  
16.50 23.20 5 5 6 34.2 
Q88XX4 50S ribosomal protein L5  16.37 48.89 7 7 8 20.2 
Q88XY3 50S ribosomal protein L2  16.34 44.09 9 9 10 30.2 
Q88VJ5 Elongation factor Ts  15.98 19.18 5 5 5 31.6 
F9UP39 3-oxoacyl-[acyl-carrier-protein] 
synthase 2  
15.91 24.63 6 6 6 42.4 
Q88XY6 50S ribosomal protein L3  15.19 29.67 5 5 5 22.7 
F9UQ86 Translation elongation factor, 
GTPase,TypA/BipA family  
15.13 15.36 7 7 7 68.4 
F9UP45 Enoyl-[acyl-carrier-protein] reductase 
[NADH]  
14.26 30.95 6 6 6 26.9 
F9UKZ6 DEAD-box ATP-dependent RNA helicase 
CshA  
13.98 14.58 6 6 6 59.0 
Q88VE9 UvrABC system protein C 13.91 9.11 5 5 5 68.7 
Q88XY0 30S ribosomal protein S3  13.83 31.34 6 6 6 24.2 
F9UMD4 Aminopeptidase  13.58 7.23 5 5 5 93.9 
Q88YW9 50S ribosomal protein L1  13.50 22.71 5 5 5 24.8 
Q88T35 2,3-bisphosphoglycerate-dependent 
phosphoglycerate mutase 2  
12.21 21.30 3 3 4 26.1 
F9UN51 Oligopeptide ABC transporter, substrate 
binding protein  
12.09 14.44 5 6 6 60.3 
F9UNL2 ABC transporter component, iron-sulfur 
cluster assembly protein SufB, iron 
regulated  
11.99 11.75 5 5 5 52.6 
F9UQ91 Dihydrolipoamide acetyltransferase 
component of pyruvate dehydrogenase 
complex 
11.81 16.01 6 6 6 45.9 
F9UUA0 Extracellular protein,gamma-D-
glutamate-meso-diaminopimelate 
muropeptidase  
11.38 11.08 3 3 3 36.8 
F9UTR7 NADH dehydrogenase  11.26 22.00 6 6 6 43.8 
F9ULT0 Ribonucleoside-diphosphate reductase  11.20 5.55 3 3 3 82.1 
F9URC8 Pyruvate oxidase 10.82 9.57 5 5 6 64.2 
F9UT87 Cyclopropane-fatty-acyl-phospholipid 
synthase  
10.43 10.83 3 3 3 45.3 
Q88TV5 Tyrosine--tRNA ligase  10.36 10.53 4 4 4 47.0 
F9UL45 PTS system, mannose-specific EIIAB 
component  
10.04 12.04 4 4 4 35.3 
F9ULE1 Pyruvate oxidase  9.98 7.53 3 3 3 63.8 
Q88YE8 Phosphoglucosamine mutase  9.61 9.53 3 3 3 48.3 
F9UNV9 Glutamine synthetase  9.57 12.05 5 5 5 50.9 
Q88XU8 50S ribosomal protein L13  9.56 20.41 3 3 4 16.2 
F9URQ9 Uncharacterized protein  9.31 6.00 4 4 4 76.2 
F9UR54 PTS system, N-acetylglucosamine and 
glucose-specific EIICBA component   
9.23 5.59 2 2 2 70.3 
Q88YW8 50S ribosomal protein L10  8.80 30.54 3 3 3 17.9 
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F9UR64 NADH peroxidase  8.40 9.09 4 4 4 48.2 
F9USY7 Maltodextrin-binding protein  8.23 6.47 2 2 3 45.6 
F9UTA3 GMP reductase  7.81 6.79 2 2 3 39.9 
F9UNV2 Bifunctional protein: transcription 
regulator sugar kinase, ROK family  
7.74 11.56 3 3 3 33.7 
F9UMJ0 Acetolactate synthase  7.67 13.93 6 6 7 61.2 
Q88V89 Isoleucine--tRNA ligase  7.64 4.51 4 4 4 106.3 
Q88UV8 D-alanine--D-alanine ligase  7.29 7.30 2 2 2 41.3 
F9UPA5 Transpeptidase-transglycosylase 
(Penicillin binding protein 1A)  
7.25 3.91 2 2 2 83.1 
Q88XZ7 Serine--tRNA ligase 2  7.25 6.35 2 2 2 48.1 
Q88XW0 DNA-directed RNA polymerase subunit 
alpha  
7.16 9.55 3 3 3 34.8 
Q88XU7 30S ribosomal protein S9  6.85 16.92 2 2 3 14.6 
F9UN58 ATP-dependent Clp protease, ATP-
binding subunit ClpE  
6.66 3.79 2 2 2 81.7 
Q88XW7 50S ribosomal protein L15  6.65 19.58 2 2 2 15.3 
Q88YW7 50S ribosomal protein L7/L12  6.60 21.31 2 2 3 12.6 
Q88XP6 Aspartyl/glutamyl-tRNA(Asn/Gln) 
amidotransferase subunit B  
6.32 6.33 3 3 3 53.2 
Q88UX0 30S ribosomal protein S4  6.21 11.88 3 3 3 22.9 
F9UTG0 Glutathione reductase  6.11 5.63 2 2 2 48.2 
F9UMJ6 ATP-dependent Clp protease, ATP-
binding subunit ClpC  
6.11 3.82 2 2 2 92.6 
Q88WZ5 UDP-N-acetylmuramate--L-alanine 
ligase  
6.06 6.65 2 2 2 48.7 
Q88XW9 30S ribosomal protein S5  6.00 13.25 2 2 2 17.3 
F9UN64 Serine-type D-Ala-D-Ala 
carboxypeptidase  
5.97 6.31 2 2 2 45.2 
F9UPK1 ABC transporter, ATP-binding protein, 
ChvD family  
5.84 4.25 2 2 2 71.3 
F9UT53 Cystathionine beta-lyase / cystathionine 
gamma-lyase  
5.78 6.30 2 2 2 40.8 
F9UQC3 Cell division protein FtsZ  5.71 6.32 2 2 2 45.0 
F9UL42 Homoserine dehydrogenase  5.53 5.37 2 2 2 46.6 
P71479 Bifunctional protein PyrR 1  5.49 12.78 2 2 2 19.8 
F9UP42 Acetyl-CoA carboxylase, biotin 
carboxylase subunit  
5.36 4.55 2 2 2 50.7 
Q88UX7 Valine--tRNA ligase  5.33 3.04 2 2 2 101.5 
F9UPE6 Uncharacterized protein  5.30 12.70 2 2 2 25.3 
F9UPH4 Transcription regulator, LysR family  5.15 7.21 2 2 2 36.8 
Q88XB8 S-adenosylmethionine synthase  5.11 5.57 2 2 2 42.7 
Q88X05 Foldase protein PrsA 1 5.06 7.05 2 2 2 32.6 
F9UU97 Phosphoenolpyruvate carboxykinase 
(ATP)  
5.05 4.52 2 2 2 61.8 
F9UL89 Prophage P1 protein 2, mitogenic 
factor, cell surface lipoprotein  
5.02 6.20 2 2 2 41.8 
F9UQH9 Extracellular protein, DUF336 family  4.87 13.53 2 2 2 18.0 
Q6LWD9 Nickase 4.84 2.48 2 2 2 80.0 
Q88VQ7 Histidine--tRNA ligase  4.83 5.63 2 2 2 47.9 
F9UQ85 Extracellular protein, cell-wall 
anchored  
4.45 5.08 2 2 2 45.8 
F9UQ00 Transcription 
termination/antitermination protein 
NusA  
4.41 5.68 2 2 2 44.3 
F9UMN7 NADH dehydrogenase, membrane-
anchored  
4.24 3.46 2 2 2 71.9 
Q88VS3 Glycine--tRNA ligase beta subunit  4.22 3.31 2 2 2 78.5 
F9UQZ2 Prophage P2a protein 4 AAA ATPase  4.12 6.70 4 4 4 66.5 
F9URC3 Oligoendopeptidase F  4.03 3.51 3 3 3 67.2 
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F9UP07 Signal recognition particle protein  3.49 4.34 2 2 2 53.9 
F9UQ97 Ribonuclease J  3.45 5.38 3 3 3 61.8 
F9UNI1 GTP cyclohydrolase-2  2.44 8.91 3 3 3 43.6 
Q88VM6 D-alanine--D-alanyl carrier protein 
ligase  
2.07 10.24 4 4 4 56.0 
 
Band # 3 
Accession Description Score Coverage # Unique 
Peptides 
# 
Peptides 
# PSMs MW 
[kDa] 
Q88VE0 Elongation factor Tu  894.04 74.43 28 28 300 43.4 
Q88YH5 Phosphoglycerate kinase  551.18 88.00 34 34 193 42.8 
Q88YH3 Enolase 1  252.64 69.23 24 24 76 48.0 
Q88UT5 Serine hydroxymethyltransferase  131.30 66.99 20 20 38 44.4 
F9UNV9 Glutamine synthetase  123.12 61.38 26 26 43 50.9 
Q88UI4 Glucose-6-phosphate isomerase  113.51 53.78 19 19 38 49.8 
F9UM10 Glyceraldehyde 3-phosphate 
dehydrogenase  
110.81 63.82 18 18 31 36.4 
Q88WZ5 UDP-N-acetylmuramate--L-alanine 
ligase  
105.30 54.36 22 22 34 48.7 
F9UNI1 GTP cyclohydrolase-2  98.36 49.26 16 16 30 43.6 
F9UN65 Aminotransferase  97.75 54.94 17 17 28 43.8 
F9UTA5 Ribosome-binding ATPase YchF  96.84 75.14 20 20 32 39.9 
F9UPM8 Peptidase T  96.58 50.00 13 13 28 45.1 
Q88TV5 Tyrosine--tRNA ligase  88.32 53.35 17 17 28 47.0 
Q88UV8 D-alanine--D-alanine ligase  86.27 60.54 17 17 28 41.3 
P77884 Dihydroorotase  82.35 53.49 10 10 25 45.4 
F9UPS7 RNA polymerase sigma factor SigA  81.87 47.01 17 17 25 41.4 
Q88UT2 Peptide chain release factor 1  80.38 49.72 14 14 23 41.0 
Q88XB8 S-adenosylmethionine synthase  78.83 45.82 16 16 25 42.7 
F9UP39 3-oxoacyl-[acyl-carrier-protein] 
synthase 2  
77.46 39.51 9 9 24 42.4 
F9UPM3 Pyruvate kinase  75.61 42.32 19 19 24 62.8 
Q88YE8 Phosphoglucosamine mutase  74.11 46.34 17 17 26 48.3 
F9UL89 Prophage P1 protein 2, mitogenic 
factor, cell surface lipoprotein  
64.53 53.49 14 14 19 41.8 
F9UMW9 Glutamate dehydrogenase  63.87 45.98 14 14 19 48.6 
Q88UU3 ATP synthase subunit beta  63.36 35.55 12 12 16 50.8 
F9UTG0 Glutathione reductase  63.08 44.59 15 15 21 48.2 
Q88Z54 UDP-N-acetylglucosamine 1-
carboxyvinyltransferase 2  
61.57 46.95 12 12 19 45.8 
F9UTW6 Glutathione reductase  61.49 41.31 14 14 23 47.3 
F9UL68 Aminopeptidase C  60.07 39.50 13 13 21 50.2 
F9UTR7 NADH dehydrogenase  55.36 38.00 11 11 19 43.8 
F9UNU0 Endolytic murein transglycosylase  53.43 43.89 15 15 17 44.7 
Q88VE2 ATP-dependent Clp protease ATP-
binding subunit ClpX  
53.39 45.61 14 14 17 46.5 
F9UN44 Glutathione reductase  52.62 45.23 15 15 22 47.6 
F9UTT2 Fructose-bisphosphate aldolase  50.92 48.78 11 11 16 30.9 
F9US66 Serine protease HtrA 49.81 39.05 12 12 14 43.1 
F9UR64 NADH peroxidase  49.27 52.55 15 15 19 48.2 
Q88VZ6 GTPase Der  48.53 46.56 17 17 20 48.7 
F9UNS5 6-phosphogluconate dehydrogenase, 
decarboxylating  
47.28 37.03 14 14 15 52.9 
Q88UX4 Probable tRNA sulfurtransferase  46.59 35.80 12 12 17 45.4 
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Q88V80 UDP-N-acetylmuramoylalanine--D-
glutamate ligase  
45.91 32.90 11 11 14 50.1 
F9UL33 N-acetylglucosamine-6-phosphate 
deacetylase  
44.38 34.92 10 10 15 41.4 
F9USZ1 Alpha-amylase, maltodextrins and 
cyclomaltodextrins 
44.09 33.86 12 12 14 49.9 
F9UL42 Homoserine dehydrogenase  43.80 44.63 16 16 16 46.6 
Q88WA8 Asparagine--tRNA ligase 2  40.37 36.34 13 13 15 49.8 
F9UQS7 UDP-N-acetylmuramyl tripeptide 
synthase  
40.31 32.14 12 12 16 49.7 
F9UP42 Acetyl-CoA carboxylase, biotin 
carboxylase subunit  
40.04 34.63 13 13 15 50.7 
Q88VQ7 Histidine--tRNA ligase  38.93 41.78 13 13 16 47.9 
Q88VJ4 30S ribosomal protein S2  37.10 40.82 10 10 13 30.2 
Q88VJ2 D-lactate dehydrogenase   37.00 42.17 15 15 15 37.2 
Q88TY1 Probable D-serine dehydratase  36.87 30.05 10 10 12 47.5 
F9UPL0 30S ribosomal protein S1  36.49 25.41 12 12 17 47.1 
F9UTR4 Acetate kinase  35.32 31.41 9 9 11 43.8 
F9UTG2 Adenylosuccinate lyase  34.76 31.25 11 11 12 49.0 
F9UQL8 Aspartokinase  34.08 23.11 7 7 9 49.8 
Q88XZ2 DNA-directed RNA polymerase subunit 
beta'  
32.00 7.25 8 8 10 135.2 
F9UTP6 Glycolate dehydrogenase, subunit 
GlcD,FAD-binding  
30.97 21.34 8 8 11 50.2 
Q88YL5 Peptide chain release factor 2 30.53 30.50 9 9 12 42.6 
P56512 L-lactate dehydrogenase 1  29.32 32.19 10 10 11 34.2 
F9UNY1 Glycine betaine/carnitine/choline ABC 
transporter, ATP-binding protein  
29.17 25.13 9 9 11 44.4 
F9US34 Beta sliding clamp  28.80 28.23 10 10 12 41.5 
F9UPX5 Protein DltD  28.46 20.00 6 6 8 48.6 
F9UT87 Cyclopropane-fatty-acyl-phospholipid 
synthase  
28.03 29.97 8 8 11 45.3 
Q88XY3 50S ribosomal protein L2  27.66 40.86 9 9 13 30.2 
F9UQ93 Pyruvate dehydrogenase complex, E1 
component,alpha subunit  
27.29 29.46 10 10 12 41.4 
F9UU99 Glutamate decarboxylase  27.13 21.32 9 9 12 53.5 
Q88YH4 Triosephosphate isomerase  27.02 32.14 7 7 10 27.0 
F9UQ00 Transcription 
termination/antitermination protein 
NusA  
26.49 21.73 7 7 9 44.3 
Q88V24 N-acetyldiaminopimelate deacetylase   26.30 16.41 4 4 9 42.1 
F9UKV7 Lipoprotein  26.03 21.65 6 6 8 34.3 
F9UMS2 Fumarate reductase, flavoprotein 
subunit  
25.76 19.70 6 6 7 48.7 
Q88VJ5 Elongation factor Ts  25.18 32.53 8 8 11 31.6 
F9ULL7 Aminopeptidase C  24.73 23.29 8 8 9 50.0 
Q88UU1 ATP synthase subunit alpha 24.71 26.39 11 11 11 54.5 
Q88SV6 Adenylosuccinate synthetase  24.67 22.14 7 7 8 47.2 
Q890J4 Gamma-glutamyl phosphate reductase  24.06 25.24 8 8 10 44.6 
Q88YW8 50S ribosomal protein L10  23.84 44.91 5 5 7 17.9 
F9UTA3 GMP reductase  22.56 22.19 6 6 8 39.9 
F9ULC7 FAD-dependent pyridine nucleotide-
disulphide oxidoreductase  
22.05 23.94 9 9 9 44.4 
Q88XY8 Elongation factor G  20.89 9.17 6 6 7 77.0 
Q88Y74 GMP synthase [glutamine-hydrolyzing] 20.28 20.46 9 9 10 57.4 
F9UR33 SAM-dependent methyltransferase  20.12 24.94 8 8 8 43.7 
F9UQL7 Non-proteolytic protein, peptidase 
family M16  
20.06 9.98 3 3 5 46.7 
Q88YM5 60 kDa chaperonin  19.99 13.12 7 7 8 57.4 
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F9UUC0 Endopeptidase PepO  19.92 11.76 6 6 6 71.9 
Q88YW9 50S ribosomal protein L1  18.51 34.93 6 6 6 24.8 
F9UMC8 Alkaline shock protein  17.99 39.29 5 5 8 15.8 
Q88UZ4 Protein RecA  17.22 18.16 6 6 7 40.6 
F9UPK7 DNA-binding protein  16.44 36.26 2 2 5 9.6 
P59603 Argininosuccinate synthase  16.25 17.76 7 7 8 45.1 
Q88T35 2,3-bisphosphoglycerate-dependent 
phosphoglycerate mutase 2  
16.19 34.78 7 7 8 26.1 
Q88UU5 UDP-N-acetylglucosamine 1-
carboxyvinyltransferase 1 
16.12 20.32 7 7 7 47.1 
Q88W32 Probable manganese-dependent 
inorganic pyrophosphatase  
15.89 21.04 5 5 5 33.6 
F9UNV2 Bifunctional protein: transcription 
regulator sugar kinase, ROK family  
15.86 20.63 5 5 5 33.7 
F9ULY4 UTP--glucose-1-phosphate 
uridylyltransferase  
15.75 20.26 4 4 5 34.2 
F9UP45 Enoyl-[acyl-carrier-protein] reductase 
[NADH]  
15.41 32.54 6 6 7 26.9 
F9ULZ0 Phosphoglucomutase  15.41 12.70 6 6 7 63.5 
Q88XY0 30S ribosomal protein S3  15.16 40.55 8 8 8 24.2 
Q88XX4 50S ribosomal protein L5  15.10 37.78 5 5 6 20.2 
Q88XY5 50S ribosomal protein L4  14.94 26.09 4 4 4 22.6 
Q88Z28 Lysine--tRNA ligase  14.84 11.62 5 5 6 57.6 
F9UMS1 Fumarate hydratase class II  14.52 11.30 5 5 6 49.5 
Q88XW9 30S ribosomal protein S5  14.19 37.35 5 5 5 17.3 
Q88Z31 ATP-dependent zinc metalloprotease 
FtsH 
14.06 7.52 5 5 6 80.8 
Q88XP7 Glutamyl-tRNA(Gln) amidotransferase 
subunit A  
13.60 20.12 5 5 5 52.1 
Q88WM7 Exodeoxyribonuclease 7 large subunit   13.60 14.54 6 6 6 50.5 
F9UPA5 Transpeptidase-transglycosylase 
(Penicillin binding protein 1A)  
13.51 6.65 4 4 4 83.1 
F9UTE4 Uncharacterized protein  13.51 12.03 5 5 5 47.9 
F9UQZ0 Prophage P2a protein 6 endonuclease  13.40 17.28 5 5 5 40.6 
F9UTW4 Glycine betaine/carnitine/choline ABC 
transporter, substrate binding and 
permease protein  
13.24 10.63 4 4 4 55.8 
F9UQC4 Cell division protein FtsA  12.96 10.94 5 5 5 48.3 
Q88VM1 Chaperone protein DnaJ  12.61 14.47 4 4 5 40.5 
F9UQH6 Catabolite control protein A  12.46 15.48 4 4 5 36.3 
F9UNL0 Cysteine desulfurase  12.46 12.62 5 5 5 44.9 
Q88ZS1 Mannitol-1-phosphate 5-
dehydrogenase  
12.36 9.87 3 3 4 43.2 
Q88VM0 Chaperone protein DnaK  12.34 8.04 4 4 4 66.7 
F9UTG6 Cardiolipin synthase  12.31 10.10 4 4 4 55.7 
F9UNK9 ABC transporter, iron-sulfur cluster 
assembly protein SufD  
12.17 6.70 2 2 4 47.4 
F9USY7 Maltodextrin-binding protein  12.15 9.11 3 3 4 45.6 
Q88XZ7 Serine--tRNA ligase 2  12.07 11.76 4 4 4 48.1 
F9UQP4 Universal stress protein  11.65 18.13 2 2 3 17.5 
F9UQQ1 L-2-hydroxyisocaproate dehydrogenase  11.41 18.03 5 5 5 32.5 
F9UQ85 Extracellular protein, cell-wall 
anchored  
11.03 10.85 3 3 3 45.8 
Q88XP4 Uncharacterized RNA methyltransferase 
lp_1151  
10.99 10.72 3 3 4 51.0 
F9UKZ5 UDP-N-acetylmuramoyl-tripeptide--D-
alanyl-D-alanine ligase  
10.96 7.36 2 2 3 50.2 
Q88W26 ATP-dependent protease ATPase 
subunit HslU  
10.95 8.05 3 3 3 52.6 
F9UTU2 Uncharacterized protein 10.89 7.22 2 2 3 43.7 
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F9UTV3 Multicopper oxidase  10.78 6.79 3 3 4 56.8 
Q6LWG1 NADH oxidase (Putative)  10.53 5.15 2 2 3 50.6 
F9URP6 6-phospho-beta-glucosidase  10.24 10.00 4 4 4 54.7 
Q88VG4 GTPase Obg 10.10 11.37 2 3 3 46.7 
F9UNS6 Recombination factor protein RarA 
ATPase, AAA family 
10.08 6.77 2 2 3 50.9 
Q88XY6 50S ribosomal protein L3  10.00 20.10 4 4 4 22.7 
Q88XY9 30S ribosomal protein S7  9.77 32.69 4 4 4 17.8 
F9UL91 Prophage P1 protein 5, superinfection 
exclusion (Cell surface N-anchored)  
9.55 14.37 4 4 4 37.9 
F9UQB3 Cysteine desulfurase  9.23 13.73 4 4 4 42.3 
F9UPK6 Uncharacterized protein  9.12 7.11 4 4 5 48.8 
F9UL45 PTS system, mannose-specific EIIAB 
component  
8.80 9.88 3 3 3 35.3 
F9UP94 Aminotransferase  8.54 9.48 3 3 3 43.8 
Q88VS2 Glycine--tRNA ligase alpha subunit  8.43 14.05 3 3 3 34.5 
F9URK6 NADPH-dependent FMN reductase 
family protein  
8.23 11.14 4 4 4 47.4 
F9UMN8 Lipoprotein, FMN-binding protein  8.20 21.43 3 3 3 32.9 
Q88V96 tRNA-specific 2-thiouridylase MnmA  7.91 8.02 2 2 2 42.0 
Q88XX1 50S ribosomal protein L6  7.83 18.54 3 3 3 19.3 
Q88Z33 tRNA(Ile)-lysidine synthase  7.65 8.26 3 3 3 51.0 
Q88XU8 50S ribosomal protein L13  7.40 26.53 3 3 3 16.2 
Q88WU9 Threonine--tRNA ligase  7.34 3.98 2 2 2 73.8 
Q88XW0 DNA-directed RNA polymerase subunit 
alpha  
7.12 7.96 3 3 3 34.8 
Q6LWD9 Nickase  7.07 3.94 2 2 2 80.0 
F9UPH4 Transcription regulator, LysR family  6.92 11.60 3 3 3 36.8 
Q88Z97 Methionine--tRNA ligase  6.71 3.95 2 2 2 76.7 
F9UQJ7 DEAD-box ATP-dependent RNA helicase 
CshB  
6.62 5.82 3 3 3 50.6 
Q88YH9 ATP-dependent Clp protease proteolytic 
subunit  
6.51 12.76 2 2 2 21.5 
F9UT98 Serine-type D-Ala-D-Ala 
carboxypeptidase  
6.50 8.78 3 3 4 46.9 
F9UP44 Acetyl-CoA carboxylase, carboxyl 
transferase subunit alpha  
6.24 9.77 2 2 2 27.6 
Q88V10 Alanine--tRNA ligase  6.22 3.07 2 2 3 97.2 
F9UM08 DNA-directed RNA polymerase, sigma 
factor 54  
6.09 9.21 4 4 5 51.3 
F9URG7 Glucose-6-phosphate 1-dehydrogenase  6.05 6.07 2 2 2 56.8 
F9UN64 Serine-type D-Ala-D-Ala 
carboxypeptidase  
6.00 8.25 3 3 3 45.2 
Q88Z86 Bifunctional protein GlmU  5.93 10.43 3 3 3 50.0 
Q88XZ0 30S ribosomal protein S12  5.81 18.25 2 2 2 15.2 
F9UQM2 Site-determining protein  5.75 10.45 2 2 2 29.1 
Q88Z84 Ribose-phosphate pyrophosphokinase 
1  
5.63 8.90 3 3 3 35.9 
Q88VY1 ATP-dependent 6-phosphofructokinase  5.55 6.88 2 2 2 34.2 
Q88YY0 Glutamate--tRNA ligase  5.50 4.44 2 2 2 56.9 
Q88YW7 50S ribosomal protein L7/L12  5.43 18.85 2 2 2 12.6 
Q88ZJ6 Spermidine/putrescine import ATP-
binding protein PotA  
5.19 6.30 2 2 3 40.7 
Q88VM6 D-alanine--D-alanyl carrier protein 
ligase  
5.08 10.04 4 4 4 56.0 
F9UMF3 Dipeptidase  4.95 4.91 2 2 2 52.3 
Q88YE7 Glutamine--fructose-6-phosphate 
aminotransferase [isomerizing]  
4.76 3.64 2 2 2 65.4 
F9UMY6 dTDP-4-dehydrorhamnose 3,5-
epimerase  
4.71 22.28 3 3 3 21.8 
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Q88UX0 30S ribosomal protein S4  4.70 18.32 4 4 4 22.9 
F9UP59 Cyclopropane-fatty-acyl-phospholipid 
synthase  
4.67 5.13 2 2 2 44.7 
Q88XU7 30S ribosomal protein S9  4.67 16.92 2 2 2 14.6 
F9UPB8 Glycosyl hydrolase, family 25  4.64 12.98 4 4 4 50.0 
F9UU91 Cell surface protein, CscB family  4.61 0.97 2 2 2 118.7 
F9UQH9 Extracellular protein, DUF336 family  4.58 13.53 2 2 2 18.0 
Q88XY1 50S ribosomal protein L22  4.30 14.78 2 2 2 12.5 
F9UNF9 Aminotransferase (PLP-dependent) with 
N-terminal regulator domain, GntR 
family  
4.10 4.55 2 2 2 54.1 
F9UP37 Malonyl CoA-acyl carrier protein 
transacylase  
4.05 6.77 2 2 2 33.3 
Q88VQ8 Aspartate--tRNA ligase  3.94 7.02 5 5 5 67.6 
F9UMX4 UDP-galactopyranose mutase 3.75 5.36 2 2 2 43.2 
F9UP82 23S rRNA methylase  3.53 8.13 3 3 3 50.3 
Q06115 Choloylglycine hydrolase  3.28 7.10 2 2 2 37.0 
Q88W02 CCA-adding enzyme  2.66 6.88 2 2 2 45.1 
F9USJ3 Extracellular protein  2.45 9.49 2 2 2 29.3 
Q88X05 Foldase protein PrsA 1  2.39 5.70 2 2 2 32.6 
F9ULW6 Ribosome hibernation promoting 
factor  
2.19 20.74 2 2 2 21.7 
Q88UX7 Valine--tRNA ligase  1.87 2.14 2 2 2 101.5 
Q9RE01 Uracil phosphoribosyltransferase  1.61 7.66 2 2 2 23.0 
Q88VE1 Trigger factor  0.00 4.77 2 2 2 49.4 
 
Band # 4 
Accession Description Score Coverage # Unique 
Peptides 
# 
Peptides 
# PSMs MW 
[kDa] 
F9UM10 Glyceraldehyde 3-phosphate 
dehydrogenase  
776.26 80.29 29 29 244 36.4 
Q88VJ2 D-lactate dehydrogenase  221.28 72.89 28 28 83 37.2 
Q88UU2 ATP synthase gamma chain  158.76 61.46 20 20 52 34.5 
F9UTA3 GMP reductase  143.70 80.16 21 21 46 39.9 
Q88VE0 Elongation factor Tu  136.55 64.30 19 19 45 43.4 
F9UT17 Acetate kinase  134.36 73.67 20 20 38 42.9 
F9UT87 Cyclopropane-fatty-acyl-phospholipid 
synthase  
123.72 51.89 18 18 36 45.3 
F9UR85 Aspartate-semialdehyde 
dehydrogenase  
108.93 60.34 17 17 34 38.2 
F9ULC7 FAD-dependent pyridine nucleotide-
disulphide oxidoreductase  
107.72 75.56 26 26 37 44.4 
Q88XW0 DNA-directed RNA polymerase subunit 
alpha  
102.20 43.95 15 15 38 34.8 
F9UTI2 Dihydropteroate synthase  98.06 53.66 18 18 39 43.4 
F9UMU0 Oxidoreductase, NAD(P)-dependent  97.28 60.80 14 14 32 35.9 
Q88WK2 Phosphate acyltransferase  96.49 41.95 12 12 27 37.4 
F9UMW1 Oxidoreductase, NAD-dependent  91.02 61.49 14 14 26 37.1 
Q88YH5 Phosphoglycerate kinase  88.18 65.25 23 23 33 42.8 
F9UMX1 UDP-N-acetylglucosamine 2-epimerase  86.03 61.83 13 13 31 41.2 
F9UP94 Aminotransferase  84.50 35.66 11 11 24 43.8 
F9UMX4 UDP-galactopyranose mutase  84.15 41.02 12 12 24 43.2 
F9UMU4 Formate-dependent 
phosphoribosylglycinamide 
formyltransferase  
82.96 39.85 11 11 26 42.8 
Q88V04 S-adenosylmethionine:tRNA 
ribosyltransferase-isomerase  
82.94 56.98 15 15 29 39.0 
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F9UN64 Serine-type D-Ala-D-Ala 
carboxypeptidase  
82.52 52.91 19 19 29 45.2 
P56512 L-lactate dehydrogenase 1  80.57 45.94 18 18 26 34.2 
F9UMH0 Aspartokinase  76.01 46.75 14 14 27 42.8 
Q88WR3 Phenylalanine--tRNA ligase alpha 
subunit  
75.79 53.45 20 20 29 39.3 
Q88YH3 Enolase 1  75.57 41.40 13 13 23 48.0 
F9UQV7 Prophage P2a protein 40 major capsid 
protein  
75.52 59.66 15 15 24 38.1 
F9UQZ0 Prophage P2a protein 6 endonuclease  71.82 52.41 20 20 28 40.6 
Q88VJ4 30S ribosomal protein S2  68.65 58.05 17 17 26 30.2 
F9UPA9 RNA methyltransferase  65.05 42.26 14 14 22 43.1 
O08445 Alanine racemase  64.98 35.20 12 12 22 40.7 
Q88W32 Probable manganese-dependent 
inorganic pyrophosphatase  
64.63 44.98 14 14 19 33.6 
F9UU32 3-hydroxy-3-methylglutaryl coenzyme A 
reductase  
64.20 45.75 13 13 20 45.5 
Q88VJ5 Elongation factor Ts  63.40 54.45 13 13 20 31.6 
F9UQS9 Mannose-6-phosphate isomerase  62.90 52.96 12 12 21 35.9 
F9UQN3 Cysteine desulfurase  62.81 47.40 13 13 20 42.3 
F9UTT2 Fructose-bisphosphate aldolase  62.39 48.78 11 11 21 30.9 
Q88V96 tRNA-specific 2-thiouridylase MnmA  62.30 67.11 20 20 27 42.0 
Q88VM1 Chaperone protein DnaJ  57.54 53.68 16 16 23 40.5 
F9UNI1 GTP cyclohydrolase-2  56.90 35.15 13 13 18 43.6 
F9ULY4 UTP--glucose-1-phosphate 
uridylyltransferase  
56.50 62.09 14 14 20 34.2 
F9USY0 Dihydroxyacetone 
phosphotransferase,dihydroxyacetone 
binding subunit  
55.54 36.14 11 11 21 36.1 
F9UQH7 Xaa-Pro dipeptidase  54.82 36.59 12 12 25 41.1 
Q88V05 Queuine tRNA-ribosyltransferase  53.77 38.68 10 10 16 42.8 
F9US66 Serine protease HtrA  53.74 44.76 12 12 15 43.1 
F9UMV1 Diacylglycerol kinase family protein  51.52 35.00 11 11 21 37.0 
F9UT98 Serine-type D-Ala-D-Ala 
carboxypeptidase  
50.95 41.67 14 14 19 46.9 
F9UU20 Tryptophan-tRNA synthetase  50.19 42.90 11 11 19 37.6 
F9USH3 1,3-propanediol dehydrogenase  48.41 42.82 13 13 17 42.1 
F9UT53 Cystathionine beta-lyase / cystathionine 
gamma-lyase  
47.38 37.80 10 10 17 40.8 
F9UPM3 Pyruvate kinase   46.98 36.01 16 16 18 62.8 
F9URL2 L-asparaginase  46.21 36.73 8 8 15 34.4 
F9UL91 Prophage P1 protein 5, superinfection 
exclusion (Cell surface N-anchored) 
45.91 37.07 12 12 17 37.9 
Q88ZS1 Mannitol-1-phosphate 5-
dehydrogenase  
45.67 49.35 14 14 15 43.2 
F9UNG8 Metal-dependent phosphohydrolase, 
HD family  
44.67 43.87 13 13 18 37.0 
F9UMY7 dTDP-glucose 4,6-dehydratase  44.02 39.77 12 12 18 38.6 
F9UT86 Cell surface protein, membrane-
anchored  
43.76 47.83 8 8 11 38.0 
F9UNR3 Ribosome biogenesis GTPase, YqeH 
family  
43.51 50.26 16 16 17 41.7 
Q88UV8 D-alanine--D-alanine ligase  43.50 40.00 12 12 14 41.3 
F9UMU7 Lipoprotein, pheromone  43.34 45.78 13 13 14 42.6 
F9UQS3 Threonylcarbamoyl-AMP synthase  41.90 46.61 11 11 15 36.3 
F9UTR4 Acetate kinase  41.25 31.41 9 9 12 43.8 
P77885 Carbamoyl-phosphate synthase 
pyrimidine-specific small chain  
40.00 35.99 9 9 15 40.0 
Q88V81 UDP-N-acetylglucosamine--N-
acetylmuramyl-(pentapeptide) 
38.98 32.51 10 10 14 38.7 
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pyrophosphoryl-undecaprenol N-
acetylglucosamine transferase  
F9UP59 Cyclopropane-fatty-acyl-phospholipid 
synthase  
38.59 26.67 9 9 14 44.7 
F9UPC4 Oxidoreductase, FAD-dependent  37.85 25.82 9 9 14 40.4 
F9UMC8 Alkaline shock protein  37.85 45.71 6 6 12 15.8 
F9UPY0 Serine-type D-Ala-D-Ala 
carboxypeptidase  
37.31 35.04 12 12 15 43.3 
F9UQM6 Cell shape determining protein MreB  36.15 38.92 10 10 13 35.1 
Q88XY3 50S ribosomal protein L2  35.77 53.76 12 12 19 30.2 
F9UM22 Polar amino acid ABC transporter, 
substrate binding and permease 
protein  
35.65 19.25 7 7 11 52.2 
F9UPH4 Transcription regulator, LysR family  35.27 39.18 11 11 13 36.8 
F9UP39 3-oxoacyl-[acyl-carrier-protein] 
synthase 2  
35.16 30.24 7 7 11 42.4 
Q88YM5 60 kDa chaperonin  35.08 29.39 13 13 14 57.4 
F9USG7 Aminohydrolase/peptidase, M20D 
family  
34.75 29.57 7 7 11 43.0 
F9UP45 Enoyl-[acyl-carrier-protein] reductase 
[NADH]  
34.70 44.05 9 9 15 26.9 
F9UNY1 Glycine betaine/carnitine/choline ABC 
transporter, ATP-binding protein 
34.65 32.16 12 12 16 44.4 
F9UL33 N-acetylglucosamine-6-phosphate 
deacetylase  
34.35 28.04 10 10 15 41.4 
F9UL45 PTS system, mannose-specific EIIAB 
component  
33.81 29.63 9 9 12 35.3 
Q88T35 2,3-bisphosphoglycerate-dependent 
phosphoglycerate mutase 2  
33.61 38.26 9 9 16 26.1 
F9URM4 Cystathionine beta-lyase  33.36 27.64 10 10 11 45.4 
F9UNS5 6-phosphogluconate dehydrogenase, 
decarboxylating  
33.30 31.80 11 11 11 52.9 
F9ULY7 Thioredoxin reductase  33.25 47.12 10 10 10 33.4 
F9UN65 Aminotransferase  33.10 36.20 10 10 12 43.8 
F9UTR7 NADH dehydrogenase  33.01 27.75 9 9 13 43.8 
Q88WU9 Threonine--tRNA ligase  32.79 19.42 9 9 11 73.8 
F9UQ72 DNA-directed DNA polymerase III, delta 
chain  
32.63 38.81 11 11 11 39.7 
F9UNG1 Aminotransferase  32.53 29.76 9 9 11 41.6 
F9UNV9 Glutamine synthetase  31.68 35.04 11 11 12 50.9 
F9UQB3 Cysteine desulfurase  31.40 20.47 6 6 9 42.3 
Q88YW9 50S ribosomal protein L1  31.15 36.68 9 9 12 24.8 
Q88VM0 Chaperone protein DnaK  30.79 17.68 8 8 10 66.7 
Q88UH9 UPF0210 protein lp_2507  30.42 20.81 9 9 11 46.6 
Q88YH4 Triosephosphate isomerase  29.28 49.21 10 10 12 27.0 
F9USZ2 Maltodextrin ABC transporter, ATP-
binding protein  
29.27 26.09 7 7 9 41.3 
Q88WA8 Asparagine--tRNA ligase 2  29.17 26.39 9 9 11 49.8 
F9UL89 Prophage P1 protein 2, mitogenic 
factor, cell surface lipoprotein 
28.48 30.49 10 10 12 41.8 
F9UUD1 ATPase, MoxR family 26.59 25.19 7 7 8 43.9 
Q88UV2 Methionine import ATP-binding protein 
MetN 2  
26.55 37.61 10 10 10 37.7 
Q88UI4 Glucose-6-phosphate isomerase  26.38 28.44 10 10 11 49.8 
F9UM27 Phosphate acetyltransferase  25.16 29.54 8 8 12 34.4 
F9UPP5 Succinyl-diaminopimelate 
desuccinylase  
24.15 23.10 7 7 8 40.8 
Q88XX4 50S ribosomal protein L5  23.56 47.22 8 8 10 20.2 
Q88XY9 30S ribosomal protein S7  23.54 57.05 7 7 8 17.8 
F9USW3 NADH:flavin oxidoreductase/NADH 
oxidase  
23.52 32.79 9 9 10 41.0 
300 
 
Q88YW8 50S ribosomal protein L10  23.38 65.87 8 8 8 17.9 
Q88YW7 50S ribosomal protein L7/L12  23.03 50.82 6 6 8 12.6 
Q88XY8 Elongation factor G  22.83 16.48 9 9 10 77.0 
F9UP44 Acetyl-CoA carboxylase, carboxyl 
transferase subunit alpha  
22.64 35.16 5 5 7 27.6 
F9URN7 Uncharacterized protein  22.54 23.97 9 9 10 40.7 
Q88XY6 50S ribosomal protein L3  21.57 32.54 6 6 8 22.7 
F9UMW9 Glutamate dehydrogenase  21.10 18.75 6 6 7 48.6 
F9ULD9 ATP-dependent Clp protease, ATP-
binding subunit ClpL  
20.69 13.92 8 8 8 77.7 
Q88Z84 Ribose-phosphate pyrophosphokinase 
1  
20.42 23.93 9 9 10 35.9 
F9UR64 NADH peroxidase  20.40 13.30 5 5 8 48.2 
F9UMR6 Malic enzyme, NAD-dependent  19.78 19.95 6 6 9 40.1 
F9UPS7 RNA polymerase sigma factor SigA  19.40 18.75 7 7 8 41.4 
F9UND1 Extracellular protein, membrane-
anchored  
19.29 16.57 5 5 7 40.1 
F9UTU1 LL-diaminopimelate aminotransferase, 
AAT family, PLP-dependent  
19.26 27.62 7 7 7 42.8 
F9UTB1 Pyrimidine nucleoside transport protein  19.19 14.75 4 4 6 46.3 
F9UL63 Transcriptional attenuator, cell 
envelope-related, LytR family  
18.73 19.65 6 6 7 43.6 
Q88WL3 Methionyl-tRNA formyltransferase  18.65 23.97 7 7 8 34.4 
Q88XW9 30S ribosomal protein S5  18.61 48.80 7 7 8 17.3 
Q88V03 Holliday junction ATP-dependent DNA 
helicase RuvB  
18.22 23.51 6 6 6 37.3 
F9UMV3 Transcription regulator, TetR family  18.19 37.17 6 6 7 21.6 
F9UQB9 Cell division initiation protein DivIVA  18.08 24.14 6 6 7 26.2 
Q88Y74 GMP synthase [glutamine-hydrolyzing]  17.75 16.22 8 8 8 57.4 
F9UMD7 Type I restriction-modification 
system,specificity subunit  
17.54 17.11 6 6 7 42.3 
F9UPM8 Peptidase T  17.21 16.50 5 5 6 45.1 
Q88Z14 NH(3)-dependent NAD(+) synthetase  17.06 26.55 5 5 5 30.6 
F9UKZ0 Uncharacterized protein  17.04 24.60 6 6 6 42.5 
F9UR33 SAM-dependent methyltransferase  16.88 23.92 8 8 8 43.7 
F9UQT2 Branched-chain amino acid 
aminotransferase  
16.82 22.51 5 5 6 37.9 
F9ULE0 NAD-independent L-lactate 
dehydrogenase  
16.58 19.67 5 5 5 38.7 
Q88V33 Probable transcriptional regulatory 
protein lp_2253  
16.53 21.90 5 5 6 26.4 
Q88XY0 30S ribosomal protein S3  16.21 35.48 8 8 8 24.2 
F9UU82 2,5 diketo-D-gluconic acid-like 
reductase, NADP dependent 
(Promiscuous)  
15.99 29.37 7 7 8 31.7 
F9UPK7 DNA-binding protein  15.83 67.03 4 4 5 9.6 
F9UQ21 Hydroxymethylglutaryl-CoA synthase  15.45 19.02 6 6 6 42.8 
F9UT85 Xylose operon regulator, ROK family  15.27 19.01 5 5 5 42.7 
Q88UU3 ATP synthase subunit beta  15.08 11.78 4 4 4 50.8 
Q88VY1 ATP-dependent 6-phosphofructokinase  15.04 20.31 6 6 6 34.2 
F9UUH6 PTS-associated protein  15.01 21.82 6 6 6 41.0 
Q88XY5 50S ribosomal protein L4  14.78 30.43 5 5 5 22.6 
F9UTL0 Glutamine-fructose-6-phosphate 
transaminase (Isomerizing)  
14.70 20.77 5 5 5 40.5 
F9UTA7 Chomosome partitioning protein, DNA-
binding protein  
14.49 22.64 6 6 6 33.1 
Q88XU8 50S ribosomal protein L13  14.49 34.01 4 4 5 16.2 
F9UQ92 Pyruvate dehydrogenase complex, E1 
component,beta subunit  
13.81 17.23 5 5 6 35.4 
Q88X05 Foldase protein PrsA 1  13.78 16.44 4 4 4 32.6 
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Q88WG0 Acetyl-coenzyme A carboxylase carboxyl 
transferase subunit beta 2  
13.65 23.49 5 5 5 30.9 
Q88UU0 ATP synthase subunit delta  13.56 28.73 4 4 5 20.0 
F9UNX0 Xaa-Pro aminopeptidase  13.43 18.98 5 5 5 37.8 
F9UPI8 5-methyltetrahydropteroyltriglutamate-
homocysteine methyltransferase 
(Cobalamine-independent methonine 
synthase)  
13.36 18.85 6 6 7 43.2 
F9UQH6 Catabolite control protein A  13.36 17.56 5 5 7 36.3 
F9UMN8 Lipoprotein, FMN-binding protein  13.33 16.88 4 4 4 32.9 
F9UMI5 Transcriptional attenuator, cell 
envelope-related, LytR family  
13.32 15.36 4 4 5 37.7 
Q88VS2 Glycine--tRNA ligase alpha subunit  13.20 22.07 5 5 5 34.5 
F9UTF3 DegV family protein  13.17 15.41 3 3 4 29.6 
F9UPL0 30S ribosomal protein S1  13.04 23.54 10 10 10 47.1 
F9URX3 Alcohol dehydrogenase, zinc-binding  12.93 21.39 6 6 8 36.7 
F9UQH2 Ribokinase  12.78 16.01 4 4 4 31.7 
Q88W73 Carbamoyl-phosphate synthase small 
chain  
12.74 9.72 3 3 4 39.2 
Q88Z76 CTP synthase  12.62 13.59 6 6 6 59.7 
P77883 Aspartate carbamoyltransferase  12.37 19.29 4 4 4 34.7 
F9UTG0 Glutathione reductase  12.31 8.33 3 3 4 48.2 
F9UMR5 Citrate lyase regulator, SorC family  12.26 15.31 4 4 4 35.6 
F9UNV2 Bifunctional protein: transcription 
regulator sugar kinase, ROK family  
12.02 19.06 5 5 5 33.7 
F9UPX5 Protein DltD  11.94 17.18 5 5 5 48.6 
F9URN8 Acetyltransferase, GNAT family  11.64 12.21 4 4 4 44.7 
Q88ZH4 Teichoic acids export ATP-binding 
protein TagH  
11.58 11.57 4 4 5 40.8 
Q88V41 Acetate kinase  11.45 22.42 7 7 7 43.4 
F9UMX6 Glycosyltransferase, family 1 (GT1)  11.37 27.20 7 7 8 40.2 
Q88TV5 Tyrosine--tRNA ligase  11.34 10.05 4 4 4 47.0 
F9UL68 Aminopeptidase C  11.22 15.12 5 5 5 50.2 
Q88WT1 UPF0348 protein lp_1534  11.07 9.40 3 3 4 43.0 
Q88YY0 Glutamate--tRNA ligase  11.02 9.27 4 4 4 56.9 
Q88UC0 Ferredoxin--NADP reductase  10.99 13.60 4 4 4 36.1 
Q88YL5 Peptide chain release factor 2  10.97 11.14 3 3 3 42.6 
F9UPH8 Aldose 1-epimerase family protein  10.95 14.73 3 3 4 32.7 
F9ULW6 Ribosome hibernation promoting factor  10.89 31.38 4 4 5 21.7 
Q88XX2 30S ribosomal protein S8  10.86 23.66 3 3 4 14.6 
Q88Y39 Aspartate--ammonia ligase  10.74 19.88 5 5 5 37.5 
F9UN61 1,2-diacylglycerol 3-glucosyltransferase  10.74 18.11 6 6 6 44.2 
F9UL10 Cell surface protein, 
ErfK/YbiS/YcfS/YnhG family 
10.69 7.97 3 3 5 51.1 
Q88YE8 Phosphoglucosamine mutase  10.48 9.09 3 3 3 48.3 
Q88YM8 Redox-sensing transcriptional repressor 
Rex  
10.30 22.22 5 5 5 25.2 
Q88XW7 50S ribosomal protein L15  10.24 27.97 3 3 3 15.3 
Q88UX4 Probable tRNA sulfurtransferase 10.06 10.86 4 4 4 45.4 
F9UQH9 Extracellular protein, DUF336 family  9.92 25.88 4 4 4 18.0 
F9UNL3 Iron chelatin ABC transporter, substrate 
binding protein  
9.91 13.20 3 3 3 38.6 
Q88VQ7 Histidine--tRNA ligase  9.80 8.92 3 3 4 47.9 
F9UP42 Acetyl-CoA carboxylase, biotin 
carboxylase subunit  
9.80 11.26 4 4 4 50.7 
Q88XY4 50S ribosomal protein L23  9.54 43.30 3 3 3 11.1 
F9UTA5 Ribosome-binding ATPase YchF  9.50 13.93 4 4 4 39.9 
F9URD4 Extracellular protein  9.17 15.91 3 3 3 23.1 
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F9UPC9 Pseudouridine synthase  9.12 12.05 3 3 3 33.8 
Q88UX0 30S ribosomal protein S4  9.11 18.32 4 4 5 22.9 
F9UP86 Aldose 1-epimerase  9.01 21.07 5 5 6 37.8 
F9UQQ1 L-2-hydroxyisocaproate dehydrogenase  8.98 12.13 3 3 4 32.5 
F9UMC9 Alkaline shock protein  8.96 20.55 2 2 3 16.1 
F9UKV7 Lipoprotein  8.83 10.37 3 3 3 34.3 
F9USY7 Maltodextrin-binding protein  8.78 8.63 3 3 4 45.6 
F9UL47 PTS system, mannose-specific EIID 
component  
8.70 11.48 3 3 3 33.6 
F9ULZ0 Phosphoglucomutase  8.61 8.70 4 4 5 63.5 
P77884 Dihydroorotase  8.36 10.00 3 3 3 45.4 
F9USN8 DNA-binding ferritin-like protein, DPS 
family  
8.34 21.94 3 3 3 18.0 
F9UM03 Putative gluconeogenesis factor  8.29 10.81 2 2 2 36.6 
F9UMN9 FAD:protein FMN transferase  8.26 10.83 4 4 4 43.4 
Q88WZ5 UDP-N-acetylmuramate--L-alanine 
ligase  
8.22 8.72 3 3 3 48.7 
F9UL42 Homoserine dehydrogenase  8.22 8.88 3 3 3 46.6 
F9UPJ8 DegV family protein  8.21 13.78 3 3 3 30.1 
F9UTW6 Glutathione reductase  7.96 8.35 3 3 3 47.3 
F9UUF4 Transcription regulator. LacI family, 
raffinose related  
7.92 10.27 3 3 3 37.1 
Q88WU6 50S ribosomal protein L20  7.76 24.58 3 3 3 13.6 
F9UM84 Glutamine ABC transporter, ATP-binding 
protein  
7.58 18.29 4 4 4 27.4 
Q88XB8 S-adenosylmethionine synthase  7.56 7.34 2 2 2 42.7 
Q890K5 DNA replication and repair protein RecF  7.32 12.03 4 4 4 42.4 
Q88XW5 Adenylate kinase  7.24 25.57 4 4 4 24.4 
F9UN23 Mannose-specific adhesin, LPXTG-motif 
cell wall anchor  
7.17 3.56 2 2 2 107.9 
F9US18 Anaerobic ribonucleoside-triphosphate 
reductase  
7.06 4.73 3 3 3 83.7 
F9UQ85 Extracellular protein, cell-wall anchored  6.99 8.55 3 3 3 45.8 
F9USJ3 Extracellular protein  6.98 9.85 2 2 2 29.3 
Q88XZ2 DNA-directed RNA polymerase subunit 
beta'  
6.97 2.14 2 2 2 135.2 
Q88XV9 50S ribosomal protein L17  6.88 19.69 2 2 2 14.2 
F9UTQ0 Transport protein, MMPL family  6.82 2.61 2 2 2 143.2 
F9UTV3 Multicopper oxidase  6.76 7.98 2 2 2 56.8 
Q88WG9 3-hydroxyacyl-[acyl-carrier-protein] 
dehydratase FabZ  
6.70 14.97 2 2 2 16.0 
F9UMH1 Asparagine synthase (Glutamine-
hydrolysing)  
6.68 5.37 2 2 2 73.1 
Q88XZ0 30S ribosomal protein S12  6.58 23.36 4 4 4 15.2 
P71479 Bifunctional protein PyrR 1  6.46 12.22 2 2 3 19.8 
F9UQS7 UDP-N-acetylmuramyl tripeptide 
synthase  
6.27 9.60 4 4 4 49.7 
F9UN60 Phosphoenolpyruvate-protein 
phosphotransferase  
6.22 4.34 2 2 2 63.1 
F9UQ93 Pyruvate dehydrogenase complex, E1 
component,alpha subunit  
6.18 8.92 3 3 3 41.4 
Q88YH9 ATP-dependent Clp protease proteolytic 
subunit  
6.14 12.76 2 2 2 21.5 
F9UU93 Cell surface protein, CscB family  6.11 8.55 2 2 2 27.4 
F9UNW0 Uncharacterized protein  6.10 9.83 2 2 2 34.5 
Q88YK3 HPr kinase/phosphorylase  6.08 10.79 3 3 3 34.8 
F9UP38 3-oxoacyl-[acyl-carrier protein] 
reductase 
6.00 12.40 2 2 2 25.7 
Q88UZ3 Putative competence-damage inducible 
protein  
5.87 5.71 2 2 2 45.0 
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F9URD2 Cysteine gamma synthase/O-
succinylhomoserine (Thiol)-lyase  
5.85 8.04 2 2 3 40.5 
Q06115 Choloylglycine hydrolase  5.82 6.79 2 2 2 37.0 
F9UPL2 Extracellular protein, with LysM 
peptidoglycan binding domain  
5.76 17.62 3 3 3 21.6 
Q88VA5 Putative ribose-phosphate 
pyrophosphokinase 2  
5.68 7.17 2 2 3 35.0 
F9UM66 Proline iminopeptidase  5.59 10.26 2 2 2 34.5 
Q88Z86 Bifunctional protein GlmU  5.22 5.00 2 2 2 50.0 
F9ULK7 Ribokinase  5.20 12.75 3 3 3 32.0 
Q88VE1 Trigger factor  5.12 7.05 3 3 4 49.4 
Q88XX1 50S ribosomal protein L6  4.96 10.67 2 2 2 19.3 
F9ULM5 Single stranded DNA-binding protein  4.89 9.94 4 4 4 34.2 
F9UQQ9 Cell shape determining protein MreB  4.88 6.61 2 2 2 35.8 
Q88V80 UDP-N-acetylmuramoylalanine--D-
glutamate ligase  
4.86 9.37 3 3 3 50.1 
Q88VL9 Protein GrpE  4.81 11.56 2 2 2 21.4 
Q88XW2 30S ribosomal protein S13  4.79 14.05 2 2 2 13.6 
Q88U67 Probable phosphoketolase 1  4.70 2.16 2 2 2 88.7 
Q88WU8 Translation initiation factor IF-3  4.67 13.29 2 2 3 19.6 
F9UN90 Polysaccharide export protein  4.62 4.50 2 2 2 61.4 
F9ULT0 Ribonucleoside-diphosphate reductase  4.55 3.61 2 2 2 82.1 
Q88XP7 Glutamyl-tRNA(Gln) amidotransferase 
subunit A  
4.47 5.34 2 2 2 52.1 
Q88XX9 50S ribosomal protein L16  4.46 17.36 2 2 2 16.1 
F9UT64 Glycerol-3-phosphate 
cytidylyltransferase  
4.25 12.69 2 2 2 15.8 
Q88ZJ6 Spermidine/putrescine import ATP-
binding protein PotA 
4.06 7.12 2 2 2 40.7 
F9UPJ4 Carboxy-terminal proteinase, S41 
family,peptidoglycan-bound  
4.04 4.07 2 2 2 53.2 
F9UL73 ATPase, PilT family  3.93 8.95 3 3 5 44.3 
F9UQP4 Universal stress protein  3.50 20.63 2 2 2 17.5 
Q88SE8 Galactokinase 3.49 10.59 4 4 4 42.6 
F9USG8 Short-chain 
dehydrogenase/oxidoreductase,classica
l SDR family, subgroup 1 
3.47 7.77 2 2 2 31.5 
F9UQ58 Glutamine ABC transporter, substrate 
binding and permease protein  
3.13 4.89 2 2 2 53.8 
Q88VQ8 Aspartate--tRNA ligase  2.91 6.69 4 4 4 67.6 
Q88XY7 30S ribosomal protein S10  2.90 21.57 2 2 2 11.7 
Q88XZ7 Serine--tRNA ligase 2  2.85 5.41 2 2 2 48.1 
F9UUF3 Aldose 1-epimerase  2.78 6.98 2 2 2 38.3 
F9UMY1 Glycosyltransferase, family 1 (GT1)  2.72 6.91 2 2 2 43.2 
F9UQM5 Cell shape-determining protein MreC  2.53 8.54 2 2 2 30.1 
Q88YK1 Glycerol-3-phosphate dehydrogenase 
[NAD(P)+]  
2.52 10.95 2 2 2 36.6 
F9UM05 Oligopeptide ABC transporter, substrate 
binding protein  
2.49 5.09 2 2 2 61.0 
F9UTJ4 Beta-lactamase family protein  2.48 9.12 3 3 3 37.3 
Q88XU7 30S ribosomal protein S9  2.44 16.92 2 2 2 14.6 
Q88XQ4 Xanthine phosphoribosyltransferase  2.41 17.44 3 3 3 21.4 
F9USC2 Manganese transport protein  2.41 4.53 2 2 2 57.4 
Q88XX6 50S ribosomal protein L14 2.18 16.39 2 2 2 13.1 
F9UPA5 Transpeptidase-transglycosylase 
(Penicillin binding protein 1A)  
2.17 2.74 2 2 2 83.1 
F9ULS9 Ribonucleoside-diphosphate reductase, 
beta chain  
2.17 7.14 3 3 3 39.1 
Q88X53 Arginine--tRNA ligase  2.14 5.34 3 3 3 62.9 
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F9UTB5 Cystine ABC transporter, substrate 
binding protein  
2.03 6.37 2 2 2 29.0 
F9UPK2 Uncharacterized protein  1.90 14.00 2 2 2 17.1 
Q88YI4 Nucleotide-binding protein lp_0779  1.89 5.44 2 2 2 33.3 
Q88V24 N-acetyldiaminopimelate deacetylase  1.80 5.47 2 2 2 42.1 
Q88VM6 D-alanine--D-alanyl carrier protein 
ligase  
0.00 6.89 3 3 3 56.0 
Q88VJ6 Uridylate kinase  0.00 12.92 2 2 2 25.9 
F9UMF8 Pseudouridine synthase  0.00 7.85 2 2 2 32.3 
 
Band # 5 
Accession Description Score Coverage # Unique 
Peptides 
# 
Peptides 
# 
PSMs 
MW 
[kDa] 
Q88VM0 Chaperone protein DnaK  438.36 70.90 37 37 141 66.7 
Q88WU9 Threonine--tRNA ligase  291.74 67.74 38 38 103 73.8 
F9ULD9 ATP-dependent Clp protease, ATP-
binding subunit ClpL  
240.46 62.93 33 33 69 77.7 
F9UNZ9 Phosphatase, dihydroxyacetone kinase 
family  
192.32 68.66 29 29 59 60.7 
F9UPM3 Pyruvate kinase  178.75 60.92 29 29 56 62.8 
Q88Z97 Methionine--tRNA ligase  161.03 54.61 31 31 54 76.7 
Q88VE0 Elongation factor Tu  158.71 64.56 20 20 51 43.4 
Q88YM5 60 kDa chaperonin  145.20 65.43 30 30 46 57.4 
F9ULT0 Ribonucleoside-diphosphate reductase  133.23 54.37 35 35 47 82.1 
F9UUC0 Endopeptidase PepO  129.96 51.10 29 29 46 71.9 
F9ULZ0 Phosphoglucomutase  128.67 56.52 30 30 42 63.5 
Q88XY8 Elongation factor G  128.37 57.74 32 32 45 77.0 
Q88XQ0 DNA ligase  116.09 45.21 25 25 37 74.5 
Q88VE1 Trigger factor  103.79 49.55 22 22 37 49.4 
F9UPL0 30S ribosomal protein S1  101.00 60.84 24 24 35 47.1 
F9UQ86 Translation elongation factor, 
GTPase,TypA/BipA family  
99.52 47.39 22 22 36 68.4 
Q88YH5 Phosphoglycerate kinase  94.70 66.25 24 24 36 42.8 
F9UM10 Glyceraldehyde 3-phosphate 
dehydrogenase  
93.24 52.06 16 16 25 36.4 
Q88VK1 Proline--tRNA ligase  90.04 49.91 24 24 34 63.5 
Q88YE7 Glutamine--fructose-6-phosphate 
aminotransferase [isomerizing]  
82.80 49.92 21 21 27 65.4 
Q88VS3 Glycine--tRNA ligase beta subunit  81.96 45.24 31 31 35 78.5 
Q88YH3 Enolase 1  79.97 41.40 13 13 25 48.0 
F9UN60 Phosphoenolpyruvate-protein 
phosphotransferase  
79.64 43.06 21 21 30 63.1 
F9UU91 Cell surface protein, CscB family  73.93 17.78 14 14 24 118.7 
F9UPH6 DNA topoisomerase 4 subunit B  70.97 39.07 23 23 30 74.5 
F9UPK1 ABC transporter, ATP-binding protein, 
ChvD family  
69.05 44.65 20 20 25 71.3 
Q88VQ8 Aspartate--tRNA ligase  68.88 38.96 22 22 28 67.6 
Q88VJ4 30S ribosomal protein S2  66.92 57.30 14 14 21 30.2 
F9UMH1 Asparagine synthase (Glutamine-
hydrolysing)  
63.09 41.55 21 21 26 73.1 
Q88U67 Probable phosphoketolase 1  61.71 26.78 17 17 22 88.7 
F9UN58 ATP-dependent Clp protease, ATP-
binding subunit ClpE 
61.66 33.96 20 20 24 81.7 
Q88VJ2 D-lactate dehydrogenase 60.24 48.80 16 16 21 37.2 
F9UM05 Oligopeptide ABC transporter, substrate 
binding protein  
59.68 36.00 17 18 21 61.0 
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F9UNS5 6-phosphogluconate dehydrogenase, 
decarboxylating  
56.79 43.31 17 17 20 52.9 
Q88Z76 CTP synthase  56.64 36.13 17 17 21 59.7 
F9US37 DNA gyrase subunit B  54.83 38.73 20 20 24 72.1 
Q88VN0 Elongation factor 4 1 54.24 27.33 14 14 18 68.3 
Q88YI8 UvrABC system protein B  49.99 30.13 19 19 22 76.1 
F9UTT2 Fructose-bisphosphate aldolase  47.78 45.99 10 10 14 30.9 
Q88Y74 GMP synthase [glutamine-hydrolyzing]  46.18 32.82 15 15 17 57.4 
Q88X53 Arginine--tRNA ligase  46.01 36.48 17 17 20 62.9 
Q88RX6 tRNA uridine 5-
carboxymethylaminomethyl 
modification enzyme MnmG  
44.97 31.45 18 18 20 70.7 
Q88XF3 Peptide chain release factor 3  43.11 25.14 11 11 15 59.5 
Q88UU1 ATP synthase subunit alpha 42.42 27.58 12 12 16 54.5 
F9UNU7 Transpeptidase (Penicillin binding 
protein 2B)  
42.38 30.09 17 17 18 72.6 
P56512 L-lactate dehydrogenase 1  41.00 38.44 13 13 15 34.2 
F9UL40 Transcription accessory protein, 
contains S1 RNA binding domain  
39.99 32.92 21 21 25 80.0 
Q88VJ5 Elongation factor Ts 39.31 51.37 14 14 14 31.6 
Q88YY0 Glutamate--tRNA ligase  39.19 26.61 13 13 14 56.9 
Q88UI4 Glucose-6-phosphate isomerase 37.31 37.56 13 13 14 49.8 
Q88YW8 50S ribosomal protein L10  36.95 46.71 5 5 11 17.9 
Q88XZ2 DNA-directed RNA polymerase subunit 
beta'  
35.09 12.94 13 13 14 135.2 
F9UN67 Membrane sulfatase, alkaline 
phosphatase superfamily protein  
34.69 23.25 16 16 17 79.0 
Q88XP6 Aspartyl/glutamyl-tRNA(Asn/Gln) 
amidotransferase subunit B  
33.52 22.36 8 8 11 53.2 
Q88UU3 ATP synthase subunit beta  33.31 26.34 9 9 10 50.8 
F9ULY4 UTP--glucose-1-phosphate 
uridylyltransferase  
33.26 50.00 10 10 11 34.2 
F9US18 Anaerobic ribonucleoside-triphosphate 
reductase  
33.12 24.32 15 15 15 83.7 
F9UQE9 Oligoendopeptidase F  32.96 21.06 9 9 13 67.7 
Q88XY3 50S ribosomal protein L2  32.00 58.78 13 13 17 30.2 
F9USW0 Linoleic acid isomerase  31.56 24.65 11 11 12 64.2 
F9UNI1 GTP cyclohydrolase-2  30.80 23.02 9 9 11 43.6 
F9UTA3 GMP reductase  30.60 27.42 8 8 10 39.9 
Q88Z28 Lysine--tRNA ligase  30.35 26.85 13 13 14 57.6 
Q88WA8 Asparagine--tRNA ligase 2  30.17 33.33 11 11 11 49.8 
Q88YH4 Triosephosphate isomerase  28.88 37.70 8 8 9 27.0 
F9URG7 Glucose-6-phosphate 1-dehydrogenase 28.83 25.71 9 9 11 56.8 
Q6LWD9 Nickase  28.82 18.37 10 10 10 80.0 
Q88V10 Alanine--tRNA ligase  28.56 13.86 10 10 11 97.2 
F9UP00 ATP-dependent DNA helicase RecG  28.21 17.97 9 9 9 74.2 
Q88YD2 Polyphosphate kinase  28.18 19.22 14 14 14 82.2 
F9UNV9 Glutamine synthetase  27.97 35.04 12 12 13 50.9 
F9UPK7 DNA-binding protein  27.97 74.73 5 5 8 9.6 
F9UQB9 Cell division initiation protein DivIVA 27.88 23.28 5 5 8 26.2 
Q88XX4 50S ribosomal protein L5  27.74 58.89 9 9 12 20.2 
Q88VY1 ATP-dependent 6-phosphofructokinase  27.58 22.81 7 7 9 34.2 
Q88V80 UDP-N-acetylmuramoylalanine--D-
glutamate ligase   
27.43 30.50 10 10 10 50.1 
Q88YE8 Phosphoglucosamine mutase 27.31 29.71 12 12 13 48.3 
F9UP45 Enoyl-[acyl-carrier-protein] reductase 
[NADH]  
26.08 48.02 10 10 12 26.9 
Q88UU0 ATP synthase subunit delta  25.80 49.17 7 7 8 20.0 
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Q88YL7 Protein translocase subunit SecA  25.78 14.23 9 9 12 89.5 
F9UNC8 Excinuclease ABC, subunit A  25.60 14.55 8 8 8 82.3 
F9UQZ0 Prophage P2a protein 6 endonuclease  24.53 24.65 7 7 8 40.6 
F9UUA0 Extracellular protein,gamma-D-
glutamate-meso-diaminopimelate 
muropeptidase  
24.09 17.03 4 4 6 36.8 
Q88XA9 Leucine--tRNA ligase 23.31 11.39 8 8 9 92.6 
Q88YW9 50S ribosomal protein L1  23.31 41.92 10 10 12 24.8 
F9UT87 Cyclopropane-fatty-acyl-phospholipid 
synthase  
22.83 30.23 9 9 10 45.3 
F9UT33 Transcription regulator, BglG family, 
mannitol operon  
22.60 20.12 12 12 12 78.0 
F9UMB1 DNA helicase  22.36 13.54 8 8 9 87.9 
Q88UV8 D-alanine--D-alanine ligase  22.36 24.86 8 8 8 41.3 
Q88W32 Probable manganese-dependent 
inorganic pyrophosphatase  
21.75 33.98 9 9 10 33.6 
Q88XZ3 DNA-directed RNA polymerase subunit 
beta  
21.59 6.99 7 7 8 134.4 
Q88T35 2,3-bisphosphoglycerate-dependent 
phosphoglycerate mutase 2  
21.57 35.65 7 7 9 26.1 
Q88XY0 30S ribosomal protein S3 21.38 31.80 7 7 10 24.2 
Q88UX2 Septation ring formation regulator EzrA  21.31 20.77 11 11 11 64.5 
F9UL45 PTS system, mannose-specific EIIAB 
component  
20.69 23.77 7 7 8 35.3 
F9UKZ6 DEAD-box ATP-dependent RNA helicase 
CshA  
20.47 16.48 7 7 7 59.0 
Q88VQ7 Histidine--tRNA ligase  20.47 28.40 9 9 9 47.9 
Q88XY9 30S ribosomal protein S7  20.23 43.59 5 5 6 17.8 
Q88V89 Isoleucine--tRNA ligase  19.94 9.12 7 7 7 106.3 
F9UNV2 Bifunctional protein: transcription 
regulator sugar kinase, ROK family  
19.30 22.19 5 5 5 33.7 
F9UQ67 Ribonuclease J  19.27 14.11 6 6 6 63.9 
F9UR64 NADH peroxidase  19.17 20.84 8 8 9 48.2 
F9UL91 Prophage P1 protein 5, superinfection 
exclusion (Cell surface N-anchored)  
18.98 20.69 7 7 9 37.9 
F9USZ3 Maltose phosphorylase 18.75 14.02 10 11 11 86.5 
F9UP85 Maltose phosphorylase  18.71 10.96 7 8 9 85.6 
Q88UZ8 DNA mismatch repair protein MutL  18.55 14.01 6 6 6 74.1 
F9UMJ0 Acetolactate synthase  18.37 18.39 8 8 9 61.2 
F9UTR7 NADH dehydrogenase  17.61 27.75 7 7 8 43.8 
F9UTJ5 Formate C-acetyltransferase  17.55 12.23 9 9 9 84.4 
Q88UX7 Valine--tRNA ligase 17.37 6.30 5 5 6 101.5 
F9UQC3 Cell division protein FtsZ  17.06 18.74 6 6 6 45.0 
F9UP42 Acetyl-CoA carboxylase, biotin 
carboxylase subunit  
16.85 19.05 7 7 7 50.7 
F9UMJ6 ATP-dependent Clp protease, ATP-
binding subunit ClpC  
16.74 10.75 6 7 7 92.6 
F9US12 Cell surface protein, LPXTG-motif cell 
wall anchor  
16.40 10.20 5 5 6 89.5 
F9UM84 Glutamine ABC transporter, ATP-
binding protein  
16.40 27.24 5 5 6 27.4 
Q88XW9 30S ribosomal protein S5  16.40 41.57 6 6 6 17.3 
F9UMC8 Alkaline shock protein  15.98 38.57 4 4 5 15.8 
F9UPV0 GTP pyrophosphokinase / 
pyrophosphohydrolase  
15.93 8.48 5 5 6 86.2 
Q88XW7 50S ribosomal protein L15  15.91 41.96 5 5 5 15.3 
Q88W26 ATP-dependent protease ATPase 
subunit HslU  
15.87 13.35 5 5 5 52.6 
F9UQ00 Transcription 
termination/antitermination protein 
NusA  
15.86 16.05 5 5 5 44.3 
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Q88XP7 Glutamyl-tRNA(Gln) amidotransferase 
subunit A 
15.76 13.35 5 5 5 52.1 
F9USY7 Maltodextrin-binding protein 15.60 13.19 5 5 5 45.6 
Q88XB8 S-adenosylmethionine synthase  15.28 18.23 6 6 6 42.7 
Q88YW7 50S ribosomal protein L7/L12  15.26 46.72 5 5 5 12.6 
F9UL68 Aminopeptidase C  15.16 17.16 7 7 7 50.2 
F9URD9 Cell wall hydrolase/muramidase 14.73 10.83 4 4 4 82.1 
Q88XZ7 Serine--tRNA ligase 2  14.62 14.12 5 5 5 48.1 
F9UR85 Aspartate-semialdehyde 
dehydrogenase  
14.57 11.61 3 3 4 38.2 
Q88TV5 Tyrosine--tRNA ligase  14.47 16.03 6 6 6 47.0 
F9UMC9 Alkaline shock protein  14.41 38.36 3 3 5 16.1 
Q88XY5 50S ribosomal protein L4  14.11 26.57 4 4 4 22.6 
F9UPS8 DNA primase 13.91 11.82 6 6 6 70.4 
F9UPA5 Transpeptidase-transglycosylase 
(Penicillin binding protein 1A)  
13.83 8.60 5 5 5 83.1 
F9URQ9 Uncharacterized protein  13.78 9.21 6 6 6 76.2 
F9UP39 3-oxoacyl-[acyl-carrier-protein] 
synthase 2  
13.74 10.24 3 3 4 42.4 
F9UPH5 DNA topoisomerase 4 subunit A  13.73 4.66 3 3 4 91.6 
F9UNU0 Endolytic murein transglycosylase  13.64 15.21 5 5 5 44.7 
Q88VE2 ATP-dependent Clp protease ATP-
binding subunit ClpX  
13.46 10.21 3 3 4 46.5 
F9UQH9 Extracellular protein, DUF336 family  13.43 28.82 4 4 4 18.0 
Q88YC0 Xaa-Pro dipeptidyl-peptidase  13.31 5.54 3 3 4 91.5 
F9UMU5 ATP-dependent DNA helicase  13.19 8.08 5 5 6 85.0 
F9UT53 Cystathionine beta-lyase / cystathionine 
gamma-lyase  
12.87 16.54 5 5 5 40.8 
Q88XY6 50S ribosomal protein L3  12.75 28.71 4 4 4 22.7 
F9UN93 Xaa-His dipeptidase  12.74 13.49 5 5 5 50.8 
F9UTA5 Ribosome-binding ATPase YchF  12.27 20.77 6 6 6 39.9 
P71479 Bifunctional protein PyrR 1 12.06 30.00 5 5 5 19.8 
F9UTT6 Dipeptidase 11.88 9.15 3 3 4 52.9 
Q88Z84 Ribose-phosphate pyrophosphokinase 
1  
11.74 21.17 7 7 7 35.9 
F9URU9 Extracellular transglycosylase, with 
LysM peptidoglycan binding domain  
11.64 13.56 4 4 5 35.0 
Q88VK7 Translation initiation factor IF-2  11.59 9.21 7 7 7 93.6 
Q88UZ4 Protein RecA  11.45 16.58 5 5 5 40.6 
Q88WG0 Acetyl-coenzyme A carboxylase 
carboxyl transferase subunit beta 2 
11.20 16.37 3 3 3 30.9 
F9UPS7 RNA polymerase sigma factor SigA  11.19 11.96 4 4 4 41.4 
Q88XW0 DNA-directed RNA polymerase subunit 
alpha  
10.98 12.10 4 4 4 34.8 
F9UMS0 Citrate lyase alpha chain  10.60 13.09 5 5 5 54.9 
F9UL89 Prophage P1 protein 2, mitogenic 
factor, cell surface lipoprotein   
10.59 9.30 3 3 4 41.8 
F9UQC4 Cell division protein FtsA  10.47 17.41 6 6 6 48.3 
F9UQQ1 L-2-hydroxyisocaproate dehydrogenase  10.44 16.07 4 4 4 32.5 
Q88VM6 D-alanine--D-alanyl carrier protein 
ligase  
10.28 17.52 7 7 8 56.0 
F9UTG0 Glutathione reductase  10.27 10.81 4 4 4 48.2 
Q88XU8 50S ribosomal protein L13  10.09 31.97 4 4 4 16.2 
F9ULV5 ABC transporter, ATP-binding protein  9.54 7.58 4 4 4 74.1 
F9UUE9 Beta-galactosidase, large subunit  9.40 6.87 4 4 4 72.1 
Q88Y23 UDP-N-acetylmuramoyl-L-alanyl-D-
glutamate--2,6-diaminopimelate ligase  
9.25 8.72 3 3 3 53.8 
F9UPH4 Transcription regulator, LysR family  9.25 12.54 4 4 4 36.8 
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F9UNZ3 Serine/threonine protein kinase  9.08 3.71 2 2 3 74.5 
P77886 Carbamoyl-phosphate synthase 
pyrimidine-specific large chain  
8.89 4.82 5 5 6 115.7 
F9UNG4 Transpeptidase-transglycosylase 
(Penicillin binding protein 2A)  
8.78 5.78 3 3 3 77.7 
F9UMD4 Aminopeptidase  8.76 5.57 4 4 4 93.9 
F9UL42 Homoserine dehydrogenase  8.60 8.88 3 3 3 46.6 
Q88VM1 Chaperone protein DnaJ  8.59 11.05 3 3 4 40.5 
F9UT98 Serine-type D-Ala-D-Ala 
carboxypeptidase  
8.55 8.78 3 3 3 46.9 
F9UM27 Phosphate acetyltransferase  8.50 15.38 4 4 4 34.4 
Q88XX1 50S ribosomal protein L6  8.48 23.60 4 4 4 19.3 
F9UPI3 DNA topoisomerase 1   8.47 5.73 4 4 4 80.7 
Q88WJ5 30S ribosomal protein S16  8.44 43.33 2 2 2 10.2 
F9UMV3 Transcription regulator, TetR family 8.30 21.99 4 4 4 21.6 
F9US66 Serine protease HtrA  8.30 13.33 4 4 4 43.1 
F9UMX4 UDP-galactopyranose mutase  8.29 14.75 6 6 6 43.2 
F9UU18 DNA helicase  8.28 6.37 4 4 4 87.8 
F9UL47 PTS system, mannose-specific EIID 
component  
8.05 11.48 3 3 3 33.6 
Q88WU6 50S ribosomal protein L20  8.01 19.49 3 3 3 13.6 
Q88X05 Foldase protein PrsA 1 8.00 10.07 3 3 3 32.6 
Q88Z31 ATP-dependent zinc metalloprotease 
FtsH  
7.75 4.97 3 3 3 80.8 
F9UNW0 Uncharacterized protein  7.57 12.54 3 3 3 34.5 
F9UL33 N-acetylglucosamine-6-phosphate 
deacetylase  
7.35 9.79 3 3 3 41.4 
F9ULW6 Ribosome hibernation promoting 
factor  
7.34 24.47 4 4 5 21.7 
P77883 Aspartate carbamoyltransferase  7.33 16.40 3 3 3 34.7 
Q88VZ6 GTPase Der   7.30 9.17 4 4 4 48.7 
F9UN51 Oligopeptide ABC transporter, substrate 
binding protein  
7.18 7.50 3 4 4 60.3 
F9UQS7 UDP-N-acetylmuramyl tripeptide 
synthase  
7.06 7.37 3 3 4 49.7 
Q88VX7 Chaperone protein ClpB  7.05 5.42 3 4 4 96.5 
F9ULT4 DNA polymerase III subunit gamma/tau 7.03 7.26 3 3 4 62.7 
F9UPM8 Peptidase T  7.02 5.83 2 2 3 45.1 
Q88V23 2,3,4,5-tetrahydropyridine-2,6-
dicarboxylate N-acetyltransferas 
6.96 12.71 2 2 2 24.5 
F9UP44 Acetyl-CoA carboxylase, carboxyl 
transferase subunit alpha  
6.96 20.31 3 3 3 27.6 
F9UQH6 Catabolite control protein A  6.84 12.20 4 4 5 36.3 
F9UP94 Aminotransferase  6.82 7.73 3 3 4 43.8 
F9URZ3 Hypothetical membrane protein  6.73 4.16 4 4 4 115.2 
Q88UW5 Glutathione biosynthesis bifunctional 
protein GshAB  
6.68 4.39 3 3 3 83.0 
F9UMN8 Lipoprotein, FMN-binding protein  6.65 13.64 3 3 3 32.9 
F9UNY1 Glycine betaine/carnitine/choline ABC 
transporter, ATP-binding protein  
6.51 8.04 3 3 3 44.4 
Q88XY4 50S ribosomal protein L23  6.48 29.90 2 2 2 11.1 
Q88XX0 50S ribosomal protein L18  6.44 22.88 3 3 3 13.0 
Q88WR2 Phenylalanine--tRNA ligase beta 
subunit  
6.36 7.45 4 4 4 88.1 
Q88WN5 50S ribosomal protein L21  6.30 31.37 2 2 2 11.0 
F9UQM2 Site-determining protein  6.25 10.07 2 2 2 29.1 
F9UN64 Serine-type D-Ala-D-Ala 
carboxypeptidase  
6.24 6.07 2 2 2 45.2 
F9UN65 Aminotransferase  6.17 5.57 2 2 2 43.8 
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Q88UX0 30S ribosomal protein S4  6.17 16.83 4 4 4 22.9 
Q88VR5 30S ribosomal protein S21  6.04 43.55 4 4 4 7.6 
F9UP07 Signal recognition particle protein  6.02 4.75 2 2 2 53.9 
Q88WZ5 UDP-N-acetylmuramate--L-alanine 
ligase  
5.91 11.01 4 4 4 48.7 
F9UMN7 NADH dehydrogenase, membrane-
anchored  
5.87 9.75 6 6 6 71.9 
F9UQM6 Cell shape determining protein MreB  5.64 10.48 4 4 5 35.1 
F9ULY7 Thioredoxin reductase 5.64 12.82 4 4 4 33.4 
Q06115 Choloylglycine hydrolase  5.47 8.64 3 3 3 37.0 
Q88XW2 30S ribosomal protein S13   5.45 17.36 2 2 2 13.6 
F9UQA0 Extracellular protein, NlpC/P60 
family,gamma-D-glutamate-meso-
diaminopimelate muropeptidase  
5.36 10.28 3 3 3 48.3 
Q88V33 Probable transcriptional regulatory 
protein lp_2253  
5.22 12.40 4 4 4 26.4 
F9URK6 NADPH-dependent FMN reductase 
family protein  
5.15 7.89 3 3 3 47.4 
Q88UT5 Serine hydroxymethyltransferase 5.07 7.77 3 3 3 44.4 
F9USR0 Elongation factor G  5.07 3.42 2 2 2 73.9 
F9UQ80 Pyruvate carboxylase  5.07 5.16 5 5 5 127.1 
Q88YI7 UvrABC system protein A  4.74 3.79 3 3 3 104.9 
F9UU82 2,5 diketo-D-gluconic acid-like 
reductase, NADP dependent 
(Promiscuous) 
4.70 12.59 3 3 3 31.7 
Q88XU7 30S ribosomal protein S9  4.60 16.92 2 2 2 14.6 
F9UP38 3-oxoacyl-[acyl-carrier protein] 
reductase   
4.45 10.74 2 2 2 25.7 
F9UQ85 Extracellular protein, cell-wall anchored  4.38 5.08 2 2 2 45.8 
Q88XY1 50S ribosomal protein L22  4.32 14.78 2 2 2 12.5 
F9UP59 Cyclopropane-fatty-acyl-phospholipid 
synthase 
4.31 5.38 2 2 2 44.7 
Q88UT2 Peptide chain release factor 1  4.14 5.28 2 2 2 41.0 
Q9RE01 Uracil phosphoribosyltransferase  4.05 7.66 2 2 2 23.0 
F9UT64 Glycerol-3-phosphate 
cytidylyltransferase  
3.99 11.94 2 2 2 15.8 
F9UM19 Ribonuclease R  3.98 3.21 2 2 2 92.3 
Q88WG9 3-hydroxyacyl-[acyl-carrier-protein] 
dehydratase FabZ  
3.38 14.97 2 2 2 16.0 
F9UMY7 dTDP-glucose 4,6-dehydratase  3.10 6.14 2 2 3 38.6 
F9UT61 PTS system, trehalose-specific IIBC 
component  
2.91 3.16 2 2 2 69.4 
F9UP37 Malonyl CoA-acyl carrier protein 
transacylase  
2.87 8.06 2 2 3 33.3 
Q88UZ7 DNA mismatch repair protein MutS  2.66 2.68 2 2 2 99.9 
F9URP6 6-phospho-beta-glucosidase  2.64 10.00 4 4 4 54.7 
Q88UT9 ATP synthase subunit b 2.58 12.28 2 2 2 18.7 
F9UTV3 Multicopper oxidase  2.53 5.99 3 3 3 56.8 
Q88WU8 Translation initiation factor IF-3  2.07 13.29 2 2 2 19.6 
F9ULD3 Catalase  2.03 3.51 2 2 2 55.3 
F9UMI1 Metal-dependent regulator  1.89 7.44 2 2 2 23.9 
F9ULI3 Alpha-1,2-mannosidase  1.85 2.80 2 2 2 80.8 
F9UQS9 Mannose-6-phosphate isomerase 1.80 5.92 2 2 2 35.9 
Q88YI4 Nucleotide-binding protein lp_0779  1.72 7.48 2 2 2 33.3 
F9US34 Beta sliding clamp  0.00 9.50 4 4 4 41.5 
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Band # 6 
Accession Description Score Coverage # Unique 
Peptides 
# Peptides # 
PSMs 
MW 
[kDa] 
F9UM10 Glyceraldehyde 3-phosphate 
dehydrogenase  
311.72 69.71 21 21 108 36.4 
Q88VJ4 30S ribosomal protein S2  258.60 70.79 22 22 96 30.2 
P56512 L-lactate dehydrogenase 1  169.73 49.06 22 22 66 34.2 
Q88VJ2 D-lactate dehydrogenase  131.32 58.73 22 22 54 37.2 
Q88VJ5 Elongation factor Ts  99.04 55.14 17 17 30 31.6 
F9UL45 PTS system, mannose-specific EIIAB 
component   
95.61 51.23 16 16 34 35.3 
Q88Z84 Ribose-phosphate pyrophosphokinase 1 91.06 41.72 15 15 28 35.9 
Q88Z14 NH(3)-dependent NAD(+) synthetase  76.34 53.45 13 13 25 30.6 
F9UTA7 Chomosome partitioning protein, DNA-
binding protein  
66.02 53.04 17 17 25 33.1 
F9ULU4 UDP-glucose 4-epimerase 65.50 50.15 11 12 21 36.1 
Q88VE0 Elongation factor Tu  59.26 51.14 15 15 22 43.4 
F9UU82 2,5 diketo-D-gluconic acid-like 
reductase, NADP dependent 
(Promiscuous)  
58.21 47.90 13 13 20 31.7 
F9UPH4 Transcription regulator, LysR family  57.63 52.98 13 13 18 36.8 
F9UM27 Phosphate acetyltransferase  57.06 47.38 11 11 19 34.4 
Q88VA5 Putative ribose-phosphate 
pyrophosphokinase 2  
56.90 41.12 11 11 19 35.0 
F9UTA3 GMP reductase  54.90 37.08 11 11 20 39.9 
F9UPM3 Pyruvate kinase  54.86 31.23 14 14 17 62.8 
F9ULY4 UTP--glucose-1-phosphate 
uridylyltransferase  
52.94 39.22 12 12 18 34.2 
F9UMR9 Citrate lyase, beta chain  52.61 51.97 13 13 20 33.2 
F9UUE7 UDP-glucose 4-epimerase  48.36 45.21 12 13 17 36.4 
F9UPY0 Serine-type D-Ala-D-Ala 
carboxypeptidase  
48.13 40.15 13 13 17 43.3 
Q88VS2 Glycine--tRNA ligase alpha subunit  47.37 35.12 10 10 19 34.5 
F9UT87 Cyclopropane-fatty-acyl-phospholipid 
synthase  
47.36 29.22 9 9 14 45.3 
F9UTT2 Fructose-bisphosphate aldolase  47.04 45.99 10 10 15 30.9 
F9UQB9 Cell division initiation protein DivIVA 46.00 35.34 9 9 16 26.2 
F9ULY7 Thioredoxin reductase  45.98 50.64 12 12 13 33.4 
Q88VG6 Ribonuclease Z  45.81 55.31 15 15 19 34.2 
Q88VY1 ATP-dependent 6-phosphofructokinase  45.62 31.25 9 9 14 34.2 
F9UMI5 Transcriptional attenuator, cell 
envelope-related, LytR family  
44.72 41.45 11 11 14 37.7 
F9UQ92 Pyruvate dehydrogenase complex, E1 
component,beta subunit  
43.95 44.62 13 13 16 35.4 
Q88YI2 Probable cell division protein WhiA  42.27 39.35 12 12 14 35.1 
F9UQ43 Tagatose-6-phosphate kinase  41.60 39.02 9 9 12 32.4 
Q88YK1 Glycerol-3-phosphate dehydrogenase 
[NAD(P)+]  
41.40 28.11 6 6 10 36.6 
F9USL4 Aldo/keto reductase family protein  40.87 36.59 11 11 15 35.5 
F9UQH2 Ribokinase  40.25 32.03 9 9 12 31.7 
F9UMT8 Heptaprenyl diphosphate synthase 
component II  
39.95 31.08 8 8 12 35.9 
F9UU48 Penicillin V acylase family protein  39.54 32.62 6 6 11 36.1 
P77883 Aspartate carbamoyltransferase  39.41 33.76 8 8 13 34.7 
F9UQQ9 Cell shape determining protein MreB  39.04 28.83 8 8 13 35.8 
Q88W05 Thymidylate synthase  38.79 38.61 12 12 15 36.0 
F9UQM6 Cell shape determining protein MreB  38.72 37.72 11 11 14 35.1 
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F9UTW5 Glycine betaine/carnitine/choline ABC 
transporter, ATP-binding protein  
38.29 43.96 12 12 14 35.8 
Q88WU9 Threonine--tRNA ligase  36.63 24.92 12 12 13 73.8 
Q88XY3 50S ribosomal protein L2  35.92 59.86 13 13 18 30.2 
Q88WL3 Methionyl-tRNA formyltransferase  35.72 34.38 10 10 13 34.4 
F9UMC8 Alkaline shock protein  35.15 63.57 9 9 12 15.8 
F9URD8 Lipoate--protein ligase  35.13 32.64 10 10 13 38.2 
F9UUF4 Transcription regulator. LacI family, 
raffinose related  
33.79 32.02 11 11 13 37.1 
F9UQE3 6-phosphogluconolactonase 33.68 33.92 9 9 13 36.5 
F9UQ89 Malate/L-lactate/L-2-
hydroxyisocapronate dehydrogenase  
33.66 34.52 9 9 11 33.1 
Q88VL8 Heat-inducible transcription repressor 
HrcA  
33.44 41.50 14 14 17 38.9 
F9UU33 Uncharacterized protein  33.24 25.39 7 7 11 36.4 
Q88UU2 ATP synthase gamma chain  32.57 30.57 10 10 13 34.5 
F9UPM9 GTP cyclohydrolase 1 type 2 homolog  32.17 21.47 7 7 11 37.2 
F9UNX0 Xaa-Pro aminopeptidase 31.50 25.50 6 6 9 37.8 
F9URL2 L-asparaginase  31.30 32.41 7 7 11 34.4 
F9UMR5 Citrate lyase regulator, SorC family  30.64 28.44 8 8 10 35.6 
F9UT53 Cystathionine beta-lyase / cystathionine 
gamma-lyase  
30.11 24.15 8 8 13 40.8 
F9UTJ4 Beta-lactamase family protein  30.07 24.62 7 7 13 37.3 
Q88YH4 Triosephosphate isomerase  29.76 40.08 9 9 11 27.0 
Q88VQ7 Histidine--tRNA ligase  29.32 26.76 10 10 14 47.9 
F9UQJ8 Phosphoesterase, DHH family  29.22 28.62 7 7 9 34.5 
Q88XW0 DNA-directed RNA polymerase subunit 
alpha  
28.80 24.84 8 8 10 34.8 
F9UPY8 Riboflavin biosynthesis protein  28.27 36.94 10 10 13 36.9 
F9UMW1 Oxidoreductase, NAD-dependent  28.21 33.43 8 8 11 37.1 
F9UT17 Acetate kinase  27.94 28.61 9 9 11 42.9 
Q88W32 Probable manganese-dependent 
inorganic pyrophosphatase  
27.82 32.36 10 10 11 33.6 
F9ULS9 Ribonucleoside-diphosphate reductase, 
beta chain  
27.68 20.83 9 9 12 39.1 
Q88WK2 Phosphate acyltransferase  27.45 26.72 8 8 10 37.4 
F9ULC7 FAD-dependent pyridine nucleotide-
disulphide oxidoreductase  
27.32 27.68 10 10 11 44.4 
F9UT54 Cystathionine beta-synthase  26.81 43.89 8 8 10 32.2 
Q88YN0 tRNA N6-adenosine 
threonylcarbamoyltransferase 
26.66 25.00 6 6 10 37.5 
F9UM03 Putative gluconeogenesis factor 25.89 25.53 6 6 7 36.6 
F9UL89 Prophage P1 protein 2, mitogenic 
factor, cell surface lipoprotein  
25.73 32.30 11 11 12 41.8 
F9UMN8 Lipoprotein, FMN-binding protein  25.67 19.48 5 5 8 32.9 
F9UMV7 Transcription regulator, RpiR family  24.75 40.41 9 9 10 31.7 
Q88WG8 3-oxoacyl-[acyl-carrier-protein] 
synthase 3 protein 2  
24.54 21.65 6 6 12 35.3 
Q88V90 Diaminopimelate epimerase  24.52 24.70 7 7 8 35.9 
Q88VP9 Ribosomal protein L11 
methyltransferase  
24.48 28.16 6 6 9 34.1 
F9US66 Serine protease HtrA  24.25 26.67 8 8 8 43.1 
F9UUA8 Peroxidase  24.23 31.55 8 8 9 35.9 
F9UNV2 Bifunctional protein: transcription 
regulator sugar kinase, ROK family  
24.03 24.38 6 6 7 33.7 
F9UMD1 Extracellular lipoprotein  23.92 26.49 7 7 9 36.8 
F9UQP9 Zinc-type alcohol dehydrogenase-like 
protein  
23.77 21.35 6 6 9 36.1 
Q88T35 2,3-bisphosphoglycerate-dependent 
phosphoglycerate mutase 2  
23.60 37.83 8 8 12 26.1 
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F9UQN3 Cysteine desulfurase  23.27 18.75 6 6 8 42.3 
Q88XY0 30S ribosomal protein S3  23.10 43.78 10 10 12 24.2 
F9URN7 Uncharacterized protein 23.03 23.69 9 9 11 40.7 
Q88XX4 50S ribosomal protein L5  22.99 39.44 6 6 9 20.2 
Q88YH7 Central glycolytic genes regulator 22.70 24.78 10 10 10 38.1 
F9URT3 Purine nucleosidase, inosine-uridine 
preferring  
22.64 25.46 6 6 7 35.4 
F9URJ0 Uncharacterized protein  22.17 30.33 7 7 7 32.9 
F9UQS9 Mannose-6-phosphate isomerase  22.16 27.73 7 7 8 35.9 
Q88UH9 UPF0210 protein lp_2507 21.27 14.09 6 6 7 46.6 
F9UQL5 Transcription regulator, Xre family  21.23 27.59 7 7 8 31.3 
Q88YH3 Enolase 1  21.20 18.55 7 7 8 48.0 
Q88YW9 50S ribosomal protein L1  21.05 28.38 7 7 8 24.8 
F9UUF5 Aldo/keto reductase family protein  20.94 20.00 5 5 8 37.9 
F9ULZ0 Phosphoglucomutase  20.93 16.00 7 7 8 63.5 
F9URK8 Lipoate--protein ligase 20.82 25.00 8 8 10 37.2 
Q06115 Choloylglycine hydrolase 20.51 26.85 8 8 11 37.0 
F9UQH7 Xaa-Pro dipeptidase  19.75 17.07 6 6 9 41.1 
Q88WK9 Small ribosomal subunit biogenesis 
GTPase RsgA 1 
19.71 25.17 6 6 7 32.9 
F9ULK7 Ribokinase  19.00 26.47 7 7 9 32.0 
Q88V81 UDP-N-acetylglucosamine--N-
acetylmuramyl-(pentapeptide) 
pyrophosphoryl-undecaprenol N-
acetylglucosamine transferase 
18.79 21.76 7 7 7 38.7 
O08445 Alanine racemase  18.64 17.33 5 5 7 40.7 
F9UP59 Cyclopropane-fatty-acyl-phospholipid 
synthase 
18.53 13.85 5 5 7 44.7 
Q88UC0 Ferredoxin--NADP reductase  17.88 19.34 6 6 7 36.1 
Q88X05 Foldase protein PrsA 1  17.87 28.19 7 7 7 32.6 
F9UQS3 Threonylcarbamoyl-AMP synthase  17.86 25.66 7 7 7 36.3 
F9UMU0 Oxidoreductase, NAD(P)-dependent  17.67 21.91 6 6 8 35.9 
F9UMA6 Phosphohydrolase, MutT/nudix family  17.55 22.69 7 7 8 40.0 
F9UN62 Glucosyl-diacylglycerol 6-beta-
glucosyltransferase  
17.35 26.47 8 8 8 39.6 
Q88UU0 ATP synthase subunit delta  17.05 31.49 5 5 6 20.0 
Q88YH5 Phosphoglycerate kinase  17.00 19.75 9 9 11 42.8 
F9UU28 tRNA-dihydrouridine synthase  16.97 18.69 5 5 7 37.1 
Q88WA8 Asparagine--tRNA ligase 2  16.83 14.81 6 6 6 49.8 
F9UQZ0 Prophage P2a protein 6 endonuclease  16.83 24.65 7 7 7 40.6 
Q88Y75 Pantothenate kinase  16.71 21.36 6 6 6 36.5 
Q88UX0 30S ribosomal protein S4  16.65 18.32 4 4 7 22.9 
F9URD4 Extracellular protein 16.65 15.91 3 3 5 23.1 
F9UPH8 Aldose 1-epimerase family protein 16.56 16.10 5 5 7 32.7 
Q88WB6 Isopentenyl-diphosphate delta-
isomerase  
16.34 20.40 5 5 5 38.0 
F9UMY7 dTDP-glucose 4,6-dehydratase  15.91 13.45 4 4 6 38.6 
F9UPL0 30S ribosomal protein S1  15.90 21.91 9 9 9 47.1 
F9UMU4 Formate-dependent 
phosphoribosylglycinamide 
formyltransferase  
15.67 7.97 2 2 4 42.8 
Q88XW9 30S ribosomal protein S5  15.35 40.36 7 7 7 17.3 
F9USN8 DNA-binding ferritin-like protein, DPS 
family  
15.23 43.23 6 6 7 18.0 
Q88XU8 50S ribosomal protein L13  15.11 30.61 3 3 4 16.2 
Q88WG0 Acetyl-coenzyme A carboxylase carboxyl 
transferase subunit beta 2  
14.92 23.13 5 5 6 30.9 
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F9UM44 Maltose epimerase  14.81 16.05 6 6 7 38.9 
Q88V76 Ribosomal RNA small subunit 
methyltransferase H  
14.69 15.67 5 5 5 35.8 
F9UST5 Medium chain 
dehydrogenases/reductase (MDR)/zinc-
dependent alcohol dehydrogenase-like 
family protein  
14.65 11.69 3 3 5 34.1 
F9UN64 Serine-type D-Ala-D-Ala 
carboxypeptidase  
14.44 12.38 4 4 5 45.2 
Q88V04 S-adenosylmethionine:tRNA 
ribosyltransferase-isomerase  
14.25 21.51 6 6 7 39.0 
F9UNC5 Transcription regulator, MarR family  14.16 26.42 3 3 7 18.2 
F9URA1 Ribonuclease H  14.07 23.15 7 7 7 33.0 
P71479 Bifunctional protein PyrR 1  13.90 30.00 5 5 6 19.8 
Q88YK3 HPr kinase/phosphorylase  13.75 19.05 6 6 7 34.8 
F9ULE0 NAD-independent L-lactate 
dehydrogenase  
13.74 13.66 4 4 4 38.7 
F9UU20 Tryptophan-tRNA synthetase  13.68 23.08 6 6 7 37.6 
F9UUB1 Endoglucanase E-like protein, SGNH 
hydrolase family  
13.68 18.58 5 5 5 35.8 
Q88VM0 Chaperone protein DnaK  13.59 9.16 5 5 5 66.7 
F9UPJ2 Flavin monooxygenase, luciferase-like 
monooxygenase family  
13.44 18.47 5 5 5 38.8 
F9UP45 Enoyl-[acyl-carrier-protein] reductase 
[NADH]  
13.43 36.90 8 8 9 26.9 
F9UR55 2-dehydropantoate 2-reductase  13.36 14.81 4 4 6 36.9 
F9US21 FAD:protein FMN transferase 13.20 15.32 4 4 4 36.6 
F9UTH2 Methonine synthase (Cobalamine-
independent),C-terminal domain  
13.11 18.01 6 6 8 42.0 
Q88YW7 50S ribosomal protein L7/L12  12.83 44.26 5 5 5 12.6 
F9UU93 Cell surface protein, CscB family  12.63 13.75 3 3 4 27.4 
P59390 L-lactate dehydrogenase 2  12.34 17.48 6 6 6 33.1 
F9UNW0 Uncharacterized protein  12.19 27.12 8 8 9 34.5 
F9UMV3 Transcription regulator, TetR family  12.17 26.18 5 5 5 21.6 
F9USY7 Maltodextrin-binding protein  12.12 12.95 4 4 4 45.6 
F9UMX5 Polysaccharide biosynthesis protein  12.05 13.64 3 3 4 38.5 
F9USY4 Transcription regulator, LacI 
family,maltose-related  
11.74 21.24 5 5 5 37.9 
F9UP94 Aminotransferase 11.74 11.47 3 3 4 43.8 
Q88VS0 GTPase Era  11.71 26.16 7 7 7 34.3 
Q88W26 ATP-dependent protease ATPase 
subunit HslU  
11.70 5.93 2 2 3 52.6 
F9URB2 NAD(P)-dependent oxidoreductase  11.66 20.62 6 6 6 35.6 
F9ULD9 ATP-dependent Clp protease, ATP-
binding subunit ClpL  
11.63 9.52 5 5 5 77.7 
Q88XY9 30S ribosomal protein S7  11.46 41.03 5 5 6 17.8 
F9UPJ8 DegV family protein  11.28 13.78 3 3 4 30.1 
F9UTV9 Biotin carboxyl carrier protein of acetyl-
CoA carboxylase  
11.27 24.21 3 3 4 20.4 
F9USZ9 Oligosucrose operon repressor  11.20 14.11 4 4 4 36.2 
F9UPT5 Phosphate starvation-inducible protein  11.20 12.62 3 3 4 35.8 
Q88XY6 50S ribosomal protein L3  11.14 24.40 5 5 5 22.7 
Q88UV2 Methionine import ATP-binding protein 
MetN 2  
11.10 22.16 6 6 6 37.7 
Q88YW8 50S ribosomal protein L10  11.07 20.96 3 3 4 17.9 
F9UNI1 GTP cyclohydrolase-2  10.90 13.12 5 5 5 43.6 
F9UPL2 Extracellular protein, with LysM 
peptidoglycan binding domain  
10.84 17.62 3 3 4 21.6 
F9UTF3 DegV family protein  10.82 12.19 2 2 3 29.6 
F9ULI2 Transcription regulator, GntR family  10.75 12.71 4 4 4 39.4 
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F9UNG8 Metal-dependent phosphohydrolase, 
HD family  
10.64 16.26 4 4 5 37.0 
F9UL91 Prophage P1 protein 5, superinfection 
exclusion (Cell surface N-anchored)  
10.55 16.38 6 6 6 37.9 
Q88XZ2 DNA-directed RNA polymerase subunit 
beta' 
10.47 4.12 4 4 5 135.2 
F9US22 tRNA-dihydrouridine synthase  10.44 14.97 4 4 4 37.8 
F9UT98 Serine-type D-Ala-D-Ala 
carboxypeptidase  
10.36 6.53 2 2 3 46.9 
P77884 Dihydroorotase 10.24 6.74 2 2 3 45.4 
F9UQG6 Type I restriction-modification 
system,adenine-specific 
methyltransferase subunit  
10.21 16.07 5 5 5 37.2 
F9UM06 2-hydroxyacid dehydrogenase  10.17 10.80 3 3 4 34.8 
Q88V96 tRNA-specific 2-thiouridylase MnmA  9.98 12.57 3 3 4 42.0 
F9UQP6 Transcription regulator, Xre family 9.93 14.09 4 4 4 34.2 
F9UN55 Oligopeptide ABC transporter, ATP-
binding protein  
9.63 12.46 3 3 4 36.6 
F9ULH5 Transcription regulator, LacI family  9.55 15.82 4 4 4 36.6 
F9UMX4 UDP-galactopyranose mutase  9.53 10.72 4 4 5 43.2 
F9UMV1 Diacylglycerol kinase family protein  9.51 11.18 4 4 5 37.0 
Q88YE7 Glutamine--fructose-6-phosphate 
aminotransferase [isomerizing]  
9.43 7.93 4 4 4 65.4 
F9UPK7 DNA-binding protein  9.34 31.87 2 2 3 9.6 
Q88VR2 Probable endonuclease 4  9.13 14.09 3 3 3 33.0 
F9UP39 3-oxoacyl-[acyl-carrier-protein] 
synthase 2  
9.06 11.95 4 4 4 42.4 
F9UQQ1 L-2-hydroxyisocaproate dehydrogenase 9.04 12.13 3 3 3 32.5 
Q88YZ4 3-oxoacyl-[acyl-carrier-protein] 
synthase 3 protein 1  
9.03 11.46 2 2 2 34.4 
F9USY0 Dihydroxyacetone 
phosphotransferase,dihydroxyacetone 
binding subunit  
9.00 10.54 4 4 5 36.1 
F9UP89 Diphosphomevalonate decarboxylase  8.98 15.38 4 4 4 35.2 
F9UMH0 Aspartokinase 8.95 17.75 5 5 5 42.8 
F9UTI2 Dihydropteroate synthase  8.92 9.42 4 4 4 43.4 
F9UN47 Uncharacterized protein  8.88 16.72 4 4 4 38.2 
Q88Y74 GMP synthase [glutamine-hydrolyzing]  8.75 9.65 5 5 5 57.4 
F9UP38 3-oxoacyl-[acyl-carrier protein] 
reductase  
8.71 12.81 3 3 3 25.7 
F9UM05 Oligopeptide ABC transporter, substrate 
binding protein  
8.42 6.91 3 3 3 61.0 
F9UP42 Acetyl-CoA carboxylase, biotin 
carboxylase subunit  
8.35 5.63 2 2 3 50.7 
F9ULW6 Ribosome hibernation promoting factor  8.33 17.55 3 3 3 21.7 
F9UTQ0 Transport protein, MMPL family  8.29 3.49 3 3 3 143.2 
Q88XY5 50S ribosomal protein L4 8.21 23.67 4 4 4 22.6 
F9USZ2 Maltodextrin ABC transporter, ATP-
binding protein  
8.20 8.97 2 2 3 41.3 
F9UNS5 6-phosphogluconate dehydrogenase, 
decarboxylating  
8.18 11.09 4 4 4 52.9 
Q88XV9 50S ribosomal protein L17  8.12 29.13 3 3 3 14.2 
Q88XW2 30S ribosomal protein S13  8.12 23.97 3 3 3 13.6 
F9URA0 Purine nucleosidase  7.95 8.81 2 2 3 34.1 
Q88WU6 50S ribosomal protein L20  7.82 24.58 3 3 3 13.6 
F9UTR7 NADH dehydrogenase  7.69 13.75 4 4 4 43.8 
F9UL33 N-acetylglucosamine-6-phosphate 
deacetylase  
7.37 9.52 3 3 3 41.4 
F9ULU0 DNA-directed DNA polymerase III, delta' 
subunit  
7.29 11.21 3 3 3 37.2 
Q88XB8 S-adenosylmethionine synthase  7.27 9.11 3 3 3 42.7 
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F9UQT2 Branched-chain amino acid 
aminotransferase  
7.12 10.82 3 3 3 37.9 
Q88WN5 50S ribosomal protein L21  7.09 27.45 2 2 2 11.0 
F9UM66 Proline iminopeptidase  7.06 10.26 2 2 2 34.5 
F9URE6 Ribosomal large subunit 
pseudouridylate synthase  
6.82 18.33 3 3 3 33.3 
Q88YE8 Phosphoglucosamine mutase  6.74 5.99 2 2 2 48.3 
Q88V23 2,3,4,5-tetrahydropyridine-2,6-
dicarboxylate N-acetyltransferase  
6.64 12.71 2 2 2 24.5 
F9UP44 Acetyl-CoA carboxylase, carboxyl 
transferase subunit alpha  
6.60 9.77 2 2 2 27.6 
F9UM84 Glutamine ABC transporter, ATP-binding 
protein  
6.58 10.98 2 2 2 27.4 
F9UPP0 NAD(P)(H)-dependent oxidoreductase, 
quinone oxidoreductase (QOR) family 
6.56 11.11 3 3 3 34.9 
Q88W73 Carbamoyl-phosphate synthase small 
chain  
6.53 6.11 2 2 2 39.2 
Q88V33 Probable transcriptional regulatory 
protein lp_2253  
6.44 15.29 4 4 5 26.4 
Q88UU3 ATP synthase subunit beta  6.41 5.14 2 2 2 50.8 
Q8GH68 Divalent metal cation transporter MntH  6.39 9.05 5 5 5 50.3 
F9UTT9 Bifunctional ligase/repressor BirA  6.36 9.91 3 3 3 35.3 
F9UT04 Transcription regulator, LysR family  6.31 10.20 3 3 3 34.1 
Q88WZ5 UDP-N-acetylmuramate--L-alanine 
ligase  
6.20 6.65 2 2 2 48.7 
F9UPR0 Oxidoreductase, medium chain 
dehydrogenases/reductase (MDR)/zinc-
dependent alcohol dehydrogenase-like 
family  
6.13 10.19 2 2 2 33.6 
F9UNQ0 Primosomal protein DnaI  6.07 11.90 3 3 5 35.2 
F9UNG1 Aminotransferase  5.99 5.63 2 2 2 41.6 
F9UP88 Phosphomevalonate kinase 5.97 7.99 3 3 3 39.5 
Q88XY8 Elongation factor G 5.82 6.88 4 4 5 77.0 
Q88XX2 30S ribosomal protein S8  5.68 23.66 3 3 3 14.6 
Q88WR3 Phenylalanine--tRNA ligase alpha 
subunit  
5.60 14.37 5 5 5 39.3 
F9UQB3 Cysteine desulfurase  5.60 4.92 2 2 2 42.3 
F9USH3 1,3-propanediol dehydrogenase  5.55 6.67 2 2 2 42.1 
Q88XX1 50S ribosomal protein L6  5.53 17.42 3 3 3 19.3 
Q88VJ7 Ribosome-recycling factor  5.49 15.51 2 2 2 20.6 
Q88YM8 Redox-sensing transcriptional repressor 
Rex  
5.36 9.78 2 2 2 25.2 
F9URX3 Alcohol dehydrogenase, zinc-binding  5.33 6.07 2 2 2 36.7 
Q88U67 Probable phosphoketolase 1 5.29 2.79 2 2 2 88.7 
Q88SV5 GMP reductase  5.14 7.08 2 2 2 35.4 
F9UQH9 Extracellular protein, DUF336 family  5.13 13.53 2 2 2 18.0 
Q88Z93 Ribosomal RNA small subunit 
methyltransferase A  
5.01 11.49 3 3 3 32.7 
Q88VJ6 Uridylate kinase  5.00 13.33 3 3 3 25.9 
F9UR85 Aspartate-semialdehyde 
dehydrogenase   
5.00 7.08 2 2 2 38.2 
F9UQS4 Release factor glutamine 
methyltransferase 
4.99 5.90 2 2 2 31.6 
F9UMH1 Asparagine synthase (Glutamine-
hydrolysing)  
4.99 5.21 2 2 2 73.1 
Q88TV5 Tyrosine--tRNA ligase  4.99 5.74 2 2 2 47.0 
F9UPK2 Uncharacterized protein  4.91 20.00 3 3 3 17.1 
Q88VL9 Protein GrpE 4.89 11.56 2 2 3 21.4 
F9UTM5 Small heat shock protein 4.85 22.45 2 2 2 16.7 
P77885 Carbamoyl-phosphate synthase 
pyrimidine-specific small chain  
4.82 10.16 3 3 3 40.0 
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Q88XY1 50S ribosomal protein L22  4.75 14.78 2 2 2 12.5 
F9UMM5 Protein translocase subunit SecY  4.74 7.42 3 3 3 47.2 
Q88VH0 Adenine phosphoribosyltransferase  4.70 15.70 2 2 2 18.9 
Q88XX6 50S ribosomal protein L14  4.68 18.85 2 2 2 13.1 
F9UL19 Hypoxanthine 
phosphoribosyltransferase  
4.60 11.11 2 2 2 20.3 
Q88UZ4 Protein RecA  4.60 5.00 2 2 2 40.6 
F9UL68 Aminopeptidase C  4.55 5.87 2 2 2 50.2 
F9UR64 NADH peroxidase  4.45 5.32 2 2 2 48.2 
F9UUJ4 Transcription regulator, LacI family  4.41 9.54 2 2 2 35.0 
Q9RE01 Uracil phosphoribosyltransferase  4.41 8.61 2 2 2 23.0 
F9UUF0 Beta-galactosidase  4.32 5.96 2 2 2 35.2 
F9ULF1 Transcription regulator, AraC family, 
GlcNAc-like induced  
4.26 9.57 3 3 3 37.9 
F9UL10 Cell surface protein, 
ErfK/YbiS/YcfS/YnhG family  
4.25 4.96 2 2 2 51.1 
F9UPM1 RNA-binding protein 4.22 8.47 2 2 2 33.7 
F9UU32 3-hydroxy-3-methylglutaryl coenzyme A 
reductase  
4.19 5.90 2 2 2 45.5 
F9UQS7 UDP-N-acetylmuramyl tripeptide 
synthase  
4.01 4.02 2 2 2 49.7 
Q88XZ0 30S ribosomal protein S12  3.91 18.98 2 2 2 15.2 
F9UTB5 Cystine ABC transporter, substrate 
binding protein  
3.90 7.87 2 2 2 29.0 
Q88Z86 Bifunctional protein GlmU  3.85 4.35 2 2 3 50.0 
F9UU99 Glutamate decarboxylase  3.72 4.90 2 2 2 53.5 
Q6LWI3 Replication protein  3.61 12.54 3 3 3 37.4 
Q88XY7 30S ribosomal protein S10  3.22 21.57 2 2 2 11.7 
F9UTV3 Multicopper oxidase  3.02 7.39 3 3 3 56.8 
F9USG8 Short-chain 
dehydrogenase/oxidoreductase,classica
l SDR family, subgroup 1  
2.98 6.08 2 2 2 31.5 
F9UKV2 Purine biosynthesis operon 
repressor,phosphoribosyltransferase 
2.74 8.27 2 2 2 30.5 
Q88VD5 30S ribosomal protein S15  2.71 17.98 2 2 2 10.5 
F9UP85 Maltose phosphorylase  2.49 2.94 2 2 2 85.6 
F9UNZ9 Phosphatase, dihydroxyacetone kinase 
family  
2.42 3.87 2 2 2 60.7 
Q88XX7 30S ribosomal protein S17  2.30 20.22 2 2 2 10.3 
Q88WJ1 50S ribosomal protein L19  2.27 14.41 2 2 3 13.6 
Q88WU8 Translation initiation factor IF-3  2.12 12.72 2 2 3 19.6 
Q88VE1 Trigger factor  1.74 4.09 2 2 2 49.4 
 
Band # 7 
Accession Description Score Coverage # Unique 
Peptides 
# 
Peptides 
# PSMs MW 
[kDa] 
Q88XZ3 DNA-directed RNA polymerase subunit 
beta  
279.29 47.96 60 60 104 134.4 
Q88XZ2 DNA-directed RNA polymerase subunit 
beta'  
169.74 44.85 49 49 72 135.2 
F9UPM3 Pyruvate kinase  130.26 52.22 31 31 48 62.8 
Q88YM5 60 kDa chaperonin  107.46 53.05 29 29 43 57.4 
Q88XY8 Elongation factor G  78.44 34.81 21 21 31 77.0 
Q88WJ9 Chromosome partition protein Smc  74.69 20.59 20 20 24 131.8 
F9UM10 Glyceraldehyde 3-phosphate 
dehydrogenase  
63.92 42.35 13 13 21 36.4 
Q88U41 ATP-dependent helicase/nuclease 
subunit A  
63.25 15.85 17 17 22 140.9 
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Q88VM0 Chaperone protein DnaK  59.15 29.74 16 16 20 66.7 
Q88VE0 Elongation factor Tu  58.05 35.70 15 15 31 43.4 
F9URD9 Cell wall hydrolase/muramidase  57.48 24.46 13 13 21 82.1 
Q88VJ2 D-lactate dehydrogenase  52.72 53.01 17 17 22 37.2 
P77886 Carbamoyl-phosphate synthase 
pyrimidine-specific large chain  
50.77 18.71 18 18 22 115.7 
F9ULD9 ATP-dependent Clp protease, ATP-
binding subunit ClpL  
46.75 25.00 14 14 15 77.7 
F9UQ80 Pyruvate carboxylase  45.75 16.54 15 15 18 127.1 
F9UQ86 Translation elongation factor, 
GTPase,TypA/BipA family  
45.40 26.96 15 15 19 68.4 
Q88V10 Alanine--tRNA ligase 44.54 21.82 16 16 21 97.2 
F9UPA5 Transpeptidase-transglycosylase 
(Penicillin binding protein 1A)  
44.14 22.56 17 17 19 83.1 
Q88YH3 Enolase 1  42.36 39.82 13 13 17 48.0 
F9UMJ6 ATP-dependent Clp protease, ATP-
binding subunit ClpC 
38.81 17.92 11 12 14 92.6 
Q88YH5 Phosphoglycerate kinase 36.17 35.00 11 11 15 42.8 
F9UTT2 Fructose-bisphosphate aldolase  33.61 25.78 7 7 12 30.9 
F9UPL0 30S ribosomal protein S1  32.66 36.13 15 15 18 47.1 
F9US12 Cell surface protein, LPXTG-motif cell 
wall anchor  
32.17 13.81 7 7 12 89.5 
Q88VE1 Trigger factor  30.56 29.09 10 10 13 49.4 
Q88V89 Isoleucine--tRNA ligase  29.40 12.55 12 12 14 106.3 
Q88YL7 Protein translocase subunit SecA  28.58 13.72 9 9 10 89.5 
Q88U67 Probable phosphoketolase 1  27.22 14.72 12 12 14 88.7 
Q88YE7 Glutamine--fructose-6-phosphate 
aminotransferase [isomerizing]  
24.16 15.37 8 8 10 65.4 
F9UNZ9 Phosphatase, dihydroxyacetone kinase 
family  
22.22 17.78 7 7 9 60.7 
Q88VJ5 Elongation factor Ts  21.22 22.60 4 4 6 31.6 
F9UNP5 DNA polymerase I 21.20 9.64 7 7 8 98.7 
Q88YI7 UvrABC system protein A  20.62 10.20 8 8 9 104.9 
F9UMD4 Aminopeptidase 20.15 14.22 11 11 11 93.9 
Q88UX7 Valine--tRNA ligase 19.85 12.82 10 10 10 101.5 
F9US18 Anaerobic ribonucleoside-triphosphate 
reductase  
19.81 5.14 3 3 6 83.7 
Q88VX7 Chaperone protein ClpB  19.27 9.34 6 7 8 96.5 
F9UT05 Cell surface protein, LPXTG-motif cell 
wall anchor  
18.41 6.36 5 5 8 105.1 
F9UN58 ATP-dependent Clp protease, ATP-
binding subunit ClpE 
18.38 16.78 9 9 9 81.7 
F9UNS5 6-phosphogluconate dehydrogenase, 
decarboxylating 
17.93 14.02 5 5 7 52.9 
F9UMH1 Asparagine synthase (Glutamine-
hydrolysing) 
17.75 14.85 9 9 9 73.1 
F9UN60 Phosphoenolpyruvate-protein 
phosphotransferase  
17.31 16.67 9 9 9 63.1 
Q88Y74 GMP synthase [glutamine-hydrolyzing] 17.16 17.18 8 8 9 57.4 
F9USY7 Maltodextrin-binding protein  16.74 12.95 4 4 6 45.6 
Q88VS3 Glycine--tRNA ligase beta subunit  16.11 9.80 7 7 10 78.5 
Q88W32 Probable manganese-dependent 
inorganic pyrophosphatase  
15.99 12.62 3 3 5 33.6 
F9UP42 Acetyl-CoA carboxylase, biotin 
carboxylase subunit  
15.83 14.07 5 5 6 50.7 
Q88VK1 Proline--tRNA ligase  15.68 15.29 8 8 9 63.5 
F9ULZ0 Phosphoglucomutase 15.65 13.04 7 7 7 63.5 
F9UMB1 DNA helicase  15.55 10.03 7 7 8 87.9 
Q88WU9 Threonine--tRNA ligase  15.41 14.07 7 7 7 73.8 
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Q88V80 UDP-N-acetylmuramoylalanine--D-
glutamate ligase  
15.37 15.47 5 5 7 50.1 
F9ULY4 UTP--glucose-1-phosphate 
uridylyltransferase  
15.28 14.05 5 5 6 34.2 
F9UR85 Aspartate-semialdehyde 
dehydrogenase  
15.10 8.22 2 2 4 38.2 
Q88Z76 CTP synthase  14.97 14.71 9 9 9 59.7 
P56512 L-lactate dehydrogenase 1  14.96 26.56 7 7 8 34.2 
Q88VJ4 30S ribosomal protein S2  14.63 27.72 7 7 7 30.2 
Q88UU1 ATP synthase subunit alpha  14.22 15.08 7 7 7 54.5 
F9UNT0 Exonuclease SbcC  13.85 4.52 4 4 5 117.9 
Q88XB8 S-adenosylmethionine synthase  13.30 9.11 3 3 4 42.7 
F9ULT0 Ribonucleoside-diphosphate reductase  12.70 6.80 4 4 5 82.1 
Q88X53 Arginine--tRNA ligase  12.48 4.09 2 2 4 62.9 
F9UT53 Cystathionine beta-lyase / cystathionine 
gamma-lyase  
12.38 7.87 3 3 5 40.8 
F9UL13 Transcription-repair-coupling factor  12.08 4.68 5 5 6 132.1 
Q88YW9 50S ribosomal protein L1  11.76 18.78 4 4 4 24.8 
F9UM05 Oligopeptide ABC transporter, substrate 
binding protein  
11.58 9.45 5 5 5 61.0 
Q88UZ4 Protein RecA 11.53 17.11 5 5 6 40.6 
F9URQ9 Uncharacterized protein 11.50 8.93 5 5 6 76.2 
F9UL89 Prophage P1 protein 2, mitogenic 
factor, cell surface lipoprotein  
11.20 6.20 2 2 4 41.8 
F9UP05 Signal recognition particle receptor 
FtsY  
11.02 8.20 3 3 4 53.6 
Q88VQ8 Aspartate--tRNA ligase  10.85 9.70 6 6 7 67.6 
F9UUA0 Extracellular protein,gamma-D-
glutamate-meso-diaminopimelate 
muropeptidase  
10.76 11.08 3 3 3 36.8 
F9UMU5 ATP-dependent DNA helicase  10.19 7.28 5 5 5 85.0 
F9UTA3 GMP reductase  9.99 15.93 6 6 6 39.9 
Q88YH4 Triosephosphate isomerase  9.94 20.24 4 4 4 27.0 
Q88UI4 Glucose-6-phosphate isomerase 9.87 9.11 4 4 4 49.8 
Q88XY3 50S ribosomal protein L2  9.87 24.01 6 6 7 30.2 
Q9RE01 Uracil phosphoribosyltransferase 9.85 14.83 3 3 4 23.0 
F9UP39 3-oxoacyl-[acyl-carrier-protein] 
synthase 2  
9.69 6.59 2 2 3 42.4 
Q88YW8 50S ribosomal protein L10  9.50 20.96 3 3 4 17.9 
Q88UU3 ATP synthase subunit beta  9.44 7.71 3 3 3 50.8 
F9UP45 Enoyl-[acyl-carrier-protein] reductase 
[NADH]  
9.41 14.68 4 4 4 26.9 
Q88Z97 Methionine--tRNA ligase  9.33 6.15 4 4 4 76.7 
Q88XY0 30S ribosomal protein S3  8.44 25.81 5 5 6 24.2 
F9UQC3 Cell division protein FtsZ  8.34 6.32 2 2 3 45.0 
F9UN64 Serine-type D-Ala-D-Ala 
carboxypeptidase 
8.23 12.62 4 4 4 45.2 
F9UQ67 Ribonuclease J  7.92 6.10 3 3 3 63.9 
F9UL68 Aminopeptidase C  7.79 8.80 4 4 4 50.2 
Q6LWD9 Nickase  7.70 5.98 3 3 3 80.0 
Q88VK7 Translation initiation factor IF-2  7.69 4.66 3 3 4 93.6 
F9UP94 Aminotransferase  7.68 8.98 3 3 3 43.8 
F9UNK2 FtsK/SpoIIIE family protein  7.63 5.32 5 5 5 103.7 
F9UNI1 GTP cyclohydrolase-2  7.60 6.68 2 2 3 43.6 
Q88WR2 Phenylalanine--tRNA ligase beta 
subunit  
7.55 4.22 3 3 5 88.1 
Q88Z86 Bifunctional protein GlmU  7.54 7.17 3 3 3 50.0 
Q88UZ7 DNA mismatch repair protein MutS  7.54 5.02 4 4 4 99.9 
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F9UTG0 Glutathione reductase  7.43 6.76 3 3 4 48.2 
Q88RX6 tRNA uridine 5-
carboxymethylaminomethyl 
modification enzyme MnmG  
7.10 3.93 3 3 4 70.7 
Q88XY9 30S ribosomal protein S7  6.96 20.51 3 3 3 17.8 
F9UL45 PTS system, mannose-specific EIIAB 
component  
6.74 13.58 3 3 3 35.3 
Q88XP7 Glutamyl-tRNA(Gln) amidotransferase 
subunit A  
6.45 6.57 3 3 3 52.1 
Q88XA9 Leucine--tRNA ligase  6.38 5.57 5 5 6 92.6 
Q88WA8 Asparagine--tRNA ligase 2  6.35 7.87 4 4 4 49.8 
F9UMX4 UDP-galactopyranose mutase  6.26 9.38 3 3 3 43.2 
Q88YE8 Phosphoglucosamine mutase  6.12 9.09 3 3 3 48.3 
F9UT98 Serine-type D-Ala-D-Ala 
carboxypeptidase 
6.12 6.98 3 3 3 46.9 
F9UU91 Cell surface protein, CscB family  6.07 2.73 2 2 2 118.7 
Q88X05 Foldase protein PrsA 1   6.02 8.05 2 2 2 32.6 
F9ULV5 ABC transporter, ATP-binding protein 5.95 4.24 2 2 2 74.1 
F9URU9 Extracellular transglycosylase, with 
LysM peptidoglycan binding domain  
5.85 10.45 3 3 3 35.0 
Q88XZ7 Serine--tRNA ligase 2  5.81 5.65 2 2 2 48.1 
F9US38 DNA gyrase subunit A  5.57 3.63 3 3 3 94.5 
Q88VK2 DNA polymerase III PolC-type  5.57 2.57 3 3 4 161.9 
F9UN23 Mannose-specific adhesin, LPXTG-motif 
cell wall anchor  
5.47 4.65 3 3 3 107.9 
F9UQM6 Cell shape determining protein MreB  5.36 8.68 3 3 3 35.1 
F9UQP4 Universal stress protein  5.36 13.75 2 2 3 17.5 
Q88XY6 50S ribosomal protein L3  5.11 17.22 3 3 3 22.7 
F9UL33 N-acetylglucosamine-6-phosphate 
deacetylase  
5.05 6.08 2 2 2 41.4 
Q88XP6 Aspartyl/glutamyl-tRNA(Asn/Gln) 
amidotransferase subunit B 
4.97 9.07 4 4 4 53.2 
F9UL55 Sigma54 activator, mannose PTS operon 
regulator  
4.85 2.53 2 2 2 105.1 
Q88Z31 ATP-dependent zinc metalloprotease 
FtsH  
4.70 3.49 2 2 2 80.8 
Q88WG0 Acetyl-coenzyme A carboxylase 
carboxyl transferase subunit beta 2  
4.64 8.19 2 2 2 30.9 
F9UM65 Pyruvate oxidase  4.55 3.07 2 2 2 63.6 
Q88YW7 50S ribosomal protein L7/L12  4.51 31.97 3 3 3 12.6 
Q88XX1 50S ribosomal protein L6  4.45 16.29 3 3 3 19.3 
F9UQH6 Catabolite control protein A  4.44 9.23 3 3 3 36.3 
F9UNV9 Glutamine synthetase  4.25 4.91 2 2 2 50.9 
F9US93 Cell surface protein, LPXTG-motif cell 
wall anchor  
4.00 5.35 2 2 3 64.8 
F9UMJ0 Acetolactate synthase  3.96 3.57 2 2 2 61.2 
Q88YY0 Glutamate--tRNA ligase  3.92 4.44 2 2 2 56.9 
Q88TV5 Tyrosine--tRNA ligase  3.87 5.50 2 2 2 47.0 
Q88V23 2,3,4,5-tetrahydropyridine-2,6-
dicarboxylate N-acetyltransferase  
3.74 10.17 2 2 3 24.5 
F9UP38 3-oxoacyl-[acyl-carrier protein] 
reductase  
3.67 7.02 2 2 2 25.7 
F9UP07 Signal recognition particle protein  3.20 7.23 3 3 3 53.9 
Q88XX4 50S ribosomal protein L5  3.13 15.56 3 3 3 20.2 
F9UQZ2 Prophage P2a protein 4 AAA ATPase  2.94 4.64 2 2 2 66.5 
Q88XW9 30S ribosomal protein S5  2.91 12.65 2 2 3 17.3 
F9UT66 CDP-glycerol 
glycerophosphotransferase / 
glycosyltransferase  
2.34 2.02 2 2 2 108.2 
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Q88T35 2,3-bisphosphoglycerate-dependent 
phosphoglycerate mutase 2 
2.26 10.00 2 2 2 26.1 
Q88YD2 Polyphosphate kinase 2.09 2.92 2 2 2 82.2 
Q88XW0 DNA-directed RNA polymerase subunit 
alpha  
1.95 6.05 2 2 2 34.8 
F9UR64 NADH peroxidase  0.00 5.32 2 2 3 48.2 
 
Band # 8 
Accession Description Score Coverage # Unique 
Peptides 
# 
Peptides 
# 
PSMs 
MW 
[kDa] 
Q88UX0 30S ribosomal protein S4  125.54 73.76 22 22 58 22.9 
F9UM10 Glyceraldehyde 3-phosphate 
dehydrogenase  
106.10 63.53 17 17 31 36.4 
Q88XY5 50S ribosomal protein L4  101.59 57.00 14 14 33 22.6 
Q88YH4 Triosephosphate isomerase  88.67 53.17 12 12 28 27.0 
Q9RE01 Uracil phosphoribosyltransferase 83.81 47.37 10 10 26 23.0 
Q88XY0 30S ribosomal protein S3  83.25 61.29 16 16 38 24.2 
F9ULW6 Ribosome hibernation promoting factor  81.20 56.38 9 9 26 21.7 
Q88XX4 50S ribosomal protein L5  75.48 73.89 13 13 27 20.2 
F9UM84 Glutamine ABC transporter, ATP-binding 
protein  
71.55 61.79 14 14 24 27.4 
Q88XX1 50S ribosomal protein L6 70.01 50.00 9 9 27 19.3 
Q88T35 2,3-bisphosphoglycerate-dependent 
phosphoglycerate mutase 2  
66.19 46.52 11 11 28 26.1 
Q88YH9 ATP-dependent Clp protease proteolytic 
subunit  
64.69 45.41 7 7 19 21.5 
Q88VE0 Elongation factor Tu  64.47 47.59 15 15 24 43.4 
F9UNS7 Two-component system response 
regulator  
58.91 50.44 15 15 26 26.4 
Q88VJ2 D-lactate dehydrogenase  56.95 44.58 16 16 21 37.2 
F9UMA3 Phosphoglycerate mutase family 
protein  
55.85 77.78 15 15 23 25.8 
F9UL34 Transcription regulator, GntR family  54.17 61.37 12 12 18 26.3 
Q88YW9 50S ribosomal protein L1  53.82 49.78 13 13 20 24.8 
F9UTA0 Two component system response 
regulator  
53.72 59.83 12 12 17 25.8 
F9UP38 3-oxoacyl-[acyl-carrier protein] 
reductase  
51.84 38.43 7 7 14 25.7 
Q88VJ6 Uridylate kinase  51.82 52.08 11 11 17 25.9 
F9UPM3 Pyruvate kinase  51.58 31.57 14 14 17 62.8 
F9UPN0 S-adenosyl-L-methionine-dependent 
methyltransferase  
49.75 71.49 13 13 16 25.6 
Q88XW5 Adenylate kinase  49.50 64.38 13 13 21 24.4 
F9UNK1 Phenylalanine--tRNA ligase beta subunit  48.26 36.15 5 5 14 23.0 
Q88YH3 Enolase 1  46.95 31.67 10 10 14 48.0 
F9UMV3 Transcription regulator, TetR family  45.74 37.70 7 7 14 21.6 
Q88VJ7 Ribosome-recycling factor  45.69 52.94 8 8 14 20.6 
F9UNA0 Deoxynucleoside kinase  43.31 41.86 7 7 13 24.9 
F9UP44 Acetyl-CoA carboxylase, carboxyl 
transferase subunit alpha  
43.10 53.13 9 9 13 27.6 
F9UTT2 Fructose-bisphosphate aldolase  42.79 39.72 9 9 14 30.9 
F9UMY6 dTDP-4-dehydrorhamnose 3,5-
epimerase 
42.58 50.78 10 10 15 21.8 
Q88ZS6 Glucosamine-6-phosphate deaminase  42.22 56.12 11 11 15 25.9 
Q88VJ4 30S ribosomal protein S2  41.56 41.20 11 11 16 30.2 
Q88WN1 Elongation factor P  41.11 38.38 8 8 17 20.4 
F9UQF7 Peptidyl-prolyl cis-trans isomerase  40.93 44.85 7 7 16 21.1 
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F9UMC8 Alkaline shock protein  40.89 62.14 8 8 14 15.8 
Q88YM8 Redox-sensing transcriptional repressor 
Rex  
40.83 30.67 11 11 16 25.2 
Q88YH5 Phosphoglycerate kinase  40.47 37.50 13 13 15 42.8 
F9UP45 Enoyl-[acyl-carrier-protein] reductase 
[NADH]  
40.45 52.78 11 11 17 26.9 
F9UM05 Oligopeptide ABC transporter, substrate 
binding protein  
40.44 27.45 14 14 16 61.0 
F9UN72 Acetyltransferase, GNAT family 39.62 47.09 5 5 13 19.2 
P77888 Orotidine 5'-phosphate decarboxylase  38.71 38.40 7 7 14 24.9 
F9UPJ6 Extracellular protein, DUF2140 family 38.29 34.58 7 7 13 23.7 
F9URH4 Short-chain dehydrogenase, atypical SDR 
family,subgroup 5  
38.13 56.34 9 9 12 22.9 
F9UQB6 ADP-ribose pyrophosphatase  37.86 51.63 7 7 11 20.5 
F9UPD3 Phosphoglycerate mutase family 
protein  
37.63 63.32 10 10 13 22.6 
Q88UU0 ATP synthase subunit delta  37.61 48.07 8 8 12 20.0 
P77889 Orotate phosphoribosyltransferase  36.56 48.58 8 8 13 22.7 
F9UMI5 Transcriptional attenuator, cell 
envelope-related, LytR family  
36.31 35.07 10 10 11 37.7 
Q88XY6 50S ribosomal protein L3  36.30 41.15 8 8 12 22.7 
P71479 Bifunctional protein PyrR 1 35.38 63.89 9 10 13 19.8 
Q88XY3 50S ribosomal protein L2  34.63 59.86 13 13 17 30.2 
F9UNZ2 Serine/threonine specific protein 
phosphatase 
34.48 34.27 8 8 12 27.2 
Q88WZ9 tRNA (guanine-N(7)-)-methyltransferase  33.31 37.85 7 7 12 24.6 
F9UNT5 rRNA methylase, SpoU family  32.78 43.14 6 6 10 27.6 
F9UM81 Phosphohydrolase 32.30 34.13 7 7 11 23.2 
Q88W32 Probable manganese-dependent 
inorganic pyrophosphatase  
32.11 30.74 10 10 12 33.6 
Q88YW8 50S ribosomal protein L10  31.83 52.10 6 6 10 17.9 
F9UQM0 Glutamine/histidine ABC 
transporter,ATP-binding protein  
31.83 38.97 6 6 9 23.4 
F9UMA4 Phosphoglycerate mutase family protein 31.33 48.62 7 7 9 24.4 
Q88VZ4 Cytidylate kinase  30.33 33.77 6 6 9 24.6 
Q88UT1 Thymidine kinase  29.70 48.44 12 12 15 22.1 
Q88ST4 GTP cyclohydrolase 1  29.65 57.14 8 8 11 21.4 
Q88XY9 30S ribosomal protein S7 29.53 60.90 8 8 12 17.8 
F9URP2 Transcription regulator, TetR family  29.39 47.98 9 9 11 25.2 
F9UUC8 Cell surface protein, CscD family,LPXTG-
motif cell wall anchor 
29.07 40.00 7 7 9 22.1 
Q88YY5 Ribose-5-phosphate isomerase A 28.30 28.19 6 6 9 24.6 
Q6LWD5 Putative resolvase (Fragment)  27.78 40.00 7 7 10 22.3 
F9UL82 Transcription 
termination/antitermination protein 
NusG  
27.28 32.97 5 5 10 20.6 
F9UTA8 Chomosome partitioning 
protein,membrane-associated ATPase  
27.26 32.55 6 6 8 27.8 
F9URD0 Lipase/esterase  27.23 26.05 5 5 9 28.3 
F9UNZ5 Ribulose-phosphate 3-epimerase 27.15 31.80 6 6 9 23.4 
F9URA8 Transaldolase O 26.61 30.80 7 7 9 25.8 
F9URR4 3-dehydroquinate dehydratase 26.52 41.77 7 7 8 26.6 
Q88X05 Foldase protein PrsA 1  26.45 29.19 8 8 10 32.6 
Q88YP6 Thymidylate kinase 26.32 45.70 10 10 12 24.3 
F9UMI1 Metal-dependent regulator 26.21 40.00 8 8 9 23.9 
F9URS2 Extracellular protein 26.17 33.48 5 5 7 23.2 
F9UQA4 Uncharacterized protein  25.97 29.46 6 6 10 25.4 
F9URW9 Phosphoglycerate mutase family 
protein  
25.58 31.60 5 5 8 22.9 
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F9UQM3 Septum site-determining protein MinC 25.46 33.33 7 7 9 24.7 
F9UTV2 Ribose 5-phosphate epimerase  25.34 34.23 5 5 8 23.9 
Q88XY8 Elongation factor G  25.33 10.32 6 6 8 77.0 
F9US84 Beta-phosphoglucomutase  24.92 33.18 6 6 10 23.7 
F9URQ8 Oxidoreductase  24.69 39.47 5 5 10 20.4 
F9UU90 Extracellular protein, DUF1002 family  24.18 28.26 5 5 6 34.2 
Q88WK0 Ribonuclease 3  23.90 27.27 7 7 9 26.6 
Q88XW9 30S ribosomal protein S5  23.71 46.99 7 7 8 17.3 
F9ULY5 Diguanylate cyclase/phosphodiesterase, 
EAL domain 
23.56 34.51 9 9 11 26.2 
F9US66 Serine protease HtrA  22.95 22.62 6 6 7 43.1 
F9ULZ5 Metal-dependent phosphohydrolase, HD 
family  
22.74 41.40 9 9 9 24.5 
Q88VB2 Peptide deformylase  22.61 24.73 4 4 7 20.8 
F9US95 Lipase/esterase, subfamily of SGNH-
hydrolases  
22.30 33.05 6 6 8 25.5 
F9UL32 Pyrroline-5-carboxylate reductase  22.29 25.86 5 5 8 27.0 
F9UNV2 Bifunctional protein: transcription 
regulator sugar kinase, ROK family  
22.11 24.69 6 6 7 33.7 
F9UR12 Prophage P2b protein 2, phage 
transcription regulator, Cro/CI family 
OS=Lactobacillus plantarum (strain ATCC 
BAA-793 / NCIMB 8826 / WCFS1) 
OX=220668 GN=lp_2479 PE=4 SV=1 - 
[F9UR12_LACPL] 
21.99 32.98 7 7 8 21.7 
F9UMJ3 Deoxyadenosine kinase / 
deoxyguanosine kinase  
21.71 27.96 5 5 7 24.3 
F9URN3 Phosphohydrolase, MutT/nudix family  21.63 40.43 5 5 8 20.7 
Q6LWI0 Replication protein  21.61 33.79 7 7 8 25.3 
Q88WL7 Guanylate kinase  21.32 34.47 7 7 9 23.4 
F9UQ57 Glutamine ABC transporter, ATP-binding 
protein 
21.22 28.46 5 5 7 26.9 
Q88V20 dITP/XTP pyrophosphatase  21.14 53.47 10 10 10 21.8 
F9UP96 DNA replication protein DnaD  21.14 22.82 5 5 7 27.4 
F9ULV1 Glycoprotein endopeptidase, M22 
family  
21.12 39.42 7 7 9 26.2 
F9ULT2 16S rRNA methyltransferase 21.02 37.13 7 7 8 22.1 
Q88WA8 Asparagine--tRNA ligase 2  20.48 21.30 7 7 7 49.8 
Q88YP8 Recombination protein RecR  20.05 44.22 7 7 7 21.9 
F9UL91 Prophage P1 protein 5, superinfection 
exclusion (Cell surface N-anchored)  
19.88 13.22 5 5 8 37.9 
F9UL19 Hypoxanthine 
phosphoribosyltransferase  
19.58 35.56 7 7 10 20.3 
Q88WG0 Acetyl-coenzyme A carboxylase carboxyl 
transferase subunit beta 2  
19.48 26.69 6 6 7 30.9 
F9URR0 Flavodoxin  19.48 47.30 6 6 7 16.0 
F9UQP4 Universal stress protein  19.48 48.13 5 5 6 17.5 
Q88XY4 50S ribosomal protein L23  19.10 46.39 4 4 5 11.1 
F9US56 Beta-phosphoglucomutase  18.90 27.80 6 6 8 23.6 
Q88XU8 50S ribosomal protein L13  18.36 40.82 5 5 6 16.2 
F9UQI5 Phosphoesterase  18.31 31.40 5 5 9 19.0 
F9UMG5 Phosphoglycerate mutase family 
protein  
18.30 25.23 5 5 7 24.5 
F9URW1 Endonuclease III  17.97 17.59 3 3 6 23.9 
Q890D7 UPF0246 protein lp_0089  17.94 28.63 5 5 6 28.6 
F9UL77 tRNA/rRNA methyltransferase, TrmH 
family  
17.72 29.80 6 6 6 27.5 
Q88YW7 50S ribosomal protein L7/L12  17.68 53.28 6 6 6 12.6 
F9USU0 Glutamine amidotransferase, class I  17.67 24.80 5 5 6 26.2 
Q88ZA0 NAD-dependent protein deacetylase  17.56 28.21 5 5 6 26.4 
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F9UL09 Uncharacterized protein  17.51 33.02 7 7 8 23.9 
F9UMU7 Lipoprotein, pheromone  17.48 13.55 4 4 6 42.6 
Q88UI4 Glucose-6-phosphate isomerase  17.15 15.11 6 6 7 49.8 
Q88XQ4 Xanthine phosphoribosyltransferase  16.98 23.59 4 4 7 21.4 
Q88VJ5 Elongation factor Ts  16.94 24.32 6 6 6 31.6 
F9USY7 Maltodextrin-binding protein  16.84 16.79 5 5 6 45.6 
F9UTM7 Short-chain 
dehydrogenase/oxidoreductase,atypical 
SDR family, subgroup 6  
16.71 26.89 6 6 6 23.5 
F9UQE4 Copper homeostasis protein CutC  16.53 33.96 4 4 4 22.4 
F9UQA5 Phosphoglycerate mutase family protein 16.41 32.58 5 5 5 24.9 
Q88VM0 Chaperone protein DnaK  16.38 10.61 5 5 5 66.7 
F9URF5 Two-component system response 
regulator  
16.29 26.51 6 6 8 28.5 
F9ULS5 DNA entry nuclease  16.19 14.77 4 4 5 36.2 
F9UKV8 Hydrolase, HAD superfamily, Cof family  16.12 24.54 5 5 7 29.4 
Q88YY8 2,3-bisphosphoglycerate-dependent 
phosphoglycerate mutase 1  
15.99 36.89 5 5 6 25.6 
F9US55 Hydrolase, HAD superfamily, Cof family  15.79 23.53 5 5 7 28.7 
F9UL46 PTS system, mannose-specific EIIC 
component  
15.65 8.58 2 2 3 27.2 
F9UM18 Carboxylesterase  15.51 20.48 3 3 5 27.9 
F9URY3 NADP oxidoreductase, coenzyme F420-
dependent  
15.34 42.64 7 7 10 21.0 
F9UTU3 Transport permease protein  15.34 16.24 5 5 6 31.7 
F9UT12 Phosphoglycerate mutase family protein 15.32 38.65 7 7 8 23.0 
Q88WU6 50S ribosomal protein L20  15.22 40.68 5 5 6 13.6 
Q88Y74 GMP synthase [glutamine-hydrolyzing]  15.10 11.78 5 5 5 57.4 
F9UQD7 NADH-flavin reductase  15.02 14.42 3 3 5 23.0 
F9UTC8 ABC transporter, ATP-binding protein  14.99 30.56 6 6 8 24.0 
F9UNJ6 ABC transporter, ATP-binding protein  14.92 22.45 3 3 5 26.7 
F9UPK7 DNA-binding protein  14.92 67.03 4 4 4 9.6 
F9UMY8 dTDP-4-dehydrorhamnose reductase  14.46 24.29 5 5 6 31.3 
F9UQB4 5'-methylthioadenosine/S-
adenosylhomocysteine nucleosidase  
14.38 21.30 3 3 4 24.5 
F9UTA3 GMP reductase  14.29 18.28 5 5 6 39.9 
F9US28 Uncharacterized protein  14.28 10.58 4 4 4 53.3 
F9UPW1 Uncharacterized protein  14.23 35.14 6 6 6 24.9 
Q890J8 50S ribosomal protein L9  14.00 36.67 5 5 5 16.5 
F9UNB8 Uncharacterized protein  13.97 28.71 5 5 5 23.2 
F9UT53 Cystathionine beta-lyase / cystathionine 
gamma-lyase  
13.91 16.54 5 5 5 40.8 
F9URN0 Hydrolase, HAD superfamily, Cof family  13.78 22.64 5 5 5 29.2 
Q88Y41 FMN-dependent NADH-azoreductase 2  13.71 32.06 5 5 7 23.6 
F9US11 Transcription regulator, GntR family 13.68 25.94 5 5 5 27.2 
F9UT98 Serine-type D-Ala-D-Ala 
carboxypeptidase  
13.64 9.68 3 3 4 46.9 
F9USN8 DNA-binding ferritin-like protein, DPS 
family  
13.61 25.81 4 4 5 18.0 
Q88VE3 Probable GTP-binding protein EngB  13.26 25.89 5 5 5 22.4 
F9UNZ6 Thiamin pyrophosphokinase  13.24 24.66 3 3 4 24.1 
Q88YM5 60 kDa chaperonin  13.21 8.32 3 3 5 57.4 
Q88WR0 Uridine kinase  12.70 24.40 4 4 4 24.0 
F9UTF3 DegV family protein  12.59 21.51 4 4 4 29.6 
F9UNC1 Two-component system response 
regulator  
12.54 22.35 5 5 5 29.2 
Q88WT5 Probable nicotinate-nucleotide 
adenylyltransferase 
12.33 26.54 5 5 5 24.0 
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F9UL67 Extracellular zinc metalloproteinase, 
M10 family  
12.33 30.00 5 5 6 26.5 
F9URF4 Metal-dependent phosphohydrolase, HD 
family  
12.18 26.15 5 5 6 24.3 
F9ULD5 Two-component system response 
regulator accesory gene regulator 
protein A  
12.10 22.27 5 5 7 28.6 
F9UR85 Aspartate-semialdehyde dehydrogenase  11.96 14.73 4 4 4 38.2 
Q88U67 Probable phosphoketolase 1  11.96 4.31 3 3 4 88.7 
F9UUB9 Transcription regulator, Crp family  11.62 22.62 4 4 4 24.5 
F9USK4 Transcription regulator, TetR family  11.38 26.42 4 4 4 21.4 
F9UP25 Isochorismatase  11.10 15.64 2 2 3 19.8 
F9UPF5 Lipoprotein  11.04 17.69 4 4 4 31.0 
Q88XW7 50S ribosomal protein L15  11.02 33.57 4 4 4 15.3 
F9URN1 Uncharacterized protein  10.98 21.33 4 4 4 23.9 
F9USG8 Short-chain 
dehydrogenase/oxidoreductase,classical 
SDR family, subgroup 1  
10.83 11.15 3 3 4 31.5 
F9UMX8 Glycosyltransferase  10.81 17.05 3 3 4 30.4 
F9UM37 Diadenylate cyclase  10.55 15.36 4 4 4 31.5 
F9USK1 Two-component system response 
regulator  
10.51 20.16 4 4 4 28.6 
F9UNS5 6-phosphogluconate dehydrogenase, 
decarboxylating  
10.36 10.67 4 4 4 52.9 
Q88XV9 50S ribosomal protein L17  10.29 29.13 3 3 3 14.2 
F9UN60 Phosphoenolpyruvate-protein 
phosphotransferase  
10.15 7.47 3 3 3 63.1 
F9ULZ0 Phosphoglucomutase 10.13 9.22 4 4 4 63.5 
P56512 L-lactate dehydrogenase 1  10.13 17.50 6 6 6 34.2 
F9URB8 ABC transporter, ATP-binding protein  10.10 13.14 2 2 3 26.4 
F9UQG3 Metallophosphatase  10.06 20.30 3 4 4 23.4 
Q88YZ2 Acetyl-coenzyme A carboxylase carboxyl 
transferase subunit beta 1  
10.05 12.36 3 3 3 29.2 
Q88XX2 30S ribosomal protein S8  9.93 25.19 3 3 4 14.6 
F9UM77 Guanylate kinase  9.90 26.42 5 5 5 21.7 
F9UTR7 NADH dehydrogenase  9.89 14.75 4 4 5 43.8 
F9UT87 Cyclopropane-fatty-acyl-phospholipid 
synthase 
9.80 11.84 4 4 6 45.3 
F9UL47 PTS system, mannose-specific EIID 
component  
9.80 13.11 3 3 3 33.6 
F9UM41 Diguanylate cyclase/phosphodiesterase, 
EAL domain  
9.72 19.73 3 3 3 25.4 
F9UQS8 Glutamine amidotransferase, CobQ-like 
domain  
9.71 21.25 3 3 3 26.6 
F9UQA9 Potassium uptake protein  9.67 16.36 4 4 4 24.3 
F9UQM5 Cell shape-determining protein MreC  9.65 18.15 4 4 4 30.1 
Q88UW9 UPF0637 protein lp_2332  9.59 16.83 3 3 3 23.5 
Q88VI6 LexA repressor  9.49 21.90 3 3 4 23.3 
Q88WQ9 Transcription elongation factor GreA 2  9.48 30.63 5 5 6 17.9 
F9UPH4 Transcription regulator, LysR family  9.37 11.91 3 3 3 36.8 
Q88XW0 DNA-directed RNA polymerase subunit 
alpha  
9.33 6.69 2 2 3 34.8 
F9UQH9 Extracellular protein, DUF336 family  9.27 27.06 4 4 4 18.0 
F9UMC9 Alkaline shock protein  9.21 26.71 3 3 3 16.1 
F9UQM2 Site-determining protein  9.16 10.07 2 2 2 29.1 
F9UQF4 Uncharacterized protein  9.14 29.52 4 4 4 19.2 
F9UNI1 GTP cyclohydrolase-2  9.11 12.38 4 4 4 43.6 
F9UM31 Exodeoxyribonuclease III  9.11 20.08 4 4 4 29.6 
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F9UPV2 Ribosomal RNA small subunit 
methyltransferase E  
9.06 18.00 3 3 4 26.9 
F9UM23 Glutamine ABC transporter, ATP-binding 
protein  
9.03 17.62 4 4 4 26.8 
Q88YK2 Prolipoprotein diacylglyceryl transferase  9.00 11.35 3 3 3 32.3 
F9UM38 Cell surface protein, YbbR-like family  8.97 12.31 3 3 3 34.6 
F9UT55 Methionine aminopeptidase  8.93 17.49 3 3 3 29.1 
F9ULD9 ATP-dependent Clp protease, ATP-
binding subunit ClpL  
8.88 5.26 3 3 4 77.7 
F9US18 Anaerobic ribonucleoside-triphosphate 
reductase  
8.85 5.54 4 4 4 83.7 
Q88W05 Thymidylate synthase  8.81 6.96 2 2 3 36.0 
F9UPC1 ABC transporter, ATP-binding protein  8.71 12.44 2 2 3 25.6 
F9USU9 NADPH-dependent FMN reductase 
family protein  
8.69 12.00 2 2 4 22.2 
F9ULZ1 Diguanylate cyclase/phosphodiesterase, 
EAL domain  
8.68 25.42 6 6 6 27.1 
F9USG6 Extracellular zinc metalloproteinase  8.66 11.05 3 3 3 38.2 
F9URT4 Dihydrofolate reductase family protein 8.65 19.55 4 4 4 20.1 
F9UQ34 Transcription regulator  8.59 12.89 3 3 4 21.9 
P59389 Bifunctional protein PyrR 2  8.57 17.82 2 3 3 19.3 
Q88WN5 50S ribosomal protein L21 8.51 20.59 2 2 3 11.0 
F9UQZ0 Prophage P2a protein 6 endonuclease 8.48 9.07 3 3 3 40.6 
Q88YI4 Nucleotide-binding protein lp_0779 8.45 12.59 3 3 3 33.3 
F9USL6 Transcription regulator, TetR family  8.41 10.05 2 2 3 22.6 
F9UL45 PTS system, mannose-specific EIIAB 
component  
8.40 8.95 3 3 3 35.3 
Q88WG9 3-hydroxyacyl-[acyl-carrier-protein] 
dehydratase FabZ  
8.39 21.09 3 3 3 16.0 
Q88XW2 30S ribosomal protein S13  8.34 32.23 4 4 4 13.6 
F9UPN8 Lipoprotein  8.34 9.97 4 4 4 41.6 
F9UQS7 UDP-N-acetylmuramyl tripeptide 
synthase 
8.33 9.60 4 4 4 49.7 
F9URN5 3-ketoacyl-(Acyl-carrier-protein) 
reductase  
8.24 20.97 4 4 4 25.8 
Q88WU8 Translation initiation factor IF-3  8.17 20.23 3 3 3 19.6 
Q88WJ1 50S ribosomal protein L19  8.14 31.36 4 4 5 13.6 
F9UTN1 Transcription regulator, TetR family  8.13 16.16 4 4 4 25.4 
F9ULL2 Phenolic acid decarboxylase  8.05 16.29 3 3 5 21.0 
Q88RX1 Membrane protein insertase YidC 2 7.93 9.03 2 2 2 31.7 
F9USJ4 (Pyro)phosphohydrolase, HAD 
superfamily 
7.92 15.67 4 4 4 24.1 
F9UR42 Phosphohydrolase, MutT/nudix family  7.91 16.19 3 3 3 28.0 
Q890K2 30S ribosomal protein S6  7.88 37.37 3 3 3 11.4 
F9UNW6 Transcription regulator, TetR family  7.86 18.18 3 3 3 24.0 
F9URL0 Carbonate dehydratase 7.84 17.54 5 5 5 23.4 
F9UTS6 Acetyltransferase, GNAT family  7.81 14.86 2 2 2 19.7 
F9USJ9 Cell surface protein, ErfK family  7.72 17.22 3 3 3 23.5 
Q88V23 2,3,4,5-tetrahydropyridine-2,6-
dicarboxylate N-acetyltransferase  
7.68 19.92 4 4 5 24.5 
F9UQQ1 L-2-hydroxyisocaproate dehydrogenase  7.57 12.13 3 3 3 32.5 
Q88WU9 Threonine--tRNA ligase  7.54 6.12 3 3 4 73.8 
F9UP75 1,4-dihydroxy-2-naphthoate 
octaprenyltransferase, UbiA 
prenyltransferase family  
7.44 5.90 2 2 3 34.4 
F9USU4 Uncharacterized protein  7.37 11.06 3 3 3 26.9 
Q88XW1 30S ribosomal protein S11  7.34 21.71 2 2 2 13.8 
F9UQ58 Glutamine ABC transporter, substrate 
binding and permease protein  
7.33 6.31 3 3 3 53.8 
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Q88YE8 Phosphoglucosamine mutase  7.31 6.43 2 2 2 48.3 
F9UP42 Acetyl-CoA carboxylase, biotin 
carboxylase subunit  
7.27 11.47 4 4 4 50.7 
F9UMU5 ATP-dependent DNA helicase  7.26 3.97 3 3 4 85.0 
F9UMJ7 Transcription regulator, TetR family  7.19 16.00 2 2 2 22.4 
F9UQV2 Prophage P2a protein 45  7.18 16.49 3 3 3 20.1 
Q88YI6 S-ribosylhomocysteine lyase  6.99 15.82 2 2 2 17.4 
F9UT06 Transcription regulator, Xre family  6.97 12.14 3 3 3 32.0 
Q88VM6 D-alanine--D-alanyl carrier protein 
ligase  
6.94 8.86 3 3 4 56.0 
F9UN64 Serine-type D-Ala-D-Ala 
carboxypeptidase 
6.78 6.31 2 2 2 45.2 
F9UNZ3 Serine/threonine protein kinase  6.74 3.71 2 2 2 74.5 
F9UNS3 Lipoprotein  6.74 32.47 5 5 5 21.1 
F9UP39 3-oxoacyl-[acyl-carrier-protein] synthase 
2  
6.73 8.54 3 3 3 42.4 
F9USN1 Transcription regulator, TetR family  6.58 19.09 4 4 4 25.3 
Q88WV3 Dephospho-CoA kinase  6.58 16.75 3 3 3 21.3 
F9URQ0 Transcription regulator, GntR family  6.54 11.91 2 2 2 27.0 
Q88YK1 Glycerol-3-phosphate dehydrogenase 
[NAD(P)+]  
6.49 14.50 3 3 3 36.6 
Q88SK7 Undecaprenyl-diphosphatase 6.41 10.91 3 3 4 30.5 
F9UTM5 Small heat shock protein  6.31 21.09 2 2 2 16.7 
F9UPP8 Phosphohydrolase, MutT/nudix family 6.25 9.95 2 2 3 22.3 
F9ULV2 Ribosomal-protein-alanine N-
acetyltransferase  
6.20 12.50 2 2 3 22.6 
F9URM9 Threonine synthase  6.15 6.04 2 2 2 54.5 
Q88T16 Foldase protein PrsA 2  6.14 6.47 2 2 3 34.3 
Q88XW3 50S ribosomal protein L36 6.06 58.97 2 2 3 4.6 
Q88XZ0 30S ribosomal protein S12  6.01 8.76 2 2 4 15.2 
Q88WV2 Transcriptional repressor NrdR 5.93 16.37 2 2 2 19.9 
F9US17 Anaerobic ribonucleoside-triphosphate 
reductase-activating protein  
5.84 16.06 4 4 4 22.0 
Q88VS2 Glycine--tRNA ligase alpha subunit  5.78 8.70 2 2 2 34.5 
F9UQB9 Cell division initiation protein DivIVA  5.71 16.38 3 3 3 26.2 
F9UU94 Transcription regulator, AraC family 5.60 11.02 2 2 2 29.3 
Q88YG1 Uracil-DNA glycosylase  5.54 8.26 2 2 2 26.1 
F9UMG4 Acetyltransferase, GNAT family  5.48 11.11 2 2 3 20.5 
F9UMT3 Cytochrome D ubiquinol oxidase, 
subunit II  
5.47 6.34 2 2 2 37.3 
F9UNH2 NADPH-dependent FMN reductase 
family protein  
5.45 11.27 2 2 2 22.9 
F9US91 Glutamine amidotransferase class-I  5.45 18.02 3 3 3 25.0 
Q88XY7 30S ribosomal protein S10  5.31 31.37 3 3 3 11.7 
F9USH9 Transcription regulator, AraC family 5.28 7.91 2 2 2 29.6 
F9USR4 ThiJ/PfpI family protein, Type 1 
glutamine amidotransferase (GATase1)-
like domain 
5.27 13.39 2 2 2 24.8 
F9UTB5 Cystine ABC transporter, substrate 
binding protein  
5.17 11.61 3 3 3 29.0 
F9UNU9 5-formyltetrahydrofolate cyclo-ligase 5.15 13.30 2 2 2 21.4 
Q88VQ7 Histidine--tRNA ligase  5.10 5.40 2 2 2 47.9 
F9UQC9 Transpeptidase, penicillin binding 
protein 2B  
5.10 3.37 2 2 2 77.2 
F9UPP7 Transcription regulator, DeoR family 5.06 11.60 3 3 3 28.0 
Q88W97 Holliday junction resolvase RecU 5.01 11.59 3 3 3 23.7 
F9UQL5 Transcription regulator, Xre family  5.01 11.72 2 2 2 31.3 
P77883 Aspartate carbamoyltransferase  4.98 7.72 2 2 2 34.7 
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F9UT61 PTS system, trehalose-specific IIBC 
component  
4.96 3.46 2 2 2 69.4 
F9UL78 Nuclease, NYN_YacP family  4.94 9.94 2 2 2 21.0 
F9UTN9 Two-component system response 
regulator  
4.92 11.54 2 2 2 26.8 
F9UQM6 Cell shape determining protein MreB  4.85 8.68 3 3 4 35.1 
Q88VJ8 Ditrans,polycis-undecaprenyl-
diphosphate synthase ((2E,6E)-farnesyl-
diphosphate specific)  
4.81 8.11 2 2 2 28.8 
Q890C0 Thiamine-phosphate synthase  4.81 11.52 2 2 2 22.8 
F9USU5 Alpha-beta hydrolase superfamily  4.80 13.08 3 3 3 29.0 
F9UKZ1 Sortase A  4.76 10.68 2 2 2 26.0 
F9UPK2 Uncharacterized protein  4.75 12.67 2 2 3 17.1 
F9UQF3 Metal-dependent hydrolase, beta-
lactamase superfamily III  
4.68 6.48 2 2 3 26.8 
Q890C2 Hydroxyethylthiazole kinase  4.64 9.13 2 2 2 27.5 
Q88XX7 30S ribosomal protein S17 4.62 20.22 2 2 2 10.3 
F9UPC2 Hypothetical membrane protein  4.62 5.57 2 2 2 41.3 
F9UQQ0 Uncharacterized protein  4.62 7.10 2 2 2 36.8 
F9UTJ4 Beta-lactamase family protein  4.57 3.65 2 2 3 37.3 
F9UL33 N-acetylglucosamine-6-phosphate 
deacetylase  
4.56 6.08 2 2 2 41.4 
F9UPB8 Glycosyl hydrolase, family 25  4.55 10.96 3 3 3 50.0 
Q88UU1 ATP synthase subunit alpha  4.47 4.17 2 2 2 54.5 
F9UPD5 Chloramphenicol O-acetyltransferase  4.20 9.01 2 2 2 25.4 
F9ULT0 Ribonucleoside-diphosphate reductase  4.19 3.74 2 2 2 82.1 
F9UQ97 Ribonuclease J  3.75 5.56 2 2 2 61.8 
F9UMX4 UDP-galactopyranose mutase  3.71 7.77 3 3 3 43.2 
F9UL62 Acetyl-CoA carboxylase, carboxyl 
transferase subunit alpha  
3.54 8.95 2 2 2 27.3 
F9UT59 Trehalose operon transcriptional 
repressor,GntR family 
3.48 9.21 2 2 2 26.9 
Q88XX9 50S ribosomal protein L16  3.17 17.36 2 2 2 16.1 
F9URK7 NADPH-dependent FMN reductase 
family protein  
3.09 8.42 2 2 2 22.8 
F9UL42 Homoserine dehydrogenase  3.05 4.44 2 2 2 46.6 
F9UMH1 Asparagine synthase (Glutamine-
hydrolysing) 
2.83 4.74 2 2 2 73.1 
Q88YM6 10 kDa chaperonin  2.74 17.02 2 2 2 10.3 
F9UMY7 dTDP-glucose 4,6-dehydratase  2.73 4.68 2 2 2 38.6 
F9UQK0 Preprotein translocase, YajC subunit  2.65 18.11 2 2 2 13.8 
F9UPL0 30S ribosomal protein S1  2.64 4.43 2 2 2 47.1 
Q88XX0 50S ribosomal protein L18  2.64 13.56 2 2 2 13.0 
F9ULY7 Thioredoxin reductase 2.61 6.41 2 2 2 33.4 
Q88VD5 30S ribosomal protein S15  2.60 17.98 2 2 2 10.5 
F9UT13 Oxidoreductase, aldo/keto reductase 
family  
2.59 7.60 2 2 2 29.3 
Q88XZ3 DNA-directed RNA polymerase subunit 
beta  
2.40 1.67 2 2 2 134.
4 
Q88YF4 UDP-N-acetylenolpyruvoylglucosamine 
reductase  
2.40 7.95 2 2 2 32.3 
Q88VQ8 Aspartate--tRNA ligase 2.39 5.02 4 4 4 67.6 
F9UPA5 Transpeptidase-transglycosylase 
(Penicillin binding protein 1A)  
2.34 2.74 2 2 2 83.1 
F9UQH7 Xaa-Pro dipeptidase  2.23 5.15 2 2 2 41.1 
Q88Z84 Ribose-phosphate pyrophosphokinase 1 2.23 6.44 2 2 2 35.9 
F9ULS9 Ribonucleoside-diphosphate reductase, 
beta chain  
2.17 9.23 3 3 3 39.1 
F9UT44 Transcription regulator, GntR family  2.15 11.26 2 2 2 26.2 
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Q88X16 6,7-dimethyl-8-ribityllumazine synthase  2.12 11.95 2 2 2 16.7 
F9UN65 Aminotransferase 2.10 9.62 3 3 3 43.8 
F9UTE1 Endonuclease III  1.97 11.71 3 3 3 25.5 
F9UTK1 Uncharacterized protein 1.88 19.01 3 3 3 16.7 
F9UTW0 Purine nucleosidase  0.00 6.86 2 2 2 33.0 
F9UTY4 Galactoside O-acetyltransferase 0.00 15.12 2 2 2 23.1 
F9URU0 Phosphohydrolase, HAD superfamily  0.00 13.64 2 2 2 25.4 
F9URL3 ABC transporter, ATP-binding protein 0.00 5.16 1 2 2 27.7 
 
Band # 9 
Accession Description Score Coverage # Unique 
Peptides 
# 
Peptides 
# 
PSMs 
MW 
[kDa] 
Q88YW7 50S ribosomal protein L7/L12  51.64 72.13 11 11 17 12.6 
Q88XY4 50S ribosomal protein L23 50.82 78.35 12 12 18 11.1 
Q88XV9 50S ribosomal protein L17  50.17 57.48 7 7 16 14.2 
F9USN8 DNA-binding ferritin-like protein, DPS 
family  
46.07 39.35 6 6 15 18.0 
Q88WN5 50S ribosomal protein L21  45.67 65.69 7 7 14 11.0 
Q88WG9 3-hydroxyacyl-[acyl-carrier-protein] 
dehydratase FabZ  
45.13 51.02 9 9 16 16.0 
Q88RX0 Ribonuclease P protein component 45.12 63.16 8 8 15 13.2 
Q88XW1 30S ribosomal protein S11  42.67 32.56 4 4 12 13.8 
Q88WU6 50S ribosomal protein L20  39.70 38.98 6 6 14 13.6 
Q88YW9 50S ribosomal protein L1  37.22 32.31 9 9 12 24.8 
F9US66 Serine protease HtrA  37.18 28.10 9 9 11 43.1 
Q88XY1 50S ribosomal protein L22  36.82 43.48 7 7 13 12.5 
F9UU90 Extracellular protein, DUF1002 family  36.31 24.53 6 6 9 34.2 
Q88XY9 30S ribosomal protein S7  35.97 55.13 9 9 15 17.8 
Q88XX2 30S ribosomal protein S8 35.81 55.73 7 7 12 14.6 
Q88WJ1 50S ribosomal protein L19  34.85 51.69 10 10 20 13.6 
F9UPV6 Uncharacterized protein  33.10 59.38 6 6 12 11.0 
F9UM10 Glyceraldehyde 3-phosphate 
dehydrogenase  
32.09 27.94 10 10 11 36.4 
Q88W95 Cell cycle protein GpsB 30.58 48.67 6 6 11 12.9 
F9UP41 (3R)-hydroxymyristoyl-[acyl carrier 
protein] dehydratase  
29.24 45.99 6 6 11 15.1 
Q88XW2 30S ribosomal protein S13  28.77 52.07 8 8 13 13.6 
Q88YH3 Enolase 1  28.69 22.17 7 7 10 48.0 
F9UQ60 Uncharacterized protein  28.67 51.11 7 7 10 14.5 
Q88X05 Foldase protein PrsA 1 28.32 27.52 7 7 9 32.6 
F9UPJ4 Carboxy-terminal proteinase, S41 
family,peptidoglycan-bound  
28.12 21.75 10 10 12 53.2 
Q88VE0 Elongation factor Tu  27.45 26.08 11 11 16 43.4 
F9UNV2 Bifunctional protein: transcription 
regulator sugar kinase, ROK family  
27.16 29.38 9 9 9 33.7 
F9UT64 Glycerol-3-phosphate 
cytidylyltransferase  
27.04 41.79 10 10 14 15.8 
Q88YM6 10 kDa chaperonin  26.17 62.77 5 5 9 10.3 
F9UMU7 Lipoprotein, pheromone  26.06 31.20 8 8 8 42.6 
F9UTV3 Multicopper oxidase 24.09 15.77 6 6 9 56.8 
Q88XY7 30S ribosomal protein S10 23.78 47.06 6 6 9 11.7 
F9UPE2 Transcription regulator, MarR family  23.33 35.00 6 6 8 15.6 
F9UTI7 7,8-dihydroneopterin aldolase  22.66 34.43 4 4 9 13.8 
F9UN59 Phosphocarrier protein Hpr  22.61 27.27 2 2 8 9.4 
Q88YH4 Triosephosphate isomerase  22.06 31.35 7 7 8 27.0 
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F9UNJ5 Nucleotide-binding protein, histidine 
triad family [F9UNJ5_LACPL] 
22.02 42.67 5 5 7 17.0 
F9UMC8 Alkaline shock protein  21.99 36.43 6 6 7 15.8 
F9UQB2 Cysteine desulfurase associated 
protein,DUF1831 family 
21.16 64.60 8 8 9 12.6 
F9UPK7 DNA-binding protein  20.76 35.16 4 4 6 9.6 
F9UNU7 Transpeptidase (Penicillin binding 
protein 2B)  
20.29 9.44 7 7 7 72.6 
Q88VJ2 D-lactate dehydrogenase  19.97 24.10 8 8 8 37.2 
F9USV1 Small heat shock protein  19.91 57.86 6 6 7 16.0 
Q88WN3 50S ribosomal protein L27  19.57 39.13 4 4 7 10.1 
F9UL15 Ribosome-associated heat shock 
protein 
19.14 35.79 5 5 6 10.9 
Q88XY2 30S ribosomal protein S19  18.79 45.05 5 5 8 10.3 
F9UU72 Prophage P3 protein 2, CI-like 
repressor  
18.75 41.27 6 6 6 13.8 
F9UNV4 Rhodanese family protein  18.74 48.18 5 5 8 15.8 
F9UU57 Uncharacterized protein  18.59 29.92 5 5 6 13.8 
Q88XX7 30S ribosomal protein S17  18.42 32.58 5 5 8 10.3 
Q88XY5 50S ribosomal protein L4  17.35 27.05 6 6 7 22.6 
F9URR0 Flavodoxin  16.62 41.89 5 5 5 16.0 
Q88T35 2,3-bisphosphoglycerate-dependent 
phosphoglycerate mutase 2 
16.59 31.74 5 5 7 26.1 
F9UNT7 Transcription regulator, MarR family  16.49 26.05 3 3 6 13.7 
Q88XX6 50S ribosomal protein L14 16.49 43.44 5 5 7 13.1 
Q88XX0 50S ribosomal protein L18  16.43 30.51 5 5 7 13.0 
F9USY7 Maltodextrin-binding protein  16.38 23.02 7 7 7 45.6 
Q88WM9 Transcription antitermination protein 
NusB 
16.31 35.25 6 6 7 15.7 
F9UM75 Phosphohydrolase, MutT/nudix family  16.25 36.69 4 4 5 15.6 
Q88YW8 50S ribosomal protein L10  16.20 25.75 4 4 5 17.9 
F9UNI1 GTP cyclohydrolase-2 16.10 11.88 4 4 6 43.6 
F9UTT2 Fructose-bisphosphate aldolase  15.95 23.00 6 6 6 30.9 
F9UPT6 Uncharacterized protein  15.81 27.89 6 6 7 16.1 
F9URF7 Uncharacterized protein  15.33 30.00 3 3 6 13.8 
F9UPZ9 Nucleic-acid-binding protein implicated 
in transcription termination  
14.93 36.36 5 5 9 11.2 
F9UUA2 Uncharacterized protein 14.70 53.66 5 5 5 14.5 
Q88XY6 50S ribosomal protein L3 14.57 33.01 5 5 5 22.7 
Q890K2 30S ribosomal protein S6 14.46 50.51 5 5 6 11.4 
Q88XU7 30S ribosomal protein S9  14.31 27.69 4 4 8 14.6 
F9UPM3 Pyruvate kinase  14.07 11.95 6 6 6 62.8 
Q88YI6 S-ribosylhomocysteine lyase  13.14 22.15 3 3 4 17.4 
F9UQM5 Cell shape-determining protein MreC  13.10 22.06 5 5 5 30.1 
F9US72 6-pyruvoyl-tetrahydropterin synthase 
family protein  
12.88 31.15 4 4 5 14.0 
Q88VD5 30S ribosomal protein S15 12.82 22.47 4 4 5 10.5 
F9UN40 Glycerol-3-phosphate 
cytidylyltransferase 
12.82 28.79 4 4 5 15.5 
Q88YX0 50S ribosomal protein L11 12.39 26.95 5 5 6 14.8 
Q88XZ6 Transcriptional regulator CtsR  12.31 23.23 4 4 4 17.6 
F9UQC9 Transpeptidase, penicillin binding 
protein 2B  
11.84 6.73 4 4 4 77.2 
Q88XW9 30S ribosomal protein S5  11.54 25.30 5 5 6 17.3 
F9USS0 Pyridoxamine 5'-phosphate oxidase 
family protein, FMN-binding 
11.41 24.31 3 3 4 16.0 
F9UMI2 Cold shock protein CspC  11.39 87.88 3 4 5 7.3 
F9UUF6 FMN-binding protein 11.35 26.23 2 2 5 13.4 
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Q88VK8 Ribosome-binding factor A  11.21 30.77 6 6 6 13.1 
F9UPF6 Uncharacterized protein  10.95 37.93 4 4 4 13.1 
Q88W32 Probable manganese-dependent 
inorganic pyrophosphatase 
10.87 17.48 4 4 4 33.6 
Q88XX4 50S ribosomal protein L5  10.71 29.44 5 5 5 20.2 
Q88XZ0 30S ribosomal protein S12  10.58 25.55 4 4 5 15.2 
Q88RZ2 D-ribose pyranase  10.51 19.85 2 2 4 14.6 
F9UQP4 Universal stress protein  10.40 24.38 3 3 4 17.5 
F9UNC2 Extracellular protein, membrane-
anchored 
10.23 22.32 2 2 3 12.5 
F9URG1 Ribonucleotide reductase protein NrdI 
CPL] 
10.21 22.36 3 3 4 18.2 
F9UT98 Serine-type D-Ala-D-Ala 
carboxypeptidase  
10.17 10.14 4 4 4 46.9 
Q6LWH2 Uncharacterized protein 10.09 24.14 4 4 4 13.0 
F9UTM5 Small heat shock protein  10.09 36.05 4 4 4 16.7 
Q6LWF2 Uncharacterized protein 10.05 21.77 4 4 4 14.0 
F9UT53 Cystathionine beta-lyase / cystathionine 
gamma-lyase  
9.96 13.91 5 5 5 40.8 
Q88WA8 Asparagine--tRNA ligase 2  9.91 8.33 3 3 3 49.8 
F9UL56 PTS system, mannose-specific 
EIIAcomponent  
9.80 19.42 2 2 4 15.3 
F9UNV8 Glutamine synthetase repressor, MerR 
family  
9.77 37.30 4 4 4 14.5 
Q88XU8 50S ribosomal protein L13  9.73 29.93 4 4 4 16.2 
F9UPV5 Uncharacterized protein 9.71 34.38 4 4 5 11.7 
F9UTM1 Uncharacterized protein  9.70 27.10 2 2 3 12.1 
F9URL6 Transcription regulator, GntR family  9.39 27.64 3 3 4 14.1 
F9UNS7 Two-component system response 
regulator  
9.33 8.33 3 3 4 26.4 
F9UM05 Oligopeptide ABC transporter, substrate 
binding protein  
9.32 9.27 5 5 5 61.0 
F9URE5 Universal stress protein 9.21 18.30 2 2 3 16.9 
F9USJ7 Transcription regulator, MarR family  9.13 40.83 5 5 6 13.8 
F9UTM0 Uncharacterized protein 9.03 39.52 5 5 5 14.4 
F9UTD0 Uncharacterized protein  8.91 27.21 4 4 4 16.8 
Q88Z97 Methionine--tRNA ligase 8.87 5.12 2 2 3 76.7 
F9UQQ5 Glycine cleavage system, H protein  8.82 24.49 2 2 3 10.5 
Q88XX1 50S ribosomal protein L6  8.81 18.54 3 3 3 19.3 
Q88VM0 Chaperone protein DnaK  8.76 5.63 3 3 3 66.7 
F9UMW7 Uncharacterized protein 8.72 23.29 2 2 3 16.2 
F9UM38 Cell surface protein, YbbR-like family  8.62 11.69 2 2 2 34.6 
P71478 Cold shock protein 1  8.62 50.00 3 4 4 7.3 
F9UMV3 Transcription regulator, TetR family  8.53 13.61 2 2 3 21.6 
Q88VC6 UPF0298 protein lp_2135  8.46 46.00 3 3 3 11.8 
Q88VJ4 30S ribosomal protein S2  8.34 11.99 3 3 3 30.2 
F9UNR4 RNA binding protein, YhbY family 8.25 38.46 3 3 3 11.7 
F9URP8 PTS system, cellobiose-specific EIIA 
component  
8.23 25.22 3 3 3 12.5 
F9UQK6 Hypothetical membrane protein  8.17 2.74 2 2 3 114.8 
F9UTR5 Acetyltransferase, GNAT family 8.11 28.57 4 4 4 17.1 
Q890K0 30S ribosomal protein S18  8.08 38.46 4 4 4 9.1 
F9UMC6 Hypothetical membrane protein  8.08 18.23 3 3 3 20.4 
Q88X16 6,7-dimethyl-8-ribityllumazine synthase  7.85 12.58 3 3 3 16.7 
F9URD6 Uncharacterized protein  7.77 21.48 2 2 2 16.0 
F9UL94 Prophage P1 protein 8, phage 
transcription regulator, Cro/CI family 
7.46 28.33 5 5 5 13.8 
F9URC4 Transcription regulator, Cro/CI family 7.38 21.74 3 3 3 16.0 
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F9URX6 Universal stress protein  7.24 20.41 3 3 5 16.3 
F9UNZ3 Serine/threonine protein kinase  7.18 4.15 2 2 2 74.5 
Q88UU0 ATP synthase subunit delta  7.17 20.99 3 3 3 20.0 
F9US78 Flavoprotein  7.17 19.15 2 2 2 15.1 
F9UTF5 Zinc-dependent proteinase  7.15 12.07 2 2 2 25.2 
Q88VQ3 D-aminoacyl-tRNA deacylase  6.95 19.59 2 2 2 16.0 
F9UNH5 Nucleoside 2-deoxyribosyltransferase  6.95 25.34 3 3 3 16.6 
F9UL76 Mini-ribonuclease 3  6.67 19.12 2 2 2 15.3 
Q88XW7 50S ribosomal protein L15 6.67 19.58 2 2 2 15.3 
F9UP44 Acetyl-CoA carboxylase, carboxyl 
transferase subunit alpha  
6.59 10.16 2 2 2 27.6 
F9UQF5 Uncharacterized protein  6.44 25.40 2 2 2 14.4 
F9URS2 Extracellular protein 6.41 12.67 2 2 2 23.2 
Q88X33 UPF0342 protein lp_1415 6.39 25.44 2 2 2 13.2 
F9UP60 Adherence protein, chitin-binding 
domain  
6.13 9.45 2 2 2 22.2 
Q88YP3 Initiation-control protein YabA 6.09 23.48 2 2 3 13.6 
P56512 L-lactate dehydrogenase 1  5.97 9.38 2 2 2 34.2 
Q88YH5 Phosphoglycerate kinase  5.94 9.50 4 4 5 42.8 
F9UN36 Transcription regulator, Cro/CI family  5.92 17.60 2 2 2 13.8 
Q88VR5 30S ribosomal protein S21  5.86 41.94 3 3 4 7.6 
F9UMI5 Transcriptional attenuator, cell 
envelope-related, LytR family 
5.69 6.38 2 2 2 37.7 
Q88WK0 Ribonuclease 3  5.64 9.09 2 2 2 26.6 
Q88Z02 Aspartate 1-decarboxylase  5.52 18.46 2 2 2 14.4 
Q6LWH4 Uncharacterized protein  5.51 23.64 2 2 2 13.0 
F9UT92 Uncharacterized protein 5.18 11.11 2 2 3 16.6 
Q88XX5 50S ribosomal protein L24 5.18 9.71 2 2 2 11.4 
F9UNR7 Ribosomal silencing factor RsfS  5.16 24.58 2 2 2 13.0 
F9UP36 Acyl carrier protein  5.12 24.39 2 2 2 9.3 
Q88Z44 Holo-[acyl-carrier-protein] synthase 5.12 15.83 2 2 2 13.2 
F9US19 Lipoprotein  5.08 12.74 2 2 3 17.3 
F9UQY9 Prophage P2a protein 7 extracellular 
protein with lipoprotein anchor  
4.91 23.42 2 2 2 12.0 
F9UL53 Uncharacterized protein 4.87 25.98 4 4 4 14.8 
Q88XY8 Elongation factor G  4.86 3.15 2 2 2 77.0 
F9UT55 Methionine aminopeptidase 4.74 9.89 2 2 2 29.1 
F9USC3 Nucleotide-binding protein, universal 
stress protein UspA family 
4.67 25.87 3 3 3 15.7 
F9UU77 Uncharacterized protein  4.57 21.15 3 3 3 17.6 
F9UL89 Prophage P1 protein 2, mitogenic 
factor, cell surface lipoprotein  
4.57 9.56 2 2 3 41.8 
F9UNU5 Uncharacterized protein  4.56 11.00 2 2 2 11.5 
F9UTM3 Uncharacterized protein  4.40 12.40 2 2 2 14.0 
F9URL9 Nucleotide-binding protein, universal 
stress protein UspA family  
4.39 14.10 2 2 2 17.1 
Q88S55 Transcription regulator, Rrf2 family  4.25 20.57 2 2 2 15.6 
F9URV6 Transcription regulator, MerR family 4.20 19.44 3 3 3 16.9 
F9URP6 6-phospho-beta-glucosidase 4.08 5.63 2 2 2 54.7 
F9URG4 Transcription regulator, MerR family 4.05 25.60 3 3 3 14.5 
F9UR52 Lactoylglutathione lyase family protein 3.91 21.48 3 3 3 16.9 
F9UP45 Enoyl-[acyl-carrier-protein] reductase 
[NADH]  
3.67 6.35 2 2 2 26.9 
F9UL47 PTS system, mannose-specific EIID 
component  
3.67 6.56 2 2 3 33.6 
Q88XY0 30S ribosomal protein S3  3.60 17.97 3 3 3 24.2 
F9UMW3 Universal stress protein  3.12 14.38 2 2 2 15.8 
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Q88XW3 50S ribosomal protein L36  2.76 30.77 2 2 2 4.6 
Q88VQ7 Histidine--tRNA ligase  2.64 5.16 2 2 2 47.9 
F9UPK2 Uncharacterized protein 2.33 14.00 2 2 2 17.1 
F9UL91 Prophage P1 protein 5, superinfection 
exclusion (Cell surface N-anchored)  
2.29 8.91 3 3 4 37.9 
F9ULD4 RNA polymerase (RNAP)-binding 
regulatory protein, arsenate reductase 
(ArsC) family, Spx subfamily  
2.18 22.07 3 3 3 16.7 
F9UN56 Transcription regulator, MarR family  2.14 17.05 2 2 2 14.4 
Q88X97 Large-conductance mechanosensitive 
channel  
2.10 13.49 2 2 3 14.0 
Q88WG0 Acetyl-coenzyme A carboxylase 
carboxyl transferase subunit beta 2 
1.86 6.76 2 2 2 30.9 
F9UMY6 dTDP-4-dehydrorhamnose 3,5-
epimerase  
0.00 8.81 2 2 2 21.8 
 
Band # 10 
Accession Description Score Coverage # Unique 
Peptides 
# 
Peptides 
# PSMs MW 
[kDa] 
F9URG7 Glucose-6-phosphate 1-dehydrogenase  41.17 24.90 10 10 16 56.8 
Q88W76 Formate--tetrahydrofolate ligase  31.94 14.34 5 5 9 57.9 
F9UPL0 30S ribosomal protein S1  30.93 30.30 10 10 13 47.1 
Q88Y74 GMP synthase [glutamine-hydrolyzing]  28.35 25.48 10 10 10 57.4 
F9UQC4 Cell division protein FtsA 27.49 21.88 7 7 9 48.3 
F9UPM3 Pyruvate kinase 27.13 16.04 7 7 9 62.8 
Q88YH5 Phosphoglycerate kinase  26.04 28.75 9 9 9 42.8 
F9UQC3 Cell division protein FtsZ  25.85 22.95 6 6 9 45.0 
F9UMF3 Dipeptidase  24.31 15.38 6 6 9 52.3 
F9UTT6 Dipeptidase  22.91 13.40 6 6 7 52.9 
Q88YM5 60 kDa chaperonin  22.16 16.27 6 6 7 57.4 
F9UM10 Glyceraldehyde 3-phosphate 
dehydrogenase  
19.34 23.24 6 6 6 36.4 
F9UT60 Trehalose-6-phosphate hydrolase  17.60 9.87 5 5 6 62.0 
F9URU7 Poly(Glycerol-phosphate) alpha-
glucosyltransferase [F9URU7_LACPL] 
17.32 11.87 6 6 6 58.3 
Q88UU1 ATP synthase subunit alpha 17.12 15.48 7 7 7 54.5 
Q88Z28 Lysine--tRNA ligase  17.01 10.82 5 5 8 57.6 
Q88UI4 Glucose-6-phosphate isomerase  16.34 6.89 3 3 6 49.8 
Q88YY0 Glutamate--tRNA ligase  15.87 17.94 6 6 8 56.9 
F9UM05 Oligopeptide ABC transporter, substrate 
binding protein 
15.72 8.18 4 4 5 61.0 
Q88UU3 ATP synthase subunit beta  15.21 12.42 4 4 4 50.8 
Q88YX9 Cysteine--tRNA ligase  13.93 12.98 5 5 6 52.7 
Q88YH3 Enolase 1  13.02 9.50 3 3 4 48.0 
Q88VM0 Chaperone protein DnaK  12.46 9.81 4 4 4 66.7 
F9UN83 Glycosyl transferase, group I  12.44 7.72 4 4 5 62.8 
Q88YE7 Glutamine--fructose-6-phosphate 
aminotransferase [isomerizing]  
11.98 7.93 4 4 4 65.4 
F9URP6 6-phospho-beta-glucosidase 11.49 11.67 4 4 4 54.7 
Q88Y23 UDP-N-acetylmuramoyl-L-alanyl-D-
glutamate--2,6-diaminopimelate ligase 
10.86 7.51 3 3 4 53.8 
F9UNS5 6-phosphogluconate dehydrogenase, 
decarboxylating 
10.71 7.11 3 3 4 52.9 
P56512 L-lactate dehydrogenase 1  10.43 10.94 3 3 3 34.2 
Q88YH4 Triosephosphate isomerase  10.28 16.67 3 3 3 27.0 
Q88XP6 Aspartyl/glutamyl-tRNA(Asn/Gln) 
amidotransferase subunit B  
10.05 8.44 3 3 3 53.2 
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F9UQ90 Dihydrolipoyl dehydrogenase  9.94 11.06 4 4 4 49.9 
F9UN93 Xaa-His dipeptidase  8.35 14.13 4 4 4 50.8 
F9UTG0 Glutathione reductase  7.91 8.56 3 3 3 48.2 
Q88VM6 D-alanine--D-alanyl carrier protein 
ligase  
7.84 6.10 2 2 4 56.0 
Q88VJ5 Elongation factor Ts  7.53 10.96 2 2 2 31.6 
Q88VE0 Elongation factor Tu  7.46 12.15 4 4 4 43.4 
F9UQ97 Ribonuclease J  7.36 6.09 3 3 3 61.8 
F9UTT2 Fructose-bisphosphate aldolase  7.32 10.80 2 2 2 30.9 
F9UTQ7 Extracellular transglycosylase  7.19 9.74 2 2 2 26.3 
F9UT31 Dipeptidase  6.90 6.37 2 2 2 52.5 
F9UT87 Cyclopropane-fatty-acyl-phospholipid 
synthase 
6.89 6.30 2 2 3 45.3 
Q88V80 UDP-N-acetylmuramoylalanine--D-
glutamate ligase  
6.59 6.10 2 2 2 50.1 
Q88X53 Arginine--tRNA ligase  5.94 3.91 2 2 2 62.9 
F9UNV2 Bifunctional protein: transcription 
regulator sugar kinase, ROK family 
5.35 7.81 2 2 2 33.7 
F9UQ85 Extracellular protein, cell-wall 
anchored  
5.23 5.08 2 2 2 45.8 
Q88VJ2 D-lactate dehydrogenase 4.74 12.95 4 4 4 37.2 
F9UUI9 6-phospho-beta-glucosidase  4.59 4.38 2 2 2 54.5 
F9UP39 3-oxoacyl-[acyl-carrier-protein] 
synthase 2  
3.14 3.66 2 2 2 42.4 
F9URU6 Poly(Glycerol-phosphate) alpha-
glucosyltransferase  
2.41 4.58 2 2 2 57.6 
F9UN84 Poly(Glycerol-phosphate) alpha-
glucosyltransferase  
2.29 4.38 2 2 2 57.8 
F9UN85 Poly(Glycerol-phosphate) alpha-
glucosyltransferase  
2.20 5.31 2 2 2 57.8 
F9URM9 Threonine synthase  1.76 5.03 3 3 3 54.5 
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Appendix II: Apoptotic effect of Lp-BS and rhamnolipid, magnified photomicrographs. 
 
1- Lp-BS apoptotic effect 
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2- Rhamnolipid apoptotic effect 
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